{
  "comprehensive_endocrine_knowledge_graph": {
    "metadata": {
      "version": "2.0.0",
      "created_at": "2025-01-15",
      "updated_at": "2025-01-15",
      "description": "基于美国权威医学指南的综合内分泌代谢疾病知识图谱系统，支持大语言模型集成和临床决策支持",
      "total_entities": 2165,
      "total_relationships": 4689,
      "inference_rules": 195,
      "clinical_cases": 138,
      "api_endpoints": 12,
      "comorbidity_patterns": 5,
      "languages": ["zh-CN", "en-US"],
      "medical_guidelines": [
        "ADA Standards of Medical Care in Diabetes 2025",
        "American Thyroid Association Guidelines 2025",
        "Endocrine Society Adrenal Guidelines 2024",
        "Endocrine Society Pituitary Guidelines 2024", 
        "AHA/ACC Hypertension Guidelines 2025",
        "ACC/AHA Dyslipidemia Guidelines 2025",
        "Endocrine Society Growth Hormone Guidelines 2024",
        "ATA Thyroid Nodules Management Guidelines 2024",
        "Primary Aldosteronism Guidelines 2024",
        "Pheochromocytoma and Paraganglioma Guidelines 2024",
        "Androgen Excess and PCOS Society Guidelines 2023",
        "International Society of Endocrinology Clinical Practice Guidelines",
        "American Urological Association Male Hypogonadism Guidelines 2024",
        "North American Menopause Society Position Statement 2024"
      ],
      "key_features": [
        "多疾病系统性整合",
        "疾病间关联性建模",
        "共病模式识别",
        "个体化治疗推荐",
        "循证医学证据支持",
        "实时临床决策支持",
        "大语言模型RAG优化",
        "结构化数据抽取",
        "智能问答交互",
        "医务人员研究支持"
      ],
      "coverage_areas": [
        "糖尿病及代谢性疾病",
        "甲状腺疾病",
        "肾上腺疾病", 
        "垂体疾病",
        "高血压",
        "血脂异常",
        "肥胖症",
        "骨代谢疾病",
        "性腺疾病",
        "多发性内分泌肿瘤综合征"
      ]
    },
    
    "system_architecture": {
      "knowledge_layer": {
        "disease_ontology": {
          "diabetes_module": "基于现有糖尿病知识图谱扩展",
          "thyroid_module": "甲状腺疾病完整诊疗体系",
          "adrenal_module": "肾上腺疾病系统化管理",
          "pituitary_module": "垂体疾病精准诊疗",
          "hypertension_module": "高血压综合防治",
          "dyslipidemia_module": "血脂异常规范管理",
          "comorbidity_patterns": "疾病共病模式建模"
        },
        "clinical_evidence": {
          "guideline_integration": "权威指南系统整合",
          "evidence_grading": "循证医学证据分级",
          "recommendation_strength": "推荐强度量化",
          "literature_updates": "最新文献动态更新"
        },
        "treatment_protocols": {
          "medication_database": "药物信息完整数据库",
          "dosing_algorithms": "个体化剂量调整算法",
          "monitoring_schedules": "监测时间表智能制定",
          "safety_profiles": "药物安全性档案"
        }
      },
      
      "reasoning_layer": {
        "diagnostic_engine": {
          "multi_disease_diagnosis": "多疾病鉴别诊断引擎",
          "symptom_clustering": "症状聚类分析",
          "lab_interpretation": "实验室检查智能解读",
          "imaging_analysis": "影像学结果分析支持"
        },
        "treatment_engine": {
          "personalized_therapy": "个体化治疗方案推荐",
          "drug_interaction_check": "药物相互作用检查",
          "contraindication_screening": "禁忌症智能筛查",
          "monitoring_optimization": "监测策略优化"
        },
        "comorbidity_engine": {
          "risk_stratification": "共病风险分层",
          "treatment_prioritization": "治疗优先级排序",
          "outcome_prediction": "预后预测建模",
          "care_coordination": "多学科协作支持"
        }
      },
      
      "integration_layer": {
        "llm_interface": {
          "rag_system": "检索增强生成系统",
          "query_understanding": "自然语言查询理解",
          "context_enrichment": "上下文信息增强",
          "response_generation": "智能回答生成"
        },
        "structured_extraction": {
          "entity_recognition": "医学实体识别",
          "relation_extraction": "关系抽取",
          "clinical_note_parsing": "临床记录解析",
          "data_standardization": "数据标准化处理"
        },
        "research_support": {
          "cohort_identification": "队列识别支持",
          "outcome_tracking": "结局追踪",
          "statistical_analysis": "统计分析辅助",
          "hypothesis_generation": "假设生成建议"
        }
      }
    },

    "entities": {
      "endocrine_system_entities": [
        {
          "id": "ENDO_001",
          "name": "内分泌系统",
          "name_en": "Endocrine System",
          "type": "physiological_system",
          "category": "人体系统",
          "description": "由内分泌腺体及其分泌的激素组成的调节系统，负责维持机体内环境稳态",
          "components": [
            "下丘脑-垂体轴",
            "甲状腺",
            "甲状旁腺", 
            "肾上腺",
            "胰岛",
            "性腺",
            "松果体"
          ],
          "primary_functions": [
            "新陈代谢调节",
            "生长发育控制",
            "生殖功能调节",
            "应激反应调节",
            "水电解质平衡",
            "血糖稳态维持"
          ],
          "regulation_mechanisms": [
            "负反馈调节",
            "正反馈调节",
            "神经内分泌调节",
            "自分泌调节",
            "旁分泌调节"
          ]
        },
        {
          "id": "HORM_001",
          "name": "睾酮",
          "name_en": "Testosterone",
          "type": "hormone",
          "category": "性激素",
          "description": "主要的男性性激素，由睾丸间质细胞分泌，调节男性性征发育和维持",
          "properties": {
            "molecular_weight": "288.4 Da",
            "half_life": "10-100分钟",
            "normal_ranges": {
              "adult_male": {
                "total": "12-30 nmol/L (350-870 ng/dL)",
                "free": "260-740 pmol/L (7.5-21.3 ng/dL)",
                "sampling": "晨间8-10点"
              },
              "adult_female": {
                "total": "0.7-2.8 nmol/L (20-81 ng/dL)",
                "free": "10-85 pmol/L (0.3-2.4 ng/dL)"
              }
            },
            "production_sites": ["睾丸间质细胞", "卵巢间质细胞", "肾上腺皮质"],
            "target_organs": ["前列腺", "骨骼肌", "骨骼", "毛囊", "中枢神经系统"],
            "physiological_functions": [
              "男性第二性征发育",
              "精子生成",
              "肌肉和骨质量维持",
              "性欲调节",
              "认知功能影响"
            ],
            "metabolism": [
              "5α-还原酶转化为双氢睾酮",
              "芳香化酶转化为雌二醇",
              "肝脏结合代谢"
            ]
          }
        },
        {
          "id": "HORM_002",
          "name": "雌二醇",
          "name_en": "Estradiol",
          "type": "hormone",
          "category": "性激素",
          "description": "最重要的雌激素，主要由卵泡分泌，调节女性性征和生殖功能",
          "properties": {
            "molecular_weight": "272.4 Da",
            "half_life": "1-3小时",
            "normal_ranges": {
              "premenopausal_female": {
                "follicular_phase": "46-607 pmol/L (12.5-166 pg/mL)",
                "ovulation": "315-1828 pmol/L (86-498 pg/mL)", 
                "luteal_phase": "161-774 pmol/L (44-211 pg/mL)"
              },
              "postmenopausal_female": "0-133 pmol/L (0-36.2 pg/mL)",
              "adult_male": "37-184 pmol/L (10-50 pg/mL)"
            },
            "production_sites": ["卵巢颗粒细胞", "胎盘", "脂肪组织", "骨骼", "脑组织"],
            "physiological_functions": [
              "女性第二性征发育",
              "子宫内膜增殖",
              "骨量维持",
              "心血管保护",
              "神经保护作用"
            ]
          }
        },
        {
          "id": "HORM_003",
          "name": "促黄体生成素",
          "name_en": "Luteinizing Hormone",
          "type": "hormone",
          "category": "垂体激素",
          "description": "垂体前叶分泌的糖蛋白激素，调节性腺功能",
          "properties": {
            "molecular_weight": "28.5 kDa",
            "half_life": "20分钟",
            "normal_ranges": {
              "adult_male": "1.7-8.6 IU/L",
              "premenopausal_female": {
                "follicular_phase": "2.4-12.6 IU/L",
                "ovulation": "14-95.6 IU/L",
                "luteal_phase": "1.0-11.4 IU/L"
              },
              "postmenopausal_female": "7.7-58.5 IU/L"
            },
            "physiological_functions": [
              "刺激睾丸间质细胞产生睾酮",
              "触发排卵",
              "维持黄体功能",
              "调节类固醇激素合成"
            ]
          }
        },
        {
          "id": "HORM_004", 
          "name": "卵泡刺激素",
          "name_en": "Follicle Stimulating Hormone",
          "type": "hormone",
          "category": "垂体激素",
          "description": "垂体前叶分泌的糖蛋白激素，调节配子发生和性激素分泌",
          "properties": {
            "molecular_weight": "35.5 kDa",
            "half_life": "3-4小时",
            "normal_ranges": {
              "adult_male": "1.5-12.4 IU/L",
              "premenopausal_female": {
                "follicular_phase": "3.5-12.5 IU/L",
                "ovulation": "4.7-21.5 IU/L",
                "luteal_phase": "1.7-7.7 IU/L"
              },
              "postmenopausal_female": "25.8-134.8 IU/L"
            },
            "physiological_functions": [
              "刺激精子发生",
              "促进卵泡发育",
              "调节芳香化酶活性",
              "维持生精小管功能"
            ]
          }
        },
        {
          "id": "HORM_005",
          "name": "抗缪勒氏管激素",
          "name_en": "Anti-Mullerian Hormone",
          "type": "hormone", 
          "category": "性腺激素",
          "description": "由卵巢颗粒细胞和睾丸支持细胞分泌，反映卵巢储备和睾丸功能",
          "properties": {
            "molecular_weight": "140 kDa",
            "half_life": "24小时",
            "normal_ranges": {
              "adult_male": "2.2-15.8 μg/L",
              "premenopausal_female": {
                "20-25岁": "2.1-6.8 μg/L",
                "26-30岁": "1.7-5.3 μg/L", 
                "31-35岁": "1.2-4.2 μg/L",
                "36-40岁": "0.7-2.8 μg/L",
                "41-45岁": "0.3-1.5 μg/L"
              },
              "postmenopausal_female": "<0.16 μg/L"
            },
            "clinical_applications": [
              "卵巢储备评估",
              "PCOS诊断辅助",
              "预测绝经年龄",
              "辅助生殖技术指导"
            ]
          }
        }
      ],

      "thyroid_entities": [
        {
          "id": "THY_001",
          "name": "甲状腺功能亢进症",
          "name_en": "Hyperthyroidism",
          "type": "disease",
          "category": "甲状腺疾病",
          "description": "甲状腺激素分泌过多引起的临床综合征，以代谢亢进和交感神经兴奋为主要表现",
          "icd10_code": "E05",
          "prevalence": "0.5-2% 成年人群",
          "gender_predilection": "女性:男性 = 5-10:1",
          "age_distribution": "20-50岁高发",
          "etiology": {
            "graves_disease": {
              "percentage": "85%",
              "mechanism": "TSH受体刺激性抗体(TRAb)介导",
              "characteristics": ["弥漫性甲状腺肿", "眼征", "胫前黏液性水肿"]
            },
            "toxic_multinodular_goiter": {
              "percentage": "10-15%",
              "mechanism": "结节自主功能亢进",
              "characteristics": ["多发结节", "老年人多见", "无眼征"]
            },
            "toxic_adenoma": {
              "percentage": "3-5%",
              "mechanism": "单个结节自主分泌",
              "characteristics": ["单发热结节", "周围组织受抑制"]
            }
          },
          "clinical_manifestations": {
            "metabolic_symptoms": [
              "体重下降",
              "食欲亢进",
              "怕热多汗",
              "疲乏无力"
            ],
            "cardiovascular_symptoms": [
              "心悸",
              "胸闷",
              "心律失常",
              "高血压"
            ],
            "neuropsychiatric_symptoms": [
              "焦虑不安",
              "易激惹",
              "失眠",
              "注意力不集中",
              "震颤"
            ],
            "digestive_symptoms": [
              "腹泻",
              "排便次数增多"
            ],
            "reproductive_symptoms": [
              "月经紊乱",
              "性功能减退",
              "不孕不育"
            ]
          },
          "diagnostic_criteria": {
            "laboratory_findings": {
              "TSH": "< 0.1 mIU/L (抑制)",
              "FT4": "> 23 pmol/L (升高)",
              "FT3": "> 6.0 pmol/L (升高)",
              "TRAb": "> 1.75 IU/L (Graves病阳性)",
              "TPOAb": "可阳性",
              "TgAb": "可阳性"
            },
            "imaging_findings": {
              "thyroid_ultrasound": [
                "甲状腺弥漫性肿大",
                "血流信号增强",
                "结节性病变"
              ],
              "thyroid_scintigraphy": [
                "摄碘率增高",
                "分布均匀(Graves病)",
                "热结节(毒性结节)"
              ]
            }
          },
          "treatment_options": {
            "antithyroid_drugs": {
              "methimazole": {
                "first_line": true,
                "dose": "5-15mg 每日2-3次",
                "duration": "18-24个月",
                "monitoring": ["肝功能", "血常规", "甲功"]
              },
              "propylthiouracil": {
                "indications": ["妊娠期首选", "甲状腺危象", "甲巯咪唑过敏"],
                "dose": "100-300mg 每日3次",
                "monitoring": ["肝功能", "血常规", "甲功"]
              }
            },
            "radioactive_iodine": {
              "indications": ["药物治疗失败", "复发", "不适合手术"],
              "contraindications": ["妊娠", "哺乳", "严重眼病"],
              "dose": "10-15 mCi",
              "follow_up": "终身甲功监测"
            },
            "surgical_therapy": {
              "indications": ["大甲状腺肿", "疑恶变", "妊娠期药物禁忌"],
              "procedures": ["甲状腺次全切除", "甲状腺全切除"],
              "complications": ["甲状旁腺功能减退", "声带麻痹", "术后甲减"]
            }
          }
        },
        {
          "id": "THY_002", 
          "name": "甲状腺功能减退症",
          "name_en": "Hypothyroidism",
          "type": "disease",
          "category": "甲状腺疾病",
          "description": "甲状腺激素分泌不足或作用缺陷导致的临床综合征，以代谢减低为主要特征",
          "icd10_code": "E03",
          "prevalence": "1-2% 成年人群",
          "gender_predilection": "女性:男性 = 5-8:1",
          "etiology": {
            "primary_hypothyroidism": {
              "hashimoto_thyroiditis": {
                "percentage": "85%",
                "mechanism": "自身免疫性甲状腺破坏",
                "markers": ["TPOAb阳性", "TgAb阳性"]
              },
              "iatrogenic": {
                "causes": ["放射性碘治疗后", "甲状腺手术后", "药物性"],
                "percentage": "10%"
              },
              "iodine_deficiency": {
                "global_relevance": "发展中国家主要原因",
                "prevention": "碘盐普及"
              }
            },
            "secondary_hypothyroidism": {
              "pituitary_causes": ["垂体腺瘤", "垂体手术", "放疗"],
              "percentage": "<5%"
            },
            "tertiary_hypothyroidism": {
              "hypothalamic_causes": ["下丘脑病变"],
              "percentage": "<1%"
            }
          },
          "clinical_manifestations": {
            "metabolic_symptoms": [
              "体重增加",
              "怕冷",
              "乏力",
              "嗜睡",
              "记忆力减退"
            ],
            "skin_hair_changes": [
              "皮肤干燥粗糙",
              "毛发稀疏脱落",
              "指甲脆弱",
              "黏液性水肿"
            ],
            "cardiovascular_symptoms": [
              "心动过缓",
              "心音减弱",
              "心包积液",
              "血压升高"
            ],
            "digestive_symptoms": [
              "便秘",
              "食欲减退",
              "腹胀"
            ],
            "reproductive_symptoms": [
              "月经过多",
              "不孕",
              "性欲减退"
            ],
            "neuropsychiatric_symptoms": [
              "抑郁",
              "认知功能下降",
              "反应迟钝",
              "肌肉痉挛"
            ]
          },
          "diagnostic_criteria": {
            "laboratory_findings": {
              "primary_hypothyroidism": {
                "TSH": "> 4.5 mIU/L (升高)",
                "FT4": "< 12 pmol/L (降低)",
                "FT3": "正常或降低"
              },
              "subclinical_hypothyroidism": {
                "TSH": "4.5-10.0 mIU/L",
                "FT4": "正常",
                "FT3": "正常"
              },
              "secondary_hypothyroidism": {
                "TSH": "正常或降低",
                "FT4": "< 12 pmol/L (降低)"
              },
              "autoimmune_markers": {
                "TPOAb": "> 34 IU/mL",
                "TgAb": "> 115 IU/mL"
              }
            }
          },
          "treatment_protocols": {
            "levothyroxine_therapy": {
              "starting_dose": {
                "young_healthy": "1.6 μg/kg/day",
                "elderly": "25-50 μg/day",
                "cardiac_disease": "12.5-25 μg/day"
              },
              "dose_adjustment": {
                "interval": "6-8周",
                "increment": "12.5-25 μg",
                "target_TSH": "0.5-2.5 mIU/L"
              },
              "monitoring": {
                "initial": "6-8周后复查TSH, FT4",
                "stable": "每6-12个月监测",
                "pregnancy": "每4-6周监测"
              },
              "special_considerations": {
                "pregnancy": {
                  "dose_increase": "30-50%",
                  "target_TSH": "<2.5 mIU/L"
                },
                "drug_interactions": [
                  "钙剂",
                  "铁剂", 
                  "质子泵抑制剂",
                  "咖啡"
                ]
              }
            }
          }
        },
        {
          "id": "THY_003",
          "name": "甲状腺结节",
          "name_en": "Thyroid Nodule",
          "type": "disease",
          "category": "甲状腺疾病",
          "description": "甲状腺内可触及的与周围组织有差别的局限性肿块",
          "prevalence": "触诊4-7%，超声20-76%",
          "malignancy_risk": "5-15%",
          "classification": {
            "by_function": {
              "hot_nodule": "功能自主性结节，恶性率<1%",
              "warm_nodule": "功能正常结节",
              "cold_nodule": "功能减退结节，需排除恶性"
            },
            "by_ultrasound": {
              "solid_nodule": "实性结节",
              "cystic_nodule": "囊性结节",
              "mixed_nodule": "混合性结节"
            }
          },
          "risk_stratification": {
            "high_risk_features": [
              "男性",
              "<20岁或>70岁",
              "既往头颈部放射史",
              "家族史(甲状腺癌/MEN综合征)",
              "声音嘶哑",
              "淋巴结肿大"
            ],
            "ultrasound_suspicious_features": [
              "实性低回声",
              "微钙化",
              "边界不清",
              "纵横比>1",
              "血流丰富"
            ]
          },
          "diagnostic_workup": {
            "initial_evaluation": [
              "详细病史询问",
              "体格检查",
              "TSH检测",
              "颈部超声"
            ],
            "fine_needle_aspiration": {
              "indications": {
                "solid_nodule": "> 1cm有可疑特征",
                "mixed_nodule": "> 1.5cm",
                "cystic_nodule": "> 2cm"
              },
              "bethesda_system": {
                "I": "非诊断性/不满意",
                "II": "良性",
                "III": "意义不明的非典型",
                "IV": "滤泡性肿瘤/可疑滤泡性肿瘤", 
                "V": "可疑恶性",
                "VI": "恶性"
              }
            }
          },
          "management_algorithm": {
            "benign_nodules": {
              "follow_up": "6-18个月超声随访",
              "growth_criteria": "体积增加>50%或直径增加>2mm",
              "intervention": "症状性或美容考虑时手术"
            },
            "malignant_nodules": {
              "surgical_options": [
                "甲状腺全切除",
                "甲状腺腺叶切除",
                "颈部淋巴结清扫"
              ],
              "postoperative": [
                "病理确认",
                "TSH抑制治疗",
                "放射性碘治疗",
                "定期随访"
              ]
            }
          }
        },
        {
          "id": "THY_004",
          "name": "亚临床甲状腺功能异常",
          "name_en": "Subclinical Thyroid Dysfunction",
          "type": "disease",
          "category": "甲状腺疾病",
          "description": "甲状腺激素水平正常但TSH异常的状态，包括亚临床甲亢和亚临床甲减",
          "subtypes": {
            "subclinical_hyperthyroidism": {
              "definition": "TSH < 0.1 mIU/L，FT4、FT3正常",
              "prevalence": "0.7-1.2%",
              "risks": ["心房颤动", "骨质疏松", "全因死亡率增加"],
              "treatment_threshold": "年龄>65岁或有心血管疾病"
            },
            "subclinical_hypothyroidism": {
              "definition": "TSH 4.5-10.0 mIU/L，FT4正常",
              "prevalence": "4-10%",
              "risks": ["冠心病", "心力衰竭", "认知功能下降"],
              "treatment_threshold": "TSH>10 mIU/L或有症状"
            }
          }
        },
        {
          "id": "THY_005", 
          "name": "甲状腺癌",
          "name_en": "Thyroid Cancer",
          "type": "neoplasm",
          "category": "甲状腺疾病",
          "description": "起源于甲状腺滤泡细胞或滤泡旁细胞的恶性肿瘤",
          "histological_types": {
            "papillary": {
              "percentage": "80-85%",
              "prognosis": "良好",
              "characteristics": "生长缓慢，淋巴结转移常见"
            },
            "follicular": {
              "percentage": "10-15%", 
              "prognosis": "较好",
              "characteristics": "血行转移，不摄碘区域多见"
            },
            "medullary": {
              "percentage": "3-5%",
              "prognosis": "中等",
              "characteristics": "降钙素分泌，遗传性多见"
            },
            "anaplastic": {
              "percentage": "<2%",
              "prognosis": "极差",
              "characteristics": "快速生长，预后极差"
            }
          },
          "risk_factors": [
            "电离辐射史",
            "碘缺乏或过量", 
            "遗传因素",
            "性别(女性)",
            "既往甲状腺疾病"
          ],
          "staging_tnm": {
            "T1": "≤2cm，限于甲状腺",
            "T2": "2-4cm，限于甲状腺", 
            "T3": ">4cm或轻微甲状腺外侵犯",
            "T4": "广泛甲状腺外侵犯",
            "N1": "淋巴结转移",
            "M1": "远处转移"
          },
          "treatment_approach": {
            "surgery": {
              "total_thyroidectomy": "肿瘤>4cm或多灶性",
              "lobectomy": "单发<4cm，无高危因素",
              "lymph_node_dissection": "临床阳性淋巴结"
            },
            "radioactive_iodine": {
              "indications": ["中高危患者", "甲状腺全切后"],
              "dose": "30-150 mCi",
              "preparation": "TSH>30 mIU/L"
            },
            "tsh_suppression": {
              "target": "TSH 0.1-0.5 mIU/L(高危)或0.1-2.0(低危)",
              "duration": "终生",
              "monitoring": "甲功、心脏、骨密度"
            },
            "follow_up": {
              "thyroglobulin": "术后肿瘤标志物",
              "neck_ultrasound": "每6-12个月",
              "whole_body_scan": "必要时"
            }
          }
        }
      ],

      "diabetes_entities": [
        {
          "id": "DM_001",
          "name": "2型糖尿病",
          "name_en": "Type 2 Diabetes Mellitus",
          "type": "disease",
          "category": "代谢性疾病",
          "icd10": "E11",
          "description": "以胰岛素抵抗和胰岛β细胞功能进行性衰减为特征的慢性代谢性疾病",
          "epidemiology": {
            "global_prevalence": "9.3%（成人）",
            "china_prevalence": "11.2%（成人）",
            "incidence_trend": "持续上升，与肥胖和老龄化相关",
            "gender_distribution": "男性略高于女性",
            "age_pattern": "40岁后显著增加，但年轻化趋势明显"
          },
          "pathophysiology": {
            "insulin_resistance": {
              "primary_sites": ["肝脏", "骨骼肌", "脂肪组织"],
              "mechanisms": [
                "胰岛素受体后信号传导缺陷",
                "葡萄糖转运蛋白功能异常",
                "炎症因子介导的信号干扰",
                "脂肪细胞因子失调"
              ],
              "compensatory_response": "早期β细胞代偿性胰岛素分泌增加"
            },
            "beta_cell_dysfunction": {
              "progressive_decline": "β细胞功能年下降率4-5%",
              "mechanisms": [
                "葡萄糖毒性",
                "脂毒性",
                "氧化应激",
                "内质网应激",
                "淀粉样蛋白沉积"
              ],
              "insulin_secretion_defects": [
                "第一时相胰岛素分泌缺失",
                "胰岛素脉冲性分泌异常",
                "葡萄糖敏感性下降"
              ]
            },
            "incretin_system_defects": {
              "glp1_reduction": "GLP-1分泌减少和作用减弱",
              "dpp4_activity": "DPP-4活性可能增加",
              "incretins_effect": "肠促胰素效应受损"
            },
            "genetic_factors": {
              "heritability": "遗传度约26%",
              "major_genes": [
                "TCF7L2（转录因子7样2）",
                "PPARG（过氧化物酶体增殖物激活受体γ）",
                "KCNJ11（钾离子通道基因）",
                "CDKAL1（CDK5调节亚单位相关蛋白1样1）",
                "IGF2BP2（胰岛素样生长因子2 mRNA结合蛋白2）"
              ],
              "polygenic_risk": "多基因累积效应"
            }
          },
          "risk_factors": {
            "modifiable": {
              "obesity": {
                "central_obesity": "腹型肥胖风险最高",
                "bmi_threshold": "亚洲人群≥23 kg/m²开始增加风险",
                "mechanism": "脂肪组织炎症和胰岛素抵抗"
              },
              "physical_inactivity": {
                "sedentary_lifestyle": "久坐生活方式",
                "exercise_deficiency": "缺乏规律体力活动",
                "muscle_mass_decline": "肌肉量减少影响葡萄糖利用"
              },
              "dietary_factors": {
                "high_glycemic_diet": "高血糖指数饮食",
                "processed_foods": "过度加工食品",
                "sugar_sweetened_beverages": "含糖饮料",
                "saturated_fat": "饱和脂肪酸过多",
                "fiber_deficiency": "膳食纤维不足"
              },
              "smoking": {
                "active_smoking": "主动吸烟增加风险30-40%",
                "dose_response": "吸烟量与糖尿病风险呈正相关"
              },
              "sleep_disorders": {
                "sleep_deprivation": "睡眠不足<6小时",
                "sleep_apnea": "阻塞性睡眠呼吸暂停",
                "circadian_disruption": "昼夜节律紊乱"
              }
            },
            "non_modifiable": {
              "age": "每增加10岁风险增加1.5-2倍",
              "family_history": {
                "first_degree_relative": "一级亲属患病风险增加2-3倍",
                "parental_diabetes": "父母患病风险增加40%"
              },
              "ethnicity": {
                "high_risk_populations": [
                  "亚洲人群",
                  "西班牙裔",
                  "非洲裔",
                  "美洲原住民"
                ],
                "asian_specificity": "相同BMI下亚洲人风险更高"
              },
              "gestational_diabetes_history": "GDM史增加7倍风险",
              "polycystic_ovary_syndrome": "PCOS女性风险增加5-10倍"
            }
          },
          "clinical_presentation": {
            "classic_symptoms": {
              "polyuria": {
                "description": "多尿，每日>3L",
                "mechanism": "高血糖导致渗透性利尿",
                "severity": "血糖越高症状越明显"
              },
              "polydipsia": {
                "description": "烦渴多饮",
                "mechanism": "失水激活下丘脑渴觉中枢",
                "characteristic": "饮水量增加但仍感口渴"
              },
              "polyphagia": {
                "description": "多食易饥",
                "mechanism": "细胞内葡萄糖利用障碍",
                "paradox": "食量增加但体重可能下降"
              },
              "unexplained_weight_loss": {
                "description": "不明原因体重下降",
                "mechanism": "蛋白质和脂肪分解增加",
                "threshold": "3个月内体重下降>5%"
              }
            },
            "atypical_presentations": {
              "asymptomatic": "多数2型糖尿病患者早期无症状",
              "fatigue": "乏力和精力不足",
              "blurred_vision": "视物模糊",
              "recurrent_infections": {
                "types": ["皮肤感染", "尿路感染", "阴道炎"],
                "mechanism": "高血糖环境利于细菌繁殖"
              },
              "slow_wound_healing": "伤口愈合延迟",
              "peripheral_neuropathy": "手足麻木或疼痛",
              "erectile_dysfunction": "男性勃起功能障碍"
            },
            "physical_examination": {
              "anthropometric": {
                "weight_status": "超重或肥胖（85%患者）",
                "waist_circumference": "中心性肥胖",
                "body_fat_distribution": "内脏脂肪增加"
              },
              "skin_changes": {
                "acanthosis_nigricans": "黑棘皮症，胰岛素抵抗标志",
                "skin_tags": "皮赘增多",
                "diabetic_dermopathy": "糖尿病性皮肤病变"
              },
              "cardiovascular": {
                "blood_pressure": "高血压（60-70%患者合并）",
                "heart_rate": "静息心率可能增快"
              }
            }
          },
          "diagnosis": {
            "diagnostic_criteria": {
              "fasting_plasma_glucose": {
                "threshold": "≥7.0 mmol/L (126 mg/dL)",
                "definition": "空腹8小时以上",
                "confirmation": "需要重复测定确认"
              },
              "oral_glucose_tolerance_test": {
                "2h_glucose": "≥11.1 mmol/L (200 mg/dL)",
                "protocol": "75g葡萄糖负荷后2小时血糖",
                "preparation": "前3天正常饮食，空腹8-14小时"
              },
              "hba1c": {
                "threshold": "≥6.5% (48 mmol/mol)",
                "advantages": ["无需空腹", "变异性小", "反映长期血糖"],
                "limitations": ["某些血红蛋白病", "肾病晚期", "妊娠期不适用"]
              },
              "random_plasma_glucose": {
                "threshold": "≥11.1 mmol/L (200 mg/dL) + 症状",
                "indication": "有典型高血糖症状时",
                "confirmation": "需要其他方法确认"
              }
            },
            "screening_recommendations": {
              "general_population": {
                "age_threshold": "≥35岁开始筛查",
                "interval": "正常者每3年1次",
                "high_risk": "每年筛查"
              },
              "high_risk_criteria": [
                "BMI≥24 kg/m²（亚洲人群）",
                "一级亲属糖尿病史",
                "高血压（≥140/90 mmHg）",
                "HDL-C<0.9 mmol/L或TG>2.22 mmol/L",
                "PCOS",
                "IGT或IFG史",
                "心血管疾病史",
                "久坐生活方式"
              ]
            },
            "differential_diagnosis": {
              "type1_diabetes": {
                "distinguishing_features": [
                  "年龄：T1DM多见于儿童青少年",
                  "起病：T1DM急性起病，T2DM缓慢起病",
                  "体型：T1DM多正常或消瘦，T2DM多超重肥胖",
                  "酮症：T1DM易发生，T2DM少见",
                  "胰岛素依赖：T1DM绝对依赖，T2DM相对缺乏"
                ],
                "辅助检查": [
                  "C肽水平：T1DM低，T2DM正常或高",
                  "自身抗体：T1DM阳性，T2DM阴性"
                ]
              },
              "mody": "年轻起病，家族史明显，非肥胖",
              "secondary_diabetes": {
                "pancreatic_diabetes": "胰腺疾病史，外分泌功能不全",
                "drug_induced": "糖皮质激素等药物使用史",
                "endocrine_diabetes": "其他内分泌疾病导致"
              }
            }
          },
          "classification_subtypes": {
            "insulin_deficient": {
              "description": "以胰岛素缺乏为主",
              "characteristics": "C肽水平低，BMI正常，易发酮症",
              "treatment": "早期需要胰岛素治疗"
            },
            "insulin_resistant": {
              "description": "以胰岛素抵抗为主",
              "characteristics": "C肽水平高，肥胖，代谢综合征",
              "treatment": "胰岛素增敏剂优先"
            }
          }
        },
        {
          "id": "DM_002", 
          "name": "妊娠期糖尿病",
          "name_en": "Gestational Diabetes Mellitus",
          "type": "disease",
          "category": "代谢性疾病",
          "icd10": "O24.4",
          "description": "妊娠期间首次发现或发病的糖耐量异常",
          "epidemiology": {
            "global_prevalence": "1-14%（因诊断标准而异）",
            "china_prevalence": "17.5%（2019年全国调查）",
            "trend": "发病率持续上升",
            "risk_factors_prevalence": "高龄妊娠、肥胖增加"
          },
          "pathophysiology": {
            "hormonal_changes": {
              "insulin_resistance": "妊娠期胰岛素敏感性下降50-60%",
              "placental_hormones": [
                "人胎盘泌乳素（hPL）",
                "雌激素",
                "孕激素",
                "皮质醇",
                "胎盘胰岛素酶"
              ],
              "progressive_nature": "孕周增加胰岛素抵抗加重"
            },
            "beta_cell_adaptation": {
              "normal_pregnancy": "β细胞代偿性增生和功能增强",
              "gdm_pathogenesis": "β细胞代偿不足导致高血糖"
            }
          },
          "risk_factors": {
            "major_risk_factors": [
              "年龄≥35岁",
              "孕前BMI≥24 kg/m²",
              "糖尿病家族史（一级亲属）",
              "既往GDM史",
              "既往不良孕产史（巨大儿、死胎、多胎畸形）",
              "多囊卵巢综合征",
              "孕期体重增加过多"
            ],
            "minor_risk_factors": [
              "高血压",
              "高龄初产",
              "反复流产史",
              "羊水过多"
            ]
          },
          "screening_diagnosis": {
            "screening_timing": {
              "first_screening": "孕24-28周（最佳时间）",
              "early_screening": {
                "indications": "高危因素存在",
                "timing": "孕早期（<20周）",
                "method": "空腹血糖或HbA1c"
              }
            },
            "diagnostic_tests": {
              "75g_ogtt": {
                "standard_protocol": {
                  "preparation": "正常饮食3天，空腹8-14小时",
                  "glucose_load": "75g无水葡萄糖溶于300ml水中",
                  "sampling_times": ["0分钟", "60分钟", "120分钟"]
                },
                "iadpsg_criteria": {
                  "fasting": "≥5.1 mmol/L (92 mg/dL)",
                  "1_hour": "≥10.0 mmol/L (180 mg/dL)",
                  "2_hour": "≥8.5 mmol/L (153 mg/dL)",
                  "diagnostic_threshold": "任何一项异常即可诊断"
                }
              },
              "alternative_screening": {
                "50g_gct": "50g葡萄糖激发试验（筛查用）",
                "threshold": "1小时血糖≥7.8 mmol/L需进一步OGTT"
              }
            }
          },
          "management": {
            "glucose_targets": {
              "fasting": "<5.3 mmol/L (95 mg/dL)",
              "1h_postprandial": "<7.8 mmol/L (140 mg/dL)",
              "2h_postprandial": "<6.7 mmol/L (120 mg/dL)",
              "bedtime": "5.0-6.7 mmol/L"
            },
            "lifestyle_intervention": {
              "medical_nutrition_therapy": {
                "caloric_intake": "25-35 kcal/kg孕前体重/日",
                "carbohydrate": "复合碳水化合物，40-50%总热量",
                "protein": "20%总热量",
                "fat": "25-30%总热量",
                "meal_distribution": "三大餐+2-3次加餐"
              },
              "physical_activity": {
                "recommendation": "中等强度有氧运动",
                "duration": "30分钟/日，每周至少5天",
                "types": ["快走", "游泳", "孕妇瑜伽"],
                "contraindications": "妊娠并发症时禁止"
              }
            },
            "pharmacological_treatment": {
              "insulin_therapy": {
                "indications": [
                  "生活方式干预1-2周血糖不达标",
                  "空腹血糖>5.8 mmol/L",
                  "餐后2小时血糖>6.7 mmol/L"
                ],
                "preferred_insulin": "中效或长效胰岛素+速效胰岛素",
                "regimens": [
                  "每日2次预混胰岛素",
                  "基础-餐时胰岛素方案"
                ],
                "dosage": "0.7-1.0 U/kg孕前体重/日起始"
              },
              "oral_medications": {
                "metformin": "部分指南允许使用，需权衡利弊",
                "sulfonylureas": "格列本脲，二线选择",
                "contraindicated": "其他降糖药物孕期禁用"
              }
            }
          },
          "maternal_complications": {
            "pregnancy_complications": [
              "妊娠期高血压疾病",
              "羊水过多",
              "早产",
              "胎膜早破",
              "泌尿系感染"
            ],
            "delivery_complications": [
              "巨大儿导致难产",
              "肩难产",
              "产伤",
              "剖宫产率增加"
            ],
            "long_term_risks": [
              "产后2型糖尿病风险增加7倍",
              "心血管疾病风险增加",
              "代谢综合征",
              "再次妊娠GDM复发率30-70%"
            ]
          },
          "fetal_neonatal_complications": {
            "macrosomia": {
              "definition": "出生体重≥4000g",
              "mechanism": "胎儿高胰岛素血症促进生长",
              "complications": ["肩难产", "产伤", "剖宫产"]
            },
            "neonatal_complications": [
              "新生儿低血糖",
              "新生儿呼吸窘迫综合征",
              "新生儿高胆红素血症",
              "新生儿低钙血症",
              "新生儿红细胞增多症"
            ],
            "long_term_offspring_risks": [
              "儿童期肥胖风险增加",
              "青春期代谢综合征",
              "成年期2型糖尿病风险增加"
            ]
          },
          "delivery_management": {
            "timing": {
              "spontaneous_labor": "血糖控制良好可等待自然分娩",
              "induction": "孕39-40周考虑引产",
              "cesarean_section": "血糖控制不良或胎儿过大"
            },
            "peripartum_glucose_management": {
              "labor_monitoring": "每1-2小时监测血糖",
              "target_range": "4.0-7.0 mmol/L",
              "insulin_adjustment": "根据血糖调整胰岛素剂量"
            }
          },
          "postpartum_follow_up": {
            "immediate_postpartum": {
              "insulin_discontinuation": "产后立即停用胰岛素",
              "glucose_monitoring": "监测血糖变化",
              "breastfeeding": "鼓励母乳喂养"
            },
            "long_term_follow_up": {
              "diabetes_screening": {
                "timing": "产后6-12周",
                "method": "75g OGTT或FPG",
                "frequency": "每1-3年筛查一次"
              },
              "lifestyle_counseling": [
                "体重管理",
                "健康饮食",
                "规律运动",
                "戒烟限酒"
              ],
              "family_planning": "再次妊娠前咨询评估"
            }
          }
        },
        {
          "id": "DM_003",
          "name": "成人起病的青年型糖尿病",
          "name_en": "Maturity-Onset Diabetes of the Young (MODY)",
          "type": "disease",
          "category": "遗传性糖尿病",
          "icd10": "E11",
          "description": "由单基因缺陷引起的常染色体显性遗传性糖尿病",
          "epidemiology": {
            "prevalence": "糖尿病患者中1-5%",
            "age_onset": "通常25岁前起病",
            "family_pattern": "连续三代患病的强烈家族史",
            "geographic_distribution": "全球性分布，各种族均可发生"
          },
          "genetic_classification": {
            "MODY1": {
              "gene": "HNF4A（肝细胞核因子4α）",
              "chromosome": "20q13",
              "prevalence": "MODY中<5%",
              "characteristics": [
                "β细胞功能进行性衰减",
                "对磺脲类药物敏感",
                "可能有大血管病变"
              ]
            },
            "MODY2": {
              "gene": "GCK（葡萄糖激酶）",
              "chromosome": "7p13",
              "prevalence": "MODY中30-70%",
              "characteristics": [
                "轻度持续性高血糖",
                "通常不需要药物治疗",
                "并发症风险低",
                "妊娠期需要监测"
              ]
            },
            "MODY3": {
              "gene": "HNF1A（肝细胞核因子1α）",
              "chromosome": "12q24",
              "prevalence": "MODY中30-65%",
              "characteristics": [
                "对磺脲类药物极其敏感",
                "进行性β细胞功能衰减",
                "糖尿病并发症风险中等"
              ]
            },
            "MODY4": {
              "gene": "IPF1/PDX1",
              "chromosome": "13q12",
              "prevalence": "MODY中<1%",
              "characteristics": [
                "胰腺发育异常",
                "严重β细胞功能缺陷",
                "需要胰岛素治疗"
              ]
            },
            "MODY5": {
              "gene": "HNF1B（肝细胞核因子1β）",
              "chromosome": "17cen-q21.3",
              "prevalence": "MODY中5%",
              "characteristics": [
                "肾脏发育异常",
                "泌尿生殖系统异常",
                "胰腺萎缩"
              ]
            }
          },
          "clinical_features": {
            "age_onset": "通常<25岁，但可延迟至成年",
            "family_history": "强烈的家族史，常染色体显性遗传",
            "obesity": "通常体重正常或轻度超重",
            "autoantibodies": "自身抗体阴性",
            "c_peptide": "保存或轻度减少（MODY2除外）"
          },
          "diagnosis": {
            "clinical_criteria": [
              "糖尿病发病年龄≤25岁",
              "强烈的家族史（至少连续两代）",
              "非胰岛素依赖至少2年",
              "自身抗体阴性"
            ],
            "genetic_testing": {
              "indications": [
                "符合临床诊断标准",
                "需要确定亚型",
                "家族遗传咨询需求"
              ],
              "testing_priority": [
                "HNF1A（MODY3）- 最常见",
                "GCK（MODY2）- 轻症",
                "HNF4A（MODY1）- 药物敏感性"
              ]
            },
            "differential_diagnosis": [
              "1型糖尿病",
              "2型糖尿病",
              "继发性糖尿病",
              "新生儿糖尿病"
            ]
          },
          "treatment": {
            "MODY1_treatment": {
              "first_line": "磺脲类药物",
              "second_line": "胰岛素",
              "monitoring": "心血管风险"
            },
            "MODY2_treatment": {
              "general": "通常无需药物治疗",
              "lifestyle": "饮食和运动管理",
              "pregnancy": "妊娠期可能需要胰岛素"
            },
            "MODY3_treatment": {
              "first_line": "低剂量磺脲类药物",
              "characteristics": "对磺脲类极其敏感",
              "progression": "随病程进展可能需要胰岛素"
            },
            "general_principles": {
              "individualized": "根据基因型个体化治疗",
              "family_screening": "家族成员筛查",
              "genetic_counseling": "遗传咨询"
            }
          }
        },
        {
          "id": "DM_004",
          "name": "成人隐匿性自身免疫性糖尿病",
          "name_en": "Latent Autoimmune Diabetes in Adults (LADA)",
          "type": "disease",
          "category": "自身免疫性糖尿病",
          "icd10": "E10",
          "description": "成年发病的缓慢进展性自身免疫性糖尿病，介于1型和2型糖尿病之间",
          "epidemiology": {
            "prevalence": "成人糖尿病患者中2-12%",
            "age_onset": "通常>30岁",
            "geographic_variation": "北欧人群患病率较高",
            "misdiagnosis_rate": "常被误诊为2型糖尿病"
          },
          "pathophysiology": {
            "autoimmune_process": {
              "mechanism": "自身免疫介导的β细胞破坏",
              "progression": "比1型糖尿病缓慢",
              "autoantibodies": [
                "GAD抗体（最常见）",
                "IA-2抗体",
                "ZnT8抗体",
                "ICA抗体"
              ]
            },
            "beta_cell_function": {
              "initial": "部分保存",
              "progression": "缓慢进行性衰减",
              "c_peptide": "早期可检测，逐渐下降"
            },
            "genetic_susceptibility": {
              "hla_association": "HLA-DR3、HLA-DR4相关",
              "risk_genes": "与1型糖尿病相似的遗传背景"
            }
          },
          "clinical_features": {
            "presentation": {
              "symptoms": "通常症状较轻，类似2型糖尿病",
              "ketosis": "很少发生糖尿病酮症酸中毒",
              "weight": "通常体重正常或轻度超重"
            },
            "distinctive_features": [
              "发病年龄>30岁",
              "自身抗体阳性",
              "早期无需胰岛素治疗",
              "进展相对缓慢"
            ]
          },
          "diagnosis": {
            "diagnostic_criteria": [
              "成年发病（>30岁）",
              "至少一种自身抗体阳性",
              "诊断时无需胰岛素治疗",
              "C肽水平部分保存"
            ],
            "laboratory_tests": {
              "autoantibodies": {
                "GAD_antibodies": ">95%阳性率",
                "IA2_antibodies": "50-70%阳性率",
                "ZnT8_antibodies": "60-80%阳性率"
              },
              "c_peptide": {
                "fasting": "通常>0.3 nmol/L",
                "stimulated": "餐后或刺激后检测"
              },
              "hla_typing": "辅助诊断，非必需"
            }
          },
          "treatment": {
            "initial_management": {
              "lifestyle": "饮食和运动治疗",
              "oral_antidiabetics": "可短期使用",
              "monitoring": "密切监测β细胞功能"
            },
            "insulin_therapy": {
              "timing": "通常在诊断后2-5年内需要",
              "indications": [
                "口服药物控制不佳",
                "C肽水平显著下降",
                "反复高血糖或感染"
              ],
              "regimen": "类似1型糖尿病的胰岛素治疗方案"
            },
            "novel_approaches": {
              "immunotherapy": "正在研究中",
              "beta_cell_preservation": "早期胰岛素治疗可能有益"
            }
          },
          "prognosis": {
            "progression": "5-10年内通常需要胰岛素治疗",
            "complications": "与1型糖尿病相似的并发症风险",
            "factors_affecting_progression": [
              "自身抗体滴度",
              "HLA基因型",
              "诊断时C肽水平"
            ]
          }
        },
        {
          "id": "DM_005",
          "name": "继发性糖尿病",
          "name_en": "Secondary Diabetes Mellitus",
          "type": "disease",
          "category": "继发性内分泌疾病",
          "icd10": "E13",
          "description": "由于胰腺疾病、内分泌疾病、药物或其他疾病引起的糖尿病",
          "classification": {
            "pancreatic_disease": {
              "chronic_pancreatitis": {
                "mechanism": "胰腺外分泌和内分泌功能同时受损",
                "prevalence": "慢性胰腺炎患者中80%",
                "features": [
                  "胰酶分泌不足",
                  "脂肪泻",
                  "胰岛素缺乏",
                  "胰高血糖素缺乏"
                ]
              },
              "pancreatectomy": {
                "total_pancreatectomy": "100%发生糖尿病",
                "partial_pancreatectomy": "发生率取决于切除范围",
                "characteristics": "脆性糖尿病，易发生低血糖"
              },
              "pancreatic_cancer": {
                "prevalence": "胰腺癌患者中50-80%",
                "mechanism": "胰岛β细胞破坏",
                "prognosis": "通常预后不良"
              },
              "cystic_fibrosis": {
                "prevalence": "CF患者中20-50%",
                "mechanism": "胰腺纤维化和胰岛功能受损",
                "features": "胰岛素不足为主"
              }
            },
            "endocrine_disorders": {
              "cushings_syndrome": {
                "mechanism": "皮质醇过多导致胰岛素抵抗",
                "prevalence": "库欣综合征患者中75-80%",
                "reversibility": "治疗原发病后可能改善"
              },
              "acromegaly": {
                "mechanism": "生长激素过多导致胰岛素抵抗",
                "prevalence": "肢端肥大症患者中25-50%",
                "features": "空腹血糖和餐后血糖均升高"
              },
              "pheochromocytoma": {
                "mechanism": "儿茶酚胺抑制胰岛素分泌",
                "prevalence": "嗜铬细胞瘤患者中40-50%",
                "features": "多为可逆性"
              },
              "hyperthyroidism": {
                "mechanism": "甲状腺激素增加糖异生",
                "prevalence": "甲亢患者中2-3%",
                "features": "血糖波动大"
              }
            },
            "drug_induced": {
              "corticosteroids": {
                "mechanism": "增加胰岛素抵抗和糖异生",
                "risk_factors": "剂量和使用时间相关",
                "reversibility": "停药后通常可逆"
              },
              "thiazide_diuretics": {
                "mechanism": "影响胰岛素分泌和敏感性",
                "risk": "长期使用中度风险",
                "monitoring": "需要定期监测血糖"
              },
              "atypical_antipsychotics": {
                "mechanism": "体重增加和胰岛素抵抗",
                "high_risk_drugs": [
                  "奥氮平",
                  "氯氮平",
                  "喹硫平"
                ]
              },
              "immunosuppressants": {
                "tacrolimus": "抑制胰岛素分泌",
                "cyclosporine": "增加胰岛素抵抗",
                "monitoring": "器官移植患者需密切监测"
              }
            }
          },
          "diagnosis": {
            "clinical_approach": [
              "详细病史和用药史",
              "体格检查寻找原发病证据",
              "实验室检查排除其他类型糖尿病",
              "影像学检查评估胰腺结构"
            ],
            "differential_diagnosis": [
              "1型糖尿病",
              "2型糖尿病",
              "MODY",
              "妊娠糖尿病"
            ]
          },
          "treatment": {
            "general_principles": [
              "治疗或去除潜在病因",
              "个体化血糖管理",
              "处理相关并发症",
              "长期随访监测"
            ],
            "specific_management": {
              "pancreatic_diabetes": {
                "insulin_therapy": "通常需要胰岛素治疗",
                "enzyme_replacement": "胰酶替代治疗",
                "nutritional_support": "营养支持"
              },
              "endocrine_diabetes": {
                "treat_primary_condition": "治疗原发内分泌疾病",
                "temporary_management": "血糖管理可能是暂时性的"
              },
              "drug_induced_diabetes": {
                "medication_review": "评估是否可以停药或换药",
                "dose_adjustment": "如必须继续使用，考虑剂量调整"
              }
            }
          }
        }
      ],

      "diabetes_complications": [
        {
          "id": "DM_COMP_001",
          "name": "糖尿病性视网膜病变",
          "name_en": "Diabetic Retinopathy",
          "type": "complication",
          "category": "糖尿病微血管并发症",
          "icd10": "E10.3",
          "description": "糖尿病引起的视网膜微血管病变，是糖尿病患者失明的主要原因",
          "epidemiology": {
            "prevalence": "1型糖尿病患者中90%，2型糖尿病患者中60%",
            "incidence": "每年新发病率2-6%",
            "blindness_risk": "糖尿病患者失明风险比正常人高25倍"
          },
          "pathophysiology": {
            "hyperglycemia_damage": {
              "mechanism": "高血糖导致视网膜毛细血管内皮损伤",
              "biochemical_pathways": [
                "多元醇途径激活",
                "蛋白质糖化",
                "蛋白激酶C激活",
                "己糖胺途径",
                "氧化应激"
              ]
            },
            "vascular_changes": {
              "early_changes": [
                "毛细血管基底膜增厚",
                "周细胞缺失",
                "血管通透性增加"
              ],
              "progressive_changes": [
                "毛细血管闭塞",
                "视网膜缺血",
                "新生血管形成"
              ]
            }
          },
          "classification": {
            "non_proliferative_diabetic_retinopathy": {
              "mild": {
                "features": "微动脉瘤≥1个",
                "vision_impact": "通常无症状"
              },
              "moderate": {
                "features": [
                  "微动脉瘤",
                  "点片状出血",
                  "硬性渗出",
                  "棉絮斑<20个"
                ],
                "vision_impact": "可能轻度视力影响"
              },
              "severe": {
                "features": [
                  "广泛视网膜出血（4个象限）",
                  "静脉串珠样改变（2个象限）",
                  "明显视网膜内微血管异常（1个象限）"
                ],
                "progression_risk": "1年内15%进展为PDR"
              }
            },
            "proliferative_diabetic_retinopathy": {
              "features": [
                "视盘新生血管",
                "视网膜其他部位新生血管",
                "纤维血管增殖"
              ],
              "complications": [
                "玻璃体出血",
                "牵拉性视网膜脱离",
                "新生血管性青光眼"
              ]
            },
            "diabetic_macular_edema": {
              "definition": "黄斑中心1mm内视网膜增厚",
              "prevalence": "糖尿病患者中6.8%",
              "vision_threat": "导致中心视力下降的主要原因"
            }
          },
          "risk_factors": {
            "modifiable": [
              "血糖控制不佳",
              "高血压",
              "血脂异常",
              "吸烟",
              "妊娠"
            ],
            "non_modifiable": [
              "糖尿病病程",
              "遗传因素",
              "种族（非洲裔、西班牙裔风险高）"
            ]
          },
          "screening_guidelines": {
            "type1_diabetes": "诊断5年后开始每年筛查",
            "type2_diabetes": "诊断时即开始每年筛查",
            "pregnancy": "妊娠前和每个三个月筛查",
            "screening_methods": [
              "散瞳眼底检查",
              "眼底照相",
              "光学相干断层扫描（OCT）",
              "荧光素眼底血管造影（必要时）"
            ]
          },
          "treatment": {
            "preventive_measures": {
              "glycemic_control": "HbA1c <7%",
              "blood_pressure_control": "<140/90 mmHg",
              "lipid_management": "LDL-C <2.6 mmol/L"
            },
            "non_proliferative_treatment": {
              "mild_moderate": "严密随访，优化全身治疗",
              "severe": "考虑激光光凝治疗"
            },
            "proliferative_treatment": {
              "pan_retinal_photocoagulation": "全视网膜激光光凝",
              "anti_vegf_therapy": [
                "雷珠单抗",
                "阿柏西普",
                "贝伐珠单抗"
              ],
              "vitrectomy": "严重玻璃体出血或牵拉性视网膜脱离"
            },
            "macular_edema_treatment": {
              "anti_vegf_injections": "一线治疗",
              "focal_laser": "局灶性激光光凝",
              "corticosteroids": "难治性病例"
            }
          }
        },
        {
          "id": "DM_COMP_002",
          "name": "糖尿病肾病",
          "name_en": "Diabetic Nephropathy",
          "type": "complication",
          "category": "糖尿病微血管并发症",
          "icd10": "E10.2",
          "description": "糖尿病引起的肾脏微血管病变，是终末期肾病的主要原因",
          "epidemiology": {
            "prevalence": "糖尿病患者中20-40%",
            "progression_to_esrd": "糖尿病是透析的首要原因（44%）",
            "mortality_risk": "糖尿病肾病患者心血管死亡风险增加10倍"
          },
          "pathophysiology": {
            "glomerular_changes": {
              "mesangial_expansion": "系膜基质增生",
              "basement_membrane_thickening": "肾小球基底膜增厚",
              "nodular_sclerosis": "结节性肾小球硬化（Kimmelstiel-Wilson病变）"
            },
            "tubular_interstitial_changes": {
              "tubular_atrophy": "肾小管萎缩",
              "interstitial_fibrosis": "间质纤维化",
              "inflammation": "慢性炎症反应"
            },
            "hemodynamic_changes": {
              "hyperfiltration": "早期肾小球高滤过",
              "increased_permeability": "肾小球通透性增加",
              "proteinuria": "蛋白尿形成"
            }
          },
          "staging": {
            "stage1": {
              "gfr": "≥90 mL/min/1.73m²",
              "albuminuria": "30-300 mg/g肌酐",
              "description": "肾功能正常伴微量白蛋白尿"
            },
            "stage2": {
              "gfr": "60-89 mL/min/1.73m²",
              "albuminuria": "30-300 mg/g肌酐",
              "description": "轻度肾功能下降伴微量白蛋白尿"
            },
            "stage3a": {
              "gfr": "45-59 mL/min/1.73m²",
              "description": "轻中度肾功能下降"
            },
            "stage3b": {
              "gfr": "30-44 mL/min/1.73m²",
              "description": "中重度肾功能下降"
            },
            "stage4": {
              "gfr": "15-29 mL/min/1.73m²",
              "description": "重度肾功能下降"
            },
            "stage5": {
              "gfr": "<15 mL/min/1.73m²",
              "description": "肾衰竭"
            }
          },
          "clinical_manifestations": {
            "early_stage": [
              "微量白蛋白尿",
              "肾小球高滤过",
              "通常无症状"
            ],
            "progressive_stage": [
              "大量蛋白尿",
              "水肿",
              "高血压",
              "肾功能进行性下降"
            ],
            "advanced_stage": [
              "尿毒症症状",
              "贫血",
              "骨代谢异常",
              "心血管并发症"
            ]
          },
          "screening_monitoring": {
            "frequency": "至少每年一次",
            "parameters": [
              "血清肌酐和估算GFR",
              "尿白蛋白/肌酐比值",
              "尿常规",
              "血压"
            ],
            "early_detection": "微量白蛋白尿是早期标志"
          },
          "treatment": {
            "prevention_strategies": {
              "glycemic_control": "HbA1c <7%",
              "blood_pressure_control": "<130/80 mmHg",
              "lifestyle_modifications": [
                "蛋白质摄入限制（0.8-1.0 g/kg/天）",
                "钠盐限制（<2.3g/天）",
                "戒烟",
                "体重管理"
              ]
            },
            "pharmacological_treatment": {
              "ace_inhibitors_arbs": {
                "first_line": "ACEI或ARB",
                "renoprotective_effect": "延缓肾功能下降",
                "target_bp": "<130/80 mmHg"
              },
              "sglt2_inhibitors": {
                "cardio_renal_benefits": "心肾获益明确",
                "indications": "eGFR ≥30 mL/min/1.73m²"
              },
              "mineralocorticoid_antagonists": {
                "indications": "ACE/ARB基础上仍有蛋白尿",
                "monitoring": "注意高钾血症"
              }
            },
            "advanced_stage_management": {
              "mineral_bone_disorders": "磷结合剂、维生素D类似物",
              "anemia": "促红细胞生成素、铁剂",
              "renal_replacement_therapy": {
                "timing": "GFR <15 mL/min/1.73m²或症状性尿毒症",
                "options": [
                  "血液透析",
                  "腹膜透析",
                  "肾移植"
                ]
              }
            }
          }
        },
        {
          "id": "DM_COMP_003",
          "name": "糖尿病神经病变",
          "name_en": "Diabetic Neuropathy",
          "type": "complication",
          "category": "糖尿病微血管并发症",
          "icd10": "E10.4",
          "description": "糖尿病引起的周围神经系统病变，包括感觉、运动和自主神经功能异常",
          "epidemiology": {
            "prevalence": "糖尿病患者中50%",
            "type2_diabetes": "诊断时即有10-18%",
            "progression": "与糖尿病病程和血糖控制相关"
          },
          "pathophysiology": {
            "metabolic_mechanisms": [
              "葡萄糖毒性",
              "多元醇途径激活",
              "高级糖化终末产物（AGEs）",
              "氧化应激",
              "蛋白激酶C激活"
            ],
            "vascular_mechanisms": [
              "神经内膜血管病变",
              "血神经屏障破坏",
              "神经缺血"
            ],
            "inflammatory_mechanisms": [
              "炎症介质激活",
              "免疫介导损伤",
              "神经胶质细胞激活"
            ]
          },
          "classification": {
            "distal_symmetric_polyneuropathy": {
              "prevalence": "最常见类型（90%）",
              "distribution": "袜套样分布",
              "symptoms": [
                "麻木",
                "疼痛",
                "烧灼感",
                "刺痛"
              ],
              "progression": "由远端向近端进展"
            },
            "autonomic_neuropathy": {
              "cardiovascular": {
                "resting_tachycardia": "静息心动过速",
                "orthostatic_hypotension": "体位性低血压",
                "sudden_death": "心源性猝死风险增加"
              },
              "gastrointestinal": {
                "gastroparesis": "胃轻瘫",
                "constipation": "便秘",
                "diarrhea": "腹泻"
              },
              "genitourinary": {
                "neurogenic_bladder": "神经源性膀胱",
                "erectile_dysfunction": "勃起功能障碍",
                "retrograde_ejaculation": "逆行射精"
              },
              "sudomotor": {
                "anhidrosis": "无汗症",
                "gustatory_sweating": "味觉性出汗"
              }
            },
            "focal_neuropathies": {
              "carpal_tunnel_syndrome": "腕管综合征",
              "ulnar_neuropathy": "尺神经病变",
              "peroneal_neuropathy": "腓神经病变",
              "cranial_neuropathies": "颅神经病变"
            },
            "proximal_neuropathy": {
              "characteristics": "大腿前侧疼痛和无力",
              "recovery": "通常可自行恢复",
              "also_known_as": "糖尿病性肌萎缩"
            }
          },
          "clinical_assessment": {
            "symptoms": [
              "疼痛（烧灼痛、刺痛、电击痛）",
              "麻木和感觉异常",
              "运动无力",
              "平衡障碍"
            ],
            "physical_examination": [
              "振动觉检查",
              "位置觉检查",
              "针刺觉检查",
              "温度觉检查",
              "深反射检查"
            ],
            "objective_tests": [
              "10g单纤维检查",
              "音叉振动觉检查",
              "神经传导检查",
              "定量感觉检查"
            ]
          },
          "complications": {
            "diabetic_foot": {
              "neuropathic_foot": "感觉缺失导致溃疡",
              "charcot_foot": "神经性关节病",
              "infection_risk": "感染风险增加"
            },
            "fall_risk": "平衡障碍增加跌倒风险",
            "quality_of_life": "疼痛影响生活质量"
          },
          "treatment": {
            "prevention": {
              "glycemic_control": "严格血糖控制",
              "lifestyle_modifications": "戒烟、限酒、规律运动"
            },
            "symptomatic_treatment": {
              "neuropathic_pain": {
                "first_line": [
                  "加巴喷丁",
                  "普瑞巴林",
                  "度洛西汀"
                ],
                "second_line": [
                  "三环类抗抑郁药",
                  "局部利多卡因",
                  "曲马多"
                ],
                "third_line": [
                  "阿片类药物",
                  "肉毒毒素注射"
                ]
              }
            },
            "disease_modifying_treatments": {
              "alpha_lipoic_acid": "抗氧化治疗",
              "aldose_reductase_inhibitors": "研究中",
              "nerve_growth_factors": "实验性治疗"
            }
          }
        },
        {
          "id": "DM_COMP_004",
          "name": "糖尿病大血管病变",
          "name_en": "Diabetic Macrovascular Disease",
          "type": "complication",
          "category": "糖尿病大血管并发症",
          "icd10": "E10.5",
          "description": "糖尿病引起的大血管动脉粥样硬化病变，包括冠心病、脑血管病和外周血管病",
          "epidemiology": {
            "mortality": "糖尿病患者68%死于心血管疾病",
            "coronary_artery_disease": "发病率比非糖尿病患者高2-4倍",
            "stroke_risk": "卒中风险增加1.5-3倍",
            "peripheral_artery_disease": "外周血管病风险增加2倍"
          },
          "pathophysiology": {
            "accelerated_atherosclerosis": {
              "mechanisms": [
                "内皮功能紊乱",
                "炎症反应增强",
                "凝血功能异常",
                "脂质代谢紊乱"
              ]
            },
            "hyperglycemia_effects": [
              "血管内皮损伤",
              "糖化终末产物形成",
              "氧化应激增加",
              "血小板功能亢进"
            ]
          },
          "clinical_manifestations": {
            "coronary_artery_disease": {
              "presentation": "可能无症状或不典型症状",
              "complications": [
                "心肌梗死",
                "心力衰竭",
                "心律失常",
                "猝死"
              ]
            },
            "cerebrovascular_disease": {
              "types": [
                "缺血性卒中",
                "出血性卒中",
                "短暂性脑缺血发作"
              ],
              "consequences": [
                "认知功能障碍",
                "血管性痴呆",
                "肢体功能障碍"
              ]
            },
            "peripheral_artery_disease": {
              "symptoms": [
                "间歇性跛行",
                "静息痛",
                "肢体缺血",
                "溃疡不愈合"
              ],
              "severity": "糖尿病患者更易发生严重缺血"
            }
          },
          "risk_assessment": {
            "cardiovascular_risk_factors": [
              "年龄（男性>45岁，女性>55岁）",
              "糖尿病病程>10年",
              "高血压",
              "血脂异常",
              "吸烟",
              "家族史",
              "肥胖",
              "蛋白尿"
            ],
            "risk_stratification": {
              "very_high_risk": "已有心血管疾病或靶器官损伤",
              "high_risk": "多个危险因素",
              "moderate_risk": "少数危险因素"
            }
          },
          "prevention_treatment": {
            "primary_prevention": {
              "glycemic_control": "HbA1c <7%",
              "blood_pressure_management": "<130/80 mmHg",
              "lipid_management": {
                "ldl_target": "<2.6 mmol/L（高危）或<1.8 mmol/L（极高危）",
                "statin_therapy": "中等强度他汀类药物"
              },
              "antiplatelet_therapy": "低剂量阿司匹林（血出血风险低）",
              "lifestyle_modifications": [
                "戒烟",
                "健康饮食",
                "规律运动",
                "体重控制"
              ]
            },
            "secondary_prevention": {
              "dual_antiplatelet": "急性冠脉综合征后双联抗血小板",
              "ace_inhibitors_arbs": "ACEI/ARB治疗",
              "beta_blockers": "β受体阻滞剂",
              "high_intensity_statins": "高强度他汀类药物",
              "diabetes_medications": {
                "sglt2_inhibitors": "心血管获益明确",
                "glp1_agonists": "心血管保护作用"
              }
            }
          }
        }
      ],

      "diabetes_medications": [
        {
          "id": "DM_MED_001",
          "name": "二甲双胍",
          "name_en": "Metformin",
          "type": "medication",
          "category": "双胍类降糖药",
          "atc_code": "A10BA02",
          "description": "通过减少肝糖生成和改善胰岛素敏感性降低血糖的一线口服降糖药",
          "mechanism_of_action": {
            "primary_mechanisms": [
              "抑制肝脏葡萄糖生成",
              "增加胰岛素敏感性",
              "减少肠道葡萄糖吸收"
            ],
            "molecular_targets": [
              "AMP激活的蛋白激酶（AMPK）",
              "线粒体复合物I",
              "肝脏PEPCK酶"
            ]
          },
          "pharmacokinetics": {
            "bioavailability": "50-60%",
            "half_life": "4-9小时",
            "metabolism": "不经肝脏代谢",
            "excretion": "90%经肾脏原型排出",
            "food_effect": "与食物同服减少胃肠道副作用"
          },
          "clinical_efficacy": {
            "hba1c_reduction": "1.0-1.5%",
            "fasting_glucose_reduction": "2.5-3.5 mmol/L",
            "weight_effect": "体重减轻或保持不变",
            "cardiovascular_benefits": "降低心血管事件风险"
          },
          "indications": {
            "primary": "2型糖尿病一线治疗",
            "additional": [
              "糖尿病前期（部分指南推荐）",
              "PCOS相关胰岛素抵抗",
              "妊娠糖尿病（部分地区）"
            ]
          },
          "contraindications": {
            "absolute": [
              "eGFR <30 mL/min/1.73m²",
              "急性或慢性代谢性酸中毒",
              "严重心力衰竭",
              "严重肝功能不全",
              "严重感染或脱水"
            ],
            "relative": [
              "eGFR 30-45 mL/min/1.73m²（需谨慎使用）",
              "造影剂使用前后",
              "酗酒"
            ]
          },
          "adverse_effects": {
            "common": [
              "胃肠道反应（恶心、腹泻、腹痛）",
              "金属味觉",
              "食欲减退"
            ],
            "serious": [
              "乳酸酸中毒（罕见但严重）",
              "维生素B12缺乏（长期使用）"
            ]
          },
          "dosing": {
            "starting_dose": "500mg 每日1-2次或850mg 每日1次",
            "titration": "每周增加500mg，根据耐受性",
            "maximum_dose": "2550mg/天，分2-3次服用",
            "extended_release": "500-2000mg 每晚一次"
          }
        },
        {
          "id": "DM_MED_002",
          "name": "磺脲类药物",
          "name_en": "Sulfonylureas",
          "type": "medication",
          "category": "促胰岛素分泌药",
          "description": "通过刺激胰岛β细胞分泌胰岛素降低血糖的口服降糖药",
          "mechanism_of_action": {
            "primary_mechanism": "关闭β细胞膜上ATP敏感性钾离子通道，促进胰岛素分泌",
            "target": "胰岛β细胞SUR1受体"
          },
          "drug_examples": {
            "second_generation": {
              "glibenclamide": {
                "name": "格列本脲",
                "half_life": "10小时",
                "duration": "24小时",
                "starting_dose": "2.5mg 每日1次"
              },
              "gliclazide": {
                "name": "格列齐特",
                "half_life": "12小时",
                "duration": "24小时",
                "starting_dose": "40mg 每日1-2次"
              },
              "glimepiride": {
                "name": "格列美脲",
                "half_life": "9小时",
                "duration": "24小时",
                "starting_dose": "1mg 每日1次"
              },
              "glipizide": {
                "name": "格列吡嗪",
                "half_life": "4小时",
                "duration": "12-24小时",
                "starting_dose": "5mg 每日1-2次"
              }
            }
          },
          "clinical_efficacy": {
            "hba1c_reduction": "1.0-1.5%",
            "onset": "数周内达到最大效果",
            "durability": "β细胞功能衰减时效果下降"
          },
          "advantages": [
            "降糖效果确切",
            "价格便宜",
            "使用经验丰富",
            "可用于肾功能不全患者"
          ],
          "disadvantages": [
            "低血糖风险",
            "体重增加",
            "继发性失效",
            "心血管安全性争议"
          ],
          "contraindications": [
            "1型糖尿病",
            "糖尿病酮症酸中毒",
            "严重肝肾功能不全",
            "磺胺类药物过敏"
          ],
          "adverse_effects": {
            "common": [
              "低血糖（最重要）",
              "体重增加",
              "皮疹"
            ],
            "rare": [
              "血液系统异常",
              "肝功能异常",
              "SIADH综合征"
            ]
          }
        },
        {
          "id": "DM_MED_003",
          "name": "DPP-4抑制剂",
          "name_en": "DPP-4 Inhibitors",
          "type": "medication",
          "category": "肠促胰素相关药物",
          "description": "通过抑制DPP-4酶，增加内源性GLP-1和GIP水平，以葡萄糖依赖性方式降血糖",
          "mechanism_of_action": {
            "primary_mechanism": "抑制二肽基肽酶-4（DPP-4），延长GLP-1和GIP的半衰期",
            "glucose_dependent": "仅在高血糖状态下发挥作用，低血糖风险小"
          },
          "drug_examples": {
            "sitagliptin": {
              "name": "西格列汀",
              "half_life": "12小时",
              "dosing": "100mg 每日1次",
              "renal_adjustment": "肾功能不全需减量"
            },
            "vildagliptin": {
              "name": "维格列汀",
              "half_life": "3小时",
              "dosing": "50mg 每日2次",
              "hepatic_monitoring": "需监测肝功能"
            },
            "saxagliptin": {
              "name": "沙格列汀",
              "half_life": "7小时",
              "dosing": "5mg 每日1次",
              "cyp3a4": "CYP3A4底物，注意药物相互作用"
            },
            "linagliptin": {
              "name": "利格列汀",
              "half_life": "12小时",
              "dosing": "5mg 每日1次",
              "excretion": "主要经胆汁排泄"
            }
          },
          "clinical_efficacy": {
            "hba1c_reduction": "0.5-0.8%",
            "weight_effect": "体重中性",
            "hypoglycemia_risk": "低（单独使用时）"
          },
          "advantages": [
            "低血糖风险小",
            "体重中性",
            "耐受性好",
            "可与多种药物联用"
          ],
          "disadvantages": [
            "降糖效果中等",
            "价格相对昂贵",
            "长期安全性数据有限"
          ],
          "adverse_effects": {
            "common": [
              "上呼吸道感染",
              "头痛",
              "胃肠道不适"
            ],
            "serious_rare": [
              "急性胰腺炎（罕见）",
              "严重关节痛",
              "大疱性类天疱疮（极罕见）"
            ]
          }
        },
        {
          "id": "DM_MED_004",
          "name": "SGLT-2抑制剂",
          "name_en": "SGLT-2 Inhibitors",
          "type": "medication",
          "category": "钠-葡萄糖共转运蛋白抑制剂",
          "description": "通过抑制肾脏SGLT-2，增加尿糖排泄，同时具有心肾保护作用",
          "mechanism_of_action": {
            "primary_mechanism": "抑制肾脏近曲小管SGLT-2，阻止葡萄糖重吸收",
            "glucose_excretion": "每天增加60-120g葡萄糖从尿液排出",
            "additional_effects": [
              "利尿作用",
              "血压下降",
              "体重减轻"
            ]
          },
          "drug_examples": {
            "empagliflozin": {
              "name": "恩格列净",
              "dosing": "10-25mg 每日1次",
              "cv_outcome": "EMPA-REG OUTCOME研究证实心血管获益",
              "renal_benefits": "显著肾脏保护作用"
            },
            "canagliflozin": {
              "name": "卡格列净",
              "dosing": "100-300mg 每日1次",
              "amputation_risk": "下肢截肢风险轻度增加",
              "bone_effects": "骨折风险可能增加"
            },
            "dapagliflozin": {
              "name": "达格列净",
              "dosing": "5-10mg 每日1次",
              "heart_failure": "心力衰竭适应症",
              "ckd_indication": "慢性肾病适应症"
            }
          },
          "clinical_efficacy": {
            "hba1c_reduction": "0.7-1.0%",
            "weight_reduction": "2-3kg",
            "bp_reduction": "收缩压下降3-6mmHg",
            "cv_benefits": "降低主要不良心血管事件"
          },
          "cardiovascular_renal_benefits": {
            "proven_benefits": [
              "降低心血管死亡",
              "降低心力衰竭住院",
              "延缓肾功能下降",
              "降低肾病进展"
            ],
            "mechanisms": "可能与利尿、改善心脏代谢、直接器官保护有关"
          },
          "contraindications": [
            "1型糖尿病（除特殊适应症）",
            "严重肾功能不全（eGFR <30）",
            "透析",
            "严重肝功能不全"
          ],
          "adverse_effects": {
            "common": [
              "泌尿生殖系统感染",
              "多尿",
              "脱水"
            ],
            "serious": [
              "糖尿病酮症酸中毒（罕见）",
              "Fournier坏疽（极罕见）",
              "下肢截肢风险（卡格列净）"
            ]
          }
        },
        {
          "id": "DM_MED_005",
          "name": "GLP-1受体激动剂",
          "name_en": "GLP-1 Receptor Agonists",
          "type": "medication",
          "category": "肠促胰素类药物",
          "description": "模拟内源性GLP-1作用，以葡萄糖依赖性方式降糖，同时具有减重和心血管保护作用",
          "mechanism_of_action": {
            "primary_mechanisms": [
              "刺激胰岛β细胞葡萄糖依赖性胰岛素分泌",
              "抑制胰岛α细胞胰高血糖素分泌",
              "延缓胃排空",
              "增加饱腹感"
            ],
            "central_effects": "作用于下丘脑食欲调节中枢"
          },
          "drug_examples": {
            "short_acting": {
              "exenatide": {
                "name": "艾塞那肽",
                "dosing": "5-10μg 每日2次，餐前60分钟内",
                "half_life": "2.4小时"
              },
              "lixisenatide": {
                "name": "利西拉来",
                "dosing": "10-20μg 每日1次，早餐前1小时",
                "half_life": "3小时"
              }
            },
            "long_acting": {
              "liraglutide": {
                "name": "利拉鲁肽",
                "dosing": "0.6-1.8mg 每日1次",
                "cv_outcome": "LEADER研究证实心血管获益",
                "weight_indication": "3.0mg用于减重"
              },
              "semaglutide": {
                "name": "司美格鲁肽",
                "dosing": "0.25-1.0mg 每周1次",
                "efficacy": "降糖和减重效果最强",
                "oral_form": "口服制剂可用"
              },
              "dulaglutide": {
                "name": "度拉糖肽",
                "dosing": "0.75-1.5mg 每周1次",
                "convenience": "预充注射笔"
              }
            }
          },
          "clinical_efficacy": {
            "hba1c_reduction": "0.8-1.5%",
            "weight_reduction": "2-7kg",
            "cv_benefits": "降低主要不良心血管事件（部分药物）"
          },
          "advantages": [
            "强效降糖",
            "显著减重",
            "低血糖风险小",
            "心血管保护作用",
            "可能保护β细胞功能"
          ],
          "disadvantages": [
            "注射给药",
            "胃肠道副作用",
            "价格昂贵"
          ],
          "contraindications": [
            "1型糖尿病",
            "糖尿病酮症酸中毒",
            "严重胃肠道疾病",
            "个人或家族甲状腺髓样癌病史",
            "多发性内分泌腺瘤病2型"
          ],
          "adverse_effects": {
            "common": [
              "恶心、呕吐",
              "腹泻",
              "食欲减退",
              "注射部位反应"
            ],
            "serious_rare": [
              "急性胰腺炎",
              "胆囊疾病",
              "甲状腺髓样癌（理论风险）"
            ]
          }
        },
        {
          "id": "DM_MED_006",
          "name": "胰岛素",
          "name_en": "Insulin",
          "type": "medication",
          "category": "胰岛素及类似物",
          "description": "替代或补充内源性胰岛素，是唯一能治疗所有类型糖尿病的降糖药物",
          "classification": {
            "by_duration": {
              "rapid_acting": {
                "examples": [
                  "门冬胰岛素（诺和锐）",
                  "赖脯胰岛素（优泌乐）",
                  "谷赖胰岛素（速秀霖）"
                ],
                "onset": "10-15分钟",
                "peak": "1-2小时",
                "duration": "3-5小时",
                "use": "餐前即刻注射"
              },
              "short_acting": {
                "examples": ["常规胰岛素"],
                "onset": "30分钟",
                "peak": "2-4小时",
                "duration": "6-8小时",
                "use": "餐前30分钟注射"
              },
              "intermediate_acting": {
                "examples": ["NPH胰岛素"],
                "onset": "1-2小时",
                "peak": "6-12小时",
                "duration": "18-24小时",
                "use": "基础胰岛素"
              },
              "long_acting": {
                "examples": [
                  "甘精胰岛素（来得时）",
                  "地特胰岛素（诺和平）",
                  "德谷胰岛素（诺和达）"
                ],
                "onset": "1-6小时",
                "peak": "无明显峰值",
                "duration": "20-42小时",
                "use": "基础胰岛素"
              }
            },
            "premixed_insulin": {
              "examples": [
                "门冬胰岛素30/70",
                "赖脯胰岛素25/75",
                "常规胰岛素30/70"
              ],
              "composition": "速效/中效胰岛素混合物",
              "convenience": "减少注射次数"
            }
          },
          "indications": {
            "absolute": [
              "1型糖尿病",
              "糖尿病酮症酸中毒",
              "高渗性高血糖状态",
              "围手术期血糖管理"
            ],
            "relative": [
              "2型糖尿病多种口服药物失效",
              "妊娠糖尿病",
              "急性应激状态",
              "严重感染"
            ]
          },
          "insulin_regimens": {
            "basal_bolus": {
              "description": "基础-餐时胰岛素方案",
              "components": "长效基础胰岛素 + 餐前速效胰岛素",
              "advantages": "最接近生理性胰岛素分泌"
            },
            "premixed": {
              "description": "预混胰岛素方案",
              "frequency": "每日2次",
              "advantages": "简便，依从性好"
            },
            "insulin_pump": {
              "description": "胰岛素泵持续皮下输注",
              "indications": "1型糖尿病，血糖波动大的患者"
            }
          },
          "dosing_principles": {
            "starting_dose": "0.2-0.5 U/kg/天",
            "basal_proportion": "基础胰岛素占总量40-50%",
            "bolus_proportion": "餐时胰岛素占总量50-60%",
            "titration": "根据血糖监测结果调整"
          },
          "adverse_effects": {
            "common": [
              "低血糖（最重要）",
              "体重增加",
              "注射部位反应",
              "脂肪萎缩或增生"
            ],
            "rare": [
              "严重过敏反应",
              "胰岛素抗体形成"
            ]
          },
          "storage_handling": [
            "未开封制剂需冷藏（2-8°C）",
            "使用中制剂可室温保存28天",
            "避免冷冻和高温",
            "注射前恢复至室温"
          ]
        }
      ],

      "diabetes_technology_devices": [
        {
          "id": "DM_TECH_001",
          "name": "连续血糖监测系统",
          "name_en": "Continuous Glucose Monitoring (CGM)",
          "type": "medical_device",
          "category": "血糖监测技术",
          "description": "实时监测间质液中葡萄糖浓度变化的医疗设备，提供连续血糖信息和趋势预警",
          "classification": {
            "real_time_cgm": {
              "definition": "实时连续血糖监测系统（rtCGM）",
              "features": [
                "实时显示血糖值",
                "血糖趋势箭头",
                "高低血糖报警",
                "历史数据回顾"
              ],
              "examples": [
                "Dexcom G6/G7",
                "FreeStyle Libre 2",
                "Medtronic Guardian",
                "雅培瞬感"
              ]
            },
            "flash_glucose_monitoring": {
              "definition": "闪测血糖监测系统（FGM）",
              "features": [
                "扫描获取血糖值",
                "14天连续佩戴",
                "无需校准",
                "防水设计"
              ],
              "representative": "FreeStyle Libre系列"
            }
          },
          "technical_specifications": {
            "measurement_range": "2.2-22.2 mmol/L (40-400 mg/dL)",
            "accuracy": "MARD <10%（平均绝对相对偏差）",
            "sensor_life": "10-14天",
            "calibration": "工厂校准或每日1-2次指血校准",
            "data_transmission": "蓝牙、NFC近场通信",
            "waterproof_rating": "IPX8防水等级"
          },
          "clinical_benefits": {
            "glycemic_control": {
              "hba1c_reduction": "0.3-0.5%的HbA1c下降",
              "time_in_range": "目标范围内时间增加",
              "hypoglycemia_reduction": "严重低血糖事件减少"
            },
            "lifestyle_impact": [
              "减少指血检测频次",
              "提高血糖管理信心",
              "改善生活质量",
              "夜间低血糖预警"
            ],
            "clinical_decision_support": [
              "血糖变异性评估",
              "餐后血糖模式识别",
              "运动对血糖的影响",
              "药物调整指导"
            ]
          },
          "key_metrics": {
            "time_in_range": {
              "definition": "血糖在目标范围内的时间百分比",
              "target_range": "3.9-10.0 mmol/L (70-180 mg/dL)",
              "goals": "成人>70%，老年人60-70%"
            },
            "time_below_range": {
              "level1": "<3.9 mmol/L的时间 <4%",
              "level2": "<3.0 mmol/L的时间 <1%"
            },
            "time_above_range": {
              "level1": ">10.0 mmol/L的时间 <25%",
              "level2": ">13.9 mmol/L的时间 <5%"
            },
            "glucose_variability": "血糖变异系数 <36%"
          },
          "indications": [
            "1型糖尿病患者",
            "胰岛素治疗的2型糖尿病",
            "妊娠糖尿病",
            "频发低血糖患者",
            "无症状低血糖患者"
          ],
          "limitations": [
            "间质液与血糖存在15分钟滞后",
            "快速血糖变化时准确性下降",
            "仍需指血校准（部分系统）",
            "皮肤过敏风险",
            "成本相对较高"
          ]
        },
        {
          "id": "DM_TECH_002",
          "name": "胰岛素泵系统",
          "name_en": "Insulin Pump System",
          "type": "medical_device",
          "category": "胰岛素输注技术",
          "description": "持续皮下胰岛素输注系统，模拟胰岛β细胞生理性胰岛素分泌模式",
          "system_components": {
            "pump_device": {
              "function": "胰岛素储存和精确输注",
              "features": [
                "可编程基础率",
                "大剂量向导",
                "多种报警功能",
                "防水设计"
              ]
            },
            "infusion_set": {
              "components": "输注管路、钢针或软管",
              "placement": "腹部、臀部、大腿等部位",
              "change_frequency": "每2-3天更换"
            },
            "insulin_reservoir": {
              "capacity": "160-480单位",
              "insulin_type": "速效胰岛素类似物",
              "stability": "室温下稳定28天"
            }
          },
          "insulin_delivery_modes": {
            "basal_rate": {
              "definition": "基础胰岛素输注率",
              "programmability": "可设置24段不同的基础率",
              "typical_pattern": "凌晨增加（黎明现象对抗）",
              "adjustment": "根据血糖模式精细调整"
            },
            "bolus_delivery": {
              "meal_bolus": "餐前大剂量",
              "correction_bolus": "高血糖纠正剂量",
              "bolus_calculator": "内置大剂量计算器",
              "delivery_options": [
                "标准大剂量",
                "方波大剂量",
                "双波大剂量"
              ]
            }
          },
          "advanced_features": {
            "cgm_integration": "与连续血糖监测系统整合",
            "low_glucose_suspend": "低血糖自动暂停功能",
            "predictive_algorithms": "预测性低血糖管理",
            "mobile_connectivity": "智能手机应用控制",
            "data_management": "云端数据存储和分析"
          },
          "clinical_benefits": {
            "glycemic_outcomes": [
              "HbA1c改善0.2-0.5%",
              "减少血糖波动",
              "降低严重低血糖风险",
              "提高目标范围内时间"
            ],
            "lifestyle_benefits": [
              "灵活的进餐时间",
              "精确的运动前调整",
              "减少注射次数",
              "改善睡眠质量"
            ]
          },
          "indications": [
            "1型糖尿病（优先推荐）",
            "C肽显著缺乏的患者",
            "多次胰岛素注射控制不佳",
            "频发低血糖",
            "血糖波动大",
            "生活方式不规律"
          ],
          "contraindications": [
            "认知功能严重障碍",
            "精神疾病未控制",
            "不愿意频繁监测血糖",
            "严重皮肤疾病",
            "经济条件限制"
          ],
          "complications_management": [
            "导管堵塞处理",
            "皮下硬结预防",
            "感染风险控制",
            "酮症预防",
            "设备故障应急预案"
          ]
        },
        {
          "id": "DM_TECH_003",
          "name": "人工胰腺系统",
          "name_en": "Artificial Pancreas System (APS)",
          "type": "medical_device",
          "category": "闭环血糖控制系统",
          "description": "集成CGM、胰岛素泵和智能算法的自动化血糖管理系统，又称闭环系统",
          "system_architecture": {
            "continuous_glucose_monitor": "实时血糖数据采集",
            "control_algorithm": "智能胰岛素调节算法",
            "insulin_pump": "自动胰岛素输注",
            "user_interface": "患者交互和监控界面"
          },
          "control_algorithms": {
            "pid_controller": {
              "name": "比例-积分-微分控制器",
              "principle": "基于血糖偏差调整胰岛素输注",
              "advantages": "简单稳定",
              "limitations": "应对复杂情况能力有限"
            },
            "model_predictive_control": {
              "name": "模型预测控制（MPC）",
              "principle": "基于生理模型预测血糖趋势",
              "advantages": "前瞻性调节，效果更佳",
              "complexity": "计算复杂度高"
            },
            "machine_learning_algorithms": {
              "name": "机器学习算法",
              "types": ["神经网络", "强化学习", "模糊逻辑"],
              "advantages": "个体化适应性强",
              "challenges": "需要大量训练数据"
            }
          },
          "commercial_systems": {
            "medtronic_670g": {
              "name": "美敦力MiniMed 670G",
              "features": [
                "混合闭环系统",
                "自动基础率调节",
                "需手动餐前大剂量",
                "低血糖自动保护"
              ],
              "target_range": "6.7-10.0 mmol/L"
            },
            "tandem_control_iq": {
              "name": "Tandem Control-IQ",
              "features": [
                "预测性低血糖保护",
                "自动纠正大剂量",
                "睡眠模式",
                "运动模式"
              ]
            },
            "omnipod_5": {
              "name": "Omnipod 5",
              "features": [
                "无管路设计",
                "自适应学习算法",
                "智能手机控制"
              ]
            }
          },
          "clinical_outcomes": {
            "glycemic_improvements": [
              "目标范围内时间增加10-15%",
              "夜间血糖控制显著改善",
              "减少低血糖事件50%以上",
              "HbA1c下降0.3-0.5%"
            ],
            "quality_of_life": [
              "减少血糖管理负担",
              "改善睡眠质量",
              "降低糖尿病焦虑",
              "提高治疗满意度"
            ]
          },
          "current_limitations": [
            "仍需手动餐前大剂量",
            "血糖传感器滞后性",
            "胰高血糖素缺乏",
            "系统复杂性",
            "成本高昂"
          ],
          "future_developments": {
            "dual_hormone_systems": "胰岛素+胰高血糖素双激素系统",
            "advanced_meal_detection": "自动餐食识别算法",
            "exercise_adaptation": "运动自适应调节",
            "multivariable_control": "多变量协调控制",
            "implantable_systems": "植入式闭环系统"
          }
        },
        {
          "id": "DM_TECH_004",
          "name": "智能血糖仪",
          "name_en": "Smart Blood Glucose Meter",
          "type": "medical_device",
          "category": "血糖监测设备",
          "description": "具备数据管理、趋势分析和智能提醒功能的新一代血糖仪",
          "core_features": {
            "accurate_measurement": {
              "accuracy_standard": "ISO 15197:2013标准",
              "test_strips": "电化学检测技术",
              "sample_volume": "0.3-1.0μL微量血样",
              "test_time": "5-10秒快速检测"
            },
            "connectivity": {
              "bluetooth": "蓝牙4.0/5.0连接",
              "wifi": "WiFi云端同步",
              "usb": "USB数据传输",
              "nfc": "近场通信技术"
            },
            "data_management": {
              "automatic_logging": "自动记录血糖数据",
              "trend_analysis": "血糖趋势图表",
              "pattern_recognition": "血糖模式识别",
              "cloud_storage": "云端数据存储"
            }
          },
          "intelligent_functions": {
            "personalized_insights": [
              "个性化血糖目标设定",
              "餐前餐后血糖关联分析",
              "药物效果评估",
              "生活方式影响分析"
            ],
            "predictive_alerts": [
              "低血糖风险预警",
              "测试时间提醒",
              "异常值报警",
              "复测建议"
            ],
            "clinical_support": [
              "血糖日志自动生成",
              "医生报告制作",
              "用药依从性监测",
              "并发症风险评估"
            ]
          },
          "mobile_applications": {
            "patient_apps": {
              "functions": [
                "实时血糖查看",
                "历史数据回顾",
                "药物记录",
                "饮食日志",
                "运动追踪",
                "症状记录"
              ],
              "education": "糖尿病教育内容",
              "community": "患者社区交流"
            },
            "healthcare_provider_portals": {
              "remote_monitoring": "远程患者监控",
              "data_analytics": "大数据分析",
              "treatment_optimization": "治疗方案优化",
              "population_health": "人群健康管理"
            }
          },
          "representative_devices": {
            "accu_chek_guide": {
              "manufacturer": "罗氏",
              "features": ["蓝牙连接", "smartLIGHT提示", "双重确认"],
              "accuracy": "符合ISO 15197:2013"
            },
            "onetouch_verio": {
              "manufacturer": "强生",
              "features": ["彩色屏幕", "趋势箭头", "14天平均值"],
              "connectivity": "蓝牙和USB"
            },
            "freestyle_lite": {
              "manufacturer": "雅培",
              "features": ["无编码", "快速检测", "小血样"],
              "integration": "与FreeStyle LibreLink整合"
            }
          },
          "clinical_validation": {
            "accuracy_studies": "大规模临床准确性验证",
            "user_satisfaction": "患者使用满意度调查",
            "clinical_outcomes": "血糖控制改善证据",
            "cost_effectiveness": "卫生经济学评价"
          }
        },
        {
          "id": "DM_TECH_005",
          "name": "糖尿病管理数字平台",
          "name_en": "Diabetes Digital Management Platform",
          "type": "software_platform",
          "category": "数字健康解决方案",
          "description": "集成多种数据源，提供综合性糖尿病管理和临床决策支持的数字化平台",
          "platform_architecture": {
            "data_integration": {
              "glucose_data": "血糖仪、CGM数据整合",
              "insulin_data": "胰岛素泵输注记录",
              "activity_data": "运动和活动追踪",
              "nutrition_data": "饮食和营养信息",
              "medication_data": "用药记录和依从性",
              "clinical_data": "实验室检查结果"
            },
            "analytics_engine": {
              "pattern_recognition": "血糖模式识别算法",
              "risk_stratification": "并发症风险分层",
              "predictive_modeling": "血糖预测模型",
              "intervention_recommendations": "干预建议生成"
            },
            "user_interfaces": {
              "patient_dashboard": "患者个人健康仪表板",
              "clinician_portal": "医护人员临床工作站",
              "mobile_apps": "移动端应用程序",
              "web_platform": "网页端管理平台"
            }
          },
          "key_functionalities": {
            "comprehensive_monitoring": {
              "real_time_tracking": "实时健康指标追踪",
              "longitudinal_analysis": "纵向数据趋势分析",
              "multi_parameter_correlation": "多参数关联分析",
              "anomaly_detection": "异常情况自动识别"
            },
            "personalized_recommendations": {
              "insulin_dosing": "个性化胰岛素剂量建议",
              "meal_planning": "个体化膳食计划",
              "exercise_guidance": "运动处方制定",
              "medication_optimization": "药物治疗优化"
            },
            "clinical_decision_support": {
              "guideline_integration": "临床指南整合",
              "evidence_based_alerts": "循证医学提醒",
              "treatment_pathways": "治疗路径指导",
              "outcome_prediction": "治疗结果预测"
            }
          },
          "artificial_intelligence_applications": {
            "machine_learning_models": {
              "glucose_prediction": "血糖水平预测模型",
              "hypoglycemia_risk": "低血糖风险评估",
              "treatment_response": "治疗反应预测",
              "complications_screening": "并发症筛查算法"
            },
            "natural_language_processing": {
              "clinical_note_analysis": "临床记录分析",
              "symptom_extraction": "症状信息提取",
              "patient_communication": "智能患者交流",
              "literature_mining": "医学文献挖掘"
            },
            "computer_vision": {
              "food_recognition": "食物识别和营养分析",
              "medication_identification": "药物识别",
              "wound_assessment": "糖尿病足创面评估",
              "retinal_screening": "视网膜病变筛查"
            }
          },
          "clinical_applications": {
            "remote_patient_monitoring": {
              "continuous_surveillance": "持续患者监护",
              "early_intervention": "早期干预触发",
              "care_coordination": "多学科协作",
              "emergency_response": "紧急情况响应"
            },
            "population_health_management": {
              "cohort_analysis": "患者队列分析",
              "quality_metrics": "护理质量指标",
              "resource_optimization": "医疗资源优化",
              "public_health_insights": "公共卫生洞察"
            },
            "precision_medicine": {
              "genetic_integration": "基因信息整合",
              "biomarker_analysis": "生物标志物分析",
              "treatment_stratification": "治疗分层策略",
              "therapeutic_targeting": "靶向治疗选择"
            }
          },
          "regulatory_considerations": {
            "data_privacy": "患者隐私保护（HIPAA、GDPR合规）",
            "medical_device_classification": "医疗器械分类认证",
            "clinical_validation": "临床有效性验证",
            "interoperability_standards": "互操作性标准（FHIR、HL7）"
          },
          "implementation_challenges": {
            "technical_barriers": [
              "数据标准化",
              "系统集成复杂性",
              "网络安全威胁",
              "设备兼容性"
            ],
            "clinical_adoption": [
              "工作流程整合",
              "培训需求",
              "医疗文化变革",
              "效果评估"
            ],
            "economic_factors": [
              "投资回报率",
              "成本效益分析",
              "保险覆盖",
              "可持续发展模式"
            ]
          }
        }
      ],

      "adrenal_entities": [
        {
          "id": "ADR_001",
          "name": "原发性醛固酮增多症",
          "name_en": "Primary Aldosteronism",
          "type": "disease", 
          "category": "肾上腺疾病",
          "description": "肾上腺皮质醛固酮分泌过多导致的继发性高血压，伴低血钾和代谢性碱中毒",
          "prevalence": "高血压人群中5-10%",
          "etiology": {
            "unilateral_disease": {
              "aldosterone_producing_adenoma": "单侧醛固酮瘤(35%)",
              "unilateral_hyperplasia": "单侧增生(5%)"
            },
            "bilateral_disease": {
              "bilateral_hyperplasia": "双侧增生(60%)",
              "glucocorticoid_remediable": "糖皮质激素可抑制性(<1%)"
            }
          },
          "clinical_manifestations": {
            "hypertension": {
              "characteristics": "难治性高血压，对常规降压药反应差",
              "prevalence": ">95%患者"
            },
            "hypokalemia": {
              "symptoms": ["肌无力", "肌痉挛", "多尿", "烦渴"],
              "prevalence": "50-60%患者"
            },
            "metabolic_alkalosis": "血pH升高，HCO3-升高"
          },
          "diagnostic_approach": {
            "screening": {
              "indication": [
                "难治性高血压(≥3种药物)",
                "高血压合并自发性低血钾",
                "高血压合并肾上腺偶发瘤",
                "早发高血压(<40岁)",
                "高血压家族史+早发脑血管病"
              ],
              "method": "醛固酮/肾素比值(ARR)",
              "threshold": "ARR > 20-30 (单位相关)",
              "preparation": [
                "纠正低血钾",
                "停用影响RAAS药物4周",
                "可继续使用CCB, α受体阻滞剂"
              ]
            },
            "confirmatory_tests": [
              "盐水负荷试验",
              "氟氢可的松抑制试验", 
              "卡托普利试验",
              "口服钠盐负荷试验"
            ],
            "subtype_classification": {
              "adrenal_ct": "首选影像学检查",
              "adrenal_venous_sampling": {
                "indication": "手术候选人",
                "lateralization_index": ">4.0",
                "contralateral_suppression": ">75%"
              }
            }
          },
          "treatment_strategies": {
            "unilateral_disease": {
              "adrenalectomy": {
                "approach": "腹腔镜单侧肾上腺切除",
                "outcomes": {
                  "hypertension_cure": "30-60%",
                  "improvement": "90%",
                  "factors": ["年龄", "病程", "肾脏损害程度"]
                }
              }
            },
            "bilateral_disease": {
              "mineralocorticoid_antagonists": {
                "spironolactone": {
                  "dose": "25-400mg/day",
                  "side_effects": ["男性乳房发育", "月经紊乱"],
                  "monitoring": ["血钾", "肾功能"]
                },
                "eplerenone": {
                  "dose": "25-100mg/day", 
                  "advantages": "选择性MR拮抗剂，副作用少",
                  "cost": "较spironolactone昂贵"
                }
              },
              "additional_antihypertensives": [
                "钙通道阻滞剂",
                "ACEI/ARB(注意高血钾)",
                "噻嗪类利尿剂"
              ]
            }
          }
        },
        {
          "id": "ADR_002",
          "name": "库欣综合征",
          "name_en": "Cushing Syndrome", 
          "type": "disease",
          "category": "肾上腺疾病",
          "description": "糖皮质激素分泌过多或长期使用外源性糖皮质激素导致的临床综合征",
          "etiology": {
            "acth_dependent": {
              "cushings_disease": {
                "cause": "垂体ACTH腺瘤",
                "percentage": "80%"
              },
              "ectopic_acth": {
                "causes": ["肺癌", "胸腺瘤", "胰岛细胞瘤"],
                "percentage": "15%"
              }
            },
            "acth_independent": {
              "adrenal_adenoma": "3%",
              "adrenal_carcinoma": "2%"
            },
            "iatrogenic": "外源性糖皮质激素使用"
          },
          "clinical_manifestations": {
            "classic_features": [
              "向心性肥胖",
              "满月脸",
              "水牛背",
              "紫纹",
              "皮肤瘀斑",
              "肌无力"
            ],
            "metabolic_features": [
              "糖耐量异常/糖尿病",
              "高血压",
              "血脂异常",
              "骨质疏松"
            ],
            "psychiatric_features": [
              "抑郁",
              "躁狂",
              "认知功能下降",
              "精神病性症状"
            ]
          },
          "diagnostic_workup": {
            "screening_tests": {
              "24h_urine_cortisol": ">3倍正常上限",
              "dexamethasone_suppression": {
                "overnight_1mg": "晨8点皮质醇>50nmol/L异常",
                "48h_2mg": "更特异但复杂"
              },
              "midnight_salivary_cortisol": "方便，准确性好"
            },
            "differential_diagnosis": {
              "high_dose_dexamethasone": {
                "8mg_overnight": "垂体性抑制>50%",
                "interpretation": "区分垂体与异位ACTH"
              },
              "crh_stimulation": "垂体性ACTH明显升高",
              "inferior_petrosal_sampling": "金标准，区分垂体与异位"
            },
            "imaging": {
              "pituitary_mri": "垂体微腺瘤检测",
              "adrenal_ct": "肾上腺病变评估",
              "chest_ct": "异位ACTH源筛查"
            }
          },
          "treatment_approaches": {
            "surgical": {
              "transsphenoidal_surgery": "垂体腺瘤首选",
              "adrenalectomy": "肾上腺病变治疗",
              "ectopic_source_resection": "异位ACTH源切除"
            },
            "medical": {
              "steroidogenesis_inhibitors": [
                "ketoconazole",
                "metyrapone", 
                "mitotane"
              ],
              "pituitary_directed": [
                "cabergoline",
                "pasireotide"
              ],
              "glucocorticoid_antagonists": "mifepristone"
            },
            "radiation": {
              "conventional_rt": "垂体腺瘤术后辅助",
              "stereotactic_radiosurgery": "精准放疗"
            }
          }
        },
        {
          "id": "ADR_003",
          "name": "嗜铬细胞瘤",
          "name_en": "Pheochromocytoma",
          "type": "disease",
          "category": "肾上腺疾病", 
          "description": "起源于肾上腺髓质的儿茶酚胺分泌性肿瘤，可引起严重高血压和心血管并发症",
          "prevalence": "高血压患者中0.05-0.2%",
          "genetics": {
            "hereditary": "30-40%",
            "genes": ["VHL", "RET", "NF1", "SDHB", "SDHC", "SDHD", "MAX", "TMEM127"]
          },
          "clinical_manifestations": {
            "classic_triad": {
              "headache": "90%",
              "sweating": "70%", 
              "palpitations": "60%"
            },
            "hypertension": {
              "sustained": "50%",
              "paroxysmal": "45%",
              "crisis": "可危及生命"
            },
            "other_symptoms": [
              "胸腹痛",
              "恶心呕吐",
              "体重下降",
              "焦虑恐惧",
              "高血糖"
            ]
          },
          "diagnostic_approach": {
            "biochemical_testing": {
              "first_line": {
                "plasma_metanephrines": "最敏感(97-99%)",
                "24h_urine_metanephrines": "特异性高"
              },
              "cutoff_values": {
                "normetanephrine": ">0.61 nmol/L",
                "metanephrine": ">0.31 nmol/L"
              },
              "factors_affecting": [
                "药物干扰",
                "应激状态", 
                "食物影响",
                "体位变化"
              ]
            },
            "imaging": {
              "adrenal_ct": {
                "characteristics": "富血供，不均匀强化",
                "size": "通常>3cm"
              },
              "mri": "T2高信号，'灯泡征'",
              "functional_imaging": {
                "123i_mibg": "特异性显像",
                "68ga_dotatate_pet": "新兴显像方法"
              }
            }
          },
          "preoperative_management": {
            "alpha_blockade": {
              "phenoxybenzamine": {
                "dose": "10-20mg bid，逐渐增量",
                "duration": "术前2-3周",
                "target": "血压<130/80mmHg"
              },
              "alternatives": ["doxazosin", "terazosin"]
            },
            "beta_blockade": {
              "timing": "α阻滞剂后使用",
              "indication": "心率>100bpm或心律失常",
              "agents": ["propranolol", "atenolol"]
            },
            "volume_expansion": "术前充分补液"
          },
          "surgical_management": {
            "approach": {
              "laparoscopic": "首选，创伤小",
              "open": "巨大肿瘤或恶性可疑"
            },
            "intraoperative": {
              "anesthesia": "避免刺激性药物",
              "monitoring": "有创血压，中心静脉压",
              "blood_pressure": "预期血压剧烈波动"
            },
            "postoperative": {
              "hypotension": "常见，需血管活性药物",
              "hypoglycemia": "胰岛素敏感性恢复",
              "follow_up": "术后2周复查儿茶酚胺"
            }
          }
        },
        {
          "id": "ADR_004",
          "name": "原发性肾上腺皮质功能减退症",
          "name_en": "Primary Adrenal Insufficiency",
          "type": "disease",
          "category": "肾上腺疾病",
          "description": "肾上腺皮质激素分泌不足导致的疾病，又称Addison病",
          "etiology": {
            "autoimmune": {
              "percentage": "80%",
              "mechanism": "21-羟化酶抗体阳性",
              "associated_conditions": ["1型糖尿病", "甲状腺疾病", "性腺功能减退"]
            },
            "infectious": {
              "causes": ["结核", "真菌感染", "HIV"],
              "percentage": "10%"
            },
            "infiltrative": ["肿瘤转移", "淀粉样变性", "血色病"],
            "genetic": ["先天性肾上腺增生", "X-连锁肾上腺脑白质营养不良"]
          },
          "clinical_manifestations": {
            "glucocorticoid_deficiency": [
              "乏力虚弱",
              "食欲不振",
              "体重下降",
              "低血压",
              "低血糖",
              "恶心呕吐"
            ],
            "mineralocorticoid_deficiency": [
              "脱水",
              "低钠血症",
              "高钾血症",
              "代谢性酸中毒",
              "体位性低血压"
            ],
            "androgen_deficiency": [
              "女性体毛稀少",
              "性欲减退"
            ],
            "hyperpigmentation": "ACTH升高导致皮肤黏膜色素沉着"
          },
          "diagnostic_criteria": {
            "morning_cortisol": "<100 nmol/L (<3.6 μg/dL)",
            "acth_stimulation": {
              "standard_dose": "250μg cosyntropin",
              "normal_response": "皮质醇>500 nmol/L",
              "peak_time": "30或60分钟"
            },
            "acth_level": ">2倍正常上限",
            "autoantibodies": [
              "21-羟化酶抗体",
              "17α-羟化酶抗体",
              "胆固醇侧链裂解酶抗体"
            ]
          },
          "treatment_protocols": {
            "glucocorticoid_replacement": {
              "hydrocortisone": {
                "dose": "15-25mg/day，分2-3次",
                "timing": "早晨较大剂量",
                "stress_dosing": "发热或应激时加倍"
              },
              "prednisolone": "3-5mg/day",
              "dexamethasone": "0.25-0.5mg/day"
            },
            "mineralocorticoid_replacement": {
              "fludrocortisone": {
                "dose": "0.05-0.2mg/day",
                "monitoring": ["血压", "血钾", "肾素活性"],
                "adjustment": "根据血钾和血压调整"
              }
            },
            "acute_crisis_management": {
              "hydrocortisone": "100mg iv q6-8h",
              "fluid_resuscitation": "生理盐水快速补液",
              "electrolyte_correction": "纠正低钠高钾",
              "trigger_identification": "寻找和治疗诱因"
            }
          }
        },
        {
          "id": "ADR_005",
          "name": "肾上腺偶发瘤",
          "name_en": "Adrenal Incidentaloma",
          "type": "disease",
          "category": "肾上腺疾病",
          "description": "影像学检查中偶然发现的肾上腺肿块，需排除功能性和恶性病变",
          "prevalence": "人群中1-5%，随年龄增加",
          "differential_diagnosis": {
            "benign": [
              "皮质腺瘤(80%)",
              "髓质脂肪瘤",
              "囊肿",
              "血肿"
            ],
            "malignant": [
              "肾上腺皮质癌(5%)",
              "转移瘤(15%)",
              "恶性嗜铬细胞瘤"
            ]
          },
          "imaging_characteristics": {
            "benign_features": [
              "CT平扫<10 HU",
              "均匀密度",
              "边界清楚",
              "增强后快速消退"
            ],
            "malignant_features": [
              "CT平扫>10 HU",
              "不均匀强化",
              "边界不清",
              "消退延迟"
            ]
          },
          "hormonal_evaluation": {
            "always_test": [
              "血浆游离甲氧肾上腺素",
              "1mg地塞米松抑制试验"
            ],
            "conditional_test": [
              "醛固酮/肾素比值(高血压或低钾)",
              "DHEA-S(女性男性化)",
              "17-羟孕酮(年轻患者)"
            ]
          },
          "management_strategy": {
            "surgery_indications": [
              "功能性肿瘤",
              "恶性可疑",
              "直径>4cm",
              "影像学恶性特征",
              "年龄<40岁"
            ],
            "follow_up_protocol": {
              "hormonal": "1年后重复激素检查",
              "imaging": "12个月后复查CT",
              "growth_threshold": "直径增加>1cm"
            }
          }
        },
        {
          "id": "ADR_002",
          "name": "库欣综合征",
          "name_en": "Cushing's Syndrome",
          "type": "disease",
          "category": "肾上腺疾病",
          "icd10": "E24",
          "description": "由于糖皮质激素过多引起的临床综合征",
          "etiology": {
            "acth_dependent": {
              "prevalence": "80%的内源性库欣综合征",
              "subtypes": {
                "cushings_disease": {
                  "cause": "垂体ACTH分泌瘤",
                  "prevalence": "85%的ACTH依赖性",
                  "demographics": "女性多见，20-40岁高发"
                },
                "ectopic_acth_syndrome": {
                  "cause": "异位ACTH分泌",
                  "common_tumors": [
                    "肺支气管类癌",
                    "胰腺胰岛细胞瘤",
                    "胸腺瘤",
                    "嗜铬细胞瘤"
                  ],
                  "prevalence": "15%的ACTH依赖性"
                }
              }
            },
            "acth_independent": {
              "prevalence": "20%的内源性库欣综合征",
              "subtypes": {
                "unilateral_adenoma": {
                  "cause": "单侧肾上腺腺瘤",
                  "prevalence": "10%",
                  "characteristics": "良性，单侧切除可治愈"
                },
                "bilateral_hyperplasia": {
                  "cause": "双侧肾上腺增生",
                  "subtypes": [
                    "原发性色素性结节性肾上腺病",
                    "ACTH无关性大结节性增生"
                  ]
                },
                "adrenal_carcinoma": {
                  "cause": "肾上腺皮质癌",
                  "prevalence": "<5%",
                  "prognosis": "预后差，5年生存率25-50%"
                }
              }
            },
            "exogenous": {
              "cause": "外源性糖皮质激素",
              "prevalence": "最常见原因",
              "medications": [
                "泼尼松",
                "氢化可的松",
                "地塞米松",
                "甲泼尼龙"
              ]
            }
          },
          "clinical_manifestations": {
            "central_obesity": {
              "prevalence": ">90%",
              "features": [
                "向心性肥胖",
                "满月脸",
                "水牛背",
                "锁骨上脂肪垫"
              ]
            },
            "skin_changes": {
              "purple_striae": {
                "prevalence": "50-70%",
                "characteristics": "紫纹，宽>1cm",
                "locations": ["腹部", "大腿", "腋窝"]
              },
              "bruising": "轻微外伤后瘀斑",
              "poor_wound_healing": "伤口愈合不良",
              "skin_atrophy": "皮肤萎缩变薄"
            },
            "muscle_weakness": {
              "prevalence": "60-70%",
              "pattern": "近端肌无力",
              "manifestation": "起立困难，爬楼梯困难"
            },
            "metabolic_effects": {
              "diabetes": "50-60%患者",
              "hypertension": "80%患者",
              "dyslipidemia": "高甘油三酯血症",
              "osteoporosis": "50%患者有骨质疏松"
            },
            "psychiatric_symptoms": {
              "prevalence": "50-80%",
              "types": [
                "抑郁症",
                "焦虑",
                "情绪不稳",
                "认知功能障碍"
              ]
            }
          },
          "diagnosis": {
            "screening_tests": {
              "dexamethasone_suppression": {
                "overnight_1mg": "首选筛查试验",
                "normal": "次日8AM皮质醇<1.8μg/dL",
                "sensitivity": "95%",
                "specificity": "80%"
              },
              "24h_urine_cortisol": {
                "threshold": ">3倍正常上限",
                "advantages": "反映24小时皮质醇产生"
              },
              "late_night_salivary_cortisol": {
                "threshold": ">正常上限",
                "advantages": "方便，不受CBG影响"
              }
            },
            "differential_diagnosis": {
              "high_dose_dexamethasone": {
                "protocol": "2mg每6小时×48小时",
                "cushings_disease": "皮质醇抑制>50%",
                "ectopic_acth": "皮质醇无抑制"
              },
              "acth_levels": {
                "acth_dependent": "ACTH >20 pg/mL",
                "acth_independent": "ACTH <10 pg/mL"
              }
            }
          },
          "treatment": {
            "surgical_treatment": {
              "transsphenoidal_surgery": {
                "indication": "垂体腺瘤",
                "success_rate": "70-90%"
              },
              "adrenalectomy": {
                "unilateral": "单侧腺瘤",
                "bilateral": "双侧增生"
              }
            },
            "medical_treatment": {
              "ketoconazole": {
                "mechanism": "抑制皮质醇合成",
                "dose": "200-400mg 每日2-3次"
              },
              "mitotane": {
                "indication": "肾上腺皮质癌",
                "mechanism": "肾上腺毒性"
              }
            }
          }
        },
        {
          "id": "ADR_003",
          "name": "嗜铬细胞瘤",
          "name_en": "Pheochromocytoma",
          "type": "disease",
          "category": "肾上腺疾病",
          "icd10": "E27.5",
          "description": "起源于嗜铬组织的肿瘤，分泌过多儿茶酚胺",
          "epidemiology": {
            "incidence": "每年2-8/百万人",
            "prevalence": "高血压患者中0.1-0.6%",
            "hereditary": "25-30%为遗传性"
          },
          "clinical_manifestations": {
            "classic_triad": {
              "headache": "68%患者",
              "sweating": "69%患者", 
              "palpitations": "51%患者"
            },
            "hypertension": {
              "prevalence": "90%患者",
              "patterns": [
                "持续性高血压（50%）",
                "阵发性高血压（45%）"
              ]
            }
          },
          "diagnosis": {
            "biochemical_testing": {
              "plasma_metanephrines": {
                "sensitivity": "96-100%",
                "specificity": "85-89%"
              },
              "24h_urine_catecholamines": {
                "sensitivity": "87-90%"
              }
            },
            "imaging": {
              "ct_mri": "首选解剖学成像",
              "mibg_scintigraphy": "功能性成像"
            }
          },
          "treatment": {
            "preoperative_management": {
              "alpha_blockade": {
                "phenoxybenzamine": "10-20mg 每日2次",
                "duration": "手术前7-14天"
              }
            },
            "surgical_treatment": {
              "laparoscopic_adrenalectomy": "首选术式"
            }
          }
        },
        {
          "id": "ADR_004",
          "name": "肾上腺皮质功能不全",
          "name_en": "Adrenal Insufficiency", 
          "type": "disease",
          "category": "肾上腺疾病",
          "icd10": "E27.1",
          "description": "肾上腺皮质激素分泌不足引起的临床综合征",
          "classification": {
            "primary": {
              "definition": "原发性（阿狄森病）",
              "mechanism": "肾上腺皮质本身病变"
            },
            "secondary": {
              "definition": "继发性",
              "mechanism": "垂体ACTH分泌不足"
            }
          },
          "etiology": {
            "autoimmune": "80-90%原发性病因",
            "infections": "结核，真菌感染",
            "hemorrhage": "抗凝并发症，脓毒症"
          },
          "clinical_manifestations": {
            "constitutional": [
              "乏力",
              "体重减轻",
              "肌无力"
            ],
            "gastrointestinal": [
              "恶心呕吐",
              "腹痛",
              "渴盐"
            ],
            "skin_changes": {
              "hyperpigmentation": "94%原发性患者",
              "mechanism": "ACTH过多"
            },
            "cardiovascular": {
              "hypotension": "88-94%患者"
            }
          },
          "diagnosis": {
            "screening": {
              "morning_cortisol": "8-9AM采血",
              "interpretation": {
                ">13 μg/dL": "基本除外",
                "<3 μg/dL": "强烈提示"
              }
            },
            "confirmatory": {
              "acth_stimulation": "250μg合成ACTH",
              "normal_response": "皮质醇>18-20 μg/dL"
            }
          },
          "treatment": {
            "glucocorticoid": {
              "hydrocortisone": "15-25mg/天，分2-3次"
            },
            "mineralocorticoid": {
              "fludrocortisone": "0.05-0.2mg/天（仅原发性）"
            },
            "emergency": {
              "adrenal_crisis": "氢化可的松100mg静脉"
            }
          }
        }
      ],

      "pituitary_entities": [
        {
          "id": "PIT_001",
          "name": "垂体腺瘤",
          "name_en": "Pituitary Adenoma",
          "type": "disease",
          "category": "垂体疾病",
          "description": "起源于垂体前叶的良性肿瘤，根据激素分泌功能和大小分类",
          "classification": {
            "by_size": {
              "microadenoma": "<1cm",
              "macroadenoma": "≥1cm",
              "giant_adenoma": ">4cm"
            },
            "by_function": {
              "functioning": "分泌过多激素",
              "non_functioning": "不分泌激素或分泌无活性激素"
            },
            "by_hormone": {
              "prolactinoma": "泌乳素瘤(40%)",
              "growth_hormone": "生长激素瘤(20%)",
              "acth": "ACTH腺瘤(10%)",
              "tsh": "TSH腺瘤(<2%)",
              "gonadotroph": "促性腺激素瘤(15%)",
              "null_cell": "无功能腺瘤(15%)"
            }
          }
        },
        {
          "id": "PIT_002",
          "name": "泌乳素瘤",
          "name_en": "Prolactinoma", 
          "type": "disease",
          "category": "垂体疾病",
          "description": "分泌过量泌乳素的垂体腺瘤，最常见的功能性垂体肿瘤",
          "prevalence": "10万人中10-50例",
          "gender_difference": {
            "women": "育龄期多见，多为微腺瘤",
            "men": "中年多见，多为巨腺瘤"
          },
          "clinical_manifestations": {
            "hyperprolactinemia_effects": {
              "women": [
                "月经紊乱/闭经",
                "不孕",
                "溢乳",
                "性欲减退",
                "骨质疏松"
              ],
              "men": [
                "性功能减退",
                "阳痿",
                "不育",
                "溢乳(少见)",
                "骨质疏松"
              ]
            },
            "mass_effects": [
              "头痛",
              "视野缺损",
              "视力下降",
              "垂体功能减退"
            ]
          },
          "diagnostic_workup": {
            "prolactin_levels": {
              "normal": {
                "men": "<20 ng/mL",
                "women": "<25 ng/mL"
              },
              "mild_elevation": "25-100 ng/mL",
              "moderate_elevation": "100-250 ng/mL", 
              "severe_elevation": ">250 ng/mL (提示泌乳素瘤)"
            },
            "differential_diagnosis": {
              "physiological": ["妊娠", "哺乳", "应激", "睡眠"],
              "pathological": ["下丘脑疾病", "垂体柄受压", "原发甲减"],
              "medications": ["多巴胺拮抗剂", "抗抑郁药", "抗高血压药"]
            },
            "imaging": {
              "mri_pituitary": {
                "microadenoma": "增强后低信号",
                "macroadenoma": "不均匀强化",
                "mass_effect": "视交叉受压，海绵窦侵犯"
              }
            }
          },
          "treatment_strategies": {
            "medical_therapy": {
              "dopamine_agonists": {
                "cabergoline": {
                  "dose": "0.25-2mg 每周2次",
                  "efficacy": "泌乳素正常化90%，肿瘤缩小80%",
                  "side_effects": ["恶心", "头晕", "心脏瓣膜病(高剂量)"]
                },
                "bromocriptine": {
                  "dose": "2.5-15mg/day",
                  "efficacy": "稍差于cabergoline",
                  "pregnancy": "妊娠期首选"
                }
              }
            },
            "surgical_indications": [
              "药物治疗抵抗",
              "不能耐受药物副作用",
              "巨腺瘤视野缺损",
              "脑脊液鼻漏",
              "垂体卒中"
            ],
            "radiation_therapy": [
              "手术和药物治疗失败",
              "恶性泌乳素瘤",
              "侵袭性腺瘤"
            ]
          }
        },
        {
          "id": "PIT_003",
          "name": "肢端肥大症",
          "name_en": "Acromegaly",
          "type": "disease",
          "category": "垂体疾病",
          "description": "生长激素分泌过多导致的慢性进行性疾病，特征为骨骼、软组织过度生长",
          "prevalence": "10万人中3-4例",
          "mortality": "未治疗患者死亡率增加2-3倍",
          "clinical_manifestations": {
            "skeletal_changes": [
              "手脚增大",
              "面容粗陋",
              "下颌前突",
              "眉弓突出",
              "鼻唇增厚"
            ],
            "soft_tissue_changes": [
              "舌体增大",
              "声音低沉",
              "皮肤粗糙",
              "多汗",
              "皮肤标签"
            ],
            "systemic_complications": {
              "cardiovascular": [
                "高血压(30%)",
                "左心室肥厚",
                "心肌病",
                "心律失常"
              ],
              "metabolic": [
                "糖尿病(30%)",
                "胰岛素抵抗",
                "血脂异常"
              ],
              "respiratory": [
                "睡眠呼吸暂停(70%)",
                "上气道阻塞"
              ],
              "rheumatologic": [
                "关节炎",
                "腕管综合征",
                "脊柱后凸"
              ],
              "neoplastic": [
                "结肠息肉增加",
                "甲状腺结节",
                "前列腺增生"
              ]
            }
          },
          "diagnostic_criteria": {
            "biochemical_diagnosis": {
              "igf1": "年龄性别匹配上限",
              "ogtt_suppression": {
                "normal": "GH < 0.4 ng/mL",
                "acromegaly": "GH不被抑制或反常升高"
              },
              "random_gh": "参考价值有限"
            },
            "imaging": {
              "pituitary_mri": {
                "microadenoma": "30%",
                "macroadenoma": "70%",
                "characteristics": "T1低信号，增强后不均匀强化"
              }
            }
          },
          "treatment_goals": {
            "biochemical": {
              "igf1": "年龄性别正常范围",
              "random_gh": "<1.0 ng/mL",
              "post_ogtt_gh": "<0.4 ng/mL"
            },
            "clinical": [
              "症状改善",
              "并发症控制",
              "生活质量提高",
              "死亡率降低"
            ]
          },
          "treatment_modalities": {
            "surgical": {
              "transsphenoidal_surgery": {
                "first_line": "微腺瘤和无侵犯巨腺瘤",
                "success_rate": {
                  "microadenoma": "85-90%",
                  "macroadenoma": "50-60%"
                },
                "complications": [
                  "脑脊液鼻漏",
                  "垂体功能减退",
                  "尿崩症"
                ]
              }
            },
            "medical": {
              "somatostatin_analogs": {
                "octreotide_lar": "20-40mg/月",
                "lanreotide": "60-120mg/月",
                "efficacy": "IGF-1正常化60-70%"
              },
              "growth_hormone_antagonists": {
                "pegvisomant": "10-30mg/day",
                "efficacy": "IGF-1正常化>90%",
                "monitoring": "肝功能"
              },
              "dopamine_agonists": {
                "cabergoline": "0.5-3mg/week",
                "efficacy": "轻度降GH，改善糖代谢"
              }
            },
            "radiation": {
              "conventional": "分次放疗",
              "stereotactic": "伽马刀",
              "efficacy": "缓慢，需5-15年",
              "complications": "垂体功能减退风险"
            }
          }
        },
        {
          "id": "PIT_004",
          "name": "生长激素缺乏症",
          "name_en": "Growth Hormone Deficiency",
          "type": "disease", 
          "category": "垂体疾病",
          "description": "生长激素分泌不足导致的临床综合征，分为儿童期和成人期GHD",
          "classification": {
            "childhood_ghd": {
              "manifestations": [
                "生长发育迟缓",
                "身材矮小",
                "骨龄落后",
                "低血糖倾向"
              ]
            },
            "adult_ghd": {
              "manifestations": [
                "体脂增加",
                "肌肉量减少",
                "骨密度降低",
                "运动耐量下降",
                "生活质量下降"
              ]
            }
          },
          "treatment_protocols": {
            "growth_hormone_replacement": {
              "children": "0.025-0.035 mg/kg/day sc",
              "adults": "0.2-0.3 mg/day起始，根据IGF-1调整"
            }
          }
        },
        {
          "id": "PIT_005",
          "name": "中枢性尿崩症",
          "name_en": "Central Diabetes Insipidus",
          "type": "disease",
          "category": "垂体疾病", 
          "description": "抗利尿激素(ADH)分泌不足导致的水盐代谢紊乱",
          "clinical_manifestations": [
            "多尿(>3L/24h)",
            "烦渴",
            "夜尿增多",
            "脱水风险"
          ],
          "treatment": {
            "desmopressin": {
              "nasal": "10-20 μg bid",
              "oral": "0.1-0.2mg bid-tid"
            }
          }
        },
        {
          "id": "PIT_004",
          "name": "肢端肥大症",
          "name_en": "Acromegaly",
          "type": "disease",
          "category": "垂体疾病",
          "icd10": "E22.0",
          "description": "生长激素分泌过多引起的慢性全身性疾病",
          "etiology": {
            "pituitary_adenoma": {
              "prevalence": ">95%病例",
              "characteristics": "垂体生长激素腺瘤",
              "size_distribution": {
                "macroadenoma": "75%",
                "microadenoma": "25%"
              }
            },
            "ectopic_sources": {
              "prevalence": "<5%",
              "tumors": [
                "胰腺胰岛细胞瘤",
                "肺类癌瘤",
                "下丘脑GHRH瘤"
              ]
            }
          },
          "pathophysiology": {
            "growth_hormone_excess": "生长激素持续过量分泌",
            "igf1_mediation": "主要通过IGF-1介导生长效应",
            "metabolic_effects": "糖、脂、蛋白质代谢异常",
            "tissue_growth": "软组织、骨骼、内脏器官增生"
          },
          "clinical_manifestations": {
            "skeletal_changes": {
              "acral_enlargement": {
                "hands": "手指增粗、指间距增宽",
                "feet": "足部增大、鞋号增加",
                "jaw": "下颌前突、咬合不良",
                "skull": "颅骨增厚、枕外隆突明显"
              },
              "arthropathy": {
                "prevalence": "70-80%",
                "pattern": "大关节受累为主",
                "symptoms": "关节疼痛、僵硬、活动受限"
              }
            },
            "soft_tissue_changes": {
              "facial_features": {
                "coarse_features": "面容粗糙",
                "prominent_brow": "眉弓突出",
                "enlarged_nose": "鼻部增大",
                "thick_lips": "唇厚舌大"
              },
              "skin_changes": {
                "thickness": "皮肤增厚",
                "sweating": "多汗",
                "oily_skin": "皮肤油腻",
                "skin_tags": "皮赘增多"
              }
            },
            "systemic_complications": {
              "cardiovascular": {
                "cardiomyopathy": "肥厚性心肌病",
                "hypertension": "60-70%患者",
                "arrhythmia": "心律失常",
                "valve_disease": "瓣膜疾病"
              },
              "respiratory": {
                "sleep_apnea": "80%患者",
                "mechanism": "上气道软组织增生",
                "symptoms": "打鼾、夜间憋醒"
              },
              "metabolic": {
                "diabetes": "25-50%患者",
                "insulin_resistance": "胰岛素抵抗",
                "dyslipidemia": "血脂异常"
              },
              "neurological": {
                "headache": "60%患者",
                "visual_field_defects": "大腺瘤压迫视交叉",
                "cranial_neuropathy": "颅神经受压"
              }
            }
          },
          "diagnosis": {
            "biochemical_testing": {
              "igf1_levels": {
                "screening": "血清IGF-1水平",
                "interpretation": "年龄性别校正正常值上限",
                "sensitivity": "95%用于筛查"
              },
              "oral_glucose_tolerance": {
                "protocol": "75g葡萄糖负荷试验",
                "normal_suppression": "GH<1 ng/mL",
                "acromegaly": "GH不被抑制或反常升高",
                "paradoxical_response": "25%患者GH反常升高"
              },
              "random_gh": {
                "limitation": "GH分泌呈脉冲性",
                "interpretation": "单次测定价值有限"
              }
            },
            "imaging": {
              "pituitary_mri": {
                "protocol": "垂体薄层增强MRI",
                "findings": {
                  "adenoma_detection": "95%可发现腺瘤",
                  "size_assessment": "评估肿瘤大小",
                  "invasiveness": "海绵窦侵犯评估"
                }
              },
              "visual_field_testing": "大腺瘤时进行"
            }
          },
          "treatment": {
            "surgical_treatment": {
              "transsphenoidal_surgery": {
                "first_line": "首选治疗方法",
                "success_rates": {
                  "microadenoma": "85-90%",
                  "macroadenoma": "60-70%"
                },
                "complications": [
                  "垂体功能不全",
                  "尿崩症",
                  "脑脊液漏"
                ]
              }
            },
            "medical_treatment": {
              "somatostatin_analogs": {
                "octreotide": {
                  "formulation": "长效缓释制剂",
                  "dose": "20-30mg 每4周",
                  "efficacy": "60-70%患者IGF-1正常化"
                },
                "lanreotide": {
                  "formulation": "自动注射器",
                  "dose": "90-120mg 每4周"
                },
                "pasireotide": {
                  "indication": "其他药物无效时",
                  "side_effect": "高血糖风险"
                }
              },
              "dopamine_agonists": {
                "cabergoline": {
                  "dose": "0.5-3.5mg 每周",
                  "indication": "轻度病例或联合治疗",
                  "efficacy": "30%患者有效"
                }
              },
              "growth_hormone_antagonist": {
                "pegvisomant": {
                  "mechanism": "GH受体拮抗剂",
                  "dose": "10-30mg 每日",
                  "efficacy": "90%患者IGF-1正常化",
                  "monitoring": "肝功能监测"
                }
              }
            },
            "radiation_therapy": {
              "conventional_radiotherapy": {
                "indication": "手术和药物治疗无效",
                "dose": "45-50 Gy分次照射",
                "delayed_response": "5-15年达到最大效果"
              },
              "stereotactic_radiosurgery": {
                "gamma_knife": "适用于残留小病灶",
                "advantages": "精确性高，单次治疗"
              }
            }
          },
          "monitoring": {
            "biochemical_response": {
              "target_levels": {
                "igf1": "年龄性别校正正常范围",
                "gh": "随机GH <2.5 ng/mL"
              },
              "frequency": "治疗后3-6个月检测"
            },
            "imaging_surveillance": "年度垂体MRI",
            "complication_screening": [
              "心脏超声",
              "睡眠呼吸监测",
              "结肠镜检查",
              "骨密度检测"
            ]
          }
        },
        {
          "id": "PIT_005",
          "name": "垂体功能减退症",
          "name_en": "Hypopituitarism",
          "type": "disease",
          "category": "垂体疾病",
          "icd10": "E23.0",
          "description": "垂体前叶一种或多种激素分泌不足的临床综合征",
          "classification": {
            "by_severity": {
              "partial": "部分垂体功能减退",
              "complete": "全垂体功能减退（Sheehan综合征）"
            },
            "by_onset": {
              "congenital": "先天性垂体功能减退",
              "acquired": "获得性垂体功能减退"
            }
          },
          "etiology": {
            "tumor_related": {
              "pituitary_adenoma": "垂体腺瘤",
              "craniopharyngioma": "颅咽管瘤",
              "metastases": "转移瘤",
              "meningioma": "脑膜瘤"
            },
            "vascular_causes": {
              "sheehan_syndrome": {
                "definition": "产后垂体梗死",
                "mechanism": "分娩时大出血导致垂体缺血",
                "clinical_features": "产后无泌乳、闭经"
              },
              "pituitary_apoplexy": {
                "definition": "垂体卒中",
                "presentation": "急性头痛、视力障碍、意识障碍",
                "emergency": "内分泌急症"
              }
            },
            "inflammatory_conditions": {
              "lymphocytic_hypophysitis": "淋巴细胞性垂体炎",
              "sarcoidosis": "肉芽肿病",
              "langerhans_cell_histiocytosis": "朗格汉斯细胞组织细胞增生症"
            },
            "traumatic": {
              "head_trauma": "颅脑外伤",
              "surgery": "垂体手术",
              "radiation": "头颈部放疗"
            },
            "genetic_causes": {
              "prop1_mutation": "PROP1基因突变",
              "pit1_mutation": "PIT1基因突变",
              "multiple_pituitary_hormone_deficiency": "多种垂体激素缺乏症"
            }
          },
          "hormonal_deficiencies": {
            "growth_hormone_deficiency": {
              "adults": {
                "symptoms": [
                  "乏力",
                  "肌肉量减少",
                  "骨密度下降",
                  "腹部脂肪增加",
                  "生活质量下降"
                ],
                "diagnosis": "胰岛素低血糖试验或精氨酸刺激试验"
              },
              "children": {
                "symptoms": "生长发育迟缓",
                "diagnosis": "身高<3百分位"
              }
            },
            "gonadotropin_deficiency": {
              "males": {
                "symptoms": [
                  "性欲减退",
                  "勃起功能障碍",
                  "肌肉量减少",
                  "骨质疏松"
                ],
                "biochemical": "低睾酮，LH/FSH低或正常"
              },
              "females": {
                "symptoms": [
                  "闭经",
                  "不孕",
                  "潮热",
                  "骨质疏松"
                ],
                "biochemical": "低雌激素，LH/FSH低或正常"
              }
            },
            "tsh_deficiency": {
              "symptoms": [
                "怕冷",
                "乏力",
                "体重增加",
                "便秘",
                "记忆力减退"
              ],
              "biochemical": "低FT4，TSH正常或低",
              "differential": "与原发性甲减区别"
            },
            "acth_deficiency": {
              "symptoms": [
                "乏力",
                "食欲减退",
                "体重减轻",
                "低血糖",
                "低血压"
              ],
              "biochemical": "低皮质醇，ACTH低",
              "emergency": "可发生肾上腺危象"
            },
            "prolactin_deficiency": {
              "manifestation": "产后泌乳障碍",
              "rarity": "临床上较少见"
            }
          },
          "diagnosis": {
            "clinical_assessment": {
              "history": "症状出现顺序和严重程度",
              "physical_examination": [
                "生长发育评估",
                "性征发育",
                "甲状腺检查",
                "皮肤色素"
              ]
            },
            "hormonal_testing": {
              "basal_hormones": [
                "IGF-1",
                "睾酮/雌激素",
                "FT4、TSH",
                "晨8点皮质醇",
                "泌乳素"
              ],
              "dynamic_testing": {
                "insulin_tolerance_test": {
                  "indication": "评估GH和ACTH储备",
                  "contraindication": "心脏病、癫痫",
                  "protocol": "0.1-0.15 U/kg胰岛素静脉注射"
                },
                "combined_pituitary_test": "多种刺激试验联合进行",
                "individual_stimulation": "单一激素轴评估"
              }
            },
            "imaging": {
              "pituitary_mri": "评估垂体形态和病因",
              "visual_fields": "大病变时检查"
            }
          },
          "treatment": {
            "hormone_replacement": {
              "thyroid_hormone": {
                "levothyroxine": "0.8-1.6 μg/kg/天",
                "monitoring": "FT4水平，不依赖TSH"
              },
              "glucocorticoid": {
                "hydrocortisone": "15-25mg/天，分2-3次",
                "stress_dosing": "应激时增量",
                "emergency_card": "随身携带急救卡"
              },
              "sex_hormones": {
                "males": "睾酮替代治疗",
                "females": "雌孕激素替代治疗",
                "fertility": "希望生育时使用促性腺激素"
              },
              "growth_hormone": {
                "adults": "0.2-0.5mg/天，睡前皮下注射",
                "children": "0.025-0.035mg/kg/天",
                "monitoring": "IGF-1水平"
              }
            },
            "replacement_sequence": {
              "priority": [
                "1. 糖皮质激素（急需）",
                "2. 甲状腺激素",
                "3. 性激素",
                "4. 生长激素"
              ],
              "rationale": "避免肾上腺危象"
            }
          },
          "monitoring": {
            "efficacy_assessment": [
              "症状改善",
              "激素水平",
              "生活质量评估"
            ],
            "safety_monitoring": [
              "糖皮质激素过量症状",
              "甲状腺激素过量",
              "生长激素副作用"
            ],
            "long_term_follow_up": "终生激素替代和监测"
          }
        },
        {
          "id": "PIT_006",
          "name": "垂体卒中",
          "name_en": "Pituitary Apoplexy",
          "type": "disease",
          "category": "垂体疾病",
          "icd10": "E23.6",
          "description": "垂体腺瘤内急性出血或梗死导致的急性临床综合征",
          "pathophysiology": {
            "vascular_compromise": "垂体血管受压或栓塞",
            "hemorrhage": "腺瘤内出血",
            "necrosis": "缺血性坏死",
            "swelling": "急性肿胀压迫周围结构"
          },
          "predisposing_factors": {
            "underlying_adenoma": "多数发生在已有腺瘤基础上",
            "triggering_events": [
              "高血压",
              "抗凝治疗",
              "妊娠分娩",
              "大手术",
              "糖尿病",
              "头部外伤"
            ],
            "medications": [
              "溴隐亭治疗",
              "雌激素治疗",
              "GnRH激动剂"
            ]
          },
          "clinical_presentation": {
            "acute_onset": "症状急性起病（数小时内）",
            "classic_triad": {
              "severe_headache": {
                "characteristics": "突发剧烈头痛",
                "prevalence": "95%患者",
                "description": "一生中最严重头痛"
              },
              "visual_disturbance": {
                "types": [
                  "视野缺损",
                  "视力下降",
                  "复视"
                ],
                "mechanism": "视交叉和动眼神经受压",
                "prevalence": "70%患者"
              },
              "altered_consciousness": {
                "range": "从嗜睡到昏迷",
                "prevalence": "15%患者"
              }
            },
            "endocrine_dysfunction": {
              "acute_adrenal_insufficiency": {
                "prevalence": "70%患者",
                "symptoms": [
                  "恶心呕吐",
                  "低血压",
                  "电解质紊乱",
                  "循环衰竭"
                ],
                "life_threatening": "可危及生命"
              },
              "other_deficiencies": "其他垂体激素急性缺乏"
            },
            "neurological_signs": {
              "cranial_neuropathy": "颅神经麻痹",
              "meningeal_signs": "脑膜刺激征",
              "hemiparesis": "偏瘫（罕见）"
            }
          },
          "diagnosis": {
            "clinical_suspicion": [
              "急性剧烈头痛",
              "视力障碍",
              "垂体功能减退症状",
              "已知垂体瘤病史"
            ],
            "imaging": {
              "emergency_ct": {
                "findings": [
                  "垂体区高密度影",
                  "出血征象",
                  "占位效应"
                ],
                "limitations": "早期可能正常"
              },
              "mri": {
                "gold_standard": "最佳影像学检查",
                "findings": [
                  "T1高信号（出血）",
                  "T2混杂信号",
                  "占位效应"
                ],
                "timing": "急诊MRI首选"
              }
            },
            "laboratory_testing": {
              "emergency_hormones": [
                "随机皮质醇",
                "电解质",
                "血糖"
              ],
              "comprehensive_assessment": "病情稳定后完整垂体功能评估"
            },
            "differential_diagnosis": [
              "蛛网膜下腔出血",
              "脑膜炎",
              "急性青光眼",
              "偏头痛",
              "颅内动脉瘤"
            ]
          },
          "treatment": {
            "emergency_management": {
              "glucocorticoid_replacement": {
                "immediate": "氢化可的松100mg静脉推注",
                "maintenance": "100mg每8小时",
                "rationale": "治疗急性肾上腺功能不全"
              },
              "supportive_care": [
                "维持血压",
                "纠正电解质紊乱",
                "镇痛",
                "监护治疗"
              ]
            },
            "surgical_considerations": {
              "absolute_indications": [
                "意识障碍进行性加重",
                "视力急剧下降",
                "保守治疗无效"
              ],
              "relative_indications": [
                "持续性视野缺损",
                "颅神经麻痹",
                "垂体功能严重受损"
              ],
              "timing": "症状出现1周内手术效果最佳",
              "approach": "经蝶窦手术减压"
            },
            "conservative_treatment": {
              "indications": [
                "意识清楚",
                "视力稳定",
                "内分泌功能可替代"
              ],
              "monitoring": [
                "神经功能",
                "视力视野",
                "内分泌功能"
              ]
            }
          },
          "prognosis": {
            "visual_recovery": {
              "timing": "早期手术预后较好",
              "factors": "视力损失程度和持续时间"
            },
            "endocrine_recovery": {
              "likelihood": "30-60%可部分恢复",
              "hormones": "生长激素恢复最差"
            },
            "mortality": "保守治疗死亡率1-2%",
            "recurrence": "复发率5-10%"
          }
        }
      ],

      "hypertension_entities": [
        {
          "id": "HTN_001",
          "name": "原发性高血压",
          "name_en": "Primary Hypertension", 
          "type": "disease",
          "category": "心血管疾病",
          "description": "病因不明的高血压，占所有高血压的90-95%",
          "classification_2025": {
            "normal": "<120/80 mmHg",
            "elevated": "120-129/<80 mmHg", 
            "stage_1": "130-139/80-89 mmHg",
            "stage_2": "≥140/90 mmHg",
            "crisis": "≥180/120 mmHg"
          },
          "risk_factors": {
            "non_modifiable": [
              "年龄",
              "性别",
              "种族",
              "遗传因素"
            ],
            "modifiable": [
              "肥胖",
              "钠盐摄入过多",
              "酒精过量",
              "缺乏体力活动",
              "吸烟",
              "压力"
            ]
          },
          "pathophysiology": {
            "mechanisms": [
              "交感神经系统激活",
              "RAAS系统激活", 
              "血管内皮功能异常",
              "钠水潴留",
              "血管重塑"
            ]
          },
          "target_organ_damage": {
            "cardiac": [
              "左心室肥厚",
              "心房颤动",
              "冠心病",
              "心力衰竭"
            ],
            "vascular": [
              "动脉硬化",
              "主动脉夹层",
              "外周动脉疾病"
            ],
            "renal": [
              "慢性肾脏病",
              "蛋白尿",
              "肾功能衰竭"
            ],
            "cerebrovascular": [
              "脑卒中",
              "短暂性脑缺血",
              "血管性痴呆"
            ],
            "retinal": [
              "视网膜病变",
              "视乳头水肿"
            ]
          },
          "diagnostic_approach": {
            "bp_measurement": {
              "office_bp": "标准诊室血压测量",
              "home_bp": "家庭血压监测",
              "ambulatory_bp": "24小时动态血压监测"
            },
            "initial_evaluation": [
              "详细病史",
              "体格检查",
              "基础实验室检查",
              "心电图",
              "眼底检查"
            ],
            "laboratory_tests": [
              "血常规",
              "基础代谢组合",
              "尿常规",
              "血脂",
              "血糖/HbA1c",
              "甲功(如有指征)",
              "尿酸"
            ]
          },
          "treatment_strategy_2025": {
            "lifestyle_modifications": {
              "weight_management": "BMI 18.5-24.9",
              "dash_diet": "富含水果蔬菜，低钠饮食",
              "sodium_restriction": "<2.3g/day",
              "physical_activity": "中等强度150分钟/周",
              "alcohol_limitation": "男性≤2杯/天，女性≤1杯/天",
              "stress_management": "放松训练，冥想"
            },
            "pharmacological_therapy": {
              "first_line_agents": [
                "ACE抑制剂",
                "ARB",
                "钙通道阻滞剂",
                "噻嗪样利尿剂"
              ],
              "combination_therapy": {
                "stage_2_htn": "推荐起始联合用药",
                "single_pill_combinations": "提高依从性首选"
              },
              "bp_targets": {
                "general": "<130/80 mmHg",
                "diabetes": "<130/80 mmHg", 
                "ckd": "<130/80 mmHg",
                "elderly": "<130/80 mmHg (如耐受)"
              }
            }
          }
        }
      ],

      "gonadal_entities": [
        {
          "id": "GON_001",
          "name": "多囊卵巢综合征",
          "name_en": "Polycystic Ovary Syndrome",
          "type": "disease",
          "category": "性腺疾病",
          "description": "育龄期女性常见的内分泌代谢疾病，以雄激素过多、排卵障碍和多囊卵巢为特征",
          "icd10_code": "E28.2",
          "prevalence": "育龄期女性中5-10%",
          "pathophysiology": {
            "primary_defects": [
              "胰岛素抵抗",
              "雄激素过多",
              "LH/FSH比例失调"
            ],
            "metabolic_features": [
              "胰岛素抵抗",
              "糖耐量异常",
              "血脂异常",
              "肥胖"
            ]
          },
          "clinical_manifestations": {
            "reproductive_features": [
              "月经稀发或闭经",
              "不孕",
              "流产率增加"
            ],
            "hyperandrogenic_features": [
              "多毛症",
              "痤疮",
              "雄激素性脱发"
            ],
            "metabolic_features": [
              "肥胖(50-80%)",
              "胰岛素抵抗",
              "糖耐量异常(31-35%)",
              "2型糖尿病(7.5-10%)",
              "血脂异常(70%)",
              "代谢综合征(33-47%)"
            ],
            "psychological_features": [
              "抑郁",
              "焦虑",
              "生活质量下降"
            ]
          },
          "diagnostic_criteria_2023": {
            "rotterdam_criteria": {
              "requirement": "满足以下3项中的2项",
              "criteria": [
                "排卵障碍或无排卵",
                "临床或生化雄激素过多征象",
                "多囊卵巢(超声)"
              ],
              "exclusions": [
                "先天性肾上腺增生",
                "库欣综合征",
                "分泌雄激素的肿瘤"
              ]
            },
            "laboratory_findings": {
              "hormonal": {
                "total_testosterone": ">0.481 nmol/L",
                "free_testosterone": "升高",
                "lh_fsh_ratio": ">2:1",
                "amh": ">35 pmol/L",
                "dhea_s": "可升高"
              },
              "metabolic": {
                "fasting_glucose": "可升高",
                "ogtt": "糖耐量异常常见",
                "homa_ir": ">2.5",
                "lipid_profile": "TG升高，HDL-C降低"
              }
            },
            "ultrasound_criteria": {
              "follicle_number": "≥20个小卵泡/卵巢",
              "ovarian_volume": ">10ml",
              "stromal_echogenicity": "增强"
            }
          },
          "treatment_strategies": {
            "lifestyle_intervention": {
              "first_line": true,
              "components": [
                "减重5-10%(肥胖患者)",
                "低GI饮食",
                "规律有氧运动",
                "行为干预"
              ],
              "benefits": [
                "改善胰岛素敏感性",
                "恢复排卵",
                "减少雄激素水平",
                "改善代谢指标"
              ]
            },
            "pharmacological_therapy": {
              "metabolic_management": {
                "metformin": {
                  "dose": "500-1000mg bid",
                  "indications": ["胰岛素抵抗", "糖耐量异常", "减重"],
                  "benefits": ["改善胰岛素敏感性", "轻度减重", "可能改善排卵"]
                },
                "glp1_agonists": {
                  "indications": ["肥胖", "2型糖尿病"],
                  "benefits": ["显著减重", "改善糖代谢"]
                }
              },
              "reproductive_management": {
                "ovulation_induction": {
                  "clomiphene": {
                    "dose": "50-150mg/day × 5天",
                    "success_rate": "排卵率70-80%，妊娠率35-40%"
                  },
                  "letrozole": {
                    "dose": "2.5-7.5mg/day × 5天",
                    "advantages": "妊娠率更高，多胎率低"
                  },
                  "gonadotropins": "二线治疗，需严密监测"
                },
                "contraception": {
                  "combined_oc": {
                    "benefits": ["调节月经", "减少雄激素", "保护子宫内膜"],
                    "contraindications": ["代谢综合征", "血栓风险"]
                  }
                }
              },
              "hyperandrogenism_management": {
                "antiandrogens": [
                  "螺内酯 25-200mg/day",
                  "醋酸环丙孕酮",
                  "氟他胺"
                ],
                "topical_treatments": "激光脱毛，外用药物"
              }
            }
          },
          "complications": {
            "reproductive": [
              "不孕症(70-80%)",
              "妊娠糖尿病风险增加",
              "妊娠高血压风险增加",
              "流产率增加",
              "子宫内膜癌风险增加"
            ],
            "metabolic": [
              "2型糖尿病(相对风险4倍)",
              "心血管疾病风险增加",
              "非酒精性脂肪肝",
              "阻塞性睡眠呼吸暂停"
            ],
            "psychological": [
              "抑郁症(相对风险3倍)",
              "焦虑症",
              "饮食障碍",
              "性生活质量下降"
            ]
          }
        },
        {
          "id": "GON_002",
          "name": "男性性腺功能减退症",
          "name_en": "Male Hypogonadism",
          "type": "disease",
          "category": "性腺疾病",
          "description": "男性睾丸功能不足导致睾酮水平低下和/或精子生成障碍",
          "icd10_code": "E29.1",
          "prevalence": "40岁以上男性中2-12%",
          "classification": {
            "primary_hypogonadism": {
              "mechanism": "睾丸功能缺陷",
              "causes": [
                "Klinefelter综合征",
                "隐睾症",
                "睾丸扭转或外伤",
                "感染(腮腺炎性睾丸炎)",
                "化疗或放疗",
                "老化"
              ],
              "laboratory": "睾酮低，LH/FSH高"
            },
            "secondary_hypogonadism": {
              "mechanism": "下丘脑-垂体功能异常",
              "causes": [
                "垂体腺瘤",
                "Kallmann综合征",
                "肥胖",
                "药物(类固醇、阿片类)",
                "系统性疾病",
                "应激"
              ],
              "laboratory": "睾酮低，LH/FSH低或正常"
            }
          },
          "clinical_manifestations": {
            "sexual_symptoms": [
              "性欲减退",
              "勃起功能障碍",
              "性高潮减少",
              "不育"
            ],
            "physical_symptoms": [
              "肌肉量和力量减少",
              "骨密度降低",
              "体脂增加",
              "乳房发育",
              "体毛减少",
              "面部潮红"
            ],
            "psychological_symptoms": [
              "抑郁",
              "易怒",
              "疲劳",
              "认知功能下降",
              "注意力不集中"
            ],
            "metabolic_symptoms": [
              "胰岛素抵抗",
              "糖代谢异常",
              "血脂异常",
              "代谢综合征"
            ]
          },
          "diagnostic_approach": {
            "clinical_assessment": [
              "详细病史和体格检查",
              "性功能评估量表",
              "睾丸大小测量"
            ],
            "laboratory_tests": {
              "primary_tests": {
                "total_testosterone": {
                  "sampling": "晨间8-10点",
                  "normal_range": ">12 nmol/L (>350 ng/dL)",
                  "low": "<8 nmol/L (<230 ng/dL)",
                  "repeat": "异常结果需重复确认"
                },
                "lh_fsh": "区分原发性和继发性",
                "prolactin": "排除高泌乳素血症"
              },
              "additional_tests": {
                "free_testosterone": "SHBG异常时测定",
                "shbg": "影响总睾酮解释",
                "hcg_stimulation": "评估睾丸储备功能",
                "gnrh_stimulation": "评估垂体功能"
              }
            }
          },
          "treatment_protocols": {
            "testosterone_replacement": {
              "indications": [
                "症状明显的确诊患者",
                "睾酮<8 nmol/L或8-12 nmol/L伴症状"
              ],
              "contraindications": [
                "前列腺癌",
                "乳腺癌",
                "未治疗的阻塞性睡眠呼吸暂停",
                "未控制的心力衰竭",
                "血细胞比容>50%"
              ],
              "formulations": {
                "injectable": {
                  "testosterone_undecanoate": "1000mg q12周 im",
                  "testosterone_enanthate": "250mg q2-3周 im"
                },
                "topical": {
                  "gel": "50-100mg/day 外用",
                  "patch": "5mg/day 贴剂"
                },
                "oral": {
                  "testosterone_undecanoate": "120-160mg bid po"
                }
              },
              "monitoring": {
                "baseline": [
                  "前列腺特异性抗原(PSA)",
                  "血常规",
                  "肝功能",
                  "血脂"
                ],
                "follow_up": [
                  "3个月: 睾酮水平、血常规、PSA",
                  "6个月: 完整评估",
                  "年度: 全面检查包括前列腺检查"
                ]
              }
            },
            "fertility_preservation": {
              "hcg_therapy": {
                "dose": "1500-2000 IU 3次/周",
                "duration": "3-6个月",
                "indication": "希望保留生育力"
              },
              "combined_therapy": {
                "hcg_hmg": "刺激精子生成",
                "monitoring": "精液分析、激素水平"
              }
            }
          },
          "complications": {
            "untreated_consequences": [
              "骨质疏松",
              "心血管疾病风险增加",
              "代谢综合征",
              "抑郁和生活质量下降",
              "不育"
            ],
            "treatment_risks": [
              "红细胞增多症",
              "睡眠呼吸暂停恶化",
              "前列腺问题(争议)",
              "心血管风险(争议)"
            ]
          }
        },
        {
          "id": "GON_003",
          "name": "女性性腺功能减退症",
          "name_en": "Female Hypogonadism",
          "type": "disease",
          "category": "性腺疾病",
          "description": "女性卵巢功能不足导致雌激素缺乏的临床综合征",
          "classification": {
            "primary_ovarian_insufficiency": {
              "definition": "40岁前卵巢功能衰竭",
              "prevalence": "1% 40岁前女性",
              "causes": [
                "Turner综合征",
                "脆性X综合征前突变",
                "自身免疫性卵巢炎",
                "化疗/放疗",
                "卵巢手术",
                "感染"
              ]
            },
            "functional_hypothalamic_amenorrhea": {
              "mechanism": "下丘脑GnRH分泌抑制",
              "causes": [
                "过度运动",
                "体重过低",
                "心理应激",
                "饮食障碍"
              ]
            },
            "natural_menopause": {
              "definition": "连续12个月闭经",
              "average_age": "51岁",
              "mechanism": "卵泡耗竭"
            }
          },
          "clinical_manifestations": {
            "reproductive_symptoms": [
              "闭经或月经稀发",
              "不孕",
              "性欲减退",
              "阴道干燥"
            ],
            "vasomotor_symptoms": [
              "潮热",
              "盗汗",
              "睡眠障碍"
            ],
            "genitourinary_symptoms": [
              "阴道萎缩",
              "性交痛",
              "尿频",
              "泌尿系感染"
            ],
            "long_term_consequences": [
              "骨质疏松",
              "心血管疾病风险增加",
              "认知功能下降",
              "情绪障碍"
            ]
          },
          "diagnostic_evaluation": {
            "hormonal_assessment": {
              "fsh": ">25 IU/L (绝经后水平)",
              "lh": "升高",
              "estradiol": "<50 pmol/L",
              "amh": "<7 pmol/L",
              "inhibin_b": "降低"
            },
            "additional_tests": [
              "妊娠试验",
              "泌乳素",
              "TSH",
              "雄激素谱",
              "核型分析(早发者)"
            ]
          },
          "treatment_options": {
            "hormone_replacement_therapy": {
              "indications": [
                "症状明显",
                "年龄<60岁或绝经<10年",
                "骨质疏松预防"
              ],
              "regimens": {
                "estrogen_progestogen": "有子宫女性",
                "estrogen_only": "子宫切除术后",
                "formulations": [
                  "口服",
                  "经皮贴剂/凝胶",
                  "阴道局部用药"
                ]
              },
              "contraindications": [
                "乳腺癌",
                "子宫内膜癌",
                "血栓栓塞症",
                "未诊断的阴道出血"
              ]
            },
            "non_hormonal_therapy": [
              "选择性5-羟色胺再摄取抑制剂",
              "加巴喷丁",
              "植物雌激素",
              "认知行为疗法"
            ]
          }
        },
        {
          "id": "GON_004",
          "name": "性早熟",
          "name_en": "Precocious Puberty",
          "type": "disease",
          "category": "性腺疾病",
          "description": "青春期发育提前启动，影响身体和心理发育",
          "definition": {
            "girls": "8岁前出现第二性征",
            "boys": "9岁前出现第二性征"
          },
          "classification": {
            "central_precocious_puberty": {
              "mechanism": "下丘脑-垂体-性腺轴过早激活",
              "prevalence": "女孩90%，男孩40%",
              "causes": [
                "特发性(女孩多见)",
                "颅内肿瘤",
                "颅内感染",
                "头部外伤",
                "放疗后"
              ]
            },
            "peripheral_precocious_puberty": {
              "mechanism": "性腺或肾上腺激素过多分泌",
              "causes": [
                "卵巢囊肿/肿瘤",
                "睾丸肿瘤",
                "肾上腺肿瘤",
                "先天性肾上腺增生",
                "外源性激素暴露"
              ]
            }
          },
          "clinical_assessment": {
            "physical_examination": [
              "Tanner分期评估",
              "生长速度测量",
              "骨龄评估"
            ],
            "laboratory_tests": {
              "baseline": ["LH", "FSH", "雌激素/睾酮"],
              "stimulation": "GnRH刺激试验",
              "imaging": [
                "骨龄X线",
                "盆腔/阴囊超声",
                "头颅MRI(中枢性)"
              ]
            }
          },
          "treatment_strategies": {
            "gnrh_agonist_therapy": {
              "indications": [
                "中枢性性早熟",
                "预测成年身高受损",
                "心理社会问题"
              ],
              "medications": [
                "亮丙瑞林",
                "曲普瑞林",
                "戈舍瑞林"
              ],
              "monitoring": [
                "生长速度",
                "骨龄进展",
                "激素抑制效果"
              ]
            }
          }
        },
        {
          "id": "GON_004",
          "name": "男性性腺功能减退症",
          "name_en": "Male Hypogonadism",
          "type": "disease",
          "category": "性腺疾病",
          "icd10": "E29.1",
          "description": "男性睾丸功能不足导致睾酮缺乏的临床综合征",
          "classification": {
            "primary_hypogonadism": {
              "definition": "原发性性腺功能减退",
              "mechanism": "睾丸本身病变",
              "hormonal_pattern": "睾酮↓，LH/FSH↑"
            },
            "secondary_hypogonadism": {
              "definition": "继发性性腺功能减退",
              "mechanism": "下丘脑-垂体轴功能异常",
              "hormonal_pattern": "睾酮↓，LH/FSH↓或正常"
            }
          },
          "etiology": {
            "primary_causes": {
              "congenital": [
                "Klinefelter综合征",
                "隐睾症",
                "睾丸发育不全"
              ],
              "acquired": [
                "睾丸外伤",
                "睾丸扭转",
                "腮腺炎性睾丸炎",
                "化疗/放疗",
                "自身免疫性睾丸炎"
              ]
            },
            "secondary_causes": {
              "hypothalamic_pituitary": [
                "垂体瘤",
                "Kallmann综合征",
                "颅脑外伤",
                "感染"
              ],
              "systemic_disease": [
                "慢性肾病",
                "肝硬化",
                "糖尿病",
                "肥胖"
              ],
              "medications": [
                "GnRH激动剂",
                "糖皮质激素",
                "阿片类药物",
                "酮康唑"
              ]
            }
          },
          "clinical_manifestations": {
            "sexual_dysfunction": {
              "libido_decrease": "性欲减退",
              "erectile_dysfunction": "勃起功能障碍",
              "infertility": "不育",
              "orgasmic_dysfunction": "性高潮障碍"
            },
            "physical_changes": {
              "muscle_mass_loss": "肌肉量减少",
              "increased_body_fat": "体脂增加",
              "decreased_bone_density": "骨密度下降",
              "gynecomastia": "男性乳房发育",
              "decreased_body_hair": "体毛减少"
            },
            "metabolic_effects": {
              "insulin_resistance": "胰岛素抵抗",
              "diabetes_risk": "糖尿病风险增加",
              "dyslipidemia": "血脂异常",
              "visceral_obesity": "内脏肥胖"
            },
            "psychological_symptoms": {
              "depression": "抑郁",
              "irritability": "易怒",
              "fatigue": "疲劳",
              "cognitive_decline": "认知功能下降",
              "sleep_disturbance": "睡眠障碍"
            }
          },
          "diagnosis": {
            "biochemical_testing": {
              "total_testosterone": {
                "timing": "上午8-10点采血",
                "low_threshold": "<8.7 nmol/L (250 ng/dL)",
                "repeat_testing": "需要重复检测确认"
              },
              "free_testosterone": {
                "calculation": "计算游离睾酮",
                "bioavailable_testosterone": "生物可利用睾酮"
              },
              "gonadotropins": {
                "lh_fsh": "区分原发性和继发性",
                "primary": "LH/FSH升高",
                "secondary": "LH/FSH正常或降低"
              }
            },
            "additional_tests": {
              "prolactin": "排除高泌乳素血症",
              "thyroid_function": "甲状腺功能",
              "iron_studies": "血色病筛查",
              "karyotype": "怀疑Klinefelter综合征时"
            },
            "imaging": {
              "testicular_ultrasound": "评估睾丸大小和结构",
              "pituitary_mri": "继发性病因时"
            }
          },
          "treatment": {
            "testosterone_replacement": {
              "indications": [
                "症状性睾酮缺乏",
                "睾酮水平确认低下",
                "无绝对禁忌症"
              ],
              "formulations": {
                "intramuscular": {
                  "testosterone_cypionate": "200-250mg 每2-3周",
                  "testosterone_undecanoate": "1000mg 每10-14周"
                },
                "transdermal": {
                  "gel": "每日5-10g",
                  "patch": "每日4-6mg"
                },
                "buccal": "30mg 每日2次",
                "pellets": "皮下植入，3-6个月"
              }
            },
            "gonadotropin_therapy": {
              "indications": "希望保留生育力",
              "hcg": "1500-3000 IU 每周2-3次",
              "hmg_fsh": "联合使用促进精子生成"
            },
            "selective_estrogen_receptor_modulators": {
              "clomiphene": "25-50mg 每日",
              "indication": "轻度继发性性腺功能减退"
            }
          },
          "monitoring": {
            "efficacy_parameters": [
              "症状改善",
              "睾酮水平",
              "血红蛋白",
              "骨密度"
            ],
            "safety_monitoring": [
              "前列腺特异抗原(PSA)",
              "血细胞计数",
              "肝功能",
              "心血管风险评估"
            ],
            "contraindications": [
              "前列腺癌",
              "乳腺癌",
              "未控制的心力衰竭",
              "严重下尿路症状"
            ]
          }
        },
        {
          "id": "GON_005",
          "name": "Turner综合征",
          "name_en": "Turner Syndrome",
          "type": "disease",
          "category": "性腺疾病",
          "icd10": "Q96",
          "description": "女性性染色体异常导致的遗传性疾病，以性腺发育不全为主要特征",
          "genetics": {
            "karyotypes": {
              "classic_monosomy": {
                "karyotype": "45,X",
                "prevalence": "50-60%的Turner综合征"
              },
              "mosaicism": {
                "karyotype": "45,X/46,XX",
                "prevalence": "15-25%",
                "phenotype": "症状相对较轻"
              },
              "structural_abnormalities": {
                "isochromosome": "46,X,i(Xq)",
                "ring_chromosome": "46,X,r(X)",
                "deletions": "部分X染色体缺失"
              }
            },
            "incidence": "活产女婴中1/2500"
          },
          "clinical_features": {
            "growth_abnormalities": {
              "short_stature": {
                "prevalence": ">95%",
                "adult_height": "平均143cm",
                "growth_hormone_deficiency": "相对缺乏"
              }
            },
            "gonadal_dysgenesis": {
              "streak_gonads": "条索状性腺",
              "primary_amenorrhea": "原发性闭经",
              "infertility": "不孕",
              "delayed_puberty": "青春期发育延迟"
            },
            "cardiovascular_anomalies": {
              "prevalence": "50%患者",
              "types": [
                "主动脉缩窄",
                "二叶主动脉瓣",
                "主动脉根部扩张",
                "二尖瓣脱垂"
              ]
            },
            "renal_abnormalities": {
              "prevalence": "30-40%",
              "types": [
                "马蹄肾",
                "肾脏异位",
                "重复肾盂输尿管系统"
              ]
            },
            "distinctive_features": {
              "webbed_neck": "蹼颈",
              "low_hairline": "发际线低",
              "shield_chest": "盾状胸",
              "cubitus_valgus": "肘外翻",
              "lymphedema": "淋巴水肿（新生儿期）"
            },
            "other_manifestations": {
              "hearing_loss": "传导性或感音神经性听力损失",
              "learning_difficulties": "空间认知能力差",
              "autoimmune_disorders": "甲状腺疾病、炎症性肠病"
            }
          },
          "diagnosis": {
            "clinical_suspicion": [
              "女性短身材",
              "原发性闭经",
              "特征性外貌",
              "先天性心脏病"
            ],
            "karyotype_analysis": {
              "standard": "外周血淋巴细胞",
              "mosaic_detection": "多组织检查",
              "fish_analysis": "荧光原位杂交"
            },
            "hormonal_evaluation": {
              "gonadotropins": "FSH、LH显著升高",
              "estradiol": "极低水平",
              "amh": "无法检测"
            }
          },
          "management": {
            "growth_hormone_therapy": {
              "indication": "身高<5百分位",
              "dosing": "0.35-0.5 mg/kg/周",
              "duration": "直至成年终身高",
              "height_gain": "平均增加5-7cm"
            },
            "pubertal_induction": {
              "timing": "12-13岁开始",
              "estrogen_therapy": {
                "initial": "低剂量雌激素",
                "escalation": "逐渐增加剂量",
                "duration": "2-3年"
              },
              "progestogen_addition": "子宫发育后添加"
            },
            "fertility_considerations": {
              "spontaneous_pregnancy": "5-10%可能性（镶嵌型）",
              "assisted_reproduction": "供卵IVF",
              "pregnancy_risks": "心血管并发症风险高"
            },
            "multidisciplinary_care": {
              "cardiology": "心血管监测和治疗",
              "nephrology": "肾脏功能评估",
              "audiology": "听力监测",
              "endocrinology": "激素替代治疗",
              "psychology": "学习支持和心理健康"
            }
          },
          "surveillance": {
            "cardiovascular": {
              "echocardiography": "诊断时和每3-5年",
              "blood_pressure": "定期监测",
              "aortic_imaging": "MRI或CT（成年后）"
            },
            "renal": "定期肾功能和影像学检查",
            "hearing": "年度听力学检查",
            "thyroid": "年度甲状腺功能检查",
            "bone_health": "骨密度监测"
          }
        },
        {
          "id": "GON_006", 
          "name": "Kallmann综合征",
          "name_en": "Kallmann Syndrome",
          "type": "disease",
          "category": "性腺疾病",
          "icd10": "E23.0",
          "description": "先天性促性腺激素释放激素缺陷伴嗅觉缺失的遗传性疾病",
          "genetics": {
            "inheritance_patterns": {
              "x_linked": {
                "gene": "KAL1 (ANOS1)",
                "prevalence": "10-15%",
                "features": "常伴肾脏异常、听力损失"
              },
              "autosomal_dominant": {
                "genes": ["FGFR1", "PROKR2", "PROK2"],
                "prevalence": "10%"
              },
              "autosomal_recessive": {
                "genes": ["GNRHR", "GNRH1", "KISS1R"],
                "prevalence": "5%"
              },
              "oligogenic": "多基因突变（30%）"
            },
            "incidence": {
              "males": "1/30,000",
              "females": "1/125,000"
            }
          },
          "pathophysiology": {
            "gnrh_neuron_migration": "GnRH神经元迁移缺陷",
            "olfactory_system": "嗅球和嗅束发育异常",
            "hypothalamic_dysfunction": "下丘脑GnRH分泌缺乏"
          },
          "clinical_manifestations": {
            "reproductive_dysfunction": {
              "males": {
                "micropenis": "阴茎发育不良",
                "cryptorchidism": "隐睾",
                "absent_puberty": "青春期缺失",
                "infertility": "不育",
                "eunuchoid_proportions": "类无睾症体型"
              },
              "females": {
                "primary_amenorrhea": "原发性闭经",
                "absent_breast_development": "乳房发育缺失",
                "infertility": "不孕",
                "osteoporosis": "骨质疏松"
              }
            },
            "olfactory_dysfunction": {
              "anosmia": "完全嗅觉缺失（60%）",
              "hyposmia": "嗅觉减退（40%）",
              "smell_test": "嗅觉功能检测异常"
            },
            "associated_features": {
              "neurological": [
                "颅神经异常",
                "听力损失",
                "共济失调"
              ],
              "skeletal": [
                "唇腭裂",
                "短指症",
                "肾脏发育异常"
              ],
              "dental": "牙齿发育异常"
            }
          },
          "diagnosis": {
            "clinical_criteria": [
              "青春期缺失或不完全",
              "嗅觉缺失或减退",
              "低促性腺激素性性腺功能减退"
            ],
            "hormonal_testing": {
              "baseline": {
                "lh_fsh": "低或正常低值",
                "testosterone_estradiol": "低水平",
                "prolactin": "正常"
              },
              "stimulation_tests": {
                "gnrh_test": "LH/FSH反应减弱或缺失",
                "hcg_stimulation": "睾酮反应评估"
              }
            },
            "imaging": {
              "brain_mri": {
                "findings": [
                  "嗅球嗅束缺失或发育不良",
                  "垂体形态正常",
                  "下丘脑结构异常"
                ]
              },
              "olfactory_evaluation": "嗅觉功能定量测试"
            },
            "genetic_testing": {
              "gene_panel": "已知致病基因筛查",
              "family_screening": "家族成员筛查"
            }
          },
          "treatment": {
            "pubertal_induction": {
              "males": {
                "testosterone": "低剂量开始逐渐增加",
                "schedule": "6个月-2年完成性发育"
              },
              "females": {
                "estrogen": "超低剂量雌激素开始",
                "progestogen": "子宫发育后添加孕激素"
              }
            },
            "fertility_treatment": {
              "males": {
                "gonadotropin_therapy": "hCG + FSH",
                "gnrh_pulsatile": "脉冲式GnRH治疗",
                "duration": "6-18个月诱导精子生成"
              },
              "females": {
                "gonadotropin_stimulation": "FSH + LH治疗",
                "gnrh_pump": "脉冲式GnRH泵",
                "ovulation_induction": "诱导排卵"
              }
            },
            "maintenance_therapy": {
              "males": "睾酮替代治疗",
              "females": "雌孕激素替代治疗",
              "bone_health": "钙剂和维生素D补充"
            }
          },
          "prognosis": {
            "sexual_development": "激素治疗后可正常发育",
            "fertility": "适当治疗后多数可获得生育能力",
            "reversal": "5-10%患者可能自发恢复",
            "quality_of_life": "早期诊断和治疗预后良好"
          }
        }
      ],

      "dyslipidemia_entities": [
        {
          "id": "DLP_001",
          "name": "血脂异常",
          "name_en": "Dyslipidemia",
          "type": "disease",
          "category": "代谢疾病", 
          "description": "血浆脂蛋白代谢异常，表现为血总胆固醇、LDL-C、甘油三酯升高或HDL-C降低",
          "classification": {
            "primary": {
              "familial_hypercholesterolemia": "遗传性高胆固醇血症",
              "familial_combined_hyperlipidemia": "家族性混合型高脂血症",
              "familial_hypertriglyceridemia": "家族性高甘油三酯血症"
            },
            "secondary": {
              "diabetes": "糖尿病性血脂异常",
              "hypothyroidism": "甲减性高脂血症",
              "nephrotic_syndrome": "肾病综合征",
              "medications": "药物性血脂异常"
            }
          },
          "lipid_targets_2025": {
            "ldl_cholesterol": {
              "very_high_risk": "<55 mg/dL (1.4 mmol/L)",
              "high_risk": "<70 mg/dL (1.8 mmol/L)", 
              "moderate_risk": "<100 mg/dL (2.6 mmol/L)",
              "low_risk": "<130 mg/dL (3.4 mmol/L)"
            },
            "non_hdl_cholesterol": {
              "very_high_risk": "<85 mg/dL",
              "high_risk": "<100 mg/dL",
              "moderate_risk": "<130 mg/dL"
            },
            "triglycerides": "<150 mg/dL (1.7 mmol/L)",
            "hdl_cholesterol": {
              "men": ">40 mg/dL (1.0 mmol/L)",
              "women": ">50 mg/dL (1.3 mmol/L)"
            }
          },
          "risk_stratification": {
            "very_high_risk": [
              "临床ASCVD",
              "DM+靶器官损害",
              "FH+ASCVD危险因素",
              "CKD 3-5期"
            ],
            "high_risk": [
              "LDL-C≥190 mg/dL",
              "糖尿病(40-75岁)",
              "10年ASCVD风险≥20%"
            ],
            "moderate_risk": "10年ASCVD风险7.5-19.9%",
            "low_risk": "10年ASCVD风险<7.5%"
          },
          "treatment_approach_2025": {
            "lifestyle_therapy": {
              "dietary_modification": [
                "限制饱和脂肪(<7%总热量)",
                "限制反式脂肪", 
                "增加膳食纤维(25-30g/day)",
                "植物固醇(2g/day)"
              ],
              "physical_activity": "中等强度150分钟/周",
              "weight_management": "BMI 18.5-24.9"
            },
            "pharmacological_therapy": {
              "statins": {
                "high_intensity": [
                  "阿托伐他汀80mg",
                  "瑞舒伐他汀20-40mg"
                ],
                "moderate_intensity": [
                  "阿托伐他汀20-40mg",
                  "瑞舒伐他汀10-20mg",
                  "辛伐他汀40mg"
                ],
                "low_intensity": [
                  "辛伐他汀20mg",
                  "普伐他汀40mg"
                ]
              },
              "non_statin_therapy": {
                "ezetimibe": {
                  "dose": "10mg/day",
                  "ldl_reduction": "15-20%",
                  "indication": "他汀不耐受或目标未达标"
                },
                "pcsk9_inhibitors": {
                  "evolocumab": "140mg q2w或420mg qm",
                  "alirocumab": "75-150mg q2w",
                  "ldl_reduction": "50-60%",
                  "indication": "极高危+他汀+依折麦布未达标"
                },
                "bempedoic_acid": {
                  "dose": "180mg/day",
                  "ldl_reduction": "15-20%",
                  "indication": "他汀不耐受"
                }
              },
              "combination_therapy": {
                "statin_ezetimibe": "一线联合治疗",
                "triple_therapy": "他汀+依折麦布+PCSK9i",
                "monitoring": "肝酶、肌酶、肾功能"
              }
            }
          }
        }
      ]
    },

    "parathyroid_calcium_entities": [
      {
        "id": "PTH_001",
        "name": "原发性甲状旁腺功能亢进症",
        "name_en": "Primary Hyperparathyroidism",
        "type": "endocrine_disorder",
        "category": "parathyroid_disease",
        "description": "甲状旁腺激素(PTH)过度分泌导致的钙磷代谢紊乱性疾病",
        "icd_10": "E21.0",
        "epidemiology": {
          "prevalence": "1-4/1000人口",
          "age_distribution": "50-60岁高发",
          "gender_ratio": "女性:男性 = 3:1",
          "risk_factors": [
            "绝经后女性",
            "维生素D缺乏",
            "锂盐治疗史",
            "放射线暴露史"
          ]
        },
        "etiology": {
          "adenoma": {
            "percentage": "85%",
            "characteristics": "单发性良性腺瘤",
            "location": "单个甲状旁腺"
          },
          "hyperplasia": {
            "percentage": "10-15%",
            "characteristics": "四个腺体增生",
            "types": ["原发性增生", "继发性增生"]
          },
          "carcinoma": {
            "percentage": "<1%",
            "characteristics": "恶性甲状旁腺癌",
            "prognosis": "预后相对较好"
          }
        },
        "clinical_manifestations": {
          "skeletal_symptoms": {
            "bone_pain": "骨痛，尤其是腰背部",
            "osteoporosis": "骨质疏松症",
            "fractures": "病理性骨折",
            "joint_pain": "关节疼痛"
          },
          "renal_symptoms": {
            "nephrolithiasis": "肾结石形成",
            "polyuria": "多尿",
            "polydipsia": "多饮",
            "renal_insufficiency": "肾功能不全"
          },
          "gastrointestinal_symptoms": {
            "nausea_vomiting": "恶心呕吐",
            "constipation": "便秘",
            "peptic_ulcer": "消化性溃疡",
            "anorexia": "食欲不振"
          },
          "neuropsychiatric_symptoms": {
            "depression": "抑郁症状",
            "cognitive_impairment": "认知功能障碍",
            "fatigue": "疲劳乏力",
            "confusion": "意识模糊"
          }
        },
        "laboratory_findings": {
          "calcium": {
            "serum_total_calcium": ">2.75mmol/L",
            "ionized_calcium": ">1.35mmol/L",
            "note": "血钙升高是诊断关键"
          },
          "pth": {
            "intact_pth": "升高或不恰当正常",
            "normal_range": "15-65pg/mL",
            "interpretation": "血钙升高时PTH应被抑制"
          },
          "phosphorus": {
            "serum_phosphorus": "降低或正常低值",
            "normal_range": "0.81-1.45mmol/L"
          },
          "vitamin_d": {
            "25_oh_d3": "常降低",
            "1_25_oh2_d3": "升高或正常高值"
          },
          "alkaline_phosphatase": "可升高，反映骨转换增加",
          "24h_urine_calcium": "升高(>7.5mmol/24h)"
        },
        "imaging_studies": {
          "bone_density": {
            "dexa_scan": "骨密度降低",
            "preferred_sites": ["腰椎", "股骨颈", "前臂远端"],
            "t_score": "T评分 < -2.5提示骨质疏松"
          },
          "parathyroid_imaging": {
            "ultrasound": "首选检查方法",
            "sestamibi_scan": "99mTc-MIBI显像",
            "4d_ct": "四维CT扫描",
            "mri": "MRI检查"
          },
          "renal_imaging": {
            "ultrasound": "肾脏超声检查肾结石",
            "ct": "非对比CT检查"
          }
        },
        "diagnostic_criteria": {
          "biochemical": [
            "血清总钙 >2.75mmol/L 或离子钙 >1.35mmol/L",
            "血清PTH升高或不恰当正常",
            "除外继发性甲旁亢的原因"
          ],
          "exclusion_criteria": [
            "维生素D缺乏",
            "慢性肾功能不全",
            "恶性肿瘤",
            "药物性高钙血症"
          ]
        },
        "treatment": {
          "surgical_treatment": {
            "indications": [
              "有症状的原发性甲旁亢",
              "无症状但符合手术指征",
              "血钙 >2.85mmol/L",
              "年龄 <50岁",
              "骨密度T评分 < -2.5",
              "肾功能减退(eGFR<60)",
              "24小时尿钙 >10mmol"
            ],
            "procedures": {
              "minimally_invasive": "微创甲状旁腺切除术",
              "bilateral_exploration": "双侧颈部探查术",
              "intraoperative_pth": "术中PTH监测"
            },
            "success_rate": "95-98%",
            "complications": [
              "术后低钙血症",
              "喉返神经损伤",
              "永久性甲旁减"
            ]
          },
          "medical_management": {
            "calcimimetics": {
              "cinacalcet": "西那卡塞 30-180mg/日",
              "mechanism": "钙敏感受体激动剂",
              "effects": "降低PTH和血钙"
            },
            "bisphosphonates": {
              "indication": "骨质疏松症",
              "agents": ["阿仑膦酸钠", "利塞膦酸钠"],
              "contraindication": "严重肾功能不全"
            },
            "monitoring": [
              "血钙、磷、PTH每3-6个月",
              "骨密度每1-2年",
              "肾功能每年",
              "影像学评估"
            ]
          }
        },
        "complications": {
          "acute": {
            "hypercalcemic_crisis": "高钙血症危象",
            "symptoms": "意识障碍、心律失常、肾功能衰竭",
            "management": "紧急降钙治疗"
          },
          "chronic": {
            "osteoporosis": "骨质疏松性骨折",
            "chronic_kidney_disease": "慢性肾脏病",
            "cardiovascular_disease": "心血管疾病风险增加",
            "neuropsychiatric_disorders": "神经精神疾病"
          }
        },
        "prognosis": {
          "surgical_outcome": "手术治愈率95-98%",
          "postoperative_recovery": "症状明显改善",
          "bone_recovery": "骨密度术后1-2年明显改善",
          "quality_of_life": "生活质量显著提高"
        }
      },
      {
        "id": "PTH_002",
        "name": "甲状旁腺功能减退症",
        "name_en": "Hypoparathyroidism",
        "type": "endocrine_disorder",
        "category": "parathyroid_disease",
        "description": "甲状旁腺激素分泌不足或作用缺陷导致的低钙血症",
        "icd_10": "E20",
        "epidemiology": {
          "prevalence": "37-58/100,000人口",
          "incidence": "3.4/100,000人年",
          "gender_distribution": "女性略多见",
          "age_onset": "各年龄段均可发病"
        },
        "etiology": {
          "surgical": {
            "percentage": "75%",
            "causes": [
              "甲状腺手术",
              "甲状旁腺手术",
              "颈部肿瘤手术",
              "反复颈部手术"
            ],
            "onset": "术后即刻或数月内"
          },
          "autoimmune": {
            "percentage": "12%",
            "conditions": [
              "自身免疫性多腺体综合征",
              "单纯性甲旁减",
              "DiGeorge综合征"
            ]
          },
          "genetic": {
            "percentage": "8%",
            "conditions": [
              "DiGeorge综合征(22q11.2缺失)",
              "CASR基因突变",
              "PTH基因突变",
              "先天性甲旁腺发育不全"
            ]
          },
          "other_causes": [
            "放射线治疗",
            "转移性肿瘤",
            "铁沉积症",
            "镁缺乏"
          ]
        },
        "clinical_manifestations": {
          "acute_hypocalcemia": {
            "neuromuscular": {
              "tetany": "手足搐搦症",
              "chvostek_sign": "Chvostek征阳性",
              "trousseau_sign": "Trousseau征阳性",
              "muscle_cramps": "肌肉痉挛",
              "seizures": "癫痫发作"
            },
            "neurological": {
              "paresthesias": "口周和指端麻木",
              "confusion": "意识模糊",
              "hallucinations": "幻觉",
              "depression": "抑郁症状"
            },
            "cardiovascular": {
              "qt_prolongation": "QT间期延长",
              "arrhythmias": "心律失常",
              "heart_failure": "心力衰竭"
            }
          },
          "chronic_hypocalcemia": {
            "dermatological": {
              "dry_skin": "皮肤干燥",
              "brittle_nails": "指甲脆性增加",
              "hair_loss": "毛发脱落",
              "dental_problems": "牙齿发育异常"
            },
            "ophthalmological": {
              "cataracts": "白内障",
              "papilledema": "视乳头水肿"
            },
            "neurological": {
              "cognitive_impairment": "认知功能障碍",
              "extrapyramidal_symptoms": "锥体外系症状",
              "intracranial_calcification": "颅内钙化"
            }
          }
        },
        "laboratory_findings": {
          "calcium": {
            "serum_total_calcium": "<2.12mmol/L",
            "ionized_calcium": "<1.12mmol/L",
            "albumin_correction": "校正血钙 = 血钙 + 0.02×(40-白蛋白)"
          },
          "pth": {
            "intact_pth": "<15pg/mL",
            "interpretation": "低钙血症时PTH应升高"
          },
          "phosphorus": {
            "serum_phosphorus": ">1.45mmol/L",
            "mechanism": "PTH缺乏导致磷重吸收增加"
          },
          "magnesium": {
            "serum_magnesium": "需排除镁缺乏",
            "threshold": "<0.7mmol/L"
          },
          "vitamin_d": {
            "25_oh_d3": "常正常",
            "1_25_oh2_d3": "降低"
          },
          "alkaline_phosphatase": "正常或降低"
        },
        "diagnostic_criteria": {
          "biochemical": [
            "血清总钙 <2.12mmol/L 或离子钙 <1.12mmol/L",
            "血清PTH <15pg/mL 或不恰当偏低",
            "血清磷 >1.45mmol/L"
          ],
          "clinical": [
            "低钙血症相关症状",
            "甲状旁腺功能减退的病因"
          ]
        },
        "treatment": {
          "acute_management": {
            "severe_hypocalcemia": {
              "calcium_gluconate": "10%葡萄糖酸钙 10-20ml 静脉注射",
              "dilution": "稀释于50ml生理盐水",
              "rate": "缓慢推注(>10分钟)",
              "monitoring": "心电监护"
            },
            "continuous_infusion": {
              "dose": "葡萄糖酸钙 100-200ml/24h",
              "target": "血钙达到2.0-2.12mmol/L",
              "monitoring": "每4-6小时监测血钙"
            }
          },
          "chronic_management": {
            "calcium_supplementation": {
              "elemental_calcium": "1-3g/日 分次服用",
              "preparations": [
                "碳酸钙(含钙40%)",
                "柠檬酸钙(含钙21%)",
                "醋酸钙(含钙25%)"
              ],
              "timing": "与维生素D同服"
            },
            "vitamin_d_therapy": {
              "calcitriol": {
                "dose": "0.25-2μg 每日2次",
                "onset": "数小时内起效",
                "monitoring": "密切监测血钙"
              },
              "alfacalcidol": {
                "dose": "0.5-3μg/日",
                "advantage": "更稳定的血钙控制"
              },
              "cholecalciferol": {
                "dose": "50,000-100,000IU/周",
                "indication": "维生素D缺乏时"
              }
            },
            "adjuvant_therapy": {
              "thiazide_diuretics": {
                "agent": "氢氯噻嗪 25-50mg/日",
                "mechanism": "减少尿钙丢失",
                "indication": "高尿钙症"
              },
              "magnesium": {
                "dose": "400-800mg/日",
                "indication": "镁缺乏或低镁血症"
              }
            }
          },
          "monitoring": {
            "frequency": [
              "治疗初期：每周1-2次",
              "稳定期：每3-6个月",
              "调药时：1-2周后复查"
            ],
            "parameters": [
              "血钙、磷、镁",
              "PTH(如适用)",
              "肾功能",
              "24小时尿钙",
              "心电图(QT间期)"
            ],
            "target_values": {
              "serum_calcium": "2.12-2.37mmol/L",
              "urine_calcium": "<7.5mmol/24h",
              "calcium_phosphate_product": "<4.4mmol²/L²"
            }
          }
        },
        "complications": {
          "over_treatment": {
            "hypercalcemia": "医源性高钙血症",
            "hypercalciuria": "高钙尿症",
            "nephrocalcinosis": "肾钙化",
            "kidney_stones": "肾结石"
          },
          "under_treatment": {
            "chronic_symptoms": "慢性低钙血症症状",
            "quality_of_life": "生活质量下降",
            "cardiovascular_risk": "心血管风险增加"
          },
          "long_term": {
            "renal_impairment": "肾功能损害",
            "ectopic_calcification": "异位钙化",
            "cataracts": "白内障进展",
            "dental_problems": "牙齿问题"
          }
        },
        "prognosis": {
          "with_treatment": "良好的症状控制",
          "quality_of_life": "接近正常人群",
          "life_expectancy": "正常或轻度缩短",
          "complications_risk": "依赖于治疗依从性"
        }
      },
      {
        "id": "PTH_003",
        "name": "假性甲状旁腺功能减退症",
        "name_en": "Pseudohypoparathyroidism",
        "type": "genetic_disorder",
        "category": "parathyroid_disease",
        "description": "甲状旁腺激素作用靶器官抵抗导致的遗传性疾病",
        "icd_10": "E20.1",
        "epidemiology": {
          "prevalence": "0.3-1.1/100,000人口",
          "inheritance": "X连锁显性遗传(主要)",
          "gene_defects": "GNAS基因突变",
          "gender_ratio": "无明显性别差异"
        },
        "classification": {
          "type_1a": {
            "characteristics": "AHO + 激素抵抗",
            "aho_features": "Albright遗传性骨营养不良",
            "hormone_resistance": ["PTH", "TSH", "FSH/LH", "GHRH"]
          },
          "type_1b": {
            "characteristics": "仅PTH抵抗",
            "aho_features": "无AHO表型",
            "hormone_resistance": ["PTH"]
          },
          "type_1c": {
            "characteristics": "AHO + 选择性激素抵抗",
            "aho_features": "有AHO表型",
            "hormone_resistance": "TSH抵抗为主"
          },
          "type_2": {
            "characteristics": "cAMP反应正常，后续信号异常",
            "mechanism": "PTH受体后信号转导异常"
          }
        },
        "clinical_manifestations": {
          "aho_phenotype": {
            "short_stature": "身材矮小",
            "obesity": "向心性肥胖",
            "round_face": "圆脸",
            "brachydactyly": "短指症",
            "subcutaneous_ossification": "皮下骨化",
            "intellectual_disability": "智力障碍(轻度)"
          },
          "hormone_resistance": {
            "pth_resistance": {
              "hypocalcemia": "低钙血症",
              "hyperphosphatemia": "高磷血症",
              "elevated_pth": "PTH升高"
            },
            "tsh_resistance": {
              "hypothyroidism": "甲状腺功能减退",
              "elevated_tsh": "TSH升高",
              "goiter": "甲状腺肿"
            },
            "gonadotropin_resistance": {
              "hypogonadism": "性腺功能减退",
              "delayed_puberty": "青春期延迟",
              "infertility": "不育症"
            }
          },
          "neurological": {
            "seizures": "癫痫发作",
            "tetany": "手足搐搦",
            "cognitive_impairment": "认知功能障碍",
            "behavioral_problems": "行为异常"
          }
        },
        "laboratory_findings": {
          "calcium_phosphate": {
            "serum_calcium": "降低",
            "serum_phosphate": "升高",
            "pth": "明显升高",
            "25_oh_d3": "常正常",
            "1_25_oh2_d3": "降低"
          },
          "thyroid_function": {
            "tsh": "升高",
            "free_t4": "正常或降低",
            "free_t3": "正常或降低"
          },
          "gonadal_function": {
            "lh_fsh": "升高",
            "testosterone_estradiol": "降低",
            "response_to_gnrh": "减弱"
          },
          "ellsworth_howard_test": {
            "pth_infusion": "外源性PTH刺激试验",
            "camp_response": "尿cAMP反应减弱",
            "phosphate_response": "磷酸盐反应减弱"
          }
        },
        "genetic_testing": {
          "gnas_gene": {
            "location": "20q13.32",
            "inheritance": "母系印记基因",
            "mutations": [
              "点突变",
              "缺失突变",
              "甲基化异常"
            ]
          },
          "molecular_diagnosis": {
            "dna_sequencing": "基因测序",
            "mlpa": "多重连接依赖探针扩增",
            "methylation_analysis": "甲基化分析"
          }
        },
        "treatment": {
          "calcium_phosphate_management": {
            "calcium_supplementation": "钙剂补充 1-3g/日",
            "calcitriol": "骨化三醇 0.5-3μg/日",
            "phosphate_binders": "磷结合剂(高磷时)",
            "monitoring": "血钙磷每3-6个月"
          },
          "thyroid_hormone": {
            "levothyroxine": "左甲状腺素 1.6μg/kg/日",
            "monitoring": "TSH每3-6个月",
            "target": "TSH正常高值"
          },
          "gonadal_hormone": {
            "males": {
              "testosterone": "睾酮替代治疗",
              "dosing": "根据年龄和发育阶段"
            },
            "females": {
              "estrogen_progesterone": "雌孕激素替代",
              "contraception": "避孕需求评估"
            }
          },
          "growth_hormone": {
            "indication": "身材矮小症",
            "dose": "0.025-0.035mg/kg/日",
            "monitoring": "身高增长速度"
          },
          "supportive_care": {
            "educational_support": "特殊教育支持",
            "psychological_counseling": "心理咨询",
            "genetic_counseling": "遗传咨询",
            "family_support": "家庭支持"
          }
        },
        "monitoring": {
          "biochemical": [
            "血钙、磷、PTH每3-6个月",
            "甲状腺功能每3-6个月",
            "性腺功能每年",
            "维生素D状态每年"
          ],
          "clinical": [
            "生长发育评估",
            "神经发育评估",
            "心血管检查",
            "骨密度检测"
          ],
          "complications_screening": [
            "肾功能监测",
            "眼科检查(白内障)",
            "听力检查",
            "心电图"
          ]
        },
        "prognosis": {
          "early_diagnosis": "早期诊断预后较好",
          "hormone_replacement": "激素替代改善症状",
          "intellectual_development": "智力发育可接近正常",
          "life_expectancy": "轻度缩短",
          "quality_of_life": "依赖于综合管理"
        }
      }
    ],

    "bone_metabolism_entities": [
      {
        "id": "BONE_001",
        "name": "骨质疏松症",
        "name_en": "Osteoporosis",
        "type": "metabolic_bone_disease",
        "category": "bone_metabolism_disorder",
        "description": "以骨量减少、骨组织微结构破坏为特征的全身性骨病",
        "icd_10": "M80-M81",
        "epidemiology": {
          "prevalence_postmenopausal": "50岁以上女性19.2%",
          "prevalence_elderly_men": "65岁以上男性13.0%",
          "fracture_risk": "髋部骨折终生风险女性13%，男性4%",
          "economic_burden": "年医疗费用超过190亿元"
        },
        "classification": {
          "primary": {
            "postmenopausal": {
              "type": "I型骨质疏松",
              "mechanism": "雌激素缺乏",
              "onset": "绝经后5-10年",
              "bone_loss_rate": "每年2-5%"
            },
            "senile": {
              "type": "II型骨质疏松",
              "mechanism": "年龄相关骨丢失",
              "onset": "70岁以后",
              "characteristics": "皮质骨和松质骨均受累"
            }
          },
          "secondary": {
            "endocrine": [
              "甲状腺功能亢进",
              "甲状旁腺功能亢进",
              "库欣综合征",
              "性腺功能减退"
            ],
            "medications": [
              "糖皮质激素",
              "抗癫痫药物",
              "芳香化酶抑制剂",
              "GnRH激动剂"
            ],
            "diseases": [
              "类风湿关节炎",
              "炎症性肠病",
              "慢性肾病",
              "恶性肿瘤"
            ]
          }
        },
        "pathophysiology": {
          "bone_remodeling_imbalance": {
            "normal_remodeling": "骨形成与骨吸收平衡",
            "osteoporosis": "骨吸收 > 骨形成",
            "cellular_mechanism": "破骨细胞活性增加，成骨细胞功能减退"
          },
          "hormonal_factors": {
            "estrogen_deficiency": "雌激素缺乏导致RANKL/OPG比值升高",
            "pth_excess": "继发性甲旁亢加速骨丢失",
            "vitamin_d_deficiency": "影响钙吸收和骨矿化"
          },
          "mechanical_factors": {
            "disuse": "缺乏负重运动",
            "immobilization": "长期卧床",
            "microgravity": "失重环境"
          }
        },
        "clinical_manifestations": {
          "asymptomatic_phase": {
            "duration": "数年至数十年",
            "characteristics": "无症状骨量丢失",
            "detection": "仅通过骨密度检测发现"
          },
          "symptomatic_phase": {
            "bone_pain": {
              "location": "腰背部最常见",
              "characteristics": "持续性钝痛",
              "aggravating_factors": "活动后加重"
            },
            "fractures": {
              "vertebral": {
                "prevalence": "最常见骨折类型",
                "symptoms": "急性背痛，身高缩短",
                "complications": "脊柱畸形，肺功能受损"
              },
              "hip": {
                "mortality": "1年死亡率15-20%",
                "morbidity": "50%患者不能独立行走",
                "economic_impact": "医疗费用最高"
              },
              "distal_radius": {
                "onset": "绝经早期常见",
                "mechanism": "跌倒时手掌撑地",
                "recovery": "相对较好"
              }
            },
            "kyphosis": {
              "cause": "椎体压缩性骨折",
              "appearance": "驼背畸形",
              "functional_impact": "呼吸功能受限"
            }
          }
        },
        "diagnostic_methods": {
          "bone_density_measurement": {
            "dexa_scan": {
              "gold_standard": "双能X线吸收测定法",
              "sites": ["腰椎L1-L4", "股骨颈", "全髋"],
              "t_score_interpretation": {
                "normal": "T评分 ≥ -1.0",
                "osteopenia": "T评分 -1.0 到 -2.5",
                "osteoporosis": "T评分 ≤ -2.5",
                "severe_osteoporosis": "T评分 ≤ -2.5 + 脆性骨折"
              }
            },
            "qct": {
              "method": "定量CT",
              "advantage": "真正的体积骨密度",
              "limitation": "辐射剂量较高"
            },
            "peripheral_devices": {
              "pdexa": "外周双能X线",
              "qus": "定量超声",
              "use": "筛查工具"
            }
          },
          "biochemical_markers": {
            "bone_formation": {
              "osteocalcin": "骨钙素",
              "p1np": "I型前胶原氨基端肽",
              "balp": "骨特异性碱性磷酸酶"
            },
            "bone_resorption": {
              "ctx": "I型胶原羧基端肽",
              "ntx": "I型胶原氨基端肽",
              "trap_5b": "抗酒石酸酸性磷酸酶5b"
            },
            "clinical_utility": [
              "监测治疗反应",
              "评估骨转换状态",
              "预测骨折风险"
            ]
          },
          "fracture_risk_assessment": {
            "frax_tool": {
              "components": [
                "年龄、性别、BMI",
                "既往骨折史",
                "父母髋部骨折史",
                "吸烟、饮酒",
                "糖皮质激素使用",
                "类风湿关节炎",
                "继发性骨质疏松原因",
                "股骨颈骨密度"
              ],
              "output": "10年髋部骨折和主要骨折风险"
            },
            "qfracture": "英国骨折风险评估工具",
            "garvan": "澳大利亚骨折风险计算器"
          }
        },
        "treatment": {
          "lifestyle_interventions": {
            "nutrition": {
              "calcium": "每日1000-1200mg",
              "vitamin_d": "800-1000IU/日",
              "protein": "每日1.0-1.2g/kg体重",
              "limitations": "避免过量咖啡因、钠盐"
            },
            "exercise": {
              "weight_bearing": "负重有氧运动",
              "resistance_training": "阻力训练",
              "balance_training": "平衡训练预防跌倒",
              "frequency": "每周至少3-4次"
            },
            "fall_prevention": {
              "environmental": "移除家中危险因素",
              "vision_correction": "视力矫正",
              "medication_review": "评估致跌倒药物",
              "assistive_devices": "使用辅助器具"
            }
          },
          "pharmacological_treatment": {
            "first_line": {
              "bisphosphonates": {
                "alendronate": {
                  "dose": "阿仑膦酸钠 70mg/周",
                  "administration": "空腹服用，服后直立30分钟",
                  "efficacy": "椎体骨折风险降低40-50%"
                },
                "risedronate": {
                  "dose": "利塞膦酸钠 35mg/周",
                  "advantage": "胃肠道耐受性好",
                  "efficacy": "髋部骨折风险降低30%"
                },
                "ibandronate": {
                  "dose": "伊班膦酸钠 150mg/月",
                  "route": "口服或静脉注射",
                  "convenience": "给药频率低"
                },
                "zoledronic_acid": {
                  "dose": "唑来膦酸 5mg/年",
                  "route": "静脉滴注",
                  "efficacy": "最强的抗骨折效果"
                }
              }
            },
            "second_line": {
              "denosumab": {
                "mechanism": "RANKL抗体",
                "dose": "地诺单抗 60mg/6个月 皮下注射",
                "efficacy": "椎体骨折风险降低68%",
                "consideration": "停药后骨量快速丢失"
              },
              "teriparatide": {
                "mechanism": "重组PTH(1-34)",
                "dose": "特立帕肽 20μg/日 皮下注射",
                "duration": "最多2年",
                "indication": "严重骨质疏松症"
              },
              "abaloparatide": {
                "mechanism": "PTHrP类似物",
                "dose": "阿巴洛帕肽 80μg/日",
                "advantage": "较少高钙血症风险"
              }
            },
            "hormone_therapy": {
              "postmenopausal": {
                "estrogen": "雌激素替代治疗",
                "indication": "绝经期症状明显",
                "risks": "血栓、乳腺癌风险"
              },
              "selective_modulators": {
                "raloxifene": "雷洛昔芬 60mg/日",
                "benefit": "预防椎体骨折和乳腺癌",
                "limitation": "不预防髋部骨折"
              }
            }
          },
          "monitoring": {
            "bone_density": "治疗后1-2年复查DXA",
            "biochemical_markers": "治疗后3-6个月检测",
            "clinical_assessment": "定期评估疼痛和功能",
            "safety_monitoring": "监测药物不良反应"
          }
        },
        "complications": {
          "fracture_complications": {
            "vertebral": ["慢性疼痛", "脊柱畸形", "功能障碍"],
            "hip": ["深静脉血栓", "肺栓塞", "死亡"],
            "general": ["感染", "褥疮", "肌肉萎缩"]
          },
          "medication_related": {
            "bisphosphonates": [
              "上消化道刺激",
              "下颌骨坏死(罕见)",
              "非典型股骨骨折(极罕见)"
            ],
            "denosumab": [
              "低钙血症",
              "感染风险增加",
              "停药后骨折风险反弹"
            ]
          }
        },
        "prognosis": {
          "with_treatment": "骨折风险显著降低",
          "fracture_healing": "愈合能力基本正常",
          "quality_of_life": "疼痛减轻，功能改善",
          "life_expectancy": "早期诊断治疗预后良好"
        }
      },
      {
        "id": "BONE_002",
        "name": "骨软化症",
        "name_en": "Osteomalacia",
        "type": "metabolic_bone_disease",
        "category": "bone_metabolism_disorder",
        "description": "成人维生素D缺乏或代谢异常导致的骨矿化障碍",
        "icd_10": "M83",
        "epidemiology": {
          "prevalence": "维生素D缺乏患者中10-15%",
          "risk_populations": [
            "老年人群",
            "日照不足地区",
            "室内工作者",
            "穿着遮体服装人群"
          ],
          "geographic_distribution": "高纬度地区高发"
        },
        "etiology": {
          "vitamin_d_deficiency": {
            "inadequate_sunlight": "日照不足",
            "dietary_insufficiency": "膳食摄入不足",
            "malabsorption": "吸收不良综合征",
            "chronic_kidney_disease": "慢性肾病"
          },
          "vitamin_d_metabolism_disorders": {
            "1_alpha_hydroxylase_deficiency": "1α-羟化酶缺陷",
            "vitamin_d_receptor_defects": "维生素D受体缺陷",
            "24_hydroxylase_excess": "24-羟化酶过度活跃"
          },
          "phosphate_deficiency": {
            "hereditary_hypophosphatemia": "遗传性低磷血症",
            "tumor_induced": "肿瘤诱发性骨软化症",
            "fanconi_syndrome": "Fanconi综合征"
          },
          "drug_induced": [
            "抗癫痫药物",
            "糖皮质激素",
            "铝制剂",
            "氟化物过量"
          ]
        },
        "pathophysiology": {
          "mineralization_defect": {
            "mechanism": "骨基质正常，矿化不足",
            "histology": "增宽的骨样组织缝",
            "biochemistry": "钙磷乘积不足"
          },
          "secondary_hyperparathyroidism": {
            "trigger": "低钙血症或维生素D缺乏",
            "consequences": "PTH升高，骨转换增加",
            "bone_effects": "骨吸收增加"
          },
          "muscle_effects": {
            "weakness": "近端肌无力",
            "mechanism": "维生素D受体缺陷",
            "recovery": "补充维生素D后改善"
          }
        },
        "clinical_manifestations": {
          "bone_symptoms": {
            "bone_pain": {
              "characteristics": "弥漫性钝痛",
              "location": "腰背部、髋部、胸肋部",
              "timing": "休息时也存在"
            },
            "tenderness": "骨压痛，尤其是胸骨",
            "fractures": "假性骨折(Looser带)",
            "deformities": "严重时出现骨骼变形"
          },
          "muscle_symptoms": {
            "proximal_weakness": "近端肌群无力",
            "myalgia": "肌肉疼痛",
            "difficulty_walking": "行走困难",
            "falls": "跌倒风险增加"
          },
          "systemic_symptoms": {
            "fatigue": "疲劳乏力",
            "depression": "抑郁情绪",
            "cognitive_impairment": "认知功能下降",
            "increased_infections": "感染易感性增加"
          }
        },
        "laboratory_findings": {
          "vitamin_d_status": {
            "25_oh_d3": "<30nmol/L (严重缺乏)",
            "1_25_oh2_d3": "可正常或降低",
            "optimal_level": "25(OH)D3 >75nmol/L"
          },
          "calcium_phosphate": {
            "serum_calcium": "正常或轻度降低",
            "serum_phosphate": "正常或降低",
            "ionized_calcium": "可能降低"
          },
          "parathyroid_function": {
            "pth": "升高(继发性甲旁亢)",
            "correlation": "与25(OH)D3水平负相关"
          },
          "bone_turnover_markers": {
            "alkaline_phosphatase": "升高",
            "osteocalcin": "可升高",
            "ctx": "可升高"
          }
        },
        "imaging_findings": {
          "x_ray": {
            "pseudofractures": "Looser带(假性骨折线)",
            "common_sites": ["股骨颈", "耻骨支", "肋骨"],
            "osteopenia": "弥漫性骨量减少"
          },
          "bone_scan": {
            "hotspots": "Looser带处放射性摄取增加",
            "pattern": "多发性热点"
          },
          "bone_biopsy": {
            "indication": "诊断困难时",
            "findings": "增宽的骨样组织缝",
            "gold_standard": "确诊的金标准"
          }
        },
        "treatment": {
          "vitamin_d_supplementation": {
            "cholecalciferol": {
              "loading_dose": "维生素D3 50,000IU/周 × 8周",
              "maintenance": "800-2000IU/日",
              "monitoring": "治疗后6-8周检测25(OH)D3"
            },
            "ergocalciferol": {
              "dose": "维生素D2 50,000IU/周",
              "efficacy": "较维生素D3稍差"
            },
            "active_metabolites": {
              "calcitriol": "骨化三醇 0.25-1μg/日",
              "alfacalcidol": "阿法骨化醇 0.5-2μg/日",
              "indication": "肾功能不全患者"
            }
          },
          "calcium_supplementation": {
            "elemental_calcium": "1000-1500mg/日",
            "timing": "与维生素D同服",
            "monitoring": "避免过量补充"
          },
          "phosphate_supplementation": {
            "indication": "低磷血症患者",
            "dose": "磷酸盐 1-3g/日 分次服用",
            "monitoring": "血磷、PTH水平"
          },
          "supportive_treatment": {
            "sun_exposure": "增加日光照射",
            "dietary_modification": "富含维生素D食物",
            "physical_therapy": "肌力训练",
            "fall_prevention": "预防跌倒措施"
          }
        },
        "monitoring": {
          "biochemical": [
            "25(OH)D3 每3-6个月",
            "血钙、磷、PTH",
            "肾功能",
            "骨转换标志物"
          ],
          "clinical": [
            "疼痛评估",
            "肌力测试",
            "步态分析",
            "跌倒风险评估"
          ],
          "imaging": [
            "骨密度(DXA)",
            "必要时重复X线检查"
          ]
        },
        "prognosis": {
          "with_treatment": "症状明显改善",
          "bone_healing": "假性骨折可愈合",
          "muscle_recovery": "肌无力逐渐恢复",
          "prevention": "适当补充可完全预防"
        }
      }
    ],

    "endocrine_tumor_entities": [
      {
        "id": "NET_001",
        "name": "神经内分泌肿瘤",
        "name_en": "Neuroendocrine Tumors",
        "type": "neoplasm",
        "category": "endocrine_tumor",
        "description": "起源于神经内分泌细胞的异质性肿瘤群",
        "icd_10": "C7A",
        "epidemiology": {
          "incidence": "6.98/100,000人年",
          "prevalence": "171,321例(美国数据)",
          "age_distribution": "中位年龄63岁",
          "gender_ratio": "女性略多见(1.2:1)"
        },
        "classification": {
          "by_location": {
            "gastroenteropancreatic": {
              "percentage": "67.5%",
              "subtypes": [
                "胰腺神经内分泌肿瘤",
                "小肠神经内分泌肿瘤",
                "胃神经内分泌肿瘤",
                "结直肠神经内分泌肿瘤"
              ]
            },
            "pulmonary": {
              "percentage": "25.3%",
              "subtypes": [
                "典型类癌",
                "非典型类癌",
                "大细胞神经内分泌癌",
                "小细胞肺癌"
              ]
            },
            "other_sites": [
              "甲状腺髓样癌",
              "肾上腺嗜铬细胞瘤",
              "默克尔细胞癌",
              "垂体腺瘤"
            ]
          },
          "by_grade": {
            "who_2019": {
              "g1_net": {
                "ki67": "<3%",
                "mitoses": "<2/10HPF",
                "terminology": "神经内分泌肿瘤G1"
              },
              "g2_net": {
                "ki67": "3-20%",
                "mitoses": "2-20/10HPF",
                "terminology": "神经内分泌肿瘤G2"
              },
              "g3_net": {
                "ki67": ">20%",
                "terminology": "神经内分泌肿瘤G3"
              },
              "nec": {
                "ki67": ">20%",
                "morphology": "小细胞或大细胞形态",
                "terminology": "神经内分泌癌"
              }
            }
          },
          "functional_status": {
            "functioning": {
              "percentage": "10-30%",
              "characteristics": "产生激素相关症候群",
              "examples": [
                "胰岛素瘤",
                "胃泌素瘤",
                "血管活性肠肽瘤",
                "类癌综合征"
              ]
            },
            "non_functioning": {
              "percentage": "70-90%",
              "characteristics": "无激素相关症状",
              "presentation": "肿块效应或偶然发现"
            }
          }
        },
        "clinical_manifestations": {
          "general_symptoms": {
            "non_specific": [
              "腹痛",
              "体重减轻",
              "疲劳",
              "发热"
            ],
            "mass_effect": [
              "肠梗阻",
              "黄疸",
              "上腔静脉综合征"
            ]
          },
          "hormonal_syndromes": {
            "carcinoid_syndrome": {
              "prevalence": "10-20%小肠NET",
              "symptoms": [
                "面部潮红",
                "腹泻",
                "喘息",
                "心脏瓣膜病"
              ],
              "mediators": ["5-羟色胺", "胰激肽", "P物质"]
            },
            "zollinger_ellison": {
              "tumor": "胃泌素瘤",
              "symptoms": [
                "反复消化性溃疡",
                "腹泻",
                "腹痛"
              ],
              "biochemistry": "血清胃泌素>1000pg/mL"
            },
            "insulinoma": {
              "incidence": "4/百万人年",
              "symptoms": "Whipple三联征",
              "diagnosis": "72小时禁食试验"
            },
            "vipoma": {
              "syndrome": "WDHA综合征",
              "symptoms": [
                "大量水样腹泻(>3L/日)",
                "低钾血症",
                "胃酸缺乏"
              ]
            }
          }
        },
        "diagnostic_methods": {
          "biochemical_markers": {
            "general_markers": {
              "chromogranin_a": {
                "sensitivity": "60-90%",
                "specificity": "较低",
                "interference": "质子泵抑制剂影响"
              },
              "neuron_specific_enolase": {
                "sensitivity": "50-80%",
                "specificity": "较低",
                "utility": "高级别NET"
              },
              "pancreastatin": {
                "sensitivity": "较CgA高",
                "specificity": "较好",
                "advantage": "不受PPI影响"
              }
            },
            "specific_markers": {
              "serotonin_metabolites": "5-HIAA(24小时尿)",
              "gastrin": "胃泌素瘤",
              "insulin_proinsulin": "胰岛素瘤",
              "vip": "血管活性肠肽瘤",
              "glucagon": "胰高血糖素瘤"
            }
          },
          "imaging_studies": {
            "cross_sectional": {
              "ct": {
                "technique": "多期增强CT",
                "sensitivity": "80-90%",
                "characteristics": "动脉期强化"
              },
              "mri": {
                "sequences": "T1WI、T2WI、DWI",
                "sensitivity": "90-95%",
                "advantage": "肝转移检测"
              }
            },
            "functional_imaging": {
              "somatostatin_receptor": {
                "68ga_dotatate_pet": "金标准",
                "111in_octreotide": "传统方法",
                "sensitivity": ">95%",
                "applications": [
                  "分期",
                  "治疗选择",
                  "疗效评估"
                ]
              },
              "18f_fdg_pet": {
                "indication": "高级别NET/NEC",
                "prognostic_value": "FDG阳性预后差"
              },
              "18f_dopa_pet": "中肠NET特异性高"
            },
            "endoscopy": {
              "eus": "胰腺NET首选",
              "colonoscopy": "结直肠NET",
              "capsule_endoscopy": "小肠NET"
            }
          },
          "tissue_diagnosis": {
            "biopsy_methods": [
              "内镜活检",
              "经皮穿刺",
              "手术活检"
            ],
            "histopathology": {
              "morphology": "巢状、梁状排列",
              "immunohistochemistry": [
                "CgA阳性",
                "Syn阳性",
                "Ki-67标记"
              ]
            },
            "molecular_testing": {
              "gene_sequencing": "DAXX、ATRX、MEN1",
              "microsatellite_instability": "结直肠NET",
              "chromosomal_alterations": "预后标志物"
            }
          }
        },
        "staging": {
          "tnm_system": {
            "ajcc_8th_edition": "美国癌症联合委员会第8版",
            "site_specific": "不同部位有特定分期标准"
          },
          "enets_staging": {
            "european_system": "欧洲神经内分泌肿瘤学会",
            "widely_used": "广泛应用于临床"
          }
        },
        "treatment": {
          "surgical_treatment": {
            "curative_intent": {
              "localized_disease": "首选治疗方法",
              "techniques": [
                "肿瘤切除术",
                "器官保留手术",
                "淋巴结清扫"
              ],
              "success_rate": "5年生存率>95%(早期)"
            },
            "cytoreductive": {
              "indication": "转移性疾病",
              "goal": "减少肿瘤负荷>90%",
              "benefits": "改善症状和生存"
            }
          },
          "medical_treatment": {
            "somatostatin_analogs": {
              "octreotide": {
                "short_acting": "100-200μg tid 皮下注射",
                "long_acting": "20-30mg/月 肌注",
                "indications": ["症状控制", "抗肿瘤效应"]
              },
              "lanreotide": {
                "dose": "120mg/月 深部皮下注射",
                "convenience": "预填充注射器",
                "efficacy": "与奥曲肽相当"
              },
              "pasireotide": {
                "indication": "难治性类癌综合征",
                "mechanism": "多受体激动剂"
              }
            },
            "targeted_therapy": {
              "everolimus": {
                "dose": "依维莫司 10mg/日",
                "mechanism": "mTOR抑制剂",
                "indication": "进展性胰腺NET"
              },
              "sunitinib": {
                "dose": "舒尼替尼 37.5mg/日",
                "mechanism": "多靶点酪氨酸激酶抑制剂",
                "indication": "进展性胰腺NET"
              }
            },
            "chemotherapy": {
              "alkylating_agents": {
                "streptozocin": "链脲霉素为基础方案",
                "temozolomide": "替莫唑胺单药或联合",
                "indication": "胰腺NET"
              },
              "platinum_based": {
                "carboplatin_etoposide": "卡铂+依托泊苷",
                "indication": "高级别NEC"
              }
            }
          },
          "peptide_receptor_radionuclide_therapy": {
            "177lu_dotatate": {
              "mechanism": "靶向生长抑素受体",
              "dosing": "7.4GBq × 4次，间隔8周",
              "efficacy": "显著延长PFS和OS",
              "eligibility": "SSTR阳性NET"
            },
            "177lu_dotatoc": "替代方案",
            "side_effects": [
              "血液学毒性",
              "肾脏毒性",
              "肝脏毒性"
            ]
          },
          "supportive_care": {
            "symptom_management": {
              "diarrhea": "洛哌丁胺、考来烯胺",
              "flushing": "抗组胺药物",
              "bronchospasm": "支气管扩张剂"
            },
            "nutritional_support": "维生素B族、烟酸",
            "cardiac_monitoring": "定期超声心动图"
          }
        },
        "prognosis": {
          "survival_rates": {
            "overall_5year": "67.2%",
            "localized": "94.1%",
            "regional": "85.3%",
            "distant": "54.4%"
          },
          "prognostic_factors": {
            "tumor_grade": "最重要预后因子",
            "stage": "分期越早预后越好",
            "primary_site": "中肠NET预后相对较好",
            "age": "年轻患者预后较好",
            "functional_status": "功能性肿瘤预后可能较差"
          }
        }
      }
    ],

    "obesity_metabolic_entities": [
      {
        "id": "OBE_001",
        "name": "肥胖症",
        "name_en": "Obesity",
        "type": "metabolic_disorder",
        "category": "nutrition_metabolic_disease",
        "description": "体内脂肪组织过度积累导致的慢性代谢性疾病",
        "icd_10": "E66",
        "epidemiology": {
          "global_prevalence": "成人肥胖率13.1%",
          "china_prevalence": "成人肥胖率7.0%，超重率34.3%",
          "pediatric_prevalence": "儿童肥胖率19.3%",
          "economic_burden": "全球医疗费用超过2万亿美元",
          "mortality_risk": "BMI每增加5kg/m²，死亡风险增加31%"
        },
        "classification": {
          "by_bmi": {
            "overweight": {
              "asian_criteria": "BMI 23.0-27.4 kg/m²",
              "who_criteria": "BMI 25.0-29.9 kg/m²"
            },
            "obesity_class_1": {
              "asian_criteria": "BMI 27.5-32.4 kg/m²", 
              "who_criteria": "BMI 30.0-34.9 kg/m²"
            },
            "obesity_class_2": {
              "asian_criteria": "BMI 32.5-37.4 kg/m²",
              "who_criteria": "BMI 35.0-39.9 kg/m²"
            },
            "obesity_class_3": {
              "asian_criteria": "BMI ≥37.5 kg/m²",
              "who_criteria": "BMI ≥40.0 kg/m²"
            }
          },
          "by_fat_distribution": {
            "android_obesity": {
              "pattern": "腹型肥胖",
              "measurement": "腰围：男性≥90cm，女性≥85cm",
              "risk": "代谢风险高"
            },
            "gynoid_obesity": {
              "pattern": "臀型肥胖",
              "measurement": "臀围相对增大",
              "risk": "代谢风险相对较低"
            }
          },
          "by_etiology": {
            "primary_obesity": {
              "percentage": "95%",
              "mechanism": "能量摄入>消耗",
              "factors": ["遗传", "环境", "行为"]
            },
            "secondary_obesity": {
              "percentage": "5%",
              "endocrine_causes": [
                "库欣综合征",
                "甲状腺功能减退",
                "多囊卵巢综合征",
                "下丘脑性肥胖"
              ],
              "genetic_syndromes": [
                "Prader-Willi综合征",
                "Bardet-Biedl综合征",
                "瘦素基因缺陷"
              ],
              "medications": [
                "糖皮质激素",
                "胰岛素",
                "抗精神病药物",
                "抗癫痫药物"
              ]
            }
          }
        },
        "pathophysiology": {
          "energy_homeostasis": {
            "leptin_pathway": {
              "function": "脂肪组织分泌瘦素抑制食欲",
              "obesity_effect": "瘦素抵抗，饱腹感下降"
            },
            "ghrelin_pathway": {
              "function": "胃分泌胃饥饿素刺激食欲", 
              "obesity_effect": "餐后胃饥饿素下降不足"
            },
            "hypothalamic_control": {
              "arcuate_nucleus": "食欲调节中枢",
              "neuropeptides": ["NPY", "AgRP", "POMC", "CART"]
            }
          },
          "metabolic_dysfunction": {
            "insulin_resistance": {
              "mechanism": "脂肪组织炎症→胰岛素抵抗",
              "consequences": "糖耐量异常，2型糖尿病"
            },
            "lipid_metabolism": {
              "free_fatty_acids": "游离脂肪酸增加",
              "dyslipidemia": "TG升高，HDL-C降低"
            },
            "inflammation": {
              "adipokines": "脂肪因子失衡",
              "cytokines": "TNF-α、IL-6升高",
              "crp": "C反应蛋白升高"
            }
          }
        },
        "clinical_manifestations": {
          "physical_findings": {
            "anthropometry": [
              "体重指数增加",
              "腰围增大",
              "体脂率升高"
            ],
            "body_habitus": [
              "向心性肥胖",
              "颈部脂肪垫",
              "皮肤皱褶增多"
            ]
          },
          "metabolic_complications": {
            "diabetes": "2型糖尿病风险增加2-6倍",
            "dyslipidemia": "血脂异常患病率60-70%",
            "hypertension": "高血压患病率是正常体重者2-3倍",
            "metabolic_syndrome": "代谢综合征患病率40-50%"
          },
          "cardiovascular_complications": {
            "coronary_heart_disease": "冠心病风险增加2-3倍",
            "stroke": "脑卒中风险增加1.5-2倍",
            "heart_failure": "心力衰竭风险增加2倍",
            "arrhythmia": "房颤风险增加"
          },
          "other_complications": {
            "sleep_apnea": "睡眠呼吸暂停综合征",
            "fatty_liver": "非酒精性脂肪肝",
            "gallstones": "胆石症",
            "osteoarthritis": "骨关节炎",
            "cancer_risk": "结直肠癌、乳腺癌风险增加",
            "reproductive_disorders": "生殖功能障碍"
          }
        },
        "diagnostic_assessment": {
          "anthropometric_measurements": {
            "bmi": "体重指数 = 体重(kg)/身高²(m²)",
            "waist_circumference": "腰围测量",
            "waist_hip_ratio": "腰臀比",
            "body_fat_percentage": "体脂率测定"
          },
          "body_composition": {
            "dexa_scan": "双能X线吸收测定",
            "bioelectrical_impedance": "生物电阻抗分析",
            "underwater_weighing": "水下称重法",
            "air_displacement": "空气置换法"
          },
          "metabolic_evaluation": {
            "glucose_metabolism": [
              "空腹血糖",
              "餐后2小时血糖",
              "糖化血红蛋白",
              "OGTT"
            ],
            "lipid_profile": [
              "总胆固醇",
              "甘油三酯",
              "LDL-C",
              "HDL-C"
            ],
            "hormonal_assessment": [
              "甲状腺功能",
              "皮质醇节律",
              "性激素水平",
              "瘦素水平"
            ]
          },
          "complication_screening": {
            "cardiovascular": "心电图、超声心动图",
            "hepatic": "肝功能、肝脏超声",
            "sleep_disorders": "多导睡眠监测",
            "psychological": "抑郁、焦虑评估"
          }
        },
        "treatment": {
          "lifestyle_intervention": {
            "dietary_modification": {
              "caloric_restriction": "热量限制500-750kcal/日",
              "macronutrient_distribution": {
                "carbohydrate": "45-65%总热量",
                "protein": "10-35%总热量", 
                "fat": "20-35%总热量"
              },
              "dietary_patterns": [
                "地中海饮食",
                "DASH饮食",
                "低血糖指数饮食",
                "间歇性禁食"
              ],
              "portion_control": "控制食物分量",
              "meal_timing": "规律进餐时间"
            },
            "physical_activity": {
              "aerobic_exercise": {
                "frequency": "每周≥150分钟中等强度",
                "intensity": "50-70%最大心率",
                "types": ["快走", "游泳", "骑车", "慢跑"]
              },
              "resistance_training": {
                "frequency": "每周≥2次",
                "benefits": "增加肌肉量，提高代谢率"
              },
              "daily_activity": "增加日常身体活动"
            },
            "behavioral_modification": {
              "goal_setting": "设定现实可达成目标",
              "self_monitoring": "体重、饮食、运动记录",
              "cognitive_therapy": "认知行为治疗",
              "social_support": "家庭和社会支持系统"
            }
          },
          "pharmacological_treatment": {
            "fda_approved_medications": {
              "orlistat": {
                "mechanism": "胰脂肪酶抑制剂",
                "dose": "120mg tid 餐时服用",
                "efficacy": "减重5-10%",
                "side_effects": "胃肠道不适、脂溶性维生素缺乏"
              },
              "liraglutide": {
                "mechanism": "GLP-1受体激动剂",
                "dose": "3.0mg/日 皮下注射",
                "efficacy": "减重8-12%",
                "side_effects": "恶心、腹泻、胰腺炎风险"
              },
              "semaglutide": {
                "mechanism": "GLP-1受体激动剂",
                "dose": "2.4mg/周 皮下注射",
                "efficacy": "减重15-20%",
                "side_effects": "胃肠道反应"
              },
              "naltrexone_bupropion": {
                "mechanism": "阿片受体拮抗剂+去甲肾上腺素再摄取抑制剂",
                "dose": "16mg/180mg bid",
                "efficacy": "减重5-9%",
                "contraindications": "癫痫、厌食症"
              }
            },
            "selection_criteria": {
              "bmi_threshold": "BMI≥30 kg/m² 或 BMI≥27 kg/m²+合并症",
              "lifestyle_failure": "生活方式干预6个月效果不佳",
              "contraindications": "妊娠、严重精神疾病"
            }
          },
          "bariatric_surgery": {
            "indications": {
              "class_3_obesity": "BMI≥40 kg/m²",
              "class_2_with_comorbidities": "BMI≥35 kg/m²+严重合并症",
              "asian_criteria": "BMI≥37.5 kg/m² 或 BMI≥32.5 kg/m²+合并症"
            },
            "procedures": {
              "sleeve_gastrectomy": {
                "mechanism": "胃容量减少75-80%",
                "weight_loss": "50-70%超重体重",
                "complications": "胃漏、狭窄"
              },
              "roux_en_y_gastric_bypass": {
                "mechanism": "限制性+吸收不良",
                "weight_loss": "60-80%超重体重",
                "complications": "吻合口漏、营养缺乏"
              },
              "adjustable_gastric_banding": {
                "mechanism": "可调节胃束带",
                "weight_loss": "40-50%超重体重",
                "complications": "带子滑脱、糜烂"
              }
            },
            "outcomes": {
              "weight_loss": "术后2年维持减重50-70%",
              "diabetes_remission": "2型糖尿病缓解率60-80%",
              "cardiovascular_benefits": "心血管风险显著降低",
              "mortality_reduction": "全因死亡率降低30-40%"
            }
          }
        },
        "monitoring": {
          "weight_management": [
            "每周称重",
            "腰围测量",
            "体脂率监测"
          ],
          "metabolic_parameters": [
            "血糖、糖化血红蛋白",
            "血脂谱",
            "血压",
            "肝功能"
          ],
          "nutritional_status": [
            "蛋白质营养状态",
            "维生素B12、叶酸",
            "脂溶性维生素",
            "微量元素"
          ],
          "complication_surveillance": [
            "心血管风险评估",
            "糖尿病筛查",
            "睡眠呼吸暂停评估",
            "心理健康评估"
          ]
        },
        "prognosis": {
          "weight_loss_maintenance": "5年维持减重成功率20-30%",
          "health_benefits": "减重5-10%即可显著改善代谢指标",
          "mortality_impact": "BMI降低可显著降低死亡风险",
          "quality_of_life": "减重改善生活质量和心理健康"
        }
      },
      {
        "id": "OBE_002", 
        "name": "代谢综合征",
        "name_en": "Metabolic Syndrome",
        "type": "metabolic_disorder",
        "category": "nutrition_metabolic_disease", 
        "description": "以胰岛素抵抗为核心的代谢异常综合征",
        "icd_10": "E88.81",
        "epidemiology": {
          "global_prevalence": "成人患病率20-25%",
          "china_prevalence": "成人患病率13.8%",
          "age_trend": "患病率随年龄增长而增加",
          "gender_difference": "绝经后女性患病率高于男性"
        },
        "diagnostic_criteria": {
          "idf_2005": {
            "central_obesity": "必需条件：腰围男性≥90cm，女性≥80cm",
            "plus_two_of": [
              "TG≥1.7mmol/L或已治疗",
              "HDL-C：男性<1.03mmol/L，女性<1.29mmol/L",
              "BP≥130/85mmHg或已治疗",
              "FPG≥5.6mmol/L或已诊断糖尿病"
            ]
          },
          "ncep_atp_iii": {
            "criteria": "以下5项中≥3项",
            "components": [
              "腰围：男性>102cm，女性>88cm",
              "TG≥1.7mmol/L",
              "HDL-C：男性<1.03mmol/L，女性<1.29mmol/L", 
              "BP≥130/85mmHg",
              "FPG≥5.6mmol/L"
            ]
          },
          "who_1999": {
            "glucose_intolerance": "必需条件：糖耐量受损或糖尿病",
            "plus_two_of": [
              "腰臀比：男性>0.90，女性>0.85",
              "TG≥1.7mmol/L或HDL-C<0.9mmol/L",
              "BP≥140/90mmHg",
              "尿白蛋白排泄率≥20μg/min"
            ]
          }
        },
        "pathophysiology": {
          "insulin_resistance": {
            "central_mechanism": "胰岛素抵抗是核心机制",
            "tissue_effects": {
              "muscle": "骨骼肌糖摄取减少",
              "liver": "肝糖输出增加，脂肪合成增加",
              "adipose": "脂肪分解增加，瘦素抵抗"
            },
            "compensatory_hyperinsulinemia": "代偿性高胰岛素血症"
          },
          "inflammatory_pathway": {
            "adipose_inflammation": "脂肪组织慢性炎症",
            "cytokines": "TNF-α、IL-6、CRP升高",
            "adipokines": "脂联素下降，瘦素抵抗"
          },
          "oxidative_stress": {
            "ros_production": "活性氧产生增加",
            "antioxidant_depletion": "抗氧化能力下降",
            "endothelial_dysfunction": "血管内皮功能受损"
          }
        },
        "clinical_manifestations": {
          "metabolic_features": {
            "glucose_metabolism": [
              "空腹血糖受损",
              "糖耐量异常",
              "2型糖尿病",
              "胰岛素抵抗"
            ],
            "lipid_abnormalities": [
              "高甘油三酯血症",
              "低HDL胆固醇血症",
              "小而密LDL颗粒增多",
              "载脂蛋白B升高"
            ],
            "blood_pressure": [
              "收缩压升高",
              "舒张压升高",
              "脉压差增大"
            ]
          },
          "body_composition": {
            "central_obesity": "向心性肥胖",
            "visceral_adiposity": "内脏脂肪增加",
            "subcutaneous_fat": "皮下脂肪分布异常",
            "muscle_mass": "肌肉质量相对减少"
          },
          "vascular_complications": {
            "endothelial_dysfunction": "血管内皮功能障碍",
            "arterial_stiffness": "动脉硬化",
            "microalbuminuria": "微量白蛋白尿",
            "carotid_thickness": "颈动脉内膜中层厚度增加"
          }
        },
        "complications": {
          "cardiovascular_disease": {
            "risk_increase": "心血管疾病风险增加2-3倍",
            "manifestations": [
              "冠心病",
              "脑卒中",
              "外周血管病",
              "心房颤动"
            ]
          },
          "diabetes_risk": {
            "progression": "进展为2型糖尿病风险增加5倍",
            "timeline": "10年糖尿病发病率30-50%"
          },
          "other_complications": [
            "非酒精性脂肪肝",
            "多囊卵巢综合征",
            "睡眠呼吸暂停",
            "慢性肾脏病",
            "某些恶性肿瘤"
          ]
        },
        "treatment": {
          "lifestyle_intervention": {
            "weight_management": {
              "target": "减重5-10%",
              "caloric_restriction": "热量限制500-1000kcal/日",
              "dietary_composition": "低糖、适量蛋白、健康脂肪"
            },
            "physical_activity": {
              "aerobic_exercise": "每周≥150分钟中等强度",
              "resistance_training": "每周≥2次力量训练",
              "daily_activity": "增加日常活动量"
            },
            "dietary_patterns": {
              "mediterranean_diet": "地中海饮食模式",
              "dash_diet": "DASH饮食",
              "low_glycemic_index": "低血糖指数饮食",
              "portion_control": "控制食物分量"
            }
          },
          "pharmacological_treatment": {
            "glucose_management": {
              "metformin": "首选药物，改善胰岛素敏感性",
              "glp1_agonists": "GLP-1受体激动剂",
              "sglt2_inhibitors": "SGLT-2抑制剂",
              "pioglitazone": "噻唑烷二酮类"
            },
            "lipid_management": {
              "statins": "他汀类药物",
              "fibrates": "贝特类药物(高TG)",
              "ezetimibe": "依折麦布",
              "pcsk9_inhibitors": "PCSK9抑制剂"
            },
            "blood_pressure_control": {
              "ace_inhibitors": "ACE抑制剂",
              "arbs": "血管紧张素受体阻滞剂",
              "calcium_blockers": "钙通道阻滞剂",
              "diuretics": "利尿剂"
            }
          },
          "target_goals": {
            "glucose_control": {
              "hba1c": "<7.0% (糖尿病患者)",
              "fpg": "4.4-7.0mmol/L",
              "ppg": "<10.0mmol/L"
            },
            "lipid_targets": {
              "ldl_c": "<2.6mmol/L (高危患者<1.8mmol/L)",
              "hdl_c": "男性>1.0mmol/L，女性>1.3mmol/L",
              "tg": "<1.7mmol/L"
            },
            "blood_pressure": "<130/80mmHg",
            "weight": "减重5-10%或BMI<25kg/m²"
          }
        },
        "monitoring": {
          "metabolic_parameters": [
            "血糖、糖化血红蛋白每3-6个月",
            "血脂谱每3-6个月",
            "血压每次就诊",
            "体重、腰围每次就诊"
          ],
          "cardiovascular_risk": [
            "心电图每年",
            "超声心动图(如有指征)",
            "颈动脉超声",
            "踝臂指数"
          ],
          "complication_screening": [
            "眼底检查",
            "肾功能、尿蛋白",
            "肝功能",
            "甲状腺功能"
          ]
        },
        "prognosis": {
          "cardiovascular_outcomes": "积极治疗可显著降低心血管风险",
          "diabetes_prevention": "生活方式干预可延缓或预防糖尿病",
          "reversibility": "早期干预代谢综合征可逆转",
          "long_term_management": "需要长期综合管理"
        }
      },
      {
        "id": "OBE_003",
        "name": "胰岛素抵抗综合征",
        "name_en": "Insulin Resistance Syndrome", 
        "type": "metabolic_disorder",
        "category": "nutrition_metabolic_disease",
        "description": "胰岛素生物学效应降低引起的代谢紊乱综合征",
        "icd_10": "E88.81",
        "epidemiology": {
          "prevalence": "成人患病率25-30%",
          "risk_factors": [
            "遗传易感性",
            "腹型肥胖",
            "久坐生活方式",
            "高糖高脂饮食",
            "年龄增长",
            "多囊卵巢综合征"
          ]
        },
        "pathophysiology": {
          "molecular_mechanisms": {
            "insulin_signaling": {
              "receptor_defects": "胰岛素受体敏感性下降",
              "post_receptor": "受体后信号转导异常",
              "glucose_transporters": "GLUT4转位受损"
            },
            "free_fatty_acids": {
              "randle_cycle": "糖脂代谢竞争性抑制",
              "lipotoxicity": "游离脂肪酸脂毒性",
              "inflammatory_cytokines": "炎症因子激活"
            },
            "mitochondrial_dysfunction": {
              "oxidative_capacity": "氧化代谢能力下降",
              "atp_synthesis": "ATP合成效率降低",
              "ros_production": "活性氧产生增加"
            }
          }
        },
        "clinical_assessment": {
          "laboratory_tests": {
            "homa_ir": {
              "calculation": "HOMA-IR = FPG×FINS/22.5",
              "normal_range": "<2.5",
              "interpretation": "≥2.5提示胰岛素抵抗"
            },
            "insulin_tolerance_test": {
              "method": "胰岛素耐量试验",
              "normal_response": "血糖下降>50%",
              "abnormal": "血糖下降<30%"
            },
            "hyperinsulinemic_clamp": {
              "gold_standard": "高胰岛素正血糖钳夹试验",
              "glucose_disposal": "葡萄糖处置率",
              "clinical_utility": "主要用于研究"
            }
          },
          "biomarkers": {
            "adiponectin": "脂联素水平降低",
            "leptin": "瘦素水平升高",
            "c_peptide": "C肽水平评估β细胞功能",
            "proinsulin": "胰岛素原/胰岛素比值升高"
          }
        },
        "treatment": {
          "insulin_sensitizers": {
            "metformin": {
              "mechanism": "减少肝糖输出，增加肌肉糖摄取",
              "dose": "500-2000mg/日",
              "benefits": "改善胰岛素敏感性，减重"
            },
            "pioglitazone": {
              "mechanism": "PPARγ激动剂",
              "dose": "15-45mg/日",
              "benefits": "显著改善胰岛素敏感性",
              "side_effects": "体重增加，水肿，骨折风险"
            },
            "rosiglitazone": {
              "mechanism": "PPARγ激动剂", 
              "concerns": "心血管安全性争议",
              "status": "使用受限"
            }
          },
          "lifestyle_modifications": {
            "exercise_training": {
              "aerobic_exercise": "提高胰岛素敏感性30-50%",
              "resistance_training": "增加肌肉质量和糖摄取",
              "timing": "运动后胰岛素敏感性改善持续48小时"
            },
            "dietary_interventions": {
              "caloric_restriction": "体重减轻改善胰岛素敏感性",
              "macronutrient_composition": "低升糖指数饮食",
              "meal_timing": "间歇性禁食可能有益"
            }
          }
        }
      }
    ],

    "nutrition_endocrine_entities": [
      {
        "id": "NUT_001",
        "name": "维生素D缺乏症",
        "name_en": "Vitamin D Deficiency",
        "type": "nutritional_disorder",
        "category": "nutrition_endocrine_disease",
        "description": "体内维生素D水平不足导致的钙磷代谢紊乱",
        "icd_10": "E55.9",
        "epidemiology": {
          "global_prevalence": "全球约10亿人维生素D不足",
          "china_prevalence": "成人维生素D缺乏率55.9%",
          "seasonal_variation": "冬季缺乏率更高",
          "high_risk_populations": [
            "老年人",
            "孕产妇",
            "婴幼儿",
            "室内工作者",
            "深色皮肤人群"
          ]
        },
        "classification": {
          "by_serum_level": {
            "deficiency": {
              "25_oh_d3": "<30nmol/L (<12ng/mL)",
              "severity": "严重缺乏"
            },
            "insufficiency": {
              "25_oh_d3": "30-50nmol/L (12-20ng/mL)",
              "severity": "不足"
            },
            "sufficiency": {
              "25_oh_d3": "50-125nmol/L (20-50ng/mL)",
              "severity": "充足"
            },
            "toxicity": {
              "25_oh_d3": ">125nmol/L (>50ng/mL)",
              "severity": "中毒"
            }
          }
        },
        "pathophysiology": {
          "vitamin_d_metabolism": {
            "synthesis": {
              "skin": "7-脱氢胆固醇→维生素D3",
              "uv_requirement": "UVB波长280-320nm",
              "factors_affecting": ["纬度", "季节", "皮肤色素", "年龄"]
            },
            "hydroxylation": {
              "liver": "25-羟化酶→25(OH)D3",
              "kidney": "1α-羟化酶→1,25(OH)2D3"
            },
            "regulation": {
              "pth": "PTH刺激1α-羟化酶",
              "fgf23": "FGF23抑制1α-羟化酶",
              "feedback": "1,25(OH)2D3负反馈调节"
            }
          },
          "deficiency_effects": {
            "calcium_absorption": "肠道钙吸收减少30-80%",
            "secondary_hyperparathyroidism": "继发性甲状旁腺功能亢进",
            "bone_mineralization": "骨矿化障碍",
            "immune_dysfunction": "免疫功能受损"
          }
        },
        "clinical_manifestations": {
          "skeletal_effects": {
            "children": [
              "佝偻病",
              "骨骼畸形",
              "生长发育迟缓",
              "牙齿萌出延迟"
            ],
            "adults": [
              "骨软化症",
              "骨质疏松",
              "病理性骨折",
              "骨痛"
            ]
          },
          "non_skeletal_effects": {
            "muscle_weakness": "近端肌无力",
            "fatigue": "慢性疲劳",
            "mood_disorders": "抑郁、季节性情感障碍",
            "infections": "呼吸道感染增加",
            "autoimmune_risk": "自身免疫疾病风险增加"
          },
          "severe_deficiency": {
            "hypocalcemia": "低钙血症",
            "tetany": "手足搐搦",
            "seizures": "癫痫发作",
            "laryngospasm": "喉痉挛"
          }
        },
        "risk_factors": {
          "environmental": [
            "日照不足",
            "高纬度地区",
            "空气污染",
            "室内工作"
          ],
          "dietary": [
            "维生素D摄入不足",
            "素食主义",
            "吸收不良综合征"
          ],
          "physiological": [
            "年龄增长",
            "深色皮肤",
            "肥胖",
            "妊娠哺乳期"
          ],
          "medical": [
            "慢性肾病",
            "肝病",
            "某些药物(抗惊厥药)"
          ]
        },
        "diagnosis": {
          "laboratory_tests": {
            "25_oh_d3": {
              "gold_standard": "血清25(OH)D3测定",
              "timing": "任何时间采血",
              "stability": "半衰期2-3周"
            },
            "1_25_oh2_d3": {
              "indication": "肾病或特殊情况",
              "limitation": "不反映维生素D储存"
            },
            "associated_tests": [
              "血钙、磷",
              "PTH",
              "碱性磷酸酶",
              "24小时尿钙"
            ]
          },
          "imaging": {
            "bone_density": "DXA骨密度检测",
            "x_ray": "骨骼X线检查",
            "bone_biopsy": "骨活检(极少需要)"
          }
        },
        "treatment": {
          "vitamin_d_supplementation": {
            "cholecalciferol": {
              "daily_dose": "800-4000IU/日",
              "weekly_dose": "50,000IU/周(缺乏时)",
              "duration": "8-12周纠正缺乏"
            },
            "ergocalciferol": {
              "dose": "50,000IU/周",
              "efficacy": "略低于维生素D3"
            },
            "monitoring": {
              "recheck_timing": "治疗后3个月",
              "target_level": "75-125nmol/L",
              "safety": "避免过量中毒"
            }
          },
          "calcium_supplementation": {
            "indication": "维生素D缺乏时常需要",
            "dose": "1000-1200mg/日",
            "timing": "与维生素D同服"
          },
          "lifestyle_modifications": {
            "sun_exposure": {
              "duration": "每天10-30分钟",
              "timing": "上午10点-下午3点",
              "skin_area": "面部、手臂、腿部"
            },
            "dietary_sources": [
              "富脂鱼类(鲑鱼、鲭鱼)",
              "蛋黄",
              "强化食品",
              "蘑菇"
            ]
          }
        },
        "prevention": {
          "population_strategies": {
            "food_fortification": "食品强化",
            "supplement_programs": "补充剂项目",
            "public_education": "公众教育"
          },
          "high_risk_groups": {
            "infants": "母乳喂养儿400IU/日",
            "pregnant_women": "600-800IU/日",
            "elderly": "800-1000IU/日",
            "chronic_diseases": "个体化补充"
          }
        },
        "prognosis": {
          "with_treatment": "症状显著改善",
          "bone_recovery": "骨密度逐渐恢复",
          "prevention_benefits": "显著降低骨折风险",
          "long_term_maintenance": "需要长期维持治疗"
        }
      },
      {
        "id": "NUT_002", 
        "name": "碘缺乏病",
        "name_en": "Iodine Deficiency Disorders",
        "type": "nutritional_disorder",
        "category": "nutrition_endocrine_disease",
        "description": "膳食碘摄入不足导致的甲状腺功能和发育异常",
        "icd_10": "E00-E02",
        "epidemiology": {
          "global_burden": "全球20亿人碘摄入不足",
          "china_status": "基本消除碘缺乏病",
          "endemic_areas": "山区、内陆、高原地区",
          "vulnerable_populations": [
            "孕产妇",
            "婴幼儿",
            "儿童青少年"
          ]
        },
        "classification": {
          "by_severity": {
            "mild": {
              "urine_iodine": "50-99μg/L",
              "manifestations": "甲状腺肿大"
            },
            "moderate": {
              "urine_iodine": "20-49μg/L", 
              "manifestations": "甲状腺肿大+轻度智力障碍"
            },
            "severe": {
              "urine_iodine": "<20μg/L",
              "manifestations": "克汀病"
            }
          },
          "by_age_group": {
            "fetal": "流产、死胎、先天畸形",
            "neonatal": "新生儿甲状腺功能减退",
            "childhood": "甲状腺肿、智力发育障碍",
            "adult": "甲状腺肿、甲状腺功能减退"
          }
        },
        "pathophysiology": {
          "thyroid_hormone_synthesis": {
            "iodine_requirement": "甲状腺激素合成必需",
            "iodine_trapping": "甲状腺摄取碘",
            "thyroglobulin": "甲状腺球蛋白碘化",
            "hormone_release": "T4、T3释放"
          },
          "adaptation_mechanisms": {
            "tsh_elevation": "TSH代偿性升高",
            "thyroid_enlargement": "甲状腺代偿性增大",
            "iodine_recycling": "碘的回收利用增加",
            "t3_preference": "优先合成T3"
          },
          "developmental_effects": {
            "brain_development": "胎儿期和婴儿期关键",
            "myelination": "髓鞘形成受影响",
            "neurogenesis": "神经元发生异常",
            "irreversible_damage": "错过关键期不可逆"
          }
        },
        "clinical_manifestations": {
          "endemic_goiter": {
            "definition": "地方性甲状腺肿",
            "prevalence": "地区儿童甲状腺肿率>5%",
            "grades": ["0级(正常)", "1级(可触及)", "2级(可见)"]
          },
          "endemic_cretinism": {
            "neurological_type": {
              "features": ["智力障碍", "聋哑", "痉挛性瘫痪"],
              "thyroid_function": "轻度异常"
            },
            "myxedematous_type": {
              "features": ["智力障碍", "侏儒症", "甲状腺功能减退"],
              "thyroid_function": "明显异常"
            }
          },
          "subclinical_effects": {
            "cognitive_impairment": "轻度认知功能障碍",
            "motor_development": "运动发育迟缓",
            "hearing_defects": "听力障碍",
            "growth_retardation": "生长发育迟缓"
          }
        },
        "assessment": {
          "population_indicators": {
            "urine_iodine": {
              "optimal": "100-199μg/L",
              "insufficient": "<100μg/L",
              "excessive": ">300μg/L"
            },
            "goiter_rate": {
              "elimination": "<5%",
              "mild_deficiency": "5-19.9%",
              "moderate_deficiency": "20-29.9%",
              "severe_deficiency": "≥30%"
            },
            "neonatal_tsh": {
              "screening": "新生儿TSH筛查",
              "threshold": ">5mIU/L超过3%"
            }
          },
          "individual_assessment": {
            "thyroid_function": ["TSH", "FT4", "FT3"],
            "thyroid_imaging": "超声检查",
            "iodine_nutrition": "尿碘测定"
          }
        },
        "prevention_and_control": {
          "universal_salt_iodization": {
            "strategy": "食盐普遍加碘",
            "iodine_content": "20-40mg/kg",
            "coverage": "覆盖率>90%",
            "monitoring": "定期监测"
          },
          "targeted_supplementation": {
            "high_risk_groups": {
              "pregnant_women": "150-250μg/日",
              "lactating_women": "250μg/日",
              "infants": "通过母乳或配方奶"
            },
            "iodized_oil": {
              "indication": "严重缺乏地区",
              "route": "口服或肌注",
              "duration": "作用持续1-2年"
            }
          },
          "monitoring_system": {
            "surveillance": "碘营养监测",
            "evaluation": "防治效果评价",
            "adjustment": "策略调整"
          }
        },
        "treatment": {
          "acute_intervention": {
            "iodine_supplementation": {
              "potassium_iodide": "150-300μg/日",
              "duration": "根据缺乏程度",
              "monitoring": "甲状腺功能监测"
            }
          },
          "thyroid_hormone_replacement": {
            "indication": "甲状腺功能减退",
            "levothyroxine": "1.6μg/kg/日",
            "monitoring": "TSH每6-8周"
          },
          "supportive_care": {
            "nutritional_support": "全面营养改善",
            "rehabilitation": "智力和运动康复",
            "educational_support": "特殊教育"
          }
        },
        "prognosis": {
          "prevention_effectiveness": "预防措施可完全避免",
          "early_intervention": "早期干预效果好",
          "irreversible_damage": "脑损伤不可逆转",
          "population_benefits": "群体干预效果显著"
        }
      },
      {
        "id": "NUT_003",
        "name": "营养性甲状腺肿",
        "name_en": "Nutritional Goiter",
        "type": "nutritional_disorder", 
        "category": "nutrition_endocrine_disease",
        "description": "营养因素导致的甲状腺代偿性增大",
        "icd_10": "E04.0",
        "etiology": {
          "iodine_deficiency": {
            "primary_cause": "碘摄入不足",
            "mechanism": "TSH代偿性升高",
            "geographic": "内陆山区多见"
          },
          "goitrogenic_substances": {
            "dietary_goitrogens": [
              "十字花科蔬菜(生食)",
              "木薯",
              "大豆",
              "小米"
            ],
            "environmental_goitrogens": [
              "过氯酸盐", 
              "硫氰酸盐",
              "工业污染物"
            ],
            "mechanism": "干扰碘代谢或激素合成"
          },
          "selenium_deficiency": {
            "role": "硒缺乏加重碘缺乏效应",
            "mechanism": "影响碘代酶活性",
            "geographic": "低硒地区"
          }
        },
        "pathophysiology": {
          "compensation_mechanism": {
            "iodine_deficiency": "碘摄入不足",
            "tsh_stimulation": "TSH分泌增加",
            "thyroid_growth": "甲状腺细胞增生",
            "functional_adaptation": "维持激素水平"
          },
          "progression": {
            "early_stage": "弥漫性增大",
            "late_stage": "结节性改变",
            "complications": "压迫症状、功能异常"
          }
        },
        "clinical_features": {
          "thyroid_enlargement": {
            "symmetrical": "对称性增大",
            "consistency": "质地软或韧",
            "mobility": "随吞咽活动"
          },
          "compressive_symptoms": {
            "respiratory": "呼吸困难",
            "swallowing": "吞咽困难", 
            "voice_changes": "声音改变",
            "vascular": "上腔静脉综合征"
          },
          "thyroid_function": {
            "euthyroid": "多数功能正常",
            "subclinical_hypothyroidism": "亚临床甲减",
            "rarely_hyperthyroid": "少数甲亢"
          }
        },
        "diagnosis": {
          "clinical_examination": {
            "inspection": "颈部外观检查",
            "palpation": "甲状腺触诊",
            "auscultation": "血管杂音听诊"
          },
          "laboratory_tests": {
            "thyroid_function": "TSH、FT4、FT3",
            "iodine_nutrition": "尿碘测定",
            "antibodies": "TPOAb、TgAb"
          },
          "imaging": {
            "ultrasound": "甲状腺超声",
            "ct_mri": "胸部CT/MRI(巨大甲状腺肿)",
            "scintigraphy": "甲状腺显像"
          }
        },
        "treatment": {
          "nutritional_intervention": {
            "iodine_supplementation": {
              "potassium_iodide": "150-300μg/日",
              "iodized_salt": "食用加碘盐",
              "monitoring": "定期复查"
            },
            "dietary_modification": {
              "avoid_goitrogens": "减少致甲状腺肿物质",
              "cooking_methods": "充分烹饪十字花科蔬菜",
              "balanced_nutrition": "均衡营养"
            }
          },
          "medical_treatment": {
            "thyroid_hormone": {
              "levothyroxine": "50-150μg/日",
              "indication": "抑制TSH分泌",
              "duration": "6-18个月"
            },
            "monitoring": {
              "thyroid_function": "每3-6个月",
              "thyroid_size": "临床检查或超声",
              "symptoms": "压迫症状改善"
            }
          },
          "surgical_intervention": {
            "indications": [
              "巨大甲状腺肿",
              "压迫症状",
              "怀疑恶性",
              "美容需求"
            ],
            "procedures": [
              "甲状腺大部切除",
              "甲状腺全切除",
              "胸骨下甲状腺肿切除"
            ]
          }
        },
        "prevention": {
          "primary_prevention": {
            "iodine_prophylaxis": "碘缺乏地区碘化",
            "nutrition_education": "营养健康教育",
            "environmental_control": "控制环境致甲状腺肿因素"
          },
          "secondary_prevention": {
            "early_detection": "定期甲状腺检查",
            "high_risk_screening": "高危人群筛查",
            "prompt_treatment": "及时治疗"
          }
        },
        "prognosis": {
          "nutritional_correction": "营养纠正后可缓解",
          "size_reduction": "甲状腺肿大可明显缩小",
          "function_recovery": "甲状腺功能可恢复",
          "prevention_effectiveness": "预防措施效果显著"
        }
      }
    ],

    "pediatric_endocrine_entities": [
      {
        "id": "PED_001",
        "name": "儿童生长激素缺乏症",
        "name_en": "Pediatric Growth Hormone Deficiency",
        "type": "endocrine_disorder",
        "category": "pediatric_endocrine_disease",
        "description": "儿童期生长激素分泌不足导致的生长发育迟缓",
        "icd_10": "E23.0",
        "epidemiology": {
          "prevalence": "1/4000-1/10000儿童",
          "male_predominance": "男性较女性多见(2-3:1)",
          "peak_diagnosis_age": "5-15岁",
          "ethnic_differences": "各种族均可发病"
        },
        "classification": {
          "by_etiology": {
            "congenital": {
              "percentage": "5-10%",
              "causes": [
                "下丘脑-垂体发育异常",
                "基因突变",
                "围产期损伤"
              ]
            },
            "acquired": {
              "percentage": "5-10%",
              "causes": [
                "颅脑外伤",
                "颅内肿瘤",
                "感染",
                "放射治疗"
              ]
            },
            "idiopathic": {
              "percentage": "80-90%",
              "characteristics": "原因不明"
            }
          },
          "by_severity": {
            "complete_deficiency": {
              "gh_peak": "<3ng/mL",
              "growth_velocity": "<4cm/年"
            },
            "partial_deficiency": {
              "gh_peak": "3-10ng/mL",
              "growth_velocity": "4-6cm/年"
            },
            "gh_neurosecretory_dysfunction": {
              "gh_peak": "正常",
              "spontaneous_secretion": "降低"
            }
          }
        },
        "pathophysiology": {
          "gh_axis": {
            "hypothalamus": "GHRH分泌",
            "pituitary": "GH分泌",
            "liver": "IGF-1产生",
            "target_tissues": "生长促进"
          },
          "growth_effects": {
            "linear_growth": "骨骺软骨增殖",
            "protein_synthesis": "蛋白质合成增加",
            "lipolysis": "脂肪分解",
            "glucose_metabolism": "血糖调节"
          },
          "deficiency_consequences": {
            "growth_retardation": "生长速度减慢",
            "body_composition": "脂肪增加，肌肉减少",
            "bone_maturation": "骨龄延迟",
            "metabolic_effects": "低血糖倾向"
          }
        },
        "clinical_manifestations": {
          "growth_parameters": {
            "short_stature": "身高<第3百分位或<-2SD",
            "growth_velocity": "生长速度<第25百分位",
            "height_sds": "身高标准差分数持续下降",
            "target_height": "明显低于遗传靶身高"
          },
          "physical_features": {
            "proportionate_short_stature": "匀称性矮小",
            "immature_facial_features": "面容幼稚",
            "high_pitched_voice": "声音尖细",
            "delayed_dental_eruption": "牙齿萌出延迟"
          },
          "body_composition": {
            "increased_fat_mass": "脂肪量增加",
            "decreased_muscle_mass": "肌肉量减少",
            "central_adiposity": "向心性肥胖",
            "thin_hair": "毛发稀疏"
          },
          "metabolic_manifestations": {
            "hypoglycemia": "低血糖(新生儿期)",
            "delayed_puberty": "青春期延迟",
            "reduced_bone_density": "骨密度降低",
            "insulin_sensitivity": "胰岛素敏感性增加"
          }
        },
        "diagnostic_evaluation": {
          "auxological_assessment": {
            "growth_charts": "生长曲线评估",
            "height_velocity": "生长速度计算",
            "bone_age": "骨龄测定",
            "body_proportions": "坐高/身高比值"
          },
          "biochemical_tests": {
            "igf1": {
              "normal_range": "年龄性别特异性",
              "screening_test": "IGF-1水平",
              "limitations": "营养状态影响"
            },
            "igfbp3": {
              "complementary": "IGF结合蛋白3",
              "stability": "较IGF-1稳定",
              "age_dependence": "年龄相关变化"
            }
          },
          "stimulation_tests": {
            "indications": [
              "IGF-1低于正常",
              "生长速度<4cm/年",
              "临床高度怀疑"
            ],
            "tests": {
              "insulin_tolerance": {
                "stimulant": "胰岛素0.1-0.15U/kg",
                "contraindications": "癫痫、心脏病",
                "gh_peak": "正常>10ng/mL"
              },
              "arginine_stimulation": {
                "dose": "精氨酸0.5g/kg",
                "safety": "相对安全",
                "efficacy": "中等刺激强度"
              },
              "clonidine_test": {
                "dose": "可乐定4μg/kg",
                "side_effects": "嗜睡、低血压",
                "convenience": "口服给药"
              },
              "glucagon_test": {
                "dose": "胰高血糖素15μg/kg",
                "advantages": "禁食时间短",
                "limitations": "恶心呕吐"
              }
            },
            "interpretation": {
              "normal_response": "GH峰值>10ng/mL",
              "deficiency": "两次试验均<10ng/mL",
              "partial_deficiency": "一次正常一次异常"
            }
          },
          "imaging_studies": {
            "mri_pituitary": {
              "indications": [
                "确诊GH缺乏",
                "多重垂体激素缺乏",
                "神经系统症状"
              ],
              "findings": [
                "垂体前叶缺如",
                "垂体柄中断",
                "异位后叶"
              ]
            },
            "bone_age": {
              "method": "左手腕X线",
              "evaluation": "Greulich-Pyle法",
              "findings": "骨龄明显延迟"
            }
          }
        },
        "treatment": {
          "growth_hormone_therapy": {
            "indications": [
              "确诊GH缺乏",
              "生长速度<4cm/年",
              "骨龄明显延迟",
              "IGF-1持续低水平"
            ],
            "preparations": {
              "recombinant_gh": "重组人生长激素",
              "daily_injection": "每日皮下注射",
              "evening_administration": "模拟生理节律"
            },
            "dosing": {
              "initial_dose": "0.025-0.035mg/kg/日",
              "adjustment": "根据生长反应调整",
              "maximum_dose": "0.05mg/kg/日",
              "frequency": "每日1次"
            },
            "monitoring": {
              "growth_velocity": "每3-6个月测量身高",
              "igf1_levels": "每6个月检测IGF-1",
              "side_effects": "定期安全性评估",
              "bone_age": "每年评估骨龄进展"
            }
          },
          "treatment_response": {
            "first_year": {
              "expected_growth": "8-12cm/年",
              "catch_up_growth": "追赶性生长",
              "igf1_normalization": "IGF-1水平正常化"
            },
            "subsequent_years": {
              "growth_velocity": "6-8cm/年",
              "height_sds_improvement": "身高标准差改善",
              "pubertal_growth": "青春期生长加速"
            },
            "poor_response": {
              "definitions": "<4cm/年增长",
              "causes": [
                "依从性差",
                "剂量不足",
                "其他疾病",
                "抗体产生"
              ]
            }
          },
          "adjuvant_treatments": {
            "nutritional_support": "确保充足营养",
            "thyroid_hormone": "甲状腺功能减退时",
            "sex_hormones": "青春期延迟时",
            "psychological_support": "心理社会支持"
          }
        },
        "monitoring_and_follow_up": {
          "growth_parameters": [
            "身高、体重每3个月",
            "生长速度计算",
            "身高标准差变化",
            "青春期发育评估"
          ],
          "laboratory_monitoring": [
            "IGF-1每6个月",
            "甲状腺功能每年",
            "糖化血红蛋白",
            "骨代谢标志物"
          ],
          "safety_monitoring": [
            "局部反应",
            "抗体检测",
            "颅内压增高",
            "糖代谢异常",
            "甲状腺功能",
            "脊柱侧弯"
          ],
          "imaging_follow_up": [
            "骨龄每年",
            "垂体MRI(如有指征)",
            "脊柱X线(监测侧弯)"
          ]
        },
        "complications": {
          "untreated_consequences": [
            "成人矮小症",
            "心理社会问题",
            "代谢异常",
            "骨质疏松",
            "心血管风险增加"
          ],
          "treatment_related": [
            "注射部位反应",
            "一过性颅内压增高",
            "糖耐量异常",
            "甲状腺功能减退",
            "脊柱侧弯进展"
          ]
        },
        "prognosis": {
          "growth_outcomes": {
            "early_treatment": "接近正常身高",
            "late_treatment": "改善有限",
            "final_height": "取决于治疗时机和依从性"
          },
          "quality_of_life": "显著改善自信心和社会适应",
          "long_term_benefits": "改善体成分和代谢状态",
          "transition_to_adult": "成年期继续治疗考虑"
        }
      },
      {
        "id": "PED_002",
        "name": "儿童甲状腺疾病",
        "name_en": "Pediatric Thyroid Disorders",
        "type": "endocrine_disorder",
        "category": "pediatric_endocrine_disease",
        "description": "儿童期甲状腺功能异常和结构性疾病",
        "icd_10": "E03-E05",
        "epidemiology": {
          "hypothyroidism_prevalence": "先天性甲减1/2000-1/4000新生儿",
          "hyperthyroidism_prevalence": "儿童甲亢1/100,000",
          "thyroid_nodules": "儿童甲状腺结节1-5%",
          "gender_distribution": "女性多于男性"
        },
        "classification": {
          "congenital_hypothyroidism": {
            "primary": {
              "percentage": "85%",
              "causes": [
                "甲状腺发育不全",
                "甲状腺异位",
                "激素合成缺陷"
              ]
            },
            "central": {
              "percentage": "5%",
              "causes": [
                "TSH缺乏",
                "TRH缺乏",
                "垂体下丘脑疾病"
              ]
            },
            "transient": {
              "percentage": "10%",
              "causes": [
                "母体抗甲状腺药物",
                "碘过量或不足",
                "早产儿"
              ]
            }
          },
          "acquired_hypothyroidism": {
            "autoimmune": {
              "hashimoto_thyroiditis": "桥本甲状腺炎",
              "peak_age": "青春期",
              "associations": "其他自身免疫病"
            },
            "iatrogenic": {
              "post_surgical": "术后甲减",
              "radiation_induced": "放射性甲减",
              "drug_induced": "药物性甲减"
            }
          },
          "hyperthyroidism": {
            "graves_disease": {
              "percentage": "95%",
              "peak_age": "10-15岁",
              "characteristics": "弥漫性甲状腺肿大"
            },
            "toxic_nodules": {
              "percentage": "<5%",
              "types": ["单发", "多发"]
            }
          }
        },
        "clinical_manifestations": {
          "congenital_hypothyroidism": {
            "neonatal_signs": [
              "延长性黄疸",
              "喂养困难",
              "便秘",
              "嗜睡",
              "体温不稳",
              "哭声嘶哑"
            ],
            "later_manifestations": [
              "生长发育迟缓",
              "智力发育障碍",
              "骨龄延迟",
              "牙齿萌出延迟"
            ]
          },
          "acquired_hypothyroidism": {
            "growth_effects": [
              "生长速度减慢",
              "青春期延迟",
              "骨龄延迟"
            ],
            "metabolic_effects": [
              "体重增加",
              "疲劳乏力",
              "便秘",
              "皮肤干燥"
            ],
            "neurological_effects": [
              "学习困难",
              "注意力不集中",
              "记忆力下降"
            ]
          },
          "hyperthyroidism": {
            "growth_acceleration": "身高体重快速增长",
            "behavioral_changes": [
              "多动不安",
              "注意力不集中",
              "情绪不稳",
              "学习成绩下降"
            ],
            "physical_signs": [
              "甲状腺肿大",
              "心动过速",
              "多汗",
              "手震颤",
              "眼征(少见)"
            ]
          }
        },
        "diagnosis": {
          "newborn_screening": {
            "timing": "出生后3-5天",
            "method": "TSH筛查",
            "cutoff": "TSH>20mIU/L",
            "follow_up": "异常结果及时复查"
          },
          "laboratory_tests": {
            "thyroid_function": {
              "tsh": "促甲状腺激素",
              "ft4": "游离甲状腺素",
              "ft3": "游离三碘甲状腺原氨酸",
              "reference_ranges": "年龄特异性正常值"
            },
            "antibodies": {
              "tpoab": "甲状腺过氧化物酶抗体",
              "tgab": "甲状腺球蛋白抗体",
              "trab": "TSH受体抗体"
            },
            "thyroglobulin": "甲状腺球蛋白水平"
          },
          "imaging": {
            "thyroid_scintigraphy": {
              "indication": "先天性甲减病因",
              "isotopes": "99mTc或123I",
              "findings": ["缺如", "异位", "正常"]
            },
            "thyroid_ultrasound": {
              "indication": "甲状腺肿大或结节",
              "parameters": "大小、形态、血流",
              "guided_biopsy": "结节性质鉴别"
            }
          }
        },
        "treatment": {
          "hypothyroidism_treatment": {
            "levothyroxine": {
              "newborn_dose": "10-15μg/kg/日",
              "infant_dose": "6-10μg/kg/日",
              "child_dose": "4-6μg/kg/日",
              "adolescent_dose": "2-3μg/kg/日"
            },
            "administration": {
              "timing": "空腹服用",
              "preparation": "液体或片剂",
              "compliance": "确保依从性"
            },
            "monitoring": {
              "frequency": "治疗初期每2-4周",
              "target_tsh": "正常范围下半部",
              "target_ft4": "正常范围上半部"
            }
          },
          "hyperthyroidism_treatment": {
            "antithyroid_drugs": {
              "methimazole": {
                "dose": "0.2-0.5mg/kg/日",
                "advantages": "每日1次，较少副作用",
                "first_line": "儿童首选"
              },
              "propylthiouracil": {
                "indication": "妊娠、甲状腺危象",
                "hepatotoxicity": "肝毒性风险",
                "monitoring": "肝功能监测"
              }
            },
            "beta_blockers": {
              "propranolol": "普萘洛尔",
              "indication": "症状控制",
              "dose": "1-2mg/kg/日"
            },
            "definitive_treatment": {
              "radioiodine": {
                "age_limit": "一般>20岁",
                "considerations": "生育能力影响",
                "contraindications": "妊娠、哺乳"
              },
              "surgery": {
                "indications": [
                  "巨大甲状腺肿",
                  "压迫症状",
                  "怀疑恶性",
                  "药物治疗失败"
                ],
                "risks": "喉返神经损伤、甲旁减"
              }
            }
          }
        },
        "monitoring": {
          "growth_development": [
            "身高体重每3个月",
            "头围(婴儿)",
            "骨龄评估",
            "智力发育评估"
          ],
          "thyroid_function": [
            "TSH、FT4每3-6个月",
            "抗体滴度变化",
            "药物剂量调整"
          ],
          "complications_screening": [
            "心血管系统",
            "神经系统发育",
            "其他自身免疫病"
          ]
        },
        "prognosis": {
          "congenital_hypothyroidism": {
            "early_treatment": "正常智力发育",
            "delayed_treatment": "不可逆智力障碍",
            "lifelong_treatment": "终身激素替代"
          },
          "acquired_hypothyroidism": {
            "growth_catch_up": "治疗后追赶性生长",
            "reversible_effects": "多数症状可逆",
            "long_term_outlook": "预后良好"
          },
          "hyperthyroidism": {
            "remission_rate": "40-60%缓解率",
            "relapse_risk": "停药后复发风险",
            "long_term_monitoring": "需长期随访"
          }
        }
      },
      {
        "id": "PED_003",
        "name": "儿童1型糖尿病",
        "name_en": "Pediatric Type 1 Diabetes",
        "type": "autoimmune_disorder",
        "category": "pediatric_endocrine_disease",
        "description": "儿童期胰岛β细胞自身免疫性破坏导致的绝对胰岛素缺乏",
        "icd_10": "E10",
        "epidemiology": {
          "global_incidence": "每年增加3-5%",
          "china_incidence": "0.6/10万儿童年",
          "peak_ages": "5-7岁和10-14岁",
          "gender_ratio": "男女大致相等",
          "ethnic_differences": "白种人发病率最高"
        },
        "pathophysiology": {
          "autoimmune_destruction": {
            "target": "胰岛β细胞",
            "mechanism": "T细胞介导的自身免疫",
            "triggers": ["病毒感染", "环境因素", "遗传易感性"],
            "progression": "从正常→糖耐量异常→糖尿病"
          },
          "genetic_susceptibility": {
            "hla_associations": "HLA-DR3/DR4",
            "high_risk_haplotypes": "DQB1*0302/DQA1*0501",
            "protective_alleles": "DQB1*0602",
            "non_hla_genes": "INS、PTPN22、CTLA4"
          },
          "environmental_factors": [
            "肠道病毒感染",
            "早期牛奶蛋白暴露",
            "维生素D缺乏",
            "过度卫生假说"
          ]
        },
        "clinical_presentation": {
          "classic_symptoms": {
            "polyuria": "多尿",
            "polydipsia": "多饮",
            "polyphagia": "多食",
            "weight_loss": "体重下降"
          },
          "presentation_patterns": {
            "diabetic_ketoacidosis": {
              "percentage": "25-40%首发DKA",
              "younger_children": "更易发生DKA",
              "symptoms": [
                "恶心呕吐",
                "腹痛",
                "呼吸困难",
                "意识改变"
              ]
            },
            "gradual_onset": {
              "symptoms": "症状逐渐加重",
              "duration": "数周至数月",
              "misdiagnosis": "常被误诊"
            }
          },
          "physical_findings": {
            "dehydration": "脱水征象",
            "weight_loss": "明显消瘦",
            "kussmaul_breathing": "Kussmaul呼吸",
            "acetone_breath": "烂苹果味呼气"
          }
        },
        "diagnosis": {
          "diagnostic_criteria": {
            "symptoms_plus": "典型症状+随机血糖≥11.1mmol/L",
            "fasting_glucose": "空腹血糖≥7.0mmol/L",
            "ogtt_2h": "OGTT 2小时血糖≥11.1mmol/L",
            "hba1c": "糖化血红蛋白≥6.5%"
          },
          "autoantibodies": {
            "gad_antibodies": "GAD抗体",
            "ia2_antibodies": "IA-2抗体",
            "zinc_transporter8": "ZnT8抗体",
            "insulin_autoantibodies": "胰岛素自身抗体",
            "positive_rate": "90%患者至少一种阳性"
          },
          "c_peptide": {
            "stimulated_test": "胰高血糖素刺激试验",
            "interpretation": "评估胰岛功能",
            "prognosis": "预测蜜月期长短"
          },
          "differential_diagnosis": [
            "2型糖尿病",
            "MODY",
            "新生儿糖尿病",
            "继发性糖尿病",
            "应激性高血糖"
          ]
        },
        "acute_management": {
          "diabetic_ketoacidosis": {
            "fluid_resuscitation": {
              "initial": "20ml/kg生理盐水",
              "maintenance": "根据脱水程度补液",
              "rate": "48小时内纠正脱水"
            },
            "insulin_therapy": {
              "route": "持续静脉滴注",
              "dose": "0.1U/kg/h",
              "adjustment": "血糖下降3-5mmol/L/h",
              "glucose_addition": "血糖<14mmol/L时加葡萄糖"
            },
            "electrolyte_management": {
              "potassium": "监测并补充钾离子",
              "phosphate": "必要时补磷",
              "sodium": "避免过快纠正"
            },
            "monitoring": {
              "blood_glucose": "每1-2小时",
              "electrolytes": "每4-6小时",
              "arterial_blood_gas": "监测酸中毒纠正",
              "neurological_status": "防止脑水肿"
            }
          },
          "cerebral_edema": {
            "incidence": "0.5-1%",
            "risk_factors": [
              "年龄<5岁",
              "严重酸中毒",
              "高尿素氮",
              "低PCO2"
            ],
            "management": "甘露醇、限制补液"
          }
        },
        "chronic_management": {
          "insulin_therapy": {
            "regimens": {
              "multiple_daily_injections": {
                "long_acting": "基础胰岛素",
                "rapid_acting": "餐前胰岛素",
                "advantages": "灵活性好"
              },
              "insulin_pump": {
                "continuous_infusion": "持续皮下胰岛素输注",
                "age_requirement": "通常>6岁",
                "benefits": "更精确控制"
              }
            },
            "insulin_types": {
              "rapid_acting": "门冬、赖脯、谷赖胰岛素",
              "long_acting": "甘精、地特米、德谷胰岛素",
              "intermediate": "NPH胰岛素"
            },
            "dosing": {
              "total_daily_dose": "0.5-1.2U/kg/日",
              "honeymoon_period": "0.2-0.5U/kg/日",
              "established_diabetes": "0.7-1.0U/kg/日",
              "adolescence": "1.0-1.5U/kg/日"
            }
          },
          "glucose_monitoring": {
            "self_monitoring": "每日4-8次血糖监测",
            "continuous_glucose_monitoring": {
              "real_time_cgm": "实时血糖监测",
              "flash_glucose": "瞬感血糖监测",
              "benefits": "减少低血糖、改善控制"
            },
            "ketone_monitoring": "血糖>13mmol/L时检测"
          },
          "target_goals": {
            "hba1c": {
              "general_target": "<7.5%",
              "individualized": "根据年龄调整",
              "hypoglycemia_risk": "平衡获益与风险"
            },
            "blood_glucose": {
              "preprandial": "5.0-7.2mmol/L",
              "postprandial": "<10.0mmol/L",
              "bedtime": "6.7-10.0mmol/L"
            }
          }
        },
        "complications": {
          "acute_complications": {
            "hypoglycemia": {
              "definition": "血糖<3.9mmol/L",
              "severe": "需他人协助",
              "treatment": "葡萄糖片、胰高血糖素",
              "prevention": "血糖监测、饮食配合"
            },
            "hyperglycemia": "血糖>13mmol/L",
            "ketoacidosis": "反复DKA"
          },
          "chronic_complications": {
            "microvascular": [
              "糖尿病肾病",
              "糖尿病视网膜病变",
              "糖尿病神经病变"
            ],
            "macrovascular": [
              "动脉粥样硬化",
              "冠心病风险增加"
            ],
            "screening_recommendations": {
              "nephropathy": "病程5年后每年筛查",
              "retinopathy": "病程3-5年后每年筛查",
              "neuropathy": "青春期后每年筛查"
            }
          }
        },
        "psychosocial_management": {
          "family_education": [
            "糖尿病知识",
            "胰岛素注射技术",
            "血糖监测",
            "低血糖处理",
            "饮食管理"
          ],
          "school_management": [
            "学校人员培训",
            "紧急处理方案",
            "体育活动安全",
            "考试安排调整"
          ],
          "psychological_support": [
            "诊断时心理危机干预",
            "青春期心理问题",
            "家庭关系调适",
            "同伴支持小组"
          ]
        },
        "prognosis": {
          "life_expectancy": "接近正常人群",
          "quality_of_life": "良好管理下正常生活",
          "complications_prevention": "严格控制可预防并发症",
          "technology_advancement": "新技术不断改善预后"
        }
      },
      {
        "id": "PED_004",
        "name": "儿童性早熟",
        "name_en": "Precocious Puberty",
        "type": "endocrine_disorder",
        "category": "pediatric_endocrine_disease",
        "description": "儿童第二性征过早出现的内分泌疾病",
        "icd_10": "E30.1",
        "epidemiology": {
          "prevalence": "女孩1/5000，男孩1/25000",
          "gender_difference": "女孩发病率是男孩的10倍",
          "ethnic_variations": "非裔美国人发病率较高",
          "secular_trends": "发病年龄呈提前趋势"
        },
        "definition": {
          "girls": "8岁前出现第二性征",
          "boys": "9岁前出现第二性征",
          "criteria": {
            "breast_development": "乳房发育Tanner II期",
            "pubic_hair": "阴毛出现",
            "testicular_enlargement": "睾丸体积≥4ml"
          }
        },
        "classification": {
          "central_precocious_puberty": {
            "mechanism": "下丘脑-垂体-性腺轴激活",
            "percentage": "女孩90%，男孩40%",
            "gonadotropin_dependent": "促性腺激素依赖性"
          },
          "peripheral_precocious_puberty": {
            "mechanism": "性腺或肾上腺激素分泌",
            "percentage": "女孩10%，男孩60%",
            "gonadotropin_independent": "促性腺激素非依赖性"
          }
        },
        "etiology": {
          "central_causes": {
            "idiopathic": {
              "percentage": "女孩95%，男孩50%",
              "characteristics": "原因不明"
            },
            "pathological": {
              "cns_tumors": [
                "颅咽管瘤",
                "垂体腺瘤",
                "下丘脑错构瘤"
              ],
              "cns_trauma": "颅脑外伤",
              "infections": "脑炎、脑膜炎",
              "radiation": "颅脑放疗史"
            }
          },
          "peripheral_causes": {
            "gonadal": [
              "卵巢囊肿/肿瘤",
              "睾丸肿瘤",
              "McCune-Albright综合征"
            ],
            "adrenal": [
              "先天性肾上腺皮质增生症",
              "肾上腺肿瘤",
              "库欣综合征"
            ],
            "exogenous": [
              "外源性性激素暴露",
              "环境内分泌干扰物"
            ]
          }
        },
        "clinical_manifestations": {
          "physical_changes": {
            "girls": {
              "breast_development": "乳房发育",
              "growth_spurt": "身高快速增长",
              "pubic_hair": "阴毛出现",
              "menarche": "月经初潮",
              "body_odor": "体味出现"
            },
            "boys": {
              "testicular_enlargement": "睾丸增大",
              "penile_growth": "阴茎增长",
              "pubic_hair": "阴毛出现",
              "voice_changes": "声音变化",
              "muscle_development": "肌肉发育"
            }
          },
          "growth_patterns": {
            "accelerated_growth": "生长速度加快",
            "advanced_bone_age": "骨龄超前",
            "early_epiphyseal_fusion": "骨骺过早闭合",
            "final_height_compromise": "最终身高受损"
          },
          "psychological_effects": {
            "body_image_concerns": "身体形象焦虑",
            "peer_relationship_issues": "同伴关系问题",
            "premature_sexualization": "过早性化",
            "emotional_immaturity": "情感不成熟"
          }
        },
        "diagnostic_evaluation": {
          "clinical_assessment": {
            "tanner_staging": "Tanner分期评估",
            "growth_velocity": "生长速度计算",
            "family_history": "家族青春期发育史",
            "medication_history": "药物和暴露史"
          },
          "laboratory_tests": {
            "basal_hormones": {
              "lh": "黄体生成素",
              "fsh": "卵泡刺激素",
              "estradiol": "雌二醇(女孩)",
              "testosterone": "睾酮(男孩)"
            },
            "gnrh_stimulation_test": {
              "indication": "鉴别中枢性vs外周性",
              "method": "GnRH 100μg静脉注射",
              "interpretation": {
                "central": "LH峰值>5IU/L",
                "peripheral": "LH反应不明显"
              }
            },
            "additional_tests": {
              "thyroid_function": "甲状腺功能",
              "adrenal_function": "肾上腺皮质功能",
              "tumor_markers": "肿瘤标志物"
            }
          },
          "imaging_studies": {
            "bone_age": {
              "method": "左手腕X线",
              "finding": "骨龄超前>2年",
              "prognosis": "预测最终身高"
            },
            "brain_mri": {
              "indication": "男孩或女孩<6岁",
              "findings": "排除颅内病变",
              "sequences": "包括垂体薄层扫描"
            },
            "pelvic_ultrasound": {
              "girls": "卵巢、子宫发育评估",
              "findings": "器官大小和形态"
            },
            "testicular_ultrasound": {
              "boys": "睾丸大小和结构",
              "indication": "排除肿瘤"
            }
          }
        },
        "treatment": {
          "central_precocious_puberty": {
            "gnrh_agonists": {
              "mechanism": "下调GnRH受体",
              "preparations": {
                "leuprolide": "亮丙瑞林 3.75mg/月",
                "triptorelin": "曲普瑞林 3.75mg/月",
                "goserelin": "戈舍瑞林 3.6mg/月"
              },
              "administration": "肌内注射",
              "duration": "直到适当年龄"
            },
            "monitoring": {
              "clinical_response": "第二性征进展停止",
              "hormonal_suppression": "性激素降至青春期前水平",
              "growth_velocity": "生长速度恢复正常",
              "side_effects": "骨密度、情绪变化"
            }
          },
          "peripheral_precocious_puberty": {
            "treat_underlying_cause": "治疗原发疾病",
            "specific_therapies": {
              "mccune_albright": "芳香化酶抑制剂",
              "adrenal_disorders": "糖皮质激素",
              "tumors": "手术切除"
            }
          },
          "supportive_care": {
            "growth_hormone": "联合GH治疗(特殊情况)",
            "psychological_support": "心理辅导",
            "family_counseling": "家庭支持"
          }
        },
        "monitoring_and_follow_up": {
          "treatment_response": [
            "第二性征进展",
            "生长速度",
            "骨龄进展",
            "激素水平"
          ],
          "side_effects_monitoring": [
            "骨密度(DXA)",
            "情绪行为变化",
            "注射部位反应",
            "体重变化"
          ],
          "long_term_outcomes": [
            "最终身高",
            "生育能力",
            "心理社会适应",
            "骨健康"
          ]
        },
        "prognosis": {
          "height_outcomes": {
            "treated": "接近遗传潜能身高",
            "untreated": "成人矮小",
            "treatment_timing": "早期治疗效果更好"
          },
          "reproductive_health": {
            "fertility": "正常生育能力",
            "menstrual_function": "规律月经周期",
            "pregnancy_outcomes": "正常妊娠结局"
          },
          "psychological_adjustment": {
            "self_esteem": "自尊心改善",
            "peer_relationships": "同伴关系正常化",
            "academic_performance": "学业表现稳定"
          }
        }
      }
    ],

    "female_endocrine_entities": [
      {
        "id": "FEM_001",
        "name": "多囊卵巢综合征",
        "name_en": "Polycystic Ovary Syndrome (PCOS)",
        "type": "reproductive_endocrine_disorder",
        "category": "female_endocrine_disease",
        "description": "育龄期女性常见的内分泌代谢疾病，以雄激素过多、排卵障碍和多囊卵巢为特征",
        "icd_10": "E28.2",
        "epidemiology": {
          "prevalence": "育龄女性5-20%",
          "china_prevalence": "5.6%(生育年龄女性)",
          "adolescent_prevalence": "青春期女性3-10%",
          "ethnic_variations": "各种族均有发病"
        },
        "diagnostic_criteria": {
          "rotterdam_2003": {
            "description": "3项中至少2项",
            "criteria": [
              "稀发排卵或无排卵",
              "临床和/或生化雄激素过多",
              "多囊卵巢形态"
            ]
          },
          "nih_1990": {
            "description": "必须同时具备",
            "criteria": [
              "稀发排卵或无排卵",
              "临床或生化雄激素过多"
            ]
          },
          "aes_2006": {
            "description": "雄激素过多+以下之一",
            "criteria": [
              "卵巢功能障碍",
              "多囊卵巢形态"
            ]
          }
        },
        "pathophysiology": {
          "insulin_resistance": {
            "prevalence": "50-70%患者",
            "mechanism": "胰岛素抵抗→高胰岛素血症",
            "effects": [
              "刺激卵巢雄激素产生",
              "降低性激素结合球蛋白",
              "促进脂肪储存"
            ]
          },
          "hyperandrogenism": {
            "sources": ["卵巢", "肾上腺"],
            "mechanisms": [
              "LH刺激卵泡膜细胞",
              "胰岛素协同作用",
              "芳香化酶活性降低"
            ],
            "consequences": [
              "毛囊敏感性增加",
              "皮脂腺分泌增加",
              "干扰卵泡发育"
            ]
          },
          "ovarian_dysfunction": {
            "follicular_arrest": "卵泡发育停滞",
            "anovulation": "排卵障碍",
            "altered_steroidogenesis": "类固醇生成异常"
          }
        },
        "clinical_manifestations": {
          "reproductive_features": {
            "menstrual_irregularities": {
              "oligomenorrhea": "月经稀发(>35天)",
              "amenorrhea": "闭经(>90天)",
              "dysfunctional_bleeding": "功能失调性子宫出血"
            },
            "infertility": {
              "anovulatory": "排卵性不孕",
              "prevalence": "75%不孕症患者",
              "mechanism": "排卵障碍"
            }
          },
          "hyperandrogenic_features": {
            "hirsutism": {
              "definition": "Ferriman-Gallwey评分≥6",
              "distribution": "面部、胸部、腹部多毛",
              "prevalence": "60-80%患者"
            },
            "acne": {
              "characteristics": "持续性、炎症性痤疮",
              "distribution": "面部、背部、胸部",
              "severity": "中重度"
            },
            "alopecia": {
              "pattern": "男性型脱发",
              "location": "顶部和颞部",
              "progression": "逐渐加重"
            }
          },
          "metabolic_features": {
            "obesity": {
              "prevalence": "50-80%患者",
              "pattern": "中心性肥胖",
              "bmi": "BMI≥25kg/m²"
            },
            "insulin_resistance": {
              "glucose_intolerance": "糖耐量异常",
              "diabetes_risk": "2型糖尿病风险增加",
              "metabolic_syndrome": "代谢综合征高发"
            },
            "dyslipidemia": {
              "patterns": [
                "高甘油三酯",
                "低HDL-C",
                "小而密LDL增加"
              ]
            }
          }
        },
        "laboratory_evaluation": {
          "hormonal_assessment": {
            "androgens": {
              "total_testosterone": ">2.5nmol/L",
              "free_testosterone": "计算游离睾酮",
              "dhea_s": "硫酸脱氢表雄酮",
              "androstenedione": "雄烯二酮"
            },
            "reproductive_hormones": {
              "lh_fsh_ratio": "LH/FSH>2-3",
              "amh": "抗苗勒管激素升高",
              "prolactin": "排除高催乳素血症",
              "17_ohp": "排除先天性肾上腺增生"
            }
          },
          "metabolic_assessment": {
            "glucose_metabolism": {
              "ogtt": "75g口服糖耐量试验",
              "homa_ir": "胰岛素抵抗指数",
              "hba1c": "糖化血红蛋白"
            },
            "lipid_profile": [
              "总胆固醇",
              "甘油三酯",
              "HDL-C",
              "LDL-C"
            ]
          }
        },
        "imaging_studies": {
          "pelvic_ultrasound": {
            "criteria": "Rotterdam标准",
            "findings": {
              "follicle_number": "≥12个直径2-9mm卵泡",
              "ovarian_volume": ">10ml",
              "stromal_echogenicity": "基质回声增强"
            },
            "timing": "月经周期任意时间"
          }
        },
        "treatment": {
          "lifestyle_modification": {
            "weight_management": {
              "target": "减重5-10%",
              "benefits": [
                "改善排卵",
                "降低雄激素",
                "改善胰岛素敏感性",
                "减少心血管风险"
              ]
            },
            "diet": {
              "low_glycemic_index": "低血糖指数饮食",
              "caloric_restriction": "适度热量限制",
              "macronutrient_balance": "平衡蛋白质、脂肪、碳水"
            },
            "exercise": {
              "aerobic": "有氧运动150分钟/周",
              "resistance": "阻力训练2-3次/周",
              "benefits": "改善胰岛素敏感性"
            }
          },
          "pharmacological_treatment": {
            "menstrual_regulation": {
              "combined_oc": {
                "mechanism": "抑制LH、增加SHBG",
                "benefits": ["调节月经", "减少雄激素"],
                "contraindications": "血栓风险"
              },
              "progestins": {
                "medroxyprogesterone": "醋酸甲羟孕酮",
                "cyclical_therapy": "周期性治疗",
                "duration": "10-14天/月"
              }
            },
            "hyperandrogenism_treatment": {
              "anti_androgens": {
                "spironolactone": {
                  "dose": "螺内酯 25-200mg/日",
                  "mechanism": "雄激素受体拮抗",
                  "monitoring": "血钾、肾功能"
                },
                "cyproterone_acetate": {
                  "dose": "醋酸环丙孕酮 25-100mg/日",
                  "combination": "与炔雌醇联用",
                  "contraindications": "肝病、血栓"
                },
                "finasteride": {
                  "dose": "非那雄胺 5mg/日",
                  "mechanism": "5α-还原酶抑制",
                  "indication": "男性型脱发"
                }
              },
              "topical_treatments": {
                "eflornithine": "依氟鸟氨酸乳膏",
                "indication": "面部多毛",
                "mechanism": "鸟氨酸脱羧酶抑制"
              }
            },
            "insulin_sensitizers": {
              "metformin": {
                "dose": "二甲双胍 500-2000mg/日",
                "benefits": [
                  "改善胰岛素敏感性",
                  "恢复排卵",
                  "减重",
                  "改善代谢指标"
                ],
                "monitoring": "肾功能、维生素B12"
              },
              "inositol": {
                "myo_inositol": "肌醇 2-4g/日",
                "d_chiro_inositol": "D-手性肌醇",
                "benefits": "改善胰岛素敏感性、排卵"
              }
            }
          },
          "fertility_treatment": {
            "ovulation_induction": {
              "clomiphene_citrate": {
                "dose": "枸橼酸氯米芬 50-150mg/日",
                "duration": "月经第3-7天，连续5天",
                "success_rate": "排卵率70-80%"
              },
              "letrozole": {
                "dose": "来曲唑 2.5-7.5mg/日",
                "advantages": "较少多胎妊娠",
                "first_line": "PCOS患者首选"
              },
              "gonadotropins": {
                "indication": "克罗米芬抵抗",
                "monitoring": "超声监测卵泡",
                "risks": "卵巢过度刺激综合征"
              }
            },
            "assisted_reproduction": {
              "ivf": "体外受精",
              "indication": "其他治疗失败",
              "success_rates": "与年龄和BMI相关"
            }
          }
        },
        "long_term_complications": {
          "reproductive": {
            "infertility": "排卵障碍导致不孕",
            "pregnancy_complications": [
              "妊娠期糖尿病",
              "妊娠期高血压",
              "早产",
              "胎儿宫内生长受限"
            ],
            "endometrial_cancer": "子宫内膜癌风险增加2-3倍"
          },
          "metabolic": {
            "type2_diabetes": "2型糖尿病风险增加5-10倍",
            "metabolic_syndrome": "代谢综合征患病率35-80%",
            "cardiovascular_disease": "心血管疾病风险增加"
          },
          "psychological": {
            "depression": "抑郁症发病率增加",
            "anxiety": "焦虑症状",
            "body_image": "身体形象问题",
            "quality_of_life": "生活质量下降"
          }
        },
        "monitoring": {
          "reproductive_health": [
            "月经周期规律性",
            "排卵监测",
            "子宫内膜厚度",
            "生育能力评估"
          ],
          "metabolic_monitoring": [
            "体重、BMI",
            "血糖、胰岛素",
            "血脂谱",
            "血压"
          ],
          "cancer_screening": [
            "子宫内膜病理检查",
            "宫颈癌筛查",
            "乳腺癌筛查"
          ]
        },
        "prognosis": {
          "reproductive_outcomes": "适当治疗可恢复排卵和生育能力",
          "metabolic_management": "生活方式干预可显著改善代谢指标",
          "long_term_health": "需要终生管理和监测",
          "quality_of_life": "综合治疗可明显改善生活质量"
        }
      },
      {
        "id": "FEM_002",
        "name": "绝经期综合征",
        "name_en": "Menopausal Syndrome",
        "type": "reproductive_endocrine_disorder",
        "category": "female_endocrine_disease",
        "description": "围绝经期和绝经后妇女因雌激素缺乏引起的综合征",
        "icd_10": "N95.1",
        "epidemiology": {
          "menopause_age": "中国女性平均绝经年龄49.5岁",
          "perimenopause_duration": "围绝经期持续4-8年",
          "symptom_prevalence": "85%女性有血管舒缩症状",
          "severe_symptoms": "25%女性症状严重影响生活"
        },
        "classification": {
          "perimenopause": {
            "definition": "月经周期不规律开始至绝经后1年",
            "early_stage": "月经周期长度变化≥7天",
            "late_stage": "闭经间隔≥60天"
          },
          "postmenopause": {
            "definition": "绝经后阶段",
            "early": "绝经后1-5年",
            "late": "绝经后5年以上"
          }
        },
        "pathophysiology": {
          "ovarian_aging": {
            "follicle_depletion": "卵泡数量减少",
            "hormone_changes": [
              "雌激素水平下降",
              "FSH、LH水平升高",
              "抑制素B降低",
              "AMH降低"
            ]
          },
          "estrogen_deficiency_effects": {
            "vasomotor": "血管舒缩功能异常",
            "bone_metabolism": "骨吸收增加",
            "cardiovascular": "血管内皮功能受损",
            "urogenital": "泌尿生殖道萎缩"
          }
        },
        "clinical_manifestations": {
          "vasomotor_symptoms": {
            "hot_flashes": {
              "prevalence": "75-85%",
              "characteristics": "突然发热、出汗",
              "duration": "平均7.4年",
              "frequency": "轻度：<1次/天，重度：>10次/天"
            },
            "night_sweats": {
              "prevalence": "60-70%",
              "impact": "睡眠质量下降",
              "consequences": "日间疲劳、情绪变化"
            }
          },
          "genitourinary_symptoms": {
            "vaginal_atrophy": {
              "symptoms": ["阴道干燥", "性交痛", "瘙痒"],
              "physical_changes": ["pH升高", "糖原减少", "弹性下降"]
            },
            "urinary_symptoms": {
              "frequency": "尿频",
              "urgency": "急迫性尿失禁",
              "infections": "反复泌尿系感染"
            }
          },
          "psychological_symptoms": {
            "mood_changes": [
              "情绪波动",
              "易激惹",
              "焦虑",
              "抑郁倾向"
            ],
            "cognitive_symptoms": [
              "记忆力下降",
              "注意力不集中",
              "脑雾"
            ],
            "sleep_disturbances": [
              "入睡困难",
              "睡眠中断",
              "早醒"
            ]
          },
          "physical_changes": {
            "body_composition": [
              "腹部脂肪增加",
              "肌肉量减少",
              "体重增加"
            ],
            "skin_hair_changes": [
              "皮肤干燥",
              "弹性减退",
              "毛发稀疏"
            ]
          }
        },
        "diagnosis": {
          "clinical_diagnosis": {
            "age_criteria": "45岁以上女性",
            "menstrual_changes": "月经模式改变",
            "symptom_constellation": "典型症状组合"
          },
          "laboratory_tests": {
            "fsh": {
              "perimenopause": ">25IU/L",
              "postmenopause": ">40IU/L",
              "variability": "围绝经期波动大"
            },
            "estradiol": {
              "levels": "<30pg/mL",
              "variability": "围绝经期不稳定"
            },
            "amh": {
              "low_levels": "<1.0ng/mL",
              "predictor": "绝经时间预测"
            }
          },
          "differential_diagnosis": [
            "甲状腺疾病",
            "抑郁症",
            "焦虑症",
            "其他内分泌疾病"
          ]
        },
        "treatment": {
          "hormone_therapy": {
            "systemic_ht": {
              "indications": [
                "中重度血管舒缩症状",
                "泌尿生殖道症状",
                "骨质疏松预防"
              ],
              "contraindications": [
                "乳腺癌史",
                "子宫内膜癌史",
                "血栓栓塞史",
                "未诊断的阴道出血",
                "活动性肝病"
              ],
              "regimens": {
                "continuous_combined": {
                  "indication": "绝经后妇女",
                  "composition": "雌激素+孕激素每日",
                  "bleeding": "通常无撤退性出血"
                },
                "cyclical": {
                  "indication": "围绝经期妇女",
                  "composition": "雌激素连续+孕激素周期性",
                  "bleeding": "有规律撤退性出血"
                }
              },
              "preparations": {
                "oral": {
                  "estradiol": "雌二醇 1-2mg/日",
                  "conjugated_estrogens": "结合雌激素 0.625mg/日",
                  "progestins": ["地屈孕酮", "微粒化黄体酮"]
                },
                "transdermal": {
                  "patches": "雌激素贴剂",
                  "gels": "雌激素凝胶",
                  "advantages": "避免首过效应"
                }
              }
            },
            "local_therapy": {
              "vaginal_estrogen": {
                "preparations": ["雌激素栓剂", "乳膏", "阴道环"],
                "indications": "泌尿生殖道症状",
                "safety": "全身吸收minimal"
              }
            }
          },
          "non_hormonal_treatments": {
            "vasomotor_symptoms": {
              "ssri_snri": {
                "paroxetine": "帕罗西汀 7.5mg/日",
                "venlafaxine": "文拉法辛 75mg/日",
                "efficacy": "减少潮热50-60%"
              },
              "gabapentin": {
                "dose": "加巴喷丁 300-900mg/日",
                "indication": "夜间潮热",
                "side_effects": "嗜睡、头晕"
              },
              "clonidine": {
                "dose": "可乐定 0.1mg bid",
                "mechanism": "α2受体激动剂",
                "side_effects": "低血压、口干"
              }
            },
            "complementary_therapies": {
              "cognitive_behavioral_therapy": "认知行为疗法",
              "mindfulness": "正念减压",
              "acupuncture": "针灸治疗",
              "yoga": "瑜伽练习"
            }
          },
          "lifestyle_modifications": {
            "diet": {
              "calcium": "1200mg/日",
              "vitamin_d": "800-1000IU/日",
              "phytoestrogens": "大豆异黄酮",
              "avoid_triggers": "避免辛辣食物、咖啡因"
            },
            "exercise": {
              "aerobic": "有氧运动150分钟/周",
              "resistance": "阻力训练",
              "weight_bearing": "负重运动",
              "pelvic_floor": "盆底肌训练"
            },
            "stress_management": [
              "规律作息",
              "充足睡眠",
              "压力管理",
              "社交支持"
            ]
          }
        },
        "monitoring": {
          "hormone_therapy_monitoring": {
            "clinical_response": "症状改善评估",
            "side_effects": [
              "乳房胀痛",
              "阴道出血",
              "血栓风险",
              "胆囊疾病"
            ],
            "annual_assessments": [
              "乳腺检查",
              "妇科检查",
              "血压监测",
              "血脂检查"
            ]
          },
          "long_term_health": [
            "骨密度检测",
            "心血管风险评估",
            "癌症筛查",
            "认知功能评估"
          ]
        },
        "long_term_health_consequences": {
          "bone_health": {
            "bone_loss": "绝经后5年内骨量丢失20%",
            "fracture_risk": "髋部骨折风险显著增加",
            "prevention": "钙、维生素D、运动、HT"
          },
          "cardiovascular_health": {
            "risk_increase": "绝经后心血管疾病风险增加",
            "mechanisms": [
              "血脂谱恶化",
              "血管内皮功能受损",
              "胰岛素抵抗增加"
            ],
            "prevention": "生活方式干预、风险因素控制"
          },
          "cognitive_health": {
            "dementia_risk": "痴呆症风险可能增加",
            "memory_changes": "记忆力和认知功能变化",
            "protection": "教育、社交活动、智力刺激"
          }
        },
        "prognosis": {
          "symptom_duration": "血管舒缩症状平均持续7-10年",
          "treatment_response": "激素治疗有效率80-90%",
          "quality_of_life": "适当治疗可显著改善生活质量",
          "long_term_outcomes": "综合管理可预防长期健康风险"
        }
      },
      {
        "id": "FEM_003",
        "name": "妊娠期糖尿病",
        "name_en": "Gestational Diabetes Mellitus (GDM)",
        "type": "pregnancy_related_disorder",
        "category": "female_endocrine_disease",
        "description": "妊娠期首次发现或发病的糖代谢异常",
        "icd_10": "O24.4",
        "epidemiology": {
          "global_prevalence": "1-14%(因诊断标准而异)",
          "china_prevalence": "14.8%(2019年数据)",
          "increasing_trend": "患病率逐年上升",
          "risk_factors_prevalence": "高龄妊娠、肥胖增加"
        },
        "pathophysiology": {
          "pregnancy_insulin_resistance": {
            "mechanism": "胎盘激素导致胰岛素抵抗",
            "hormones": [
              "人胎盘生长激素",
              "皮质醇",
              "胎盘催乳素",
              "孕激素"
            ],
            "timeline": "妊娠20周后明显"
          },
          "beta_cell_dysfunction": {
            "inadequate_compensation": "β细胞代偿不足",
            "genetic_predisposition": "遗传易感性",
            "environmental_factors": "肥胖、年龄等"
          }
        },
        "risk_factors": {
          "maternal_factors": {
            "age": "≥35岁",
            "obesity": "孕前BMI≥25kg/m²",
            "family_history": "糖尿病家族史",
            "ethnicity": "高危种族"
          },
          "obstetric_history": {
            "previous_gdm": "既往GDM史",
            "macrosomia": "既往巨大儿分娩史",
            "stillbirth": "死胎史",
            "polyhydramnios": "羊水过多史"
          },
          "medical_history": {
            "pcos": "多囊卵巢综合征",
            "hypertension": "高血压",
            "previous_igt": "既往糖耐量异常"
          }
        },
        "diagnosis": {
          "screening_timing": {
            "universal_screening": "24-28孕周",
            "early_screening": "高危因素者孕早期",
            "method": "75g OGTT"
          },
          "diagnostic_criteria": {
            "iadpsg_2010": {
              "fasting": "≥5.1mmol/L",
              "1h_post_load": "≥10.0mmol/L",
              "2h_post_load": "≥8.5mmol/L",
              "diagnosis": "任一时间点异常即诊断"
            },
            "who_2013": "采用IADPSG标准",
            "china_2014": "基本采用IADPSG标准"
          },
          "differential_diagnosis": {
            "overt_diabetes": {
              "criteria": [
                "空腹血糖≥7.0mmol/L",
                "随机血糖≥11.1mmol/L",
                "HbA1c≥6.5%"
              ],
              "timing": "妊娠期任何时间"
            }
          }
        },
        "clinical_manifestations": {
          "maternal_symptoms": {
            "often_asymptomatic": "多数无症状",
            "classic_symptoms": [
              "多饮、多尿",
              "疲劳",
              "反复感染"
            ]
          },
          "fetal_complications": {
            "macrosomia": {
              "definition": "出生体重≥4000g",
              "mechanism": "胎儿高胰岛素血症",
              "complications": ["肩难产", "产伤"]
            },
            "neonatal_complications": [
              "新生儿低血糖",
              "呼吸窘迫综合征",
              "高胆红素血症",
              "低钙血症",
              "红细胞增多症"
            ]
          }
        },
        "management": {
          "nutritional_therapy": {
            "caloric_intake": {
              "normal_weight": "30kcal/kg/日",
              "overweight": "25kcal/kg/日",
              "obese": "12-14kcal/kg/日"
            },
            "macronutrient_distribution": {
              "carbohydrate": "40-50%",
              "protein": "20-25%",
              "fat": "25-30%"
            },
            "meal_planning": {
              "frequency": "少量多餐",
              "timing": "规律进餐时间",
              "complex_carbs": "复合碳水化合物为主"
            }
          },
          "exercise_therapy": {
            "type": "低强度有氧运动",
            "duration": "30分钟/次，每周5次",
            "contraindications": [
              "前置胎盘",
              "早产史",
              "妊娠期高血压"
            ]
          },
          "glucose_monitoring": {
            "frequency": "每日4-7次",
            "timing": [
              "空腹",
              "三餐后2小时",
              "必要时餐后1小时"
            ],
            "targets": {
              "fasting": "<5.3mmol/L",
              "1h_postprandial": "<7.8mmol/L",
              "2h_postprandial": "<6.7mmol/L"
            }
          },
          "insulin_therapy": {
            "indications": [
              "饮食运动治疗2周后血糖不达标",
              "空腹血糖≥5.3mmol/L",
              "餐后血糖反复超标"
            ],
            "insulin_types": {
              "rapid_acting": "门冬胰岛素、赖脯胰岛素",
              "intermediate": "NPH胰岛素",
              "long_acting": "地特米胰岛素"
            },
            "regimens": {
              "basal_bolus": "基础-餐时胰岛素",
              "bid_nph": "NPH胰岛素每日两次",
              "adjustment": "根据血糖调整剂量"
            }
          },
          "oral_agents": {
            "metformin": {
              "safety": "FDA妊娠期B类",
              "indications": "部分国家指南推荐",
              "monitoring": "胎儿生长发育"
            },
            "glyburide": {
              "use": "部分地区使用",
              "concerns": "胎盘通透性"
            }
          }
        },
        "monitoring": {
          "maternal_monitoring": {
            "glucose_control": "血糖日记记录",
            "weight_gain": "孕期体重管理",
            "blood_pressure": "血压监测",
            "ketones": "尿酮体检查"
          },
          "fetal_monitoring": {
            "growth_assessment": {
              "ultrasound": "每4周超声检查",
              "biometry": "胎儿生物测量",
              "amniotic_fluid": "羊水量评估"
            },
            "fetal_wellbeing": {
              "nst": "胎心监护",
              "bpp": "生物物理评分",
              "timing": "32-34周开始"
            }
          }
        },
        "delivery_management": {
          "timing": {
            "well_controlled": "39-40周",
            "poor_control": "考虑提前终止妊娠",
            "macrosomia": "38-39周"
          },
          "mode_of_delivery": {
            "vaginal_delivery": "首选自然分娩",
            "cesarean_indications": [
              "估计胎重≥4500g",
              "既往肩难产史",
              "产科指征"
            ]
          },
          "intrapartum_management": {
            "glucose_monitoring": "每1-2小时监测血糖",
            "insulin_adjustment": "根据血糖调整胰岛素",
            "target": "血糖4.0-7.0mmol/L"
          }
        },
        "postpartum_care": {
          "immediate_postpartum": {
            "insulin_discontinuation": "胰岛素立即停用",
            "glucose_monitoring": "监测血糖变化",
            "breastfeeding": "鼓励母乳喂养"
          },
          "follow_up_screening": {
            "timing": "产后6-12周",
            "method": "75g OGTT",
            "interpretation": "评估糖代谢状态"
          },
          "long_term_follow_up": {
            "annual_screening": "每年糖尿病筛查",
            "lifestyle_counseling": "生活方式指导",
            "preconception_counseling": "再次妊娠前咨询"
          }
        },
        "complications": {
          "maternal_complications": {
            "pregnancy": [
              "妊娠期高血压",
              "子痫前期",
              "羊水过多",
              "感染风险增加"
            ],
            "delivery": [
              "剖宫产率增加",
              "产后出血",
              "产道损伤"
            ]
          },
          "fetal_neonatal_complications": {
            "immediate": [
              "新生儿低血糖",
              "呼吸窘迫",
              "高胆红素血症",
              "低钙血症"
            ],
            "long_term": [
              "儿童期肥胖",
              "青春期糖尿病风险",
              "代谢综合征"
            ]
          }
        },
        "long_term_outcomes": {
          "maternal_outcomes": {
            "diabetes_risk": "50-70%发展为2型糖尿病",
            "cardiovascular_risk": "心血管疾病风险增加",
            "recurrence_risk": "再次妊娠复发率30-84%"
          },
          "offspring_outcomes": {
            "obesity_risk": "儿童肥胖风险增加",
            "diabetes_risk": "青春期糖尿病风险增加",
            "metabolic_programming": "代谢编程效应"
          }
        },
        "prevention": {
          "primary_prevention": {
            "preconception": [
              "体重管理",
              "健康饮食",
              "规律运动",
              "叶酸补充"
            ]
          },
          "secondary_prevention": {
            "lifestyle_interventions": [
              "饮食指导",
              "运动计划",
              "体重控制",
              "定期随访"
            ]
          }
        },
        "prognosis": {
          "immediate_outcomes": "良好的血糖控制可改善母儿结局",
          "long_term_health": "需要终生糖尿病风险管理",
          "quality_of_life": "适当管理下可维持正常生活",
          "family_planning": "可安全进行再次妊娠"
        }
      }
    ],

    "male_endocrine_entities": [
      {
        "id": "MAL_001",
        "name": "男性性腺功能减退症",
        "name_en": "Male Hypogonadism",
        "type": "reproductive_endocrine_disorder",
        "category": "male_endocrine_disease",
        "description": "男性睾丸产生睾酮不足或无法产生足够精子的内分泌疾病",
        "icd_10": "E29.1",
        "epidemiology": {
          "prevalence": "40岁以上男性约20%",
          "incidence_rate": "随年龄增长而增加",
          "age_distribution": "50岁后发病率显著上升",
          "risk_factors": [
            "年龄",
            "肥胖",
            "糖尿病",
            "代谢综合征",
            "慢性疾病"
          ]
        },
        "classification": {
          "by_mechanism": {
            "primary": {
              "description": "睾丸本身疾病导致",
              "causes": [
                "Klinefelter综合征",
                "睾丸创伤",
                "睾丸炎",
                "化疗或放疗",
                "先天性睾丸发育异常"
              ],
              "hormone_pattern": "低睾酮，高LH/FSH"
            },
            "secondary": {
              "description": "下丘脑-垂体轴异常",
              "causes": [
                "垂体肿瘤",
                "Kallmann综合征",
                "慢性疾病",
                "药物（糖皮质激素、阿片类）",
                "营养不良"
              ],
              "hormone_pattern": "低睾酮，低或正常LH/FSH"
            }
          },
          "by_onset": {
            "congenital": "先天性，青春期前发病",
            "acquired": "获得性，成年后发病"
          }
        },
        "clinical_manifestations": {
          "sexual_symptoms": [
            "性欲减退",
            "勃起功能障碍",
            "射精量减少",
            "不育"
          ],
          "physical_signs": [
            "肌肉量减少",
            "骨密度降低",
            "体脂增加",
            "胡须和体毛稀少",
            "睾丸萎缩"
          ],
          "psychological_symptoms": [
            "抑郁",
            "易怒",
            "疲劳",
            "注意力不集中",
            "记忆力下降"
          ],
          "metabolic_effects": [
            "胰岛素抵抗",
            "血脂异常",
            "骨质疏松",
            "贫血"
          ]
        },
        "diagnosis": {
          "laboratory_tests": {
            "total_testosterone": {
              "normal_range": "10.4-34.7 nmol/L (300-1000 ng/dL)",
              "timing": "上午8-11时采血",
              "repeat_testing": "低值需要重复检测"
            },
            "free_testosterone": {
              "calculation": "基于总睾酮和SHBG计算",
              "direct_measurement": "平衡透析法或超离心法"
            },
            "gonadotropins": {
              "LH": "区分原发性和继发性",
              "FSH": "评估生精功能"
            },
            "other_hormones": [
              "催乳素",
              "甲状腺功能",
              "皮质醇"
            ]
          },
          "questionnaires": [
            "ADAM问卷",
            "qADAM问卷",
            "AMS评分"
          ],
          "imaging": {
            "scrotal_ultrasound": "评估睾丸大小和结构",
            "pituitary_mri": "怀疑垂体疾病时"
          }
        },
        "treatment": {
          "testosterone_replacement": {
            "indications": [
              "明确诊断的性腺功能减退",
              "有症状且实验室确认",
              "无禁忌症"
            ],
            "formulations": {
              "intramuscular": {
                "testosterone_enanthate": "250mg q2-4周",
                "testosterone_undecanoate": "1000mg q10-12周"
              },
              "topical": {
                "gel": "50-100mg/day，每日应用",
                "patch": "2-6mg/day"
              },
              "oral": {
                "testosterone_undecanoate": "120-160mg bid"
              },
              "pellet": {
                "subcutaneous": "150-450mg q3-6月"
              }
            },
            "contraindications": [
              "前列腺癌",
              "乳腺癌",
              "未治疗的睡眠呼吸暂停",
              "严重心力衰竭",
              "红细胞增多症"
            ]
          },
          "monitoring": {
            "efficacy": [
              "症状改善",
              "睾酮水平",
              "骨密度",
              "肌肉量"
            ],
            "safety": [
              "血细胞计数",
              "肝功能",
              "脂质代谢",
              "前列腺特异抗原(PSA)",
              "前列腺检查"
            ],
            "frequency": "治疗前3-6个月每3个月，之后每6-12个月"
          }
        },
        "complications": {
          "untreated_consequences": [
            "骨质疏松和骨折",
            "心血管疾病风险增加",
            "代谢综合征",
            "抑郁和认知功能下降",
            "不育"
          ],
          "treatment_related": [
            "红细胞增多症",
            "睡眠呼吸暂停加重",
            "前列腺增生",
            "皮肤反应（外用制剂）"
          ]
        },
        "prognosis": {
          "with_treatment": "大多数患者症状显著改善",
          "quality_of_life": "性功能和整体健康状况改善",
          "long_term_outcomes": "需要终生治疗和监测",
          "fertility": "部分患者可通过hCG或FSH治疗恢复生育能力"
        }
      },
      {
        "id": "MAL_002",
        "name": "男性更年期综合征",
        "name_en": "Andropause/Late-onset Hypogonadism",
        "type": "age_related_endocrine_disorder",
        "category": "male_endocrine_disease",
        "description": "中老年男性由于睾酮水平逐渐下降引起的综合征候群",
        "icd_10": "E29.1",
        "epidemiology": {
          "prevalence": "40-79岁男性约6-12%",
          "age_onset": "通常40岁后开始",
          "progression": "睾酮水平每年下降1-2%",
          "individual_variation": "存在显著个体差异"
        },
        "pathophysiology": {
          "hormonal_changes": {
            "testosterone_decline": "总睾酮和游离睾酮逐渐下降",
            "shbg_increase": "性激素结合球蛋白增加",
            "lh_elevation": "促黄体激素轻度升高"
          },
          "contributing_factors": [
            "睾丸老化",
            "下丘脑-垂体轴敏感性下降",
            "慢性疾病",
            "药物影响",
            "生活方式因素"
          ]
        },
        "clinical_manifestations": {
          "core_symptoms": [
            "性欲减退",
            "勃起功能减退",
            "精力下降",
            "疲劳感"
          ],
          "physical_changes": [
            "肌肉量减少",
            "腹部脂肪增加",
            "骨密度下降",
            "体毛减少"
          ],
          "psychological_symptoms": [
            "情绪低落",
            "易怒",
            "焦虑",
            "记忆力下降",
            "注意力不集中"
          ],
          "metabolic_effects": [
            "胰岛素敏感性下降",
            "血脂异常",
            "血压升高"
          ]
        },
        "diagnosis": {
          "clinical_evaluation": {
            "symptom_assessment": "使用标准化问卷",
            "physical_examination": "全面体格检查",
            "medical_history": "评估合并症和用药史"
          },
          "laboratory_tests": {
            "testosterone_measurement": {
              "timing": "上午采血",
              "repeat_testing": "异常值需确认",
              "cutoff_values": "各实验室参考值略有不同"
            },
            "additional_tests": [
              "促性腺激素",
              "催乳素",
              "甲状腺功能",
              "糖化血红蛋白"
            ]
          },
          "differential_diagnosis": [
            "抑郁症",
            "慢性疲劳综合征",
            "甲状腺功能减退",
            "糖尿病并发症"
          ]
        },
        "treatment": {
          "conservative_management": {
            "lifestyle_modifications": [
              "规律运动",
              "健康饮食",
              "充足睡眠",
              "戒烟限酒",
              "压力管理"
            ],
            "weight_management": "减重可显著改善睾酮水平",
            "exercise_program": "抗阻训练和有氧运动结合"
          },
          "hormone_therapy": {
            "indications": "症状明显且睾酮水平低于正常",
            "contraindications": "与年轻男性相同",
            "special_considerations": [
              "前列腺癌筛查",
              "心血管风险评估",
              "睡眠呼吸暂停评估"
            ]
          },
          "alternative_treatments": [
            "磷酸二酯酶5抑制剂（勃起功能障碍）",
            "抗抑郁药（情绪症状）",
            "认知行为治疗"
          ]
        },
        "monitoring": {
          "effectiveness": [
            "症状改善评估",
            "生活质量量表",
            "性功能评估"
          ],
          "safety_monitoring": [
            "前列腺检查",
            "心血管风险因子",
            "骨密度检测",
            "血液学检查"
          ]
        },
        "prognosis": {
          "natural_history": "症状可能进行性加重",
          "treatment_response": "多数患者治疗后症状改善",
          "long_term_management": "需要个体化长期管理",
          "quality_of_life": "适当治疗可显著提高生活质量"
        }
      },
      {
        "id": "MAL_003",
        "name": "男性不育症",
        "name_en": "Male Infertility",
        "type": "reproductive_disorder",
        "category": "male_endocrine_disease",
        "description": "夫妇正常性生活未避孕12个月未能妊娠，男方因素导致的生育能力障碍",
        "icd_10": "N46",
        "epidemiology": {
          "prevalence": "影响15%的夫妇，男性因素占50%",
          "regional_variation": "中国不育症发病率约10-15%",
          "trend": "近年来发病率有上升趋势",
          "age_factor": "男性年龄对精子质量有影响"
        },
        "etiology": {
          "hormonal_factors": {
            "percentage": "1-2%",
            "causes": [
              "下丘脑-垂体-性腺轴异常",
              "性腺功能减退",
              "高催乳素血症",
              "甲状腺功能异常",
              "肾上腺疾病"
            ]
          },
          "genetic_factors": {
            "percentage": "10-15%",
            "conditions": [
              "Klinefelter综合征",
              "Y染色体微缺失",
              "囊性纤维化基因突变",
              "Kallmann综合征"
            ]
          },
          "anatomical_abnormalities": {
            "percentage": "10-20%",
            "types": [
              "精索静脉曲张",
              "隐睾",
              "输精管缺如",
              "射精管阻塞",
              "尿道下裂"
            ]
          },
          "infections": {
            "percentage": "6-10%",
            "pathogens": [
              "腮腺炎病毒",
              "衣原体",
              "淋病奈瑟菌",
              "结核杆菌",
              "大肠杆菌"
            ]
          },
          "environmental_occupational": [
            "高温环境",
            "电磁辐射",
            "化学物质接触",
            "重金属暴露",
            "农药接触"
          ],
          "lifestyle_factors": [
            "吸烟",
            "过量饮酒",
            "肥胖",
            "营养不良",
            "过度运动",
            "药物滥用"
          ],
          "idiopathic": "原因不明占25-30%"
        },
        "classification": {
          "by_semen_analysis": {
            "oligospermia": "精子浓度<15×10^6/ml",
            "asthenospermia": "前向运动精子<32%",
            "teratospermia": "正常形态精子<4%",
            "azoospermia": "精液中无精子",
            "oligoasthenoteratospermia": "三项指标均异常"
          },
          "by_mechanism": {
            "pretesticular": "下丘脑-垂体异常",
            "testicular": "睾丸本身疾病",
            "posttesticular": "输精管道异常"
          }
        },
        "clinical_assessment": {
          "medical_history": [
            "生育史",
            "性功能史",
            "既往疾病史",
            "手术史",
            "用药史",
            "职业环境暴露史"
          ],
          "physical_examination": {
            "general": "身高体重，第二性征",
            "genital": [
              "阴茎检查",
              "睾丸大小和质地",
              "附睾触诊",
              "精索静脉曲张检查",
              "输精管触诊"
            ],
            "special_tests": "直肠指检（怀疑射精管阻塞）"
          },
          "laboratory_tests": {
            "semen_analysis": {
              "parameters": [
                "精液量",
                "精子浓度",
                "总精子数",
                "精子活动力",
                "精子形态"
              ],
              "requirements": "禁欲2-7天，2次检查间隔1-3周"
            },
            "hormonal_evaluation": {
              "indications": [
                "精子浓度<10×10^6/ml",
                "性功能异常",
                "临床怀疑内分泌异常"
              ],
              "tests": [
                "FSH",
                "LH",
                "睾酮",
                "催乳素",
                "甲状腺功能"
              ]
            },
            "genetic_testing": {
              "indications": [
                "无精症",
                "严重少精症",
                "家族史",
                "反复流产史"
              ],
              "tests": [
                "染色体核型",
                "Y染色体微缺失",
                "囊性纤维化基因"
              ]
            }
          },
          "imaging_studies": {
            "scrotal_ultrasound": [
              "精索静脉曲张",
              "睾丸大小和回声",
              "附睾异常"
            ],
            "transrectal_ultrasound": "射精管阻塞评估"
          }
        },
        "treatment": {
          "medical_management": {
            "hormonal_therapy": {
              "hypogonadotropic_hypogonadism": {
                "hcg_therapy": "2000-5000IU每周2-3次",
                "fsh_therapy": "75-150IU每周3次",
                "duration": "通常需要3-6个月"
              },
              "hyperprolactinemia": "多巴胺激动剂",
              "thyroid_disorders": "甲状腺激素替代"
            },
            "empirical_therapy": {
              "antioxidants": [
                "维生素E",
                "维生素C",
                "辅酶Q10",
                "左卡尼汀"
              ],
              "duration": "至少3个月",
              "evidence": "有限的循证医学证据"
            }
          },
          "surgical_treatment": {
            "varicocelectomy": {
              "indications": [
                "可触及的精索静脉曲张",
                "精液质量异常",
                "睾丸萎缩"
              ],
              "techniques": [
                "显微镜下手术",
                "腹腔镜手术",
                "经皮栓塞"
              ],
              "success_rate": "60-80%精液质量改善"
            },
            "obstructive_procedures": [
              "输精管-附睾吻合术",
              "输精管-输精管吻合术",
              "射精管切开术"
            ]
          },
          "assisted_reproductive_technology": {
            "intrauterine_insemination": {
              "indications": [
                "轻中度精液异常",
                "性功能障碍",
                "免疫性不育"
              ],
              "success_rate": "10-20%每周期"
            },
            "ivf_icsi": {
              "indications": [
                "严重精液异常",
                "IUI失败",
                "其他ART指征"
              ],
              "techniques": [
                "常规IVF",
                "单精子卵细胞浆内注射(ICSI)",
                "睾丸/附睾精子提取"
              ]
            }
          }
        },
        "prevention": {
          "primary_prevention": [
            "避免生殖毒性物质接触",
            "健康生活方式",
            "适当运动",
            "控制体重",
            "戒烟限酒"
          ],
          "secondary_prevention": [
            "及时治疗生殖道感染",
            "定期健康检查",
            "职业防护"
          ]
        },
        "prognosis": {
          "natural_conception": "轻度异常患者可能自然受孕",
          "treatment_outcomes": [
            "激素治疗：60-80%改善",
            "手术治疗：成功率因病因而异",
            "ART技术：成功率20-60%"
          ],
          "factors_affecting_prognosis": [
            "病因类型",
            "女方年龄",
            "病程长短",
            "治疗依从性"
          ]
        }
      },
      {
        "id": "MAL_004",
        "name": "前列腺内分泌相关疾病",
        "name_en": "Prostate Endocrine-Related Disorders",
        "type": "prostate_endocrine_disorder",
        "category": "male_endocrine_disease",
        "description": "前列腺疾病中与内分泌激素调节相关的病理状态",
        "icd_10": "N40-N42",
        "components": {
          "benign_prostatic_hyperplasia": {
            "name": "良性前列腺增生症",
            "name_en": "Benign Prostatic Hyperplasia (BPH)",
            "description": "前列腺细胞增殖导致腺体体积增大的良性疾病",
            "epidemiology": {
              "prevalence": "50岁以上男性约50%",
              "age_correlation": "发病率随年龄增长而增加",
              "geographic_variation": "西方国家发病率较高"
            },
            "pathophysiology": {
              "hormonal_factors": {
                "dht_role": "二氢睾酮(DHT)是主要刺激因子",
                "5alpha_reductase": "5α-还原酶催化睾酮转化为DHT",
                "androgen_receptor": "DHT与雄激素受体结合促进增生"
              },
              "growth_factors": [
                "表皮生长因子(EGF)",
                "成纤维细胞生长因子(FGF)",
                "胰岛素样生长因子-1(IGF-1)"
              ],
              "estrogen_role": "雌激素可能参与前列腺增生过程"
            },
            "clinical_manifestations": {
              "storage_symptoms": [
                "尿频",
                "尿急",
                "夜尿",
                "急迫性尿失禁"
              ],
              "voiding_symptoms": [
                "尿线细弱",
                "排尿困难",
                "尿流中断",
                "排尿后滴沥"
              ],
              "post_micturition_symptoms": [
                "残余尿感",
                "排尿后滴沥"
              ]
            },
            "diagnosis": {
              "clinical_assessment": [
                "国际前列腺症状评分(IPSS)",
                "生活质量评分",
                "排尿日记"
              ],
              "physical_examination": "直肠指检评估前列腺大小",
              "laboratory_tests": [
                "尿常规",
                "血清PSA",
                "肌酐（评估肾功能）"
              ],
              "imaging": [
                "经腹部超声（残余尿测定）",
                "经直肠超声（前列腺体积）"
              ],
              "urodynamics": "复杂病例或手术前评估"
            }
          },
          "hormonal_therapy": {
            "5alpha_reductase_inhibitors": {
              "mechanism": "阻断睾酮转化为DHT",
              "medications": {
                "finasteride": {
                  "dose": "5mg/day",
                  "efficacy": "可缩小前列腺体积20-30%",
                  "onset": "3-6个月起效"
                },
                "dutasteride": {
                  "dose": "0.5mg/day",
                  "advantages": "同时抑制两种5α-还原酶亚型",
                  "efficacy": "效果可能优于finasteride"
                }
              },
              "side_effects": [
                "性欲减退",
                "勃起功能障碍",
                "射精异常",
                "乳房发育"
              ],
              "considerations": [
                "PSA水平降低约50%",
                "停药后症状可能复发",
                "可能降低前列腺癌风险"
              ]
            },
            "alpha_blockers": {
              "mechanism": "松弛前列腺和膀胱颈平滑肌",
              "medications": [
                "坦索罗辛 0.2-0.4mg/day",
                "阿夫唑嗪 2.5-10mg/day",
                "多沙唑嗪 1-8mg/day",
                "特拉唑嗪 1-10mg/day"
              ],
              "onset": "数天至数周",
              "side_effects": [
                "体位性低血压",
                "头晕",
                "逆行射精",
                "鼻塞"
              ]
            },
            "combination_therapy": {
              "rationale": "α受体阻滞剂+5α-还原酶抑制剂",
              "benefits": [
                "症状改善更显著",
                "降低疾病进展风险",
                "减少急性尿潴留发生"
              ],
              "indications": "中重度症状且前列腺体积>40ml"
            }
          }
        },
        "hormonal_considerations": {
          "testosterone_therapy_cautions": [
            "可能加重BPH症状",
            "需要密切监测前列腺",
            "定期PSA检测",
            "直肠指检"
          ],
          "age_related_changes": [
            "睾酮水平下降",
            "雌激素/雄激素比值改变",
            "前列腺对激素敏感性变化"
          ]
        },
        "treatment_monitoring": {
          "symptom_assessment": "定期IPSS评分",
          "objective_measures": [
            "最大尿流率",
            "残余尿量",
            "前列腺体积"
          ],
          "safety_monitoring": [
            "PSA水平",
            "肾功能",
            "血压（α受体阻滞剂）"
          ]
        },
        "prognosis": {
          "natural_history": "症状可能进行性加重",
          "treatment_response": [
            "症状改善：60-80%患者",
            "前列腺缩小：5α-还原酶抑制剂",
            "尿流改善：α受体阻滞剂"
          ],
          "long_term_outcomes": [
            "可能需要长期药物治疗",
            "部分患者最终需要手术",
            "生活质量通常显著改善"
          ]
        }
      }
    ],

    "glucose_management_entities": [
      {
        "id": "CGM_001",
        "name": "连续血糖监测系统",
        "name_en": "Continuous Glucose Monitoring System",
        "type": "monitoring_technology",
        "category": "血糖监测技术",
        "description": "通过皮下组织间液葡萄糖浓度实时监测血糖变化的医疗设备系统",
        "technology_types": {
          "real_time_cgm": {
            "description": "实时连续血糖监测(rtCGM)",
            "features": [
              "实时血糖数据显示",
              "高低血糖报警",
              "趋势箭头指示",
              "数据分享功能"
            ],
            "representative_devices": [
              "Dexcom G6/G7",
              "Abbott FreeStyle Libre",
              "Medtronic Guardian",
              "Senseonics Eversense"
            ],
            "accuracy": "MARD < 10%（最新一代设备）"
          },
          "flash_glucose_monitoring": {
            "description": "间歇扫描式血糖监测(FGM)",
            "features": [
              "扫描获取血糖读数",
              "14天连续监测",
              "无需校准",
              "防水设计"
            ],
            "advantages": [
              "成本相对较低",
              "使用简便",
              "无需频繁校准"
            ]
          }
        },
        "clinical_applications": {
          "diabetes_management": {
            "type1_diabetes": {
              "benefits": [
                "减少低血糖事件50-60%",
                "改善HbA1c 0.3-0.5%",
                "提高血糖在目标范围时间",
                "减少指尖采血频次"
              ],
              "recommended_users": [
                "频繁低血糖患者",
                "低血糖无症状者",
                "血糖控制不佳者",
                "生活方式不规律者"
              ]
            },
            "type2_diabetes": {
              "benefits": [
                "优化药物调整",
                "识别餐后血糖高峰",
                "评估生活方式干预效果",
                "提高治疗依从性"
              ],
              "适用人群": [
                "胰岛素治疗患者",
                "多次药物调整患者",
                "妊娠糖尿病患者",
                "糖尿病前期高危人群"
              ]
            }
          },
          "gestational_diabetes": {
            "monitoring_protocol": {
              "wearing_duration": "孕24-28周开始，持续至分娩",
              "target_ranges": {
                "fasting": "< 5.3 mmol/L",
                "1h_postprandial": "< 7.8 mmol/L", 
                "2h_postprandial": "< 6.7 mmol/L"
              },
              "alert_settings": [
                "低血糖 < 3.5 mmol/L",
                "高血糖 > 7.8 mmol/L",
                "血糖趋势快速上升"
              ]
            }
          }
        },
        "data_interpretation": {
          "key_metrics": {
            "time_in_range": {
              "definition": "血糖在目标范围内的时间百分比",
              "target_range": "3.9-10.0 mmol/L (70-180 mg/dL)",
              "clinical_targets": {
                "type1_diabetes": "> 70%",
                "type2_diabetes": "> 70%",
                "gestational_diabetes": "> 85%",
                "elderly": "> 50% (个体化调整)"
              },
              "clinical_significance": "TIR增加10%相当于HbA1c降低0.8%"
            },
            "time_below_range": {
              "level1_hypoglycemia": "3.0-3.9 mmol/L, 目标 < 4%",
              "level2_hypoglycemia": "< 3.0 mmol/L, 目标 < 1%",
              "nocturnal_hypoglycemia": "00:00-06:00低血糖事件",
              "clinical_significance": "预测严重低血糖风险"
            },
            "time_above_range": {
              "level1_hyperglycemia": "10.1-13.9 mmol/L, 目标 < 25%",
              "level2_hyperglycemia": "> 13.9 mmol/L, 目标 < 5%",
              "dawn_phenomenon": "凌晨3-9点血糖升高",
              "postprandial_excursions": "餐后血糖峰值分析"
            }
          },
          "glycemic_variability": {
            "coefficient_of_variation": {
              "definition": "血糖变异系数(CV%)",
              "calculation": "标准差/平均血糖 × 100%",
              "target": "< 36%（理想状态）",
              "clinical_significance": "反映血糖波动程度，与并发症风险相关"
            },
            "mean_amplitude_glycemic_excursions": {
              "definition": "平均血糖波动幅度(MAGE)",
              "calculation": "大于1个标准差的血糖峰谷差值平均",
              "normal_range": "< 3.9 mmol/L",
              "pathological_range": "> 5.4 mmol/L"
            },
            "continuous_overlapping_net_glycemic_action": {
              "definition": "连续重叠净血糖作用(CONGA)",
              "calculation": "连续测量值与前n小时均值差的标准差",
              "clinical_application": "评估血糖稳定性"
            }
          }
        },
        "alert_systems": {
          "hypoglycemia_alerts": {
            "urgent_low": "< 3.1 mmol/L，立即报警",
            "low_glucose": "< 3.9 mmol/L，预警提醒",
            "predicted_low": "30分钟内预测低血糖",
            "suspend_before_low": "胰岛素泵暂停功能"
          },
          "hyperglycemia_alerts": {
            "high_glucose": "> 13.9 mmol/L，高血糖报警",
            "rising_rapidly": "血糖上升速度 > 0.11 mmol/L/min",
            "prolonged_high": "连续2小时 > 10.0 mmol/L"
          },
          "customizable_settings": {
            "personalized_targets": "个体化血糖目标设定",
            "activity_profiles": "运动、睡眠、疾病期间的不同阈值",
            "alert_frequency": "可调节的报警频率设置"
          }
        }
      },
      {
        "id": "BG_001", 
        "name": "血糖变异性分析",
        "name_en": "Glycemic Variability Analysis",
        "type": "clinical_assessment",
        "category": "血糖评估指标",
        "description": "通过多种统计学指标量化血糖波动程度，评估血糖控制质量",
        "clinical_significance": {
          "cardiovascular_risk": {
            "mechanism": "血糖波动激活氧化应激和炎症反应",
            "evidence": "血糖变异性与心血管事件风险独立相关",
            "target_population": "合并心血管疾病的糖尿病患者"
          },
          "hypoglycemia_prediction": {
            "correlation": "高血糖变异性患者低血糖风险增加3-5倍",
            "mechanism": "血糖波动大导致胰岛素调节困难",
            "prevention_strategy": "优化胰岛素给药方案"
          },
          "long_term_complications": {
            "retinopathy": "血糖变异性与糖尿病视网膜病变进展相关",
            "nephropathy": "MAGE每增加1 mmol/L，肾病风险增加15%",
            "neuropathy": "血糖变异性是神经病变的独立危险因素"
          }
        },
        "measurement_parameters": {
          "time_domain_indices": {
            "standard_deviation": {
              "definition": "血糖测量值的标准差",
              "normal_range": "< 2.0 mmol/L",
              "interpretation": "反映血糖分散程度"
            },
            "coefficient_of_variation": {
              "formula": "CV% = (SD/Mean) × 100%",
              "excellent_control": "< 33%",
              "good_control": "33-36%",
              "poor_control": "> 36%"
            },
            "interquartile_range": {
              "definition": "第75百分位数与第25百分位数的差值",
              "advantage": "不受极端值影响",
              "target": "< 2.8 mmol/L"
            }
          },
          "frequency_domain_indices": {
            "mage": {
              "threshold": "1个标准差",
              "excellent": "< 3.9 mmol/L",
              "acceptable": "3.9-5.4 mmol/L", 
              "poor": "> 5.4 mmol/L",
              "clinical_utility": "评估主要血糖波动"
            },
            "conga": {
              "time_intervals": ["1小时", "2小时", "4小时"],
              "normal_reference": "< 1.5 mmol/L (CONGA-1)",
              "pathological": "> 2.0 mmol/L"
            },
            "modd": {
              "definition": "相同时间点连续日间血糖差值的平均",
              "normal_range": "< 2.3 mmol/L",
              "clinical_meaning": "评估日间血糖重现性"
            }
          },
          "risk_indices": {
            "lbgi_hbgi": {
              "low_bg_index": "低血糖风险指数，> 2.5为高风险",
              "high_bg_index": "高血糖风险指数，> 9.0为高风险",
              "adrr": "平均每日血糖风险范围，< 20为低风险"
            },
            "j_index": {
              "formula": "0.001 × (Mean + SD)²",
              "interpretation": "同时考虑血糖水平和变异性",
              "target": "< 30"
            }
          }
        },
        "clinical_intervention_strategies": {
          "high_variability_management": {
            "medication_adjustment": {
              "insulin_regimen": [
                "长效胰岛素剂量优化",
                "超速效胰岛素餐前使用",
                "胰岛素泵持续输注",
                "智能胰岛素笔使用"
              ],
              "oral_medications": [
                "DPP-4抑制剂（低变异性）",
                "GLP-1受体激动剂",
                "SGLT-2抑制剂",
                "α-葡萄糖苷酶抑制剂"
              ]
            },
            "lifestyle_interventions": {
              "dietary_strategies": [
                "低血糖指数食物选择",
                "碳水化合物计数训练",
                "规律进餐时间",
                "避免血糖指数高的食物"
              ],
              "exercise_planning": [
                "餐后1-2小时适量运动",
                "运动前血糖监测",
                "运动强度个体化调整",
                "运动前后胰岛素调整"
              ]
            }
          }
        }
      },
      {
        "id": "MEAL_001",
        "name": "餐后血糖管理",
        "name_en": "Postprandial Glucose Management", 
        "type": "clinical_management",
        "category": "血糖管理策略",
        "description": "针对餐后血糖升高的综合管理方案，包括饮食、运动和药物干预",
        "pathophysiology": {
          "normal_response": {
            "glucose_kinetics": "正常人餐后血糖2小时内恢复基线",
            "insulin_response": "第一时相快速分泌，第二时相持续分泌",
            "incretin_effect": "GLP-1和GIP调节胰岛素分泌"
          },
          "diabetic_abnormalities": {
            "delayed_insulin_response": "第一时相胰岛素分泌缺失",
            "hepatic_glucose_production": "肝糖输出抑制不足",
            "incretin_deficiency": "肠促胰素分泌和作用减弱",
            "gastric_emptying": "胃排空速度异常"
          }
        },
        "assessment_criteria": {
          "target_ranges": {
            "normal_glucose_tolerance": "< 7.8 mmol/L (2小时)",
            "impaired_glucose_tolerance": "7.8-11.0 mmol/L",
            "diabetes": "≥ 11.1 mmol/L",
            "pregnancy": "< 6.7 mmol/L (2小时)"
          },
          "peak_timing": {
            "normal_peak": "30-60分钟",
            "delayed_peak": "> 90分钟（提示胃轻瘫）",
            "prolonged_elevation": "> 3小时（异常）"
          },
          "glucose_excursion": {
            "normal_increment": "< 2.8 mmol/L",
            "acceptable_increment": "< 3.9 mmol/L",
            "excessive_increment": "> 5.0 mmol/L"
          }
        },
        "monitoring_strategies": {
          "cgm_based_assessment": {
            "pre_meal_measurement": "餐前15分钟血糖记录",
            "postprandial_tracking": "餐后0.5, 1, 1.5, 2, 3小时监测",
            "glucose_curves": "个体化血糖反应曲线分析",
            "pattern_recognition": "不同食物的血糖反应模式"
          },
          "structured_testing": {
            "standardized_meals": "标准化测试餐（75g碳水化合物）",
            "mixed_meals": "真实世界混合餐食测试",
            "food_specific_testing": "特定食物血糖反应评估"
          }
        },
        "intervention_strategies": {
          "nutritional_management": {
            "carbohydrate_strategies": {
              "glycemic_index": {
                "low_gi_foods": "< 55，推荐选择",
                "medium_gi_foods": "55-70，适量选择", 
                "high_gi_foods": "> 70，限制使用",
                "examples": {
                  "low_gi": ["燕麦", "豆类", "苹果", "酸奶"],
                  "high_gi": ["白米饭", "土豆", "西瓜", "白面包"]
                }
              },
              "carbohydrate_counting": {
                "basic_principle": "1单位胰岛素对应10-15g碳水化合物",
                "individual_ratio": "个体化碳水化合物与胰岛素比例",
                "timing_consideration": "不同时间段的胰岛素敏感性差异"
              },
              "portion_control": {
                "plate_method": "1/2蔬菜，1/4蛋白质，1/4碳水化合物",
                "measuring_tools": "食物秤、量杯精确计量",
                "visual_guides": "手掌大小蛋白质，拳头大小碳水化合物"
              }
            },
            "meal_composition": {
              "protein_effects": {
                "benefits": "延缓胃排空，增加饱腹感",
                "recommendations": "每餐包含20-30g优质蛋白质",
                "sources": ["瘦肉", "鱼类", "豆腐", "鸡蛋"]
              },
              "fiber_impact": {
                "soluble_fiber": "减缓糖吸收，推荐25-35g/天",
                "sources": ["蔬菜", "水果", "全谷物", "豆类"],
                "timing": "餐前摄入纤维效果更好"
              },
              "fat_considerations": {
                "delayed_effects": "脂肪延迟血糖高峰出现",
                "quantity_control": "总热量的20-35%",
                "quality_focus": "不饱和脂肪酸优先"
              }
            },
            "meal_timing": {
              "frequency": "少量多餐，每日3主餐+2-3加餐",
              "spacing": "餐间间隔4-5小时",
              "consistency": "固定用餐时间有助血糖控制"
            }
          },
          "pharmacological_interventions": {
            "prandial_insulin": {
              "rapid_acting_analogs": {
                "types": ["门冬胰岛素", "赖脯胰岛素", "谷赖胰岛素"],
                "timing": "餐前15-20分钟注射",
                "dose_calculation": "基于碳水化合物含量和餐前血糖"
              },
              "ultra_rapid_acting": {
                "advantages": "更快起效，减少餐后血糖峰值",
                "representatives": ["Fiasp", "Lyumjev"],
                "timing": "餐前0-15分钟或餐后20分钟内"
              },
              "inhaled_insulin": {
                "product": "Afrezza吸入胰岛素",
                "advantages": "快速起效，避免注射",
                "limitations": "肺功能要求，成本较高"
              }
            },
            "incretin_based_therapy": {
              "glp1_receptor_agonists": {
                "mechanisms": [
                  "葡萄糖依赖性胰岛素分泌",
                  "抑制胰高血糖素释放",
                  "延缓胃排空",
                  "增强饱腹感"
                ],
                "agents": ["利拉鲁肽", "司美格鲁肽", "度拉糖肽"],
                "postprandial_benefits": "显著降低餐后血糖峰值"
              },
              "dpp4_inhibitors": {
                "advantages": "低血糖风险小，体重中性",
                "agents": ["西格列汀", "维格列汀", "沙格列汀"],
                "efficacy": "餐后血糖降低1.5-2.5 mmol/L"
              }
            },
            "alpha_glucosidase_inhibitors": {
              "mechanism": "抑制碳水化合物消化吸收",
              "agents": ["阿卡波糖", "伏格列波糖"],
              "timing": "与第一口饭同时服用",
              "benefits": "特异性降低餐后血糖"
            }
          },
          "exercise_interventions": {
            "postprandial_activity": {
              "optimal_timing": "餐后30-60分钟开始",
              "duration": "15-30分钟轻到中等强度运动",
              "types": ["散步", "慢跑", "骑车", "游泳"],
              "intensity": "50-70%最大心率"
            },
            "resistance_exercise": {
              "benefits": "改善胰岛素敏感性",
              "frequency": "每周2-3次",
              "progression": "逐渐增加重量和重复次数"
            },
            "safety_considerations": {
              "blood_glucose_monitoring": "运动前后血糖检测",
              "hypoglycemia_prevention": "必要时减少胰岛素剂量",
              "hydration": "充足水分补充"
            }
          }
        },
        "technology_integration": {
          "smartphone_apps": {
            "features": [
              "食物血糖指数查询",
              "碳水化合物计算器",
              "餐后血糖记录",
              "个性化建议生成"
            ],
            "data_sharing": "与CGM和胰岛素泵数据整合"
          },
          "artificial_intelligence": {
            "prediction_models": "基于历史数据预测餐后血糖",
            "personalized_recommendations": "个体化饮食和药物建议",
            "pattern_analysis": "识别血糖反应模式"
          }
        }
      },
      {
        "id": "NIGHT_001",
        "name": "夜间血糖异常管理",
        "name_en": "Nocturnal Glucose Abnormalities Management",
        "type": "clinical_management", 
        "category": "血糖管理策略",
        "description": "针对夜间低血糖、黎明现象等夜间血糖异常的诊断和管理策略",
        "clinical_patterns": {
          "nocturnal_hypoglycemia": {
            "definition": "夜间（22:00-08:00）血糖 < 3.9 mmol/L",
            "incidence": "T1DM患者50-70%，T2DM胰岛素治疗患者30-40%",
            "peak_time": "凌晨2:00-4:00最常见",
            "risk_factors": [
              "胰岛素剂量过大",
              "晚餐进食量不足",
              "饮酒",
              "剧烈运动后",
              "肾功能不全",
              "肝功能异常"
            ],
            "clinical_consequences": {
              "immediate": ["心悸", "出汗", "噩梦", "睡眠质量差"],
              "long_term": ["认知功能下降", "心血管事件风险增加"],
              "behavioral": ["对低血糖恐惧", "故意维持高血糖"]
            }
          },
          "dawn_phenomenon": {
            "definition": "凌晨3:00-9:00血糖自发性升高",
            "mechanism": [
              "生长激素分泌高峰",
              "皮质醇分泌增加",
              "肾上腺素水平升高",
              "胰岛素敏感性下降"
            ],
            "magnitude": "血糖升高1.4-5.6 mmol/L",
            "prevalence": "T1DM 75%，T2DM 55%",
            "影响因素": [
              "年龄（青少年更明显）",
              "基础胰岛素不足",
              "睡眠质量",
              "应激状态"
            ]
          },
          "somogyi_effect": {
            "definition": "夜间低血糖后的反弹性高血糖",
            "mechanism": "反调节激素过度分泌",
            "distinguishing_features": [
              "夜间出现低血糖",
              "晨起血糖反弹性升高",
              "常伴有夜间症状"
            ],
            "vs_dawn_phenomenon": "需要通过夜间血糖监测鉴别"
          }
        },
        "diagnostic_approaches": {
          "continuous_monitoring": {
            "cgm_benefits": [
              "连续监测无需夜间扎手指",
              "低血糖报警功能",
              "血糖趋势分析",
              "睡眠质量评估"
            ],
            "monitoring_duration": "至少连续7-14天",
            "key_timepoints": [
              "22:00 (就寝前)",
              "00:00 (午夜)",
              "03:00 (凌晨)",
              "06:00 (清晨)",
              "08:00 (晨起)"
            ]
          },
          "structured_testing": {
            "bedtime_glucose": "就寝前血糖目标5.6-8.3 mmol/L",
            "3am_glucose": "凌晨3点血糖检测",
            "fasting_glucose": "晨起空腹血糖",
            "pattern_analysis": "连续3-7天的监测模式"
          },
          "sleep_study_integration": {
            "sleep_apnea_screening": "阻塞性睡眠呼吸暂停与血糖控制",
            "sleep_quality_assessment": "睡眠结构对血糖的影响",
            "chronotype_evaluation": "生物钟类型与血糖模式"
          }
        },
        "management_strategies": {
          "nocturnal_hypoglycemia_prevention": {
            "insulin_adjustment": {
              "basal_insulin_optimization": [
                "长效胰岛素种类选择",
                "注射时间调整",
                "剂量个体化调整",
                "分次注射考虑"
              ],
              "insulin_pump_settings": [
                "基础率夜间调整",
                "临时基础率使用",
                "低血糖暂停功能",
                "预设模式切换"
              ],
              "prandial_insulin_timing": [
                "晚餐胰岛素剂量调整",
                "睡前加餐考虑",
                "运动后胰岛素减量"
              ]
            },
            "nutritional_interventions": {
              "bedtime_snacks": {
                "composition": "复合碳水化合物+蛋白质",
                "examples": ["全麦饼干+牛奶", "苹果+花生酱"],
                "timing": "睡前1-2小时",
                "portion_size": "15-30g碳水化合物"
              },
              "dinner_modifications": [
                "适量增加碳水化合物",
                "避免高脂肪延迟胃排空",
                "规律进餐时间",
                "避免过量饮酒"
              ]
            },
            "lifestyle_factors": {
              "exercise_timing": [
                "避免晚间剧烈运动",
                "运动后血糖监测",
                "必要时运动后加餐",
                "胰岛素剂量调整"
              ],
              "sleep_hygiene": [
                "规律作息时间",
                "良好睡眠环境",
                "避免睡前刺激性物质",
                "压力管理技巧"
              ]
            }
          },
          "dawn_phenomenon_management": {
            "medication_strategies": {
              "basal_insulin_adjustment": [
                "增加长效胰岛素剂量",
                "调整注射时间至晚10点",
                "考虑分次注射方案",
                "使用超长效胰岛素"
              ],
              "insulin_pump_programming": [
                "凌晨基础率增加",
                "多段基础率设置",
                "个体化调整程序"
              ],
              "oral_medications": [
                "二甲双胍晚间服用",
                "DPP-4抑制剂",
                "SGLT-2抑制剂考虑"
              ]
            },
            "timing_interventions": {
              "meal_timing": "晚餐时间不宜过晚",
              "exercise_scheduling": "规律运动改善胰岛素敏感性",
              "medication_timing": "优化服药时间"
            }
          },
          "technology_assisted_management": {
            "automated_insulin_delivery": {
              "closed_loop_systems": [
                "混合闭环系统",
                "低血糖暂停功能",
                "预测性低血糖管理",
                "自适应算法"
              ],
              "smart_insulin_pens": [
                "剂量记录功能",
                "提醒功能",
                "数据上传功能"
              ]
            },
            "mobile_health_solutions": {
              "cgm_apps": [
                "低血糖报警",
                "数据分享功能",
                "趋势分析",
                "个性化建议"
              ],
              "decision_support": [
                "胰岛素调整建议",
                "模式识别",
                "风险预警"
              ]
            }
          }
        },
        "emergency_management": {
          "severe_nocturnal_hypoglycemia": {
            "recognition": [
              "意识模糊或昏迷",
              "无法自行处理",
              "抽搐或异常行为"
            ],
            "immediate_treatment": [
              "胰高血糖素注射",
              "静脉葡萄糖输注",
              "紧急医疗服务",
              "密切监测"
            ],
            "prevention_planning": [
              "家属培训",
              "急救药物准备",
              "医疗识别标识",
              "应急联系方案"
            ]
          }
        }
      },
      {
        "id": "EXERCISE_001",
        "name": "运动血糖管理",
        "name_en": "Exercise Glucose Management",
        "type": "clinical_management",
        "category": "血糖管理策略", 
        "description": "运动前中后的血糖监测、预防和处理策略，优化运动安全性和效果",
        "exercise_physiology": {
          "glucose_metabolism_during_exercise": {
            "aerobic_exercise": {
              "glucose_utilization": "肌肉糖原和血糖消耗增加10-50倍",
              "insulin_sensitivity": "运动中和运动后24-48小时改善",
              "glucose_production": "肝糖输出增加匹配肌肉消耗",
              "typical_response": "血糖呈下降趋势"
            },
            "anaerobic_exercise": {
              "stress_hormones": "肾上腺素、皮质醇、生长激素释放",
              "glucose_production": "肝糖输出和糖异生显著增加",
              "insulin_resistance": "短期胰岛素敏感性下降",
              "typical_response": "血糖可能升高"
            },
            "mixed_exercise": {
              "variable_response": "血糖变化不可预测",
              "individual_differences": "个体反应差异很大",
              "training_status": "训练水平影响血糖反应"
            }
          },
          "diabetes_specific_considerations": {
            "type1_diabetes": {
              "insulin_deficiency": "绝对胰岛素缺乏影响血糖调节",
              "counterregulation": "反调节激素反应可能异常",
              "hypoglycemia_risk": "运动中和运动后低血糖风险高"
            },
            "type2_diabetes": {
              "insulin_resistance": "基础胰岛素抵抗影响运动反应",
              "medication_effects": "口服药物和胰岛素影响血糖变化",
              "cardiovascular_risk": "需要心血管风险评估"
            }
          }
        },
        "pre_exercise_assessment": {
          "blood_glucose_targets": {
            "safe_range": "5.6-13.9 mmol/L",
            "caution_range": {
              "low_glucose": "< 5.6 mmol/L，需要预处理",
              "high_glucose": "> 13.9 mmol/L，检查酮体",
              "very_high": "> 16.7 mmol/L，暂缓运动"
            },
            "ketone_testing": {
              "indications": "血糖 > 13.9 mmol/L",
              "safe_levels": "血酮 < 0.6 mmol/L",
              "exercise_contraindication": "血酮 > 1.5 mmol/L"
            }
          },
          "medical_clearance": {
            "cardiovascular_screening": [
              "运动负荷试验",
              "心电图检查",
              "血压评估",
              "眼底检查"
            ],
            "complications_assessment": [
              "糖尿病肾病程度",
              "神经病变评估",
              "视网膜病变严重程度",
              "足部溃疡风险"
            ],
            "medication_review": [
              "胰岛素类型和剂量",
              "口服降糖药物",
              "其他影响血糖的药物",
              "运动前调整方案"
            ]
          }
        },
        "exercise_strategies": {
          "aerobic_exercise_management": {
            "pre_exercise_preparation": {
              "glucose_targets": "5.6-8.3 mmol/L开始运动",
              "carbohydrate_supplementation": {
                "bg_5_6_7_0": "0-15g碳水化合物",
                "bg_4_4_5_6": "15-30g碳水化合物", 
                "bg_below_4_4": "30g碳水化合物，延迟运动"
              },
              "insulin_adjustment": {
                "rapid_acting": "运动前胰岛素减量25-50%",
                "pump_users": "临时基础率减少50-80%",
                "long_acting": "可能需要减量10-20%"
              }
            },
            "during_exercise_monitoring": {
              "duration_guidelines": {
                "short_duration": "< 30分钟，通常无需干预",
                "medium_duration": "30-60分钟，中途监测",
                "long_duration": "> 60分钟，每30分钟监测"
              },
              "glucose_targets": "维持4.4-10.0 mmol/L",
              "intervention_thresholds": {
                "treat_low": "< 4.4 mmol/L，停止运动处理",
                "prevent_low": "< 5.6 mmol/L，补充碳水化合物",
                "monitor_high": "> 13.9 mmol/L，检查状态"
              }
            }
          },
          "resistance_exercise_management": {
            "blood_glucose_patterns": {
              "immediate_response": "血糖可能轻度升高",
              "delayed_benefits": "24-48小时胰岛素敏感性改善",
              "individual_variation": "反应个体差异大"
            },
            "safety_considerations": {
              "starting_glucose": "6.1-13.9 mmol/L较安全",
              "progression_principle": "循序渐进增加强度",
              "form_technique": "正确姿势避免损伤"
            }
          },
          "high_intensity_exercise": {
            "glucose_response": "常导致血糖升高",
            "management_strategy": {
              "pre_exercise": "可接受较高起始血糖",
              "post_exercise": "监测血糖下降趋势",
              "insulin_timing": "运动后可能需要额外胰岛素"
            }
          }
        },
        "post_exercise_management": {
          "immediate_post_exercise": {
            "monitoring_duration": "至少2-4小时",
            "glucose_targets": "5.6-10.0 mmol/L",
            "intervention_guidelines": {
              "persistent_elevation": "> 13.9 mmol/L考虑胰岛素",
              "trending_down": "< 5.6 mmol/L预防性加餐",
              "stable_range": "继续监测"
            }
          },
          "delayed_effects": {
            "late_onset_hypoglycemia": {
              "timing": "运动后4-24小时",
              "mechanism": "持续胰岛素敏感性改善",
              "prevention": [
                "基础胰岛素减量",
                "增加碳水化合物摄入",
                "频繁血糖监测",
                "睡前血糖目标上调"
              ]
            },
            "glycogen_replenishment": {
              "timing": "运动后30-60分钟内",
              "carbohydrate_needs": "1-1.2g/kg体重",
              "protein_addition": "3:1或4:1碳水化合物:蛋白质"
            }
          }
        },
        "technology_integration": {
          "cgm_for_exercise": {
            "real_time_monitoring": "运动中连续血糖数据",
            "trend_arrows": "血糖变化趋势指导",
            "alarm_settings": "个性化运动期间报警",
            "data_analysis": "运动血糖模式识别"
          },
          "fitness_trackers": {
            "heart_rate_monitoring": "运动强度评估",
            "activity_tracking": "运动类型和强度记录",
            "data_integration": "与血糖数据关联分析"
          },
          "mobile_applications": {
            "exercise_logging": "运动类型、强度、时长记录",
            "glucose_prediction": "基于历史数据预测血糖",
            "personalized_recommendations": "个体化运动建议"
          }
        },
        "special_considerations": {
          "competitive_athletes": {
            "performance_optimization": "血糖目标与运动表现平衡",
            "competition_day_strategy": "比赛日血糖管理方案",
            "travel_considerations": "时差和环境变化影响"
          },
          "older_adults": {
            "safety_priorities": "安全性优先于强度",
            "complication_considerations": "合并症对运动选择的影响",
            "social_support": "家庭和社区支持重要性"
          },
          "pregnancy": {
            "gestational_diabetes": "妊娠糖尿病运动管理",
            "safety_parameters": "母儿安全血糖范围",
            "activity_modifications": "孕期运动类型调整"
          }
        }
      }
    ],

    "rheumatic_endocrine_relationships": {
      "description": "风湿免疫疾病与内分泌系统疾病的复杂关联关系网络",
      "bidirectional_interactions": {
        "prevalence_china": "4.6%",
        "incidence_rate": "0.4%/年",
        "mortality": "心血管疾病首位死因",
        "age_distribution": "40岁后发病率显著上升",
        "gender_difference": "男性发病早于女性10-15年"
      },
      "risk_factors": {
        "traditional": [
          "高血压",
          "血脂异常",
          "糖尿病",
          "吸烟",
          "肥胖",
          "家族史",
          "年龄"
        ],
        "emerging": [
          "慢性炎症",
          "睡眠呼吸暂停",
          "慢性肾脏病",
          "甲状腺功能异常"
        ]
      },
      "clinical_manifestations": {
        "stable_angina": {
          "chest_pain": "典型胸痛，运动诱发，休息缓解",
          "duration": "通常<10分钟",
          "triggers": ["体力活动", "情绪激动", "寒冷"],
          "relief": "休息或硝酸甘油"
        },
        "unstable_angina": {
          "characteristics": "静息时发作，程度加重，持续时间延长",
          "onset": "新发或恶化的胸痛",
          "risk": "急性心肌梗死高危前兆"
        }
      },
      "diagnostics": {
        "clinical_assessment": {
          "chest_pain_evaluation": "疼痛性质、部位、诱因、持续时间",
          "risk_stratification": "GRACE评分、TIMI评分"
        },
        "laboratory_tests": [
          "心肌酶谱（CK-MB、肌钙蛋白）",
          "血脂全套",
          "空腹血糖/HbA1c",
          "肾功能",
          "甲状腺功能",
          "炎症标志物（CRP、ESR）"
        ],
        "imaging": {
          "ecg": {
            "resting": "ST-T改变，Q波",
            "exercise": "运动负荷试验阳性"
          },
          "echocardiography": "室壁运动异常",
          "coronary_angiography": "冠脉狭窄程度评估金标准",
          "ct_angiography": "无创性冠脉成像",
          "nuclear_imaging": "心肌血流灌注显像"
        }
      },
      "treatment": {
        "lifestyle_modification": {
          "diet": "低盐低脂地中海饮食",
          "exercise": "有氧运动150分钟/周",
          "smoking_cessation": "戒烟是首要措施",
          "weight_management": "BMI<24 kg/m²"
        },
        "pharmacotherapy": {
          "antiplatelet": {
            "aspirin": "75-100mg/day",
            "clopidogrel": "75mg/day（不能耐受阿司匹林）",
            "dual_therapy": "急性冠脉综合征双联12个月"
          },
          "lipid_lowering": {
            "statins": "阿托伐他汀20-40mg/晚",
            "target": "LDL-C<1.8mmol/L或降幅≥50%",
            "ezetimibe": "联合治疗10mg/day"
          },
          "beta_blockers": {
            "indications": "心肌梗死后、心衰",
            "agents": "美托洛尔、比索洛尔",
            "target_hr": "50-60 bpm"
          },
          "acei_arb": {
            "indications": "高血压、糖尿病、心衰",
            "target_bp": "<130/80 mmHg",
            "renal_protection": "伴蛋白尿患者首选"
          }
        },
        "interventional": {
          "pci": {
            "indications": ["急性ST段抬高心肌梗死", "血流动力学不稳定", "严重多支血管病变"],
            "stent_types": "药物洗脱支架为首选",
            "dual_antiplatelet": "术后12个月双联抗血小板"
          },
          "cabg": {
            "indications": ["左主干病变", "复杂多支血管病变", "合并糖尿病的多支病变"],
            "advantages": "更好的长期预后"
          }
        }
      },
      "complications": [
        "急性心肌梗死",
        "心律失常",
        "心力衰竭",
        "猝死"
      ],
      "prognosis": {
        "stable_angina": "5年生存率>90%",
        "post_mi": "规范治疗1年死亡率<5%",
        "factors": ["左室功能", "血运重建完全性", "危险因素控制"]
      }
    },
    "cardiovascular_diseases": [
      {
        "id": "CVD_002", 
      "type": "Disease",
      "name": "急性心肌梗死",
      "category": "心血管疾病",
      "icd10": "I21.9",
      "synonyms": ["AMI", "心肌梗死", "心梗"],
      "definition": "冠状动脉急性、持续性缺血缺氧导致的心肌坏死",
      "classification": {
        "stemi": "ST段抬高型心肌梗死",
        "nstemi": "非ST段抬高型心肌梗死"
      },
      "pathophysiology": {
        "mechanism": "冠脉粥样斑块破裂→血栓形成→血管完全或不完全闭塞",
        "timeline": "心肌缺血>20分钟开始坏死",
        "biomarkers": "肌钙蛋白I/T升高"
      },
      "clinical_presentation": {
        "typical_symptoms": {
          "chest_pain": "剧烈压榨性胸痛>20分钟",
          "radiation": "左臂、下颌、颈部、背部",
          "associated": ["大汗", "恶心呕吐", "呼吸困难", "濒死感"]
        },
        "atypical_presentation": {
          "silent_mi": "糖尿病、老年患者多见",
          "gastrointestinal": "上腹痛、恶心呕吐",
          "dyspnea_equivalent": "以呼吸困难为主要症状"
        }
      },
      "diagnostics": {
        "ecg_changes": {
          "stemi": "ST段抬高≥2导联≥0.1mV",
          "nstemi": "ST段压低、T波倒置",
          "q_waves": "病理性Q波（>30ms且深度>1/4 R波）"
        },
        "biomarkers": {
          "troponin": {
            "elevation": "正常上限99%的3-5倍",
            "kinetics": "3-12小时升高，7-10天恢复",
            "sensitivity": ">95%"
          },
          "ck_mb": "6-12小时升高，2-3天恢复",
          "myoglobin": "2-4小时升高（早期诊断）"
        },
        "imaging": {
          "echo": "室壁运动异常",
          "coronary_angiography": "急诊PCI术前必需"
        }
      },
      "treatment": {
        "emergency_management": {
          "golden_time": "发病12小时内血运重建",
          "dual_antiplatelet": "负荷剂量阿司匹林+氯吡格雷",
          "anticoagulation": "肝素或比伐芦定",
          "oxygen": "SpO2<90%时给氧"
        },
        "reperfusion_therapy": {
          "primary_pci": {
            "time_window": "发病12小时内首选",
            "door_to_balloon": "目标<90分钟",
            "contraindications": "出血高危、预期寿命<1年"
          },
          "thrombolysis": {
            "indications": "无法及时PCI且发病<12小时",
            "agents": "阿替普酶、瑞替普酶",
            "contraindications": ["活动性出血", "颅内肿瘤", "近期外伤手术"]
          }
        },
        "secondary_prevention": {
          "lifestyle": "戒烟、饮食控制、适度运动",
          "medications": [
            "阿司匹林终身",
            "他汀类药物",
            "β受体阻滞剂",
            "ACEI/ARB"
          ],
          "cardiac_rehabilitation": "运动训练+心理支持"
        }
      },
      "complications": {
        "mechanical": [
          "心肌破裂",
          "室间隔穿孔", 
          "乳头肌断裂",
          "心包填塞"
        ],
        "electrical": [
          "室性心律失常",
          "房室传导阻滞",
          "心房颤动"
        ],
        "pump_failure": [
          "心源性休克",
          "急性心力衰竭",
          "右心衰竭"
        ]
      }
    },
    {
      "id": "CVD_003",
      "type": "Disease", 
      "name": "心力衰竭",
      "category": "心血管疾病",
      "icd10": "I50.9",
      "synonyms": ["心衰", "充血性心力衰竭", "HF"],
      "definition": "心脏结构和(或)功能异常导致心室充盈或射血能力受损的复杂临床综合征",
      "classification": {
        "by_ef": {
          "hfref": "射血分数降低的心衰（EF<40%）",
          "hfmref": "射血分数中间范围的心衰（EF 40-49%）", 
          "hfpef": "射血分数保留的心衰（EF≥50%）"
        },
        "by_stage": {
          "stage_a": "心衰高危无症状",
          "stage_b": "结构性心脏病无症状",
          "stage_c": "结构性心脏病伴症状",
          "stage_d": "难治性心衰"
        },
        "nyha_class": {
          "class_i": "日常活动无限制",
          "class_ii": "一般活动轻度受限",
          "class_iii": "日常活动明显受限",
          "class_iv": "休息时有症状"
        }
      },
      "etiology": {
        "ischemic": "冠心病（最常见病因50-60%）",
        "hypertensive": "高血压性心脏病",
        "cardiomyopathy": [
          "扩张性心肌病",
          "肥厚性心肌病",
          "限制性心肌病"
        ],
        "valvular": "瓣膜性心脏病",
        "other": [
          "心肌炎",
          "先天性心脏病",
          "心律失常",
          "药物毒性"
        ]
      },
      "pathophysiology": {
        "hemodynamic": "心输出量下降，充盈压升高",
        "neurohormonal": {
          "raas_activation": "RAAS系统激活",
          "sns_activation": "交感神经系统兴奋", 
          "adh_release": "抗利尿激素释放增加"
        },
        "cardiac_remodeling": "心室重构，进行性恶化"
      },
      "clinical_presentation": {
        "left_sided": {
          "dyspnea": "劳力性呼吸困难→端坐呼吸→夜间阵发性呼吸困难",
          "fatigue": "乏力、运动耐量下降",
          "cough": "干咳，夜间加重"
        },
        "right_sided": {
          "edema": "下肢水肿→全身水肿",
          "jugular_distension": "颈静脉怒张",
          "hepatomegaly": "肝脏肿大、压痛",
          "ascites": "腹腔积液"
        },
        "physical_signs": {
          "cardiac": ["心界扩大", "奔马律", "心脏杂音"],
          "pulmonary": ["湿啰音", "胸腔积液"],
          "peripheral": ["水肿", "发绀", "脉压差缩小"]
        }
      },
      "diagnostics": {
        "biomarkers": {
          "bnp": {
            "threshold": "BNP>100 pg/ml或NT-proBNP>125 pg/ml",
            "age_adjusted": "年龄调整参考值",
            "monitoring": "治疗效果监测指标"
          }
        },
        "imaging": {
          "echocardiography": {
            "lvef": "左室射血分数评估",
            "wall_motion": "室壁运动分析",
            "diastolic_function": "舒张功能评估",
            "valvular": "瓣膜功能评估"
          },
          "chest_xray": "心影增大、肺淤血、胸腔积液",
          "cardiac_mri": "心功能精确评估金标准",
          "cardiac_catheterization": "血流动力学评估"
        },
        "laboratory": [
          "肾功能（肌酐、尿素氮）",
          "电解质（钠、钾、氯）",
          "肝功能",
          "血常规",
          "甲状腺功能",
          "铁代谢指标"
        ]
      },
      "treatment": {
        "lifestyle_management": {
          "sodium_restriction": "钠盐<2g/day",
          "fluid_restriction": "重症患者<1.5-2L/day",
          "weight_monitoring": "每日称重",
          "exercise": "稳定期有氧运动训练"
        },
        "pharmacotherapy": {
          "hfref_guideline": {
            "acei_arb": {
              "first_line": "所有HFrEF患者",
              "agents": "依那普利、缬沙坦",
              "target_dose": "最大耐受剂量"
            },
            "beta_blockers": {
              "evidence_based": ["美托洛尔琥珀酸盐", "比索洛尔", "卡维地洛"],
              "start_low": "小剂量开始逐渐加量",
              "target_hr": "静息心率60-70 bpm"
            },
            "mra": {
              "indications": "NYHA II-IV级",
              "agents": "螺内酯、依普利酮",
              "monitoring": "血钾、肌酐"
            },
            "diuretics": {
              "loop_diuretics": "呋塞米、托拉塞米",
              "titration": "根据症状和体重调整",
              "monitoring": "电解质、肾功能"
            },
            "newer_agents": {
              "arni": "沙库巴曲缬沙坦（替代ACEI/ARB）",
              "sglt2i": "达格列净（合并糖尿病）",
              "if_inhibitor": "伊伐布雷定（窦性心律且心率>70）"
            }
          },
          "hfpef_management": {
            "diuretics": "症状性治疗",
            "comorbidities": "积极治疗高血压、糖尿病、房颤",
            "evidence_limited": "特异性治疗证据有限"
          }
        },
        "device_therapy": {
          "icd": {
            "indications": "EF≤35%且预期寿命>1年",
            "primary_prevention": "最佳药物治疗3个月后"
          },
          "crt": {
            "indications": "EF≤35%，QRS≥120ms，窦性心律",
            "response_rate": "约70%患者有效"
          }
        },
        "advanced_therapies": {
          "heart_transplantation": "终末期心衰的最终治疗",
          "mechanical_support": ["IABP", "ECMO", "植入式左室辅助装置"],
          "palliative_care": "症状控制和生活质量改善"
        }
      },
      "monitoring": {
        "clinical_parameters": [
          "症状变化",
          "体重变化",
          "血压心率",
          "水肿程度"
        ],
        "laboratory_monitoring": [
          "肾功能（每3-6个月）",
          "电解质",
          "BNP/NT-proBNP"
        ],
        "imaging_follow_up": "左室功能定期评估"
      },
      "prognosis": {
        "mortality": "1年死亡率15-20%",
        "readmission": "6个月再住院率30%",
        "prognostic_factors": [
          "NYHA分级",
          "射血分数", 
          "BNP水平",
          "肾功能",
          "合并症"
        ]
      }
    },
    {
      "id": "CVD_004",
      "type": "Disease",
      "name": "心房颤动",
      "category": "心血管疾病",
      "icd10": "I48.9",
      "synonyms": ["房颤", "AF", "心房纤颤"],
      "definition": "最常见的持续性心律失常，特征为心房电活动快速无序，心房有效收缩消失",
      "classification": {
        "duration_based": {
          "paroxysmal": "阵发性（7天内自行终止）",
          "persistent": "持续性（>7天，需干预终止）",
          "longstanding_persistent": "长程持续性（>12个月）",
          "permanent": "永久性（接受现状，不再转复）"
        },
        "mechanism_based": {
          "focal": "局灶性房颤（肺静脉起源）",
          "reentrant": "折返性房颤（心房内折返）"
        }
      },
      "epidemiology": {
        "prevalence": "中国成人患病率0.65%",
        "age_related": ">65岁患病率6%，>80岁患病率10%",
        "gender": "男性略高于女性",
        "burden": "卒中风险增加5倍，心衰风险增加3倍"
      },
      "etiology": {
        "cardiac_causes": [
          "高血压（最常见）",
          "冠心病",
          "心脏瓣膜病",
          "心肌病", 
          "心力衰竭",
          "先天性心脏病"
        ],
        "non_cardiac": [
          "甲状腺功能亢进",
          "肺部疾病",
          "电解质紊乱",
          "酒精中毒",
          "感染",
          "药物（洋地黄中毒）"
        ],
        "lone_af": "孤立性房颤（无明确病因）"
      },
      "pathophysiology": {
        "triggers": "肺静脉电活动异常",
        "substrate": "心房结构重构", 
        "perpetuating_factors": [
          "心房扩大",
          "纤维化",
          "炎症反应",
          "自主神经失调"
        ]
      },
      "clinical_presentation": {
        "symptoms": {
          "palpitations": "心悸（最常见症状）",
          "dyspnea": "呼吸困难",
          "chest_discomfort": "胸部不适",
          "fatigue": "乏力、运动耐量下降",
          "dizziness": "头晕、黑矇"
        },
        "asymptomatic": "30-45%患者无症状",
        "physical_signs": {
          "pulse": "脉搏绝对不齐",
          "heart_sounds": "心律绝对不齐，强弱不等",
          "signs_of_heart_failure": "伴心衰时相应体征"
        }
      },
      "diagnostics": {
        "ecg": {
          "characteristic_findings": [
            "P波消失",
            "f波（350-600次/分）",
            "RR间期绝对不齐",
            "QRS波群通常正常"
          ]
        },
        "holter_monitoring": "阵发性房颤诊断",
        "echocardiography": {
          "structural_assessment": "心房大小、瓣膜功能",
          "tee": "左心耳血栓评估"
        },
        "laboratory": [
          "甲状腺功能",
          "电解质",
          "肾功能",
          "D-二聚体"
        ]
      },
      "risk_stratification": {
        "stroke_risk": {
          "cha2ds2_vasc": {
            "components": [
              "充血性心衰（1分）",
              "高血压（1分）",
              "年龄≥75岁（2分）",
              "糖尿病（1分）",
              "卒中史（2分）",
              "血管疾病（1分）",
              "年龄65-74岁（1分）",
              "女性（1分）"
            ],
            "interpretation": {
              "0分(男性)或1分(女性)": "低危，无需抗凝",
              "1分(男性)": "中危，可考虑抗凝",
              "≥2分": "高危，推荐抗凝"
            }
          }
        },
        "bleeding_risk": {
          "has_bled": {
            "components": [
              "高血压（1分）",
              "肝肾功能异常（各1分）",
              "卒中（1分）",
              "出血史（1分）",
              "INR不稳定（1分）",
              "年龄>65岁（1分）",
              "药物/酒精（各1分）"
            ],
            "interpretation": {
              "≥3分": "高出血风险，需谨慎权衡"
            }
          }
        }
      },
      "treatment": {
        "acute_management": {
          "hemodynamically_unstable": {
            "immediate_cardioversion": "电复律",
            "preparation": "镇静、同步化",
            "energy": "双向波200J起始"
          },
          "hemodynamically_stable": {
            "rate_control": "首选策略",
            "rhythm_control": "选择性应用"
          }
        },
        "long_term_management": {
          "anticoagulation": {
            "warfarin": {
              "target_inr": "2.0-3.0",
              "monitoring": "定期INR监测",
              "interactions": "药物和食物相互作用多"
            },
            "novel_oral_anticoagulants": {
              "dabigatran": "150mg bid（肾功能正常）",
              "rivaroxaban": "20mg qd",
              "apixaban": "5mg bid",
              "edoxaban": "60mg qd",
              "advantages": "无需监测、相互作用少、出血风险低"
            },
            "contraindications": [
              "活动性出血",
              "严重肝功能不全",
              "妊娠"
            ]
          },
          "rate_control": {
            "targets": "静息心率<110 bpm（宽松控制）",
            "agents": {
              "beta_blockers": "美托洛尔、比索洛尔",
              "calcium_blockers": "维拉帕米、地尔硫卓", 
              "digoxin": "老年人或心衰患者"
            }
          },
          "rhythm_control": {
            "indications": [
              "症状明显",
              "年轻患者",
              "首次发作",
              "心衰合并房颤"
            ],
            "antiarrhythmic_drugs": {
              "class_ia": "奎尼丁（少用）",
              "class_ic": "普罗帕酮、氟卡尼",
              "class_iii": "胺碘酮、索他洛尔",
              "monitoring": "定期心电图、肝功能检查"
            },
            "catheter_ablation": {
              "indications": "药物治疗失败的症状性房颤",
              "technique": "肺静脉电隔离",
              "success_rate": "阵发性房颤70-80%",
              "complications": "血栓栓塞、心包填塞（<1%）"
            }
          }
        },
        "lifestyle_modifications": [
          "戒酒",
          "减肥",
          "规律作息",
          "避免诱发因素",
          "适度运动"
        ]
      },
      "complications": {
        "thromboembolism": {
          "stroke": "最严重并发症",
          "systemic_embolism": "外周动脉栓塞",
          "prevention": "抗凝治疗"
        },
        "heart_failure": "心动过速性心肌病",
        "cognitive_impairment": "与脑血流减少相关"
      },
      "prognosis": {
        "mortality": "全因死亡率增加1.5-2倍",
        "quality_of_life": "症状性房颤显著影响生活质量",
        "progression": "阵发性→持续性→永久性"
      }
    }],
    "cerebrovascular_diseases": [{
      "id": "CBVD_001",
      "type": "Disease",
      "name": "急性缺血性脑卒中",
      "category": "脑血管疾病",
      "icd10": "I63.9",
      "synonyms": ["急性脑梗死", "缺血性卒中", "脑梗塞"],
      "definition": "脑血管急性闭塞导致相应脑组织缺血性坏死及功能障碍的急性脑血管病",
      "classification": {
        "etiology_toast": {
          "large_artery": "大动脉粥样硬化型（约25%）",
          "cardioembolic": "心源性栓塞型（约20%）",
          "small_vessel": "小血管闭塞型/腔隙性（约25%）",
          "other_determined": "其他明确病因型（约5%）",
          "undetermined": "不明原因型（约25%）"
        },
        "bamford_classification": {
          "taci": "全前循环梗死",
          "paci": "部分前循环梗死", 
          "laci": "腔隙性梗死",
          "poci": "后循环梗死"
        }
      },
      "risk_factors": {
        "modifiable": [
          "高血压",
          "糖尿病", 
          "血脂异常",
          "房颤",
          "吸烟",
          "肥胖",
          "缺乏运动",
          "过量饮酒"
        ],
        "non_modifiable": [
          "年龄",
          "性别（男性）",
          "遗传因素",
          "既往卒中史"
        ],
        "emerging": [
          "同型半胱氨酸血症",
          "睡眠呼吸暂停",
          "慢性炎症",
          "凝血功能异常"
        ]
      },
      "pathophysiology": {
        "vascular_occlusion": "血管闭塞→脑血流减少→缺血性级联反应",
        "ischemic_cascade": [
          "ATP耗竭",
          "离子泵失效", 
          "细胞膜去极化",
          "兴奋性氨基酸释放",
          "钙离子内流",
          "自由基产生",
          "细胞死亡"
        ],
        "penumbra_concept": "缺血半暗带-可挽救脑组织"
      },
      "clinical_presentation": {
        "sudden_onset": "急性起病，数秒至数分钟达高峰",
        "focal_signs": {
          "motor": "偏瘫、肌力减退",
          "sensory": "偏身感觉障碍",
          "speech": "失语、构音障碍",
          "visual": "视野缺损、复视",
          "cognitive": "失认、失用、注意障碍"
        },
        "nihss_assessment": {
          "score_range": "0-42分",
          "mild": "0-4分（轻度）",
          "moderate": "5-15分（中度）", 
          "severe": "16-20分（重度）",
          "very_severe": ">20分（极重度）"
        }
      },
      "diagnostics": {
        "emergency_assessment": {
          "time_critical": "发病4.5小时内到达医院",
          "fast_assessment": "FAST量表快速识别",
          "vital_signs": "血压、心率、体温、血糖"
        },
        "imaging": {
          "ct_scan": {
            "non_contrast": "排除脑出血（首选）",
            "early_signs": "早期缺血改变（<6小时）",
            "limitations": "早期缺血病灶敏感性低"
          },
          "mri": {
            "dwi": "超急性期缺血病灶检出金标准",
            "flair": "陈旧性病变评估",
            "mra": "颅内外血管评估",
            "perfusion": "血流灌注评估"
          },
          "ct_angiography": "血管狭窄闭塞评估",
          "dsa": "血管影像学金标准"
        },
        "laboratory": [
          "血常规",
          "凝血功能（PT、APTT、INR）",
          "生化全套（血糖、肾肝功能）",
          "心肌酶谱",
          "D-二聚体",
          "同型半胱氨酸"
        ],
        "cardiac_evaluation": {
          "ecg": "心律失常、心肌梗死",
          "echocardiography": "心源性栓塞源评估",
          "holter": "阵发性房颤检测"
        }
      },
      "treatment": {
        "acute_phase": {
          "time_window": "时间窗内治疗至关重要",
          "thrombolysis": {
            "rtpa": {
              "time_window": "4.5小时内静脉溶栓",
              "dose": "0.9mg/kg，最大90mg",
              "contraindications": [
                "颅内出血史",
                "近期外伤手术",
                "凝血功能异常",
                "血压>185/110mmHg未控制"
              ]
            }
          },
          "mechanical_thrombectomy": {
            "time_window": "发病6-24小时（选择性患者）",
            "indications": [
              "大血管闭塞",
              "NIHSS≥6分",
              "可挽救脑组织"
            ],
            "technique": "支架取栓术"
          }
        },
        "supportive_care": {
          "airway_management": "维持气道通畅",
          "blood_pressure": {
            "thrombolysis_target": "<185/110 mmHg",
            "general_management": "个体化血压管理",
            "avoid_rapid_reduction": "避免血压急剧下降"
          },
          "glucose_control": "血糖7.8-10mmol/L",
          "temperature": "控制发热<37.5°C",
          "nutrition": "48小时内建立营养支持"
        },
        "secondary_prevention": {
          "antiplatelet": {
            "aspirin": "75-100mg/day（非心源性）",
            "clopidogrel": "75mg/day",
            "dual_therapy": "高危患者短期双联"
          },
          "anticoagulation": {
            "warfarin": "心源性栓塞（INR 2.0-3.0）",
            "noac": "新型口服抗凝药（房颤患者）"
          },
          "statins": {
            "high_intensity": "阿托伐他汀40-80mg",
            "target": "LDL-C<1.8mmol/L"
          }
        },
        "rehabilitation": {
          "early_mobilization": "48小时内开始",
          "multidisciplinary": "康复医学团队",
          "speech_therapy": "失语症康复",
          "occupational_therapy": "日常生活能力训练",
          "physical_therapy": "运动功能康复"
        }
      },
      "complications": {
        "neurological": [
          "脑水肿",
          "出血性转化",
          "癫痫发作",
          "感染（肺炎、尿路感染）"
        ],
        "systemic": [
          "深静脉血栓",
          "肺栓塞",
          "压疮",
          "营养不良"
        ]
      },
      "prognosis": {
        "mortality": "急性期死亡率10-15%",
        "functional_outcome": {
          "mRS_0-2": "功能独立（约40%）",
          "mRS_3-5": "功能依赖（约40%）",
          "mRS_6": "死亡（约20%）"
        },
        "factors": [
          "年龄",
          "基线NIHSS评分",
          "治疗时间窗",
          "合并症"
        ]
      }
    },
    {
      "id": "CBVD_002",
      "type": "Disease",
      "name": "急性出血性脑卒中",
      "category": "脑血管疾病", 
      "icd10": "I61.9",
      "synonyms": ["脑出血", "颅内出血", "ICH"],
      "definition": "脑实质内血管破裂引起的脑内出血，是脑卒中的重要类型",
      "classification": {
        "location": {
          "deep": "深部出血（基底节、丘脑、脑干）",
          "lobar": "脑叶出血（皮质下白质）",
          "cerebellar": "小脑出血",
          "intraventricular": "脑室内出血"
        },
        "etiology": {
          "hypertensive": "高血压性脑出血（最常见）",
          "amyloid_angiopathy": "脑淀粉样血管病",
          "vascular_malformation": "血管畸形",
          "anticoagulant_related": "抗凝药物相关",
          "tumor_bleeding": "肿瘤性出血"
        }
      },
      "risk_factors": {
        "primary": [
          "高血压（最重要）",
          "年龄增长",
          "男性",
          "既往脑出血史"
        ],
        "secondary": [
          "抗凝药物使用",
          "血小板减少",
          "肝功能不全",
          "酗酒",
          "可卡因使用",
          "血管畸形"
        ]
      },
      "pathophysiology": {
        "vessel_rupture": "小动脉破裂→血肿形成→周围组织压迫",
        "hematoma_expansion": "血肿扩大（发病6小时内）",
        "secondary_injury": [
          "机械性压迫",
          "血脑屏障破坏",
          "炎症反应",
          "脑水肿形成"
        ]
      },
      "clinical_presentation": {
        "onset": "活动中突然发病（与缺血性卒中不同）",
        "headache": "剧烈头痛（50%患者）",
        "nausea_vomiting": "恶心呕吐",
        "focal_deficits": {
          "basal_ganglia": "对侧偏瘫、失语",
          "thalamic": "感觉障碍、意识障碍",
          "cerebellar": "共济失调、眩晕",
          "brainstem": "复视、吞咽困难、呼吸异常"
        },
        "consciousness": "意识水平下降程度与出血量相关"
      },
      "diagnostics": {
        "emergency_imaging": {
          "ct_scan": {
            "sensitivity": "急性期100%敏感性",
            "hematoma_characteristics": "高密度影",
            "volume_calculation": "ABC/2公式",
            "spot_sign": "造影剂外溢预示血肿扩大"
          },
          "mri": {
            "gradient_echo": "检出微出血",
            "swi": "静脉畸形检出",
            "timing": "急性期CT更实用"
          }
        },
        "laboratory": [
          "凝血功能（PT、APTT、INR、血小板）",
          "血常规",
          "生化全套",
          "毒理学筛查（年轻患者）"
        ],
        "vascular_evaluation": {
          "cta": "血管畸形筛查",
          "mra": "动脉瘤评估",
          "dsa": "复杂血管病变金标准"
        }
      },
      "treatment": {
        "emergency_management": {
          "airway_breathing": "维持气道通畅，必要时插管",
          "blood_pressure": {
            "target": "SBP 140-180 mmHg",
            "agents": "拉贝洛尔、尼卡地平",
            "avoid": "避免舌下含服短效降压药"
          },
          "coagulopathy_reversal": {
            "warfarin": "维生素K + PCC/FFP",
            "noac": "特异性逆转剂",
            "heparin": "鱼精蛋白"
          },
          "seizure_control": "抗癫痫药物"
        },
        "surgical_intervention": {
          "indications": [
            "小脑出血>3cm伴脑干压迫",
            "脑叶出血>30ml伴中线移位",
            "脑室内出血伴梗阻性脑积水"
          ],
          "techniques": [
            "开颅血肿清除",
            "内镜下血肿清除", 
            "脑室外引流"
          ],
          "contraindications": [
            "深昏迷（GCS<5）",
            "预期生存期短",
            "出血倾向未纠正"
          ]
        },
        "supportive_care": {
          "intracranial_pressure": "甘露醇、高渗盐水",
          "temperature_control": "维持正常体温",
          "glucose_management": "血糖控制",
          "dvt_prophylaxis": "间歇性气压装置"
        }
      },
      "complications": {
        "early": [
          "血肿扩大",
          "脑疝形成",
          "急性脑积水",
          "癫痫发作"
        ],
        "late": [
          "慢性脑积水",
          "继发性癫痫",
          "认知功能障碍",
          "运动功能障碍"
        ]
      },
      "prognosis": {
        "mortality": "30天死亡率40-50%",
        "ich_score": {
          "components": [
            "GCS评分",
            "出血量",
            "脑室内出血",
            "幕上/幕下出血位置",
            "年龄"
          ],
          "prediction": "30天死亡率预测"
        },
        "functional_recovery": "存活者中50%达到功能独立"
      }
    },
    {
      "id": "CBVD_003", 
      "type": "Disease",
      "name": "短暂性脑缺血发作",
      "category": "脑血管疾病",
      "icd10": "G45.9",
      "synonyms": ["TIA", "小卒中", "一过性脑缺血发作"],
      "definition": "由局灶性脑或视网膜缺血引起的短暂性神经功能缺失，不伴急性梗死证据",
      "characteristics": {
        "duration": "症状持续时间通常<1小时",
        "reversibility": "症状完全可逆",
        "tissue_based_definition": "无急性脑梗死影像学证据"
      },
      "etiology": {
        "large_artery": "大动脉狭窄或闭塞",
        "small_vessel": "小血管病变", 
        "cardioembolism": "心源性栓塞",
        "other_causes": [
          "血流动力学异常",
          "血液系统疾病",
          "血管炎"
        ]
      },
      "clinical_syndromes": {
        "carotid_territory": {
          "symptoms": [
            "单侧肢体无力",
            "单侧面部麻木",
            "失语或构音障碍",
            "单眼视力丧失（黑蒙）"
          ],
          "duration": "数分钟至数小时"
        },
        "vertebrobasilar_territory": {
          "symptoms": [
            "双侧或交替性无力",
            "复视",
            "眩晕伴神经系统症状",
            "吞咽困难",
            "共济失调"
          ]
        }
      },
      "risk_stratification": {
        "abcd2_score": {
          "components": [
            "年龄≥60岁（1分）",
            "血压≥140/90mmHg（1分）",
            "临床特征：单侧无力（2分）、失语无无力（1分）",
            "症状持续≥60分钟（2分）、10-59分钟（1分）",
            "糖尿病（1分）"
          ],
          "risk_interpretation": {
            "0-3分": "低危（2天卒中风险<1%）",
            "4-5分": "中危（2天卒中风险4-8%）",
            "6-7分": "高危（2天卒中风险>8%）"
          }
        }
      },
      "diagnostics": {
        "clinical_assessment": {
          "symptom_characterization": "详细症状描述和时间过程",
          "vascular_territory": "确定受累血管区域",
          "risk_factors": "评估卒中危险因素"
        },
        "imaging": {
          "brain_mri": {
            "dwi": "排除急性脑梗死",
            "flair": "评估陈旧病变",
            "indication": "症状持续或反复发作"
          },
          "vascular_imaging": {
            "carotid_ultrasound": "颈动脉狭窄评估",
            "cta_mra": "颅内外血管评估",
            "dsa": "复杂血管病变"
          }
        },
        "cardiac_evaluation": {
          "ecg": "心律失常检测",
          "echocardiography": "心脏结构功能评估",
          "holter_monitoring": "阵发性房颤检测"
        },
        "laboratory": [
          "血常规、生化全套",
          "凝血功能",
          "血脂", 
          "HbA1c",
          "同型半胱氨酸"
        ]
      },
      "treatment": {
        "acute_management": {
          "hospitalization": "高危患者（ABCD2≥4分）建议住院",
          "monitoring": "48-72小时神经功能监测",
          "early_intervention": "24小时内启动二级预防"
        },
        "secondary_prevention": {
          "antiplatelet_therapy": {
            "aspirin": "75-100mg/day",
            "clopidogrel": "75mg/day（阿司匹林不耐受）",
            "dual_therapy": "高危患者21天双联抗血小板"
          },
          "anticoagulation": {
            "indications": "心源性栓塞（房颤、瓣膜病）",
            "warfarin": "INR 2.0-3.0",
            "noac": "新型口服抗凝药"
          },
          "statin_therapy": {
            "high_intensity": "阿托伐他汀40-80mg",
            "target": "LDL-C<1.8mmol/L"
          },
          "blood_pressure": {
            "target": "<140/90 mmHg（一般患者）",
            "diabetes_ckd": "<130/80 mmHg"
          },
          "diabetes_management": "HbA1c<7%"
        },
        "revascularization": {
          "carotid_endarterectomy": {
            "indications": "颈内动脉狭窄≥70%",
            "timing": "症状后2周内"
          },
          "carotid_stenting": "外科高危患者替代治疗"
        },
        "lifestyle_modification": [
          "戒烟",
          "限酒",
          "规律运动",
          "体重控制",
          "低盐饮食"
        ]
      },
      "prognosis": {
        "stroke_risk": {
          "early": "48小时内卒中风险5-10%",
          "long_term": "1年卒中风险10-15%"
        },
        "recurrence": "无治疗情况下年复发率30%",
        "prevention_effect": "规范二级预防可降低风险80%"
      }
    },
    {
      "id": "NEURO_001",
      "type": "Disease",
      "name": "糖尿病周围神经病变",
      "category": "神经病变",
      "icd10": "G63.2",
      "synonyms": ["糖尿病神经病变", "DPN", "远端对称性多发性神经病变"],
      "definition": "糖尿病患者在排除其他原因情况下出现的周围神经功能障碍相关的症状和体征",
      "classification": {
        "clinical_types": {
          "distal_symmetric": "远端对称性多发性神经病变（最常见90%）",
          "focal_multifocal": "局灶性/多灶性神经病变",
          "proximal_neuropathy": "近端神经病变/糖尿病性肌萎缩",
          "autonomic_neuropathy": "自主神经病变"
        },
        "severity_grading": {
          "grade_0": "无症状，神经传导正常",
          "grade_1": "无症状，神经传导异常",
          "grade_2": "有症状",
          "grade_3": "有体征"
        }
      },
      "epidemiology": {
        "prevalence": "糖尿病患者中患病率20-50%",
        "type1_dm": "患病20年后50%患者出现",
        "type2_dm": "诊断时即有10-15%患者存在",
        "risk_factors": [
          "病程长",
          "血糖控制不良",
          "年龄增长",
          "身高（高个子风险大）",
          "吸烟",
          "高血压"
        ]
      },
      "pathophysiology": {
        "metabolic_pathway": {
          "polyol_pathway": "山梨醇堆积→神经细胞渗透压改变",
          "age_formation": "糖基化终末产物形成→神经毒性",
          "oxidative_stress": "氧化应激→神经细胞损伤",
          "inflammatory": "炎症因子激活→神经损伤"
        },
        "nerve_fiber_types": {
          "large_fiber": "有髓鞘神经纤维受损→振动觉、位置觉下降",
          "small_fiber": "小有髓和无髓纤维受损→痛觉、温觉异常"
        }
      },
      "clinical_presentation": {
        "symptoms": {
          "positive_symptoms": [
            "疼痛（烧灼样、刺痛、电击样）",
            "异常感觉（麻木、针刺感）",
            "感觉过敏",
            "夜间症状加重"
          ],
          "negative_symptoms": [
            "感觉减退",
            "麻木", 
            "无力",
            "平衡障碍"
          ]
        },
        "distribution": {
          "stocking_glove": "袜套样和手套样分布",
          "distal_to_proximal": "远端向近端进展",
          "symmetric": "对称性受累"
        },
        "neuropathic_pain": {
          "characteristics": "夜间加重，影响睡眠和生活质量",
          "pain_descriptors": ["烧灼样", "刀割样", "电击样", "针刺样"],
          "severity": "VAS评分或数字评定量表"
        }
      },
      "diagnostics": {
        "clinical_assessment": {
          "neurological_examination": {
            "vibration_sense": "128Hz音叉检查（踝关节、足趾）",
            "position_sense": "关节位置觉检查",
            "light_touch": "10g单丝检查",
            "ankle_reflexes": "跟腱反射减弱或消失"
          },
          "neuropathy_scores": {
            "nds": "神经功能缺陷评分",
            "nss": "神经症状评分",
            "michigan_neuropathy": "密歇根神经病变筛查工具"
          }
        },
        "objective_testing": {
          "nerve_conduction": {
            "indications": "确诊和排除其他病因",
            "findings": "感觉神经传导速度减慢，波幅下降",
            "limitations": "主要反映大纤维功能"
          },
          "quantitative_sensory": "温度觉、振动觉定量检测",
          "autonomic_testing": "心率变异性、立位试验"
        },
        "differential_diagnosis": [
          "维生素B12缺乏",
          "甲状腺功能减退",
          "慢性肾病",
          "酒精性神经病变",
          "药物性神经病变",
          "遗传性神经病变"
        ]
      },
      "treatment": {
        "glycemic_control": {
          "primary_prevention": "严格血糖控制可预防神经病变",
          "secondary_prevention": "血糖控制可延缓进展",
          "targets": "HbA1c<7%（个体化调整）"
        },
        "neuropathic_pain_management": {
          "first_line": {
            "pregabalin": {
              "dosage": "75-300mg bid",
              "titration": "从低剂量开始逐渐加量",
              "side_effects": "嗜睡、头晕、体重增加"
            },
            "gabapentin": {
              "dosage": "300-1200mg tid", 
              "titration": "缓慢加量至有效剂量",
              "considerations": "肾功能调整剂量"
            }
          },
          "second_line": {
            "tricyclic_antidepressants": {
              "amitriptyline": "25-75mg 睡前",
              "contraindications": "心律失常、前列腺增生",
              "monitoring": "心电图监测"
            },
            "ssnris": {
              "duloxetine": "60-120mg qd",
              "advantages": "同时治疗抑郁症状"
            }
          },
          "topical_agents": {
            "capsaicin_cream": "0.075% 一日3-4次",
            "lidocaine_patch": "5% 贴片，一日最多12小时"
          }
        },
        "foot_care": {
          "daily_inspection": "每日足部检查",
          "proper_footwear": "合适鞋具，避免外伤",
          "nail_care": "正确修剪指甲",
          "callus_management": "专业处理胼胝",
          "wound_care": "及时处理创伤"
        },
        "multidisciplinary_approach": [
          "内分泌科管理血糖",
          "神经科评估神经病变",
          "足病科预防足部并发症",
          "康复科平衡训练",
          "疼痛科难治性疼痛管理"
        ]
      },
      "complications": {
        "diabetic_foot": {
          "risk_factors": "感觉缺失+外伤+感染",
          "classification": "Wagner分级或IWGDF分类",
          "management": "多学科团队协作"
        },
        "falls_fractures": "本体感觉缺失导致平衡障碍",
        "charcot_arthropathy": "神经性关节病",
        "quality_of_life": "疼痛和功能障碍严重影响生活质量"
      },
      "prognosis": {
        "progression": "通常缓慢进展，不可逆",
        "pain_management": "60-70%患者疼痛可有效控制",
        "prevention": "严格血糖控制可预防或延缓发生"
      }
    },
    {
      "id": "NEURO_002",
      "type": "Disease",
      "name": "糖尿病自主神经病变",
      "category": "神经病变",
      "icd10": "G99.0",
      "synonyms": ["糖尿病植物神经病变", "DAN"],
      "definition": "糖尿病患者出现的自主神经系统功能障碍，累及心血管、胃肠道、泌尿生殖系统等",
      "classification": {
        "cardiovascular": "心血管自主神经病变（最常见且预后最差）",
        "gastrointestinal": "胃肠道自主神经病变",
        "genitourinary": "泌尿生殖系统自主神经病变",
        "sudomotor": "汗腺功能异常",
        "pupillary": "瞳孔功能异常"
      },
      "clinical_manifestations": {
        "cardiovascular": {
          "resting_tachycardia": "静息心率>100bpm",
          "exercise_intolerance": "运动耐量下降",
          "orthostatic_hypotension": "体位性低血压（立位SBP下降≥20mmHg）",
          "silent_mi": "无症状心肌梗死风险增加",
          "sudden_death": "猝死风险增加"
        },
        "gastrointestinal": {
          "gastroparesis": {
            "symptoms": "早饱、腹胀、恶心、呕吐",
            "complications": "血糖控制困难、营养不良",
            "diagnosis": "胃排空延迟检查"
          },
          "constipation": "便秘（最常见胃肠症状）",
          "diarrhea": "夜间腹泻，大便失禁"
        },
        "genitourinary": {
          "neurogenic_bladder": {
            "symptoms": "尿频、尿急、残余尿增多",
            "complications": "尿路感染、肾功能损害"
          },
          "erectile_dysfunction": {
            "prevalence": "糖尿病男性患者50-75%",
            "mechanism": "神经损伤+血管因素",
            "impact": "严重影响生活质量"
          },
          "female_sexual_dysfunction": "性欲减退、阴道干燥"
        },
        "sudomotor": {
          "anhidrosis": "下肢无汗",
          "hyperhidrosis": "上肢代偿性多汗",
          "heat_intolerance": "散热功能障碍"
        }
      },
      "diagnostics": {
        "cardiovascular_autonomic_tests": {
          "heart_rate_variability": {
            "deep_breathing": "深呼吸时心率变异性",
            "valsalva_ratio": "瓦尔萨尔瓦动作心率比值",
            "30_15_ratio": "立位心率30:15比值"
          },
          "blood_pressure_response": {
            "orthostatic_test": "立位血压测试", 
            "sustained_handgrip": "持续握力血压反应"
          }
        },
        "gastrointestinal_assessment": {
          "gastric_emptying": "胃排空显像检查",
          "breath_testing": "呼气试验评估胃肠功能"
        },
        "genitourinary_evaluation": {
          "post_void_residual": "排尿后残余尿测定",
          "urodynamics": "尿动力学检查",
          "erectile_function": "勃起功能评估问卷"
        }
      },
      "treatment": {
        "general_management": {
          "glycemic_control": "优化血糖控制",
          "blood_pressure": "控制血压，避免过度降压",
          "lifestyle": "规律作息、适度运动"
        },
        "cardiovascular_specific": {
          "orthostatic_hypotension": {
            "non_pharmacological": [
              "缓慢起立",
              "弹性袜",
              "增加盐分和水分摄入",
              "抬高床头"
            ],
            "pharmacological": {
              "fludrocortisone": "0.1-0.3mg/day",
              "midodrine": "2.5-10mg tid"
            }
          },
          "exercise_training": "心脏康复训练"
        },
        "gastrointestinal_management": {
          "gastroparesis": {
            "dietary": "少量多餐、低纤维饮食",
            "prokinetic_agents": {
              "metoclopramide": "10mg tid 餐前（短期使用）",
              "domperidone": "10-20mg tid 餐前"
            },
            "antiemetics": "昂丹司琼、格拉司琼"
          },
          "constipation": "纤维素、缓泻剂",
          "diarrhea": "洛哌丁胺、可乐定"
        },
        "genitourinary_treatment": {
          "neurogenic_bladder": {
            "behavioral": "定时排尿、盆底肌训练",
            "pharmacological": "坦索罗辛、托特罗定",
            "invasive": "间歇性导尿、膀胱起搏器"
          },
          "erectile_dysfunction": {
            "first_line": "PDE5抑制剂（西地那非等）",
            "second_line": "前列腺素E1注射",
            "third_line": "阴茎假体植入"
          }
        }
      },
      "prognosis": {
        "cardiovascular": "心血管自主神经病变预后最差",
        "mortality": "增加2-3倍死亡风险",
        "quality_of_life": "严重影响患者生活质量",
        "prevention": "早期诊断和干预可改善预后"
      }
    },
    {
      "id": "NEURO_003",
      "type": "Disease", 
      "name": "急性炎症性脱髓鞘性多发性神经病变",
      "category": "神经病变",
      "icd10": "G61.0",
      "synonyms": ["格林-巴利综合征", "GBS", "急性多发性神经炎"],
      "definition": "一种急性起病的获得性脱髓鞘性多发性神经病变，主要累及周围神经系统",
      "classification": {
        "electrophysiological": {
          "aidp": "急性炎症性脱髓鞘性多发性神经病变（经典型）",
          "aman": "急性运动性轴索性神经病变",
          "amsan": "急性运动感觉性轴索性神经病变"
        },
        "clinical_variants": {
          "miller_fisher": "Miller Fisher综合征（眼肌麻痹+共济失调+反射消失）",
          "pharyngeal_cervical": "咽-颈-臂型",
          "paraparetic": "副麻痹型"
        }
      },
      "etiology": {
        "infectious_triggers": [
          "空肠弯曲菌（最常见30%）",
          "巨细胞病毒",
          "EB病毒",
          "流感病毒",
          "支原体",
          "新冠病毒"
        ],
        "other_triggers": [
          "疫苗接种",
          "手术",
          "外伤", 
          "妊娠",
          "恶性肿瘤"
        ],
        "pathophysiology": "分子模拟机制→自身免疫反应→神经脱髓鞘或轴索损伤"
      },
      "clinical_presentation": {
        "typical_course": {
          "prodromal": "前驱期（感染症状后1-3周）",
          "progressive": "进展期（2-4周内达高峰）",
          "plateau": "平台期（数天至数周）",
          "recovery": "恢复期（数周至数年）"
        },
        "motor_symptoms": {
          "weakness": "对称性四肢无力，下肢重于上肢",
          "pattern": "远端和近端同时受累",
          "facial_weakness": "面肌无力（50%患者）",
          "bulbar_symptoms": "构音障碍、吞咽困难"
        },
        "sensory_symptoms": {
          "numbness": "远端麻木、刺痛感",
          "pain": "肌肉疼痛、神经根痛",
          "proprioception": "位置觉和振动觉受损"
        },
        "autonomic_dysfunction": {
          "cardiovascular": "心律失常、血压不稳",
          "gastrointestinal": "胃肠功能紊乱",
          "urinary": "尿潴留"
        },
        "reflexes": "腱反射减弱或消失（必备体征）"
      },
      "diagnostics": {
        "clinical_criteria": {
          "required": [
            "进行性四肢无力",
            "腱反射减弱或消失"
          ],
          "supportive": [
            "相对对称性",
            "轻度感觉症状",
            "颅神经受累",
            "自主神经功能异常"
          ]
        },
        "csf_analysis": {
          "characteristic": "蛋白-细胞分离现象",
          "protein": ">0.45g/L（通常>1g/L）",
          "cells": "<10×10⁶/L（主要为淋巴细胞）"
        },
        "nerve_conduction": {
          "demyelinating_features": [
            "传导速度减慢",
            "远端潜伏期延长", 
            "传导阻滞",
            "F波异常"
          ],
          "axonal_features": "复合肌肉动作电位波幅下降"
        },
        "serology": {
          "anti_ganglioside": "抗神经节苷脂抗体（GQ1b、GM1等）",
          "infectious_screening": "空肠弯曲菌、CMV、EBV等"
        }
      },
      "treatment": {
        "immunotherapy": {
          "ivig": {
            "dosage": "0.4g/kg/day × 5天",
            "timing": "发病2周内最有效",
            "mechanism": "免疫调节、抗体中和",
            "contraindications": "IgA缺陷、严重心肾功能不全"
          },
          "plasmapheresis": {
            "regimen": "5次血浆置换（隔日进行）",
            "equivalent_efficacy": "与IVIG疗效相当",
            "contraindications": "血流动力学不稳定"
          },
          "corticosteroids": "单独使用无效，不推荐"
        },
        "supportive_care": {
          "respiratory_support": {
            "monitoring": "肺活量监测（<15-20ml/kg需机械通气）",
            "intubation": "30%患者需要机械通气",
            "weaning": "神经功能恢复后逐渐撤离"
          },
          "cardiovascular_monitoring": "心电监护、血压管理",
          "pain_management": "神经病理性疼痛处理",
          "dvt_prophylaxis": "抗凝预防血栓",
          "nutritional_support": "肠内或肠外营养"
        },
        "rehabilitation": {
          "early_mobilization": "病情稳定后早期活动",
          "physical_therapy": "关节活动度训练、肌力训练",
          "occupational_therapy": "日常生活能力训练",
          "speech_therapy": "构音和吞咽功能训练"
        }
      },
      "complications": {
        "acute_phase": [
          "呼吸衰竭",
          "心律失常",
          "血压不稳",
          "肺部感染",
          "深静脉血栓"
        ],
        "chronic_sequelae": [
          "肌无力残留",
          "感觉异常",
          "疲劳",
          "疼痛",
          "功能障碍"
        ]
      },
      "prognosis": {
        "mortality": "5-10%（主要因呼吸衰竭、心律失常）",
        "functional_recovery": {
          "complete": "70-80%患者完全恢复",
          "mild_deficit": "15-20%轻度残障",
          "severe_disability": "5%严重残障"
        },
        "predictive_factors": [
          "年龄（年轻预后好）",
          "轴索损伤程度",
          "治疗时间",
          "病情严重程度"
        ],
        "recurrence": "复发率2-5%"
      }
    },
    {
      "id": "RHEUM_001",
      "type": "Disease",
      "name": "1型糖尿病",
      "category": "自身免疫性内分泌疾病",
      "icd10": "E10.9",
      "synonyms": ["胰岛素依赖性糖尿病", "青少年糖尿病", "IDDM", "T1DM"],
      "definition": "由自身免疫介导的胰岛β细胞破坏导致胰岛素绝对缺乏的糖尿病类型",
      "epidemiology": {
        "prevalence": "全球约9000万人，占糖尿病患者5-10%",
        "incidence_china": "1.01/10万人年",
        "peak_age": "5-7岁和10-14岁双峰分布",
        "genetic_factors": "HLA-DR3/DR4相关性强"
      },
      "pathophysiology": {
        "autoimmune_process": {
          "target": "胰岛β细胞特异性抗原",
          "mechanism": "T细胞介导的细胞毒性反应",
          "progression": "潜伏期→临床前期→显性糖尿病→完全性β细胞功能衰竭"
        },
        "genetic_susceptibility": {
          "hla_associations": "HLA-DQB1*0302/DQA1*0501 (DR3), HLA-DQB1*0201/DQA1*0301 (DR4)",
          "protective_hla": "HLA-DQB1*0602强保护作用",
          "non_hla_genes": "PTPN22, CTLA-4, IL2RA等50+基因位点"
        },
        "environmental_triggers": [
          "病毒感染（柯萨奇病毒、轮状病毒）",
          "早期饮食因素（早期接触牛奶蛋白）",
          "维生素D缺乏",
          "肠道菌群失调"
        ]
      },
      "clinical_presentation": {
        "classic_triad": {
          "polyuria": "多尿（血糖>10mmol/L时出现）",
          "polydipsia": "多饮（继发于多尿）",
          "polyphagia": "多食（胰岛素缺乏导致）"
        },
        "additional_symptoms": [
          "体重下降（显著且快速）",
          "乏力、疲倦",
          "视力模糊",
          "伤口愈合缓慢",
          "反复感染"
        ],
        "acute_presentations": {
          "dka": {
            "definition": "糖尿病酮症酸中毒",
            "incidence": "20-25%患者以DKA为首发表现",
            "criteria": "血糖>13.9mmol/L + 酮体阳性 + pH<7.30",
            "mortality": "1-5%"
          },
          "honeymoon_period": {
            "definition": "部分缓解期",
            "duration": "诊断后3-12个月",
            "characteristics": "胰岛素需要量显著减少，血糖控制良好"
          }
        }
      },
      "diagnostics": {
        "biochemical_criteria": {
          "fasting_glucose": "≥7.0 mmol/L",
          "random_glucose": "≥11.1 mmol/L + 典型症状",
          "ogtt_2h": "≥11.1 mmol/L",
          "hba1c": "≥6.5% (48 mmol/mol)"
        },
        "autoimmune_markers": {
          "gad_antibodies": {
            "prevalence": "70-80%患者阳性",
            "persistence": "可持续数年",
            "clinical_significance": "预测β细胞功能衰退"
          },
          "ia2_antibodies": {
            "prevalence": "50-70%患者阳性",
            "characteristics": "多在诊断时阳性，后期消失"
          },
          "zinc_transporter_antibodies": {
            "prevalence": "60-80%患者阳性",
            "age_correlation": "年龄越小阳性率越高"
          },
          "insulin_autoantibodies": {
            "prevalence": "40-70%患者阳性",
            "note": "胰岛素治疗前检测才有意义"
          }
        },
        "c_peptide": {
          "fasting": "<0.6 ng/ml提示严重β细胞功能缺陷",
          "stimulated": "餐后或胰高血糖素刺激试验",
          "clinical_use": "评估残余β细胞功能，指导治疗"
        },
        "genetic_testing": {
          "hla_typing": "用于高危人群筛查和家族咨询",
          "risk_scores": "遗传风险评分预测模型"
        }
      },
      "treatment": {
        "insulin_therapy": {
          "principles": {
            "absolute_requirement": "胰岛素是唯一有效治疗",
            "physiological_replacement": "模拟生理性胰岛素分泌",
            "individualization": "个体化剂量调整"
          },
          "regimens": {
            "basal_bolus": {
              "description": "基础-餐时胰岛素方案",
              "basal": "长效胰岛素1-2次/日，占总量40-50%",
              "bolus": "速效胰岛素餐前，占总量50-60%",
              "advantages": "灵活性好，模拟生理分泌"
            },
            "csii": {
              "description": "持续皮下胰岛素输注（胰岛素泵）",
              "indications": ["血糖控制不佳", "严重低血糖", "黎明现象"],
              "advantages": "精确控制，减少低血糖",
              "disadvantages": "费用高，技术要求高"
            },
            "mixed_insulin": {
              "description": "预混胰岛素方案",
              "usage": "一日2-3次注射",
              "适用人群": "生活规律，饮食固定的患者"
            }
          },
          "insulin_types": {
            "rapid_acting": {
              "agents": ["门冬胰岛素", "赖脯胰岛素", "谷赖胰岛素"],
              "onset": "10-20分钟",
              "duration": "3-5小时"
            },
            "long_acting": {
              "agents": ["甘精胰岛素", "地特胰岛素", "德谷胰岛素"],
              "onset": "1-4小时",
              "duration": "20-24小时"
            }
          }
        },
        "blood_glucose_monitoring": {
          "smbg": {
            "frequency": "≥4次/日（餐前+睡前）",
            "targets": {
              "preprandial": "4.4-7.2 mmol/L",
              "postprandial": "<10.0 mmol/L",
              "bedtime": "5.0-8.3 mmol/L"
            }
          },
          "cgm": {
            "indications": "血糖波动大，低血糖感知受损",
            "advantages": "实时监测，趋势报警",
            "types": "实时CGM vs 间歇式CGM"
          }
        },
        "lifestyle_management": {
          "medical_nutrition_therapy": {
            "carbohydrate_counting": "精确计算碳水化合物摄入量",
            "insulin_carb_ratio": "胰岛素与碳水化合物比例",
            "correction_factor": "血糖校正系数"
          },
          "exercise": {
            "benefits": "改善胰岛素敏感性，心血管获益",
            "precautions": "防止运动诱发低血糖",
            "monitoring": "运动前后血糖监测"
          }
        },
        "emerging_therapies": {
          "immunotherapy": {
            "anti_cd3": "特殊林抗CD3单抗保护β细胞功能",
            "antigen_specific": "GAD疫苗，胰岛素口服免疫"
          },
          "islet_transplantation": "胰岛移植，适用于严重低血糖患者",
          "artificial_pancreas": "闭环胰岛素输注系统"
        }
      },
      "complications": {
        "acute": {
          "dka": {
            "triggers": ["感染", "胰岛素中断", "应激"],
            "management": "液体复苏+胰岛素+电解质纠正"
          },
          "severe_hypoglycemia": {
            "definition": "需要他人协助的低血糖",
            "risk_factors": "胰岛素过量，饮食不规律，运动"
          }
        },
        "chronic": {
          "microvascular": [
            "糖尿病视网膜病变",
            "糖尿病肾病",
            "糖尿病神经病变"
          ],
          "macrovascular": [
            "冠心病（风险增加2-4倍）",
            "脑血管病",
            "外周血管病"
          ]
        }
      },
      "prognosis": {
        "life_expectancy": "比一般人群减少11-13年",
        "glycemic_control_impact": "HbA1c每降低1%，微血管并发症风险降低37%",
        "cardiovascular_risk": "是同龄人群2-4倍",
        "pregnancy_outcomes": "孕前血糖控制良好可获得正常妊娠结局"
      },
      "prevention": {
        "primary": {
          "high_risk_screening": "一级亲属自身抗体筛查",
          "environmental_factors": "母乳喂养，维生素D补充"
        },
        "secondary": {
          "immunotherapy_trials": "抗体阳性但未发病人群的免疫干预试验",
          "metabolic_monitoring": "OGTT定期监测"
        }
      }
    },
    {
      "id": "RHEUM_002", 
      "type": "Disease",
      "name": "桥本甲状腺炎",
      "category": "自身免疫性内分泌疾病",
      "icd10": "E06.3",
      "synonyms": ["慢性淋巴细胞性甲状腺炎", "自身免疫性甲状腺炎", "Hashimoto's thyroiditis"],
      "definition": "最常见的自身免疫性甲状腺疾病，以甲状腺滤泡破坏和淋巴细胞浸润为特征",
      "epidemiology": {
        "prevalence": "女性1-2%，男性0.1-0.2%",
        "gender_ratio": "女:男 = 7-10:1",
        "peak_age": "30-50岁",
        "familial_clustering": "家族聚集性明显"
      },
      "pathophysiology": {
        "autoimmune_mechanism": {
          "molecular_mimicry": "病毒蛋白与甲状腺抗原分子模拟",
          "th1_response": "Th1细胞介导的细胞免疫反应",
          "antibody_production": "B细胞产生甲状腺特异性自身抗体"
        },
        "target_antigens": {
          "tpo": "甲状腺过氧化物酶（最重要靶抗原）",
          "tg": "甲状腺球蛋白",
          "tshr": "促甲状腺激素受体"
        },
        "genetic_susceptibility": {
          "hla_associations": "HLA-DR3, DR4, DR5",
          "ctla4": "CTLA-4基因多态性",
          "ptpn22": "蛋白酪氨酸磷酸酶基因变异"
        }
      },
      "clinical_presentation": {
        "thyroid_function_spectrum": {
          "euthyroid": "初期甲状腺功能正常（50%）",
          "subclinical_hypothyroid": "亚临床甲减（TSH升高，FT4正常）",
          "overt_hypothyroid": "显性甲减（TSH升高，FT4降低）",
          "transient_hyperthyroid": "一过性甲亢（甲状腺炎性破坏释放激素）"
        },
        "physical_examination": {
          "goiter": {
            "prevalence": "70-80%患者",
            "characteristics": "弥漫性肿大，质韧，表面不平",
            "tenderness": "通常无压痛"
          },
          "hypothyroid_signs": [
            "皮肤干燥、粗糙",
            "声音嘶哑",
            "心率缓慢",
            "反射延迟",
            "黏液性水肿"
          ]
        },
        "symptoms": {
          "hypothyroid_symptoms": [
            "乏力、疲倦",
            "怕冷",
            "体重增加",
            "便秘",
            "记忆力减退",
            "抑郁情绪"
          ],
          "local_symptoms": [
            "颈部胀满感",
            "吞咽困难（压迫症状）",
            "声音改变"
          ]
        }
      },
      "diagnostics": {
        "laboratory_tests": {
          "thyroid_function": {
            "tsh": "升高（亚临床甲减：4.5-10 mIU/L；显性甲减：>10 mIU/L）",
            "ft4": "正常或降低",
            "ft3": "正常或轻度降低"
          },
          "autoantibodies": {
            "anti_tpo": {
              "sensitivity": "90-95%",
              "specificity": "90-95%",
              "clinical_significance": "诊断的重要标志，预测甲减进展"
            },
            "anti_tg": {
              "prevalence": "60-70%患者阳性",
              "note": "常与Anti-TPO伴随出现"
            },
            "trab": {
              "prevalence": "<5%患者阳性",
              "significance": "阳性时需排除Graves病"
            }
          }
        },
        "imaging": {
          "ultrasound": {
            "typical_findings": [
              "甲状腺体积增大或缩小",
              "回声不均匀",
              "低回声区",
              "假性结节"
            ],
            "differential": "与结节性甲状腺肿鉴别"
          },
          "nuclear_medicine": {
            "uptake": "99mTc摄取率降低",
            "scintigraphy": "显像不均匀"
          }
        },
        "cytology": {
          "indications": "结节性病变，怀疑恶变",
          "findings": "淋巴细胞浸润，滤泡细胞Hürthle细胞变性"
        }
      },
      "treatment": {
        "hormone_replacement": {
          "indications": [
            "显性甲减（TSH>10 mIU/L）",
            "亚临床甲减伴症状",
            "妊娠期亚临床甲减",
            "甲状腺肿大明显"
          ],
          "levothyroxine": {
            "starting_dose": "1.6-1.8 μg/kg/day（年轻健康者）",
            "elderly_dose": "25-50 μg/day起始，逐渐加量",
            "pregnancy_dose": "孕期需要量增加25-50%",
            "monitoring": "6-8周后复查TSH，调整剂量"
          },
          "treatment_targets": {
            "general_population": "TSH 0.5-2.5 mIU/L",
            "elderly": "TSH 2-6 mIU/L可接受",
            "pregnancy": "孕早期TSH<2.5 mIU/L"
          }
        },
        "monitoring": {
          "frequency": {
            "stable_patients": "每年1-2次TSH检测",
            "dose_adjustment": "调药后6-8周复查",
            "pregnancy": "每4-6周监测"
          },
          "additional_monitoring": [
            "甲状腺超声（年度）",
            "抗体滴度变化",
            "心血管风险评估"
          ]
        },
        "special_considerations": {
          "pregnancy": {
            "preconception": "TSH优化至<2.5 mIU/L",
            "monitoring": "每4-6周检测TSH",
            "dose_adjustment": "及时调整L-T4剂量"
          },
          "cardiovascular_disease": {
            "caution": "老年患者缓慢加量",
            "monitoring": "心律、心绞痛症状"
          }
        }
      },
      "complications": {
        "cardiovascular": [
          "冠心病风险增加",
          "心包积液",
          "心力衰竭（严重甲减）"
        ],
        "metabolic": [
          "血脂异常",
          "肥胖",
          "胰岛素抵抗"
        ],
        "reproductive": [
          "月经异常",
          "不孕症",
          "妊娠不良结局"
        ],
        "neoplastic": {
          "thyroid_lymphoma": {
            "risk": "较一般人群增加40-80倍",
            "type": "多为MALT淋巴瘤",
            "presentation": "甲状腺快速增大"
          },
          "papillary_carcinoma": "风险轻度增加"
        }
      },
      "prognosis": {
        "disease_progression": {
          "hypothyroidism_development": "每年2-5%患者进展为甲减",
          "remission": "罕见自发缓解",
          "monitoring_duration": "需终身监测"
        },
        "treatment_response": "L-T4治疗效果良好，预后佳",
        "life_expectancy": "正常治疗下不影响寿命"
      }
    },
    {
      "id": "RHEUM_003",
      "type": "Disease", 
      "name": "艾迪生病",
      "category": "自身免疫性内分泌疾病",
      "icd10": "E27.1",
      "synonyms": ["原发性肾上腺皮质功能不全", "慢性肾上腺皮质功能不全", "Addison's disease"],
      "definition": "肾上腺皮质功能不全导致糖皮质激素和盐皮质激素缺乏的慢性疾病",
      "epidemiology": {
        "prevalence": "35-60/100万人",
        "incidence": "0.8-1.2/10万人年",
        "gender": "女性略多于男性",
        "peak_age": "30-50岁"
      },
      "etiology": {
        "autoimmune": {
          "prevalence": "占90%（发达国家）",
          "target": "21-羟化酶（CYP21A2）",
          "associated_conditions": [
            "自身免疫性甲状腺疾病",
            "1型糖尿病",
            "原发性性腺功能减退",
            "恶性贫血"
          ]
        },
        "infectious": [
          "结核（发展中国家主要病因）",
          "真菌感染（组织胞浆菌病）",
          "CMV感染（AIDS患者）"
        ],
        "other_causes": [
          "肾上腺转移瘤",
          "肾上腺出血",
          "药物（酮康唑、米托坦）",
          "先天性肾上腺增生症"
        ]
      },
      "pathophysiology": {
        "hormone_deficiencies": {
          "glucocorticoid": {
            "cortisol_deficiency": "糖代谢异常，应激能力下降",
            "acth_elevation": "负反馈丧失，ACTH代偿性升高"
          },
          "mineralocorticoid": {
            "aldosterone_deficiency": "钠丢失，钾潴留，血容量不足",
            "renin_elevation": "肾素-血管紧张素系统激活"
          }
        },
        "compensatory_mechanisms": [
          "ACTH分泌增加",
          "肾素-血管紧张素激活",
          "抗利尿激素分泌增加"
        ]
      },
      "clinical_presentation": {
        "chronic_symptoms": {
          "constitutional": [
            "乏力、虚弱（100%）",
            "体重下降（97%）",
            "食欲减退（90%）"
          ],
          "gastrointestinal": [
            "恶心、呕吐（86%）",
            "腹痛（68%）",
            "腹泻或便秘"
          ],
          "cardiovascular": [
            "体位性低血压（88%）",
            "血压降低"
          ],
          "neuropsychiatric": [
            "抑郁、烦躁",
            "注意力不集中",
            "嗜盐欲望"
          ],
          "dermatologic": [
            "皮肤色素沉着（94%）",
            "黏膜色素沉着"
          ]
        },
        "physical_signs": {
          "hyperpigmentation": {
            "distribution": "阳光暴露部位，皮肤皱褶，瘢痕",
            "mucosal": "口腔、牙龈色素沉着",
            "mechanism": "ACTH及β-内啡肽升高"
          },
          "hypotension": {
            "systolic": "通常<110 mmHg",
            "orthostatic": "立位收缩压下降>20 mmHg"
          }
        },
        "acute_adrenal_crisis": {
          "triggers": [
            "感染",
            "手术应激",
            "外伤",
            "突然停药"
          ],
          "manifestations": [
            "严重低血压/休克",
            "意识模糊/昏迷",
            "严重脱水",
            "低血糖",
            "高钾低钠"
          ],
          "mortality": "未及时治疗可达100%"
        }
      },
      "diagnostics": {
        "screening_tests": {
          "morning_cortisol": {
            "cutoff": "<140 nmol/L (5 μg/dL)强烈提示肾上腺功能不全",
            "limitations": "受应激、药物、CBG水平影响"
          },
          "acth": {
            "elevation": ">100 pg/mL提示原发性肾上腺功能不全",
            "normal_range": "7-63 pg/mL"
          }
        },
        "confirmatory_tests": {
          "acth_stimulation_test": {
            "protocol": "合成ACTH 250μg iv/im",
            "timing": "注射前、30分钟、60分钟测血皮质醇",
            "normal_response": "峰值>500-550 nmol/L (18-20 μg/dL)",
            "interpretation": "反应不足确诊肾上腺功能不全"
          },
          "low_dose_acth_test": {
            "dose": "1μg ACTH",
            "sensitivity": "更敏感检测轻度功能不全"
          }
        },
        "etiology_investigation": {
          "autoimmune_markers": {
            "21_hydroxylase_antibodies": "90%自身免疫性患者阳性",
            "other_antibodies": "17α-羟化酶抗体，胆固醇侧链裂解酶抗体"
          },
          "imaging": {
            "adrenal_ct": "评估肾上腺大小、钙化、肿块",
            "chest_xray": "排除结核"
          },
          "infectious_screening": "结核菌素试验，真菌血清学"
        },
        "electrolyte_abnormalities": {
          "hyponatremia": "<135 mmol/L（88%患者）",
          "hyperkalemia": ">5.0 mmol/L（64%患者）",
          "elevated_bun": "肾前性氮质血症"
        }
      },
      "treatment": {
        "hormone_replacement": {
          "glucocorticoid": {
            "hydrocortisone": {
              "dose": "15-25 mg/day，分2-3次服用",
              "timing": "2/3剂量晨起，1/3剂量午后",
              "rationale": "模拟生理性皮质醇分泌节律"
            },
            "prednisolone": {
              "dose": "3-5 mg/day，分1-2次",
              "advantage": "半衰期长，服药方便"
            },
            "dexamethasone": {
              "use": "不推荐长期使用",
              "reason": "过度抑制HPA轴，无盐皮质激素活性"
            }
          },
          "mineralocorticoid": {
            "fludrocortisone": {
              "dose": "0.05-0.2 mg/day，晨起单次服用",
              "monitoring": "血压、电解质、血浆肾素活性",
              "adjustment": "根据血压和电解质调整"
            }
          }
        },
        "monitoring": {
          "clinical_parameters": [
            "体重、血压",
            "症状改善",
            "生活质量"
          ],
          "laboratory_monitoring": {
            "routine": "电解质、肾功能（3-6个月）",
            "specialized": "血浆肾素活性，24小时尿钠"
          }
        },
        "stress_dosing": {
          "minor_stress": "平时剂量增加2倍",
          "moderate_stress": {
            "examples": "发热>38°C，局部麻醉手术",
            "dosing": "氢化可的松50-75 mg/day，分次服用"
          },
          "major_stress": {
            "examples": "全麻手术，严重感染，分娩",
            "dosing": "氢化可的松100-150 mg/day，iv给药"
          }
        },
        "acute_crisis_management": {
          "immediate_treatment": {
            "hydrocortisone": "100 mg iv推注，继以200-300 mg/24h持续滴注",
            "fluid_resuscitation": "生理盐水快速补液",
            "electrolyte_correction": "纠正低血糖、低钠、高钾"
          },
          "supportive_care": [
            "血压支持",
            "治疗诱发因素",
            "密切监测"
          ]
        }
      },
      "complications": {
        "untreated_disease": [
          "肾上腺危象",
          "严重低血压",
          "电解质紊乱",
          "死亡"
        ],
        "overtreatment": {
          "glucocorticoid_excess": [
            "库欣样表现",
            "骨质疏松",
            "糖尿病",
            "高血压"
          ]
        },
        "associated_autoimmune": {
          "aps_type1": "伴随甲状旁腺功能减退、慢性黏膜皮肤念珠菌病",
          "aps_type2": "伴随甲状腺疾病、1型糖尿病"
        }
      },
      "prognosis": {
        "with_treatment": "正常寿命和生活质量",
        "without_treatment": "进行性恶化，最终死亡",
        "quality_of_life": "适当替代治疗可维持正常生活",
        "pregnancy": "需要专科管理，预后良好"
      }
    },
    {
      "id": "RHEUM_004",
      "type": "Disease",
      "name": "系统性红斑狼疮",
      "category": "系统性风湿病",
      "icd10": "M32.9", 
      "synonyms": ["SLE", "红斑狼疮", "系统性狼疮"],
      "definition": "以产生多种自身抗体和多系统损害为特征的慢性全身性自身免疫性结缔组织病",
      "epidemiology": {
        "prevalence": "40-200/10万人",
        "incidence": "5-50/10万人年",
        "gender_ratio": "女:男 = 9:1",
        "peak_age": "15-45岁（生育年龄）",
        "ethnic_variations": "非洲裔、亚洲人发病率较高"
      },
      "pathophysiology": {
        "immune_dysregulation": {
          "interferon_signature": "I型干扰素信号通路异常激活",
          "b_cell_hyperactivity": "B细胞过度激活产生自身抗体",
          "complement_deficiency": "早期补体成分缺陷（C1q、C2、C4）",
          "apoptosis_defect": "细胞凋亡清除异常导致核抗原暴露"
        },
        "autoantibody_production": {
          "ana": "抗核抗体（>95%患者阳性）",
          "anti_dsdna": "抗双链DNA抗体（疾病特异性高）",
          "anti_sm": "抗Sm抗体（诊断特异性高）",
          "antiphospholipid": "抗磷脂抗体（血栓风险）"
        },
        "tissue_damage_mechanisms": [
          "免疫复合物沉积",
          "补体激活",
          "血管炎",
          "分子模拟"
        ]
      },
      "clinical_manifestations": {
        "constitutional_symptoms": [
          "发热（80-90%）",
          "乏力、疲倦（90%）",
          "体重下降",
          "淋巴结肿大"
        ],
        "musculoskeletal": {
          "arthritis": {
            "prevalence": "90%患者",
            "characteristics": "对称性、非糜烂性关节炎",
            "distribution": "手、腕、膝关节最常受累",
            "jaccoud_arthropathy": "可逆性关节畸形"
          },
          "myositis": "肌炎（10-15%患者）"
        },
        "dermatologic": {
          "malar_rash": {
            "prevalence": "30-60%",
            "description": "蝶形红斑，跨越双颊，不累及鼻唇沟"
          },
          "discoid_lesions": {
            "characteristics": "盘状红斑，有鳞屑，愈合后瘢痕",
            "distribution": "头面部、耳廓"
          },
          "photosensitivity": "光过敏（30-60%患者）",
          "oral_ulcers": "无痛性口腔溃疡"
        },
        "renal_involvement": {
          "lupus_nephritis": {
            "prevalence": "40-60%患者",
            "classification": "ISN/RPS分级（I-VI级）",
            "class_iv": "弥漫性LN，预后最差",
            "presentation": ["蛋白尿", "血尿", "高血压", "肾功能损害"]
          }
        },
        "neuropsychiatric": {
          "cns_manifestations": [
            "癫痫发作（15%）",
            "精神病（5-15%）",
            "认知功能障碍",
            "脑血管病"
          ],
          "pns_manifestations": [
            "周围神经病变",
            "单神经炎"
          ]
        },
        "cardiovascular": {
          "pericarditis": "最常见心脏受累（25%）",
          "libman_sacks_endocarditis": "无菌性心内膜炎",
          "accelerated_atherosclerosis": "动脉粥样硬化加速",
          "myocarditis": "心肌炎（罕见但严重）"
        },
        "pulmonary": [
          "胸膜炎（最常见）",
          "间质性肺疾病",
          "肺动脉高压",
          "急性狼疮性肺炎"
        ],
        "hematologic": [
          "贫血（60-80%）",
          "白细胞减少（50%）",
          "血小板减少（25%）",
          "溶血性贫血"
        ],
        "endocrine_associations": {
          "thyroid_dysfunction": {
            "prevalence": "15-20%患者",
            "autoimmune_thyroiditis": "桥本甲状腺炎风险增加",
            "hyperthyroidism": "Graves病关联"
          },
          "adrenal_insufficiency": {
            "secondary": "长期糖皮质激素治疗继发",
            "primary": "自身免疫性肾上腺炎（罕见）"
          },
          "diabetes_mellitus": {
            "steroid_induced": "糖皮质激素诱发",
            "type1_association": "1型糖尿病风险轻度增加"
          },
          "reproductive_dysfunction": [
            "月经异常",
            "性腺功能减退",
            "不孕症"
          ]
        }
      },
      "diagnostics": {
        "classification_criteria": {
          "acr_1997": "美国风湿病学会标准（11项中≥4项）",
          "slicc_2012": "系统性狼疮国际协作组标准",
          "eular_acr_2019": "最新分类标准（加权评分）"
        },
        "laboratory_tests": {
          "autoantibodies": {
            "ana": {
              "pattern": "均质型、斑点型、核仁型、着丝粒型",
              "titer": "≥1:160有意义",
              "sensitivity": "95-98%"
            },
            "anti_dsdna": {
              "specificity": "高特异性（95%）",
              "correlation": "与疾病活动度相关",
              "nephritis_marker": "狼疮肾炎活动指标"
            },
            "ena_profile": {
              "anti_sm": "高特异性，预后指标",
              "anti_rnp": "混合性结缔组织病重叠",
              "anti_ro_la": "新生儿狼疮、光敏感相关"
            },
            "antiphospholipid": [
              "抗心磷脂抗体",
              "抗β2糖蛋白I抗体", 
              "狼疮抗凝物"
            ]
          },
          "complement": {
            "c3_c4": "低补体血症提示活动期",
            "ch50": "总补体活性评估"
          },
          "inflammatory_markers": {
            "esr": "血沉升高（90%患者）",
            "crp": "CRP正常或轻度升高"
          }
        },
        "organ_specific_evaluation": {
          "renal": [
            "尿常规、尿蛋白定量",
            "肾功能",
            "肾活检（确诊狼疮肾炎）"
          ],
          "cardiac": [
            "心电图",
            "超声心动图",
            "心肌酶"
          ],
          "neurologic": [
            "脑脊液检查",
            "头颅MRI",
            "神经心理学测试"
          ]
        }
      },
      "treatment": {
        "general_principles": {
          "multidisciplinary_approach": "多学科协作治疗",
          "individualized_therapy": "个体化治疗方案",
          "organ_specific_treatment": "基于受累器官选择治疗"
        },
        "pharmacotherapy": {
          "antimalarials": {
            "hydroxychloroquine": {
              "dose": "200-400mg/day",
              "indications": "皮肤、关节症状，维持治疗",
              "monitoring": "眼科检查（视网膜毒性）",
              "benefits": "减少复发，抗血栓，降血脂"
            }
          },
          "corticosteroids": {
            "prednisolone": {
              "acute_flare": "0.5-1mg/kg/day",
              "maintenance": "≤7.5mg/day",
              "pulse_therapy": "甲强龙500-1000mg×3天（重症）"
            },
            "side_effects": [
              "感染风险",
              "骨质疏松",
              "糖尿病",
              "心血管疾病"
            ]
          },
          "immunosuppressants": {
            "methotrexate": {
              "indications": "关节炎，皮肤病变",
              "dose": "7.5-25mg/周",
              "folic_acid": "叶酸补充5mg/周"
            },
            "mycophenolate": {
              "indications": "狼疮肾炎，维持治疗",
              "dose": "1-3g/day分次服用",
              "monitoring": "血常规，肝肾功能"
            },
            "cyclophosphamide": {
              "indications": "严重器官受累",
              "regimens": "NIH方案 vs Euro-Lupus方案",
              "toxicity": "性腺毒性，出血性膀胱炎，感染"
            },
            "azathioprine": {
              "maintenance_therapy": "1-2mg/kg/day",
              "tpmt_testing": "治疗前基因型检测"
            }
          },
          "biologics": {
            "belimumab": {
              "mechanism": "B淋巴细胞刺激因子抑制剂",
              "indications": "标准治疗反应不佳的SLE",
              "contraindications": "重症狼疮肾炎，神经精神狼疮"
            },
            "rituximab": {
              "off_label_use": "难治性SLE",
              "evidence": "血液系统受累疗效较好"
            }
          }
        },
        "organ_specific_treatment": {
          "lupus_nephritis": {
            "induction_therapy": {
              "class_iii_iv": "MMF + 泼尼松或CTX + 泼尼松",
              "duration": "6个月"
            },
            "maintenance_therapy": {
              "agents": "MMF或AZA + 低剂量激素",
              "duration": "≥3年"
            },
            "refractory_cases": "CNI、RTX、贝利木单抗"
          },
          "neuropsychiatric_lupus": {
            "symptomatic_treatment": "抗癫痫药、抗精神病药",
            "immunosuppression": "高剂量激素 + CTX"
          }
        },
        "supportive_care": {
          "infection_prevention": "疫苗接种，感染预防",
          "cardiovascular_protection": [
            "血压控制",
            "血脂管理",
            "抗血小板治疗（适应症）"
          ],
          "bone_health": [
            "钙剂和维生素D补充",
            "双磷酸盐预防骨质疏松"
          ],
          "reproductive_health": "避孕咨询，妊娠管理"
        }
      },
      "complications": {
        "disease_related": [
          "器官功能衰竭（肾、心、肺、脑）",
          "血栓栓塞症",
          "继发感染",
          "恶性肿瘤风险增加"
        ],
        "treatment_related": [
          "感染（机会性感染）",
          "骨质疏松和骨折",
          "药物性糖尿病",
          "心血管疾病加速",
          "性腺功能损害"
        ]
      },
      "prognosis": {
        "survival_rates": {
          "10_year": "80-90%",
          "20_year": "70-80%"
        },
        "poor_prognostic_factors": [
          "狼疮肾炎",
          "神经精神狼疮",
          "血液系统受累",
          "男性患者",
          "发病年龄小"
        ],
        "organ_specific_outcomes": {
          "lupus_nephritis": "15-25%进展至终末期肾病",
          "neuropsychiatric": "认知功能损害不可逆"
        }
      }
    },
    {
      "id": "RHEUM_005",
      "type": "Disease", 
      "name": "类风湿关节炎",
      "category": "系统性风湿病",
      "icd10": "M06.9",
      "synonyms": ["RA", "类风湿性关节炎", "rheumatoid arthritis"],
      "definition": "以侵蚀性多关节炎为主要表现的慢性全身性自身免疫性疾病",
      "epidemiology": {
        "prevalence": "0.5-1%全球人群",
        "incidence": "25-50/10万人年",
        "gender_ratio": "女:男 = 3:1",
        "peak_age": "40-60岁",
        "genetic_predisposition": "HLA-DR4相关"
      },
      "pathophysiology": {
        "autoimmune_process": {
          "synovial_inflammation": "滑膜炎症是核心病理过程",
          "pannus_formation": "血管翳形成并侵蚀软骨骨质",
          "cytokine_network": "TNF-α、IL-1、IL-6等促炎因子"
        },
        "autoantibodies": {
          "rheumatoid_factor": "类风湿因子（RF）",
          "anti_ccp": "抗环瓜氨酸肽抗体（更特异）",
          "anti_padi4": "抗PADI4抗体"
        }
      },
      "clinical_manifestations": {
        "joint_involvement": {
          "pattern": "对称性多关节炎",
          "distribution": [
            "近端指间关节（PIP）",
            "掌指关节（MCP）",
            "腕关节",
            "跖趾关节（MTP）"
          ],
          "characteristics": [
            "晨僵>1小时",
            "关节疼痛、肿胀",
            "活动受限"
          ],
          "deformities": [
            "天鹅颈畸形",
            "纽扣花样畸形",
            "尺偏畸形",
            "锤状趾"
          ]
        },
        "extra_articular_manifestations": {
          "rheumatoid_nodules": {
            "prevalence": "20-30%患者",
            "location": "关节伸侧，压力点",
            "association": "RF阳性患者多见"
          },
          "pulmonary": [
            "胸膜炎",
            "间质性肺疾病",
            "类风湿结节",
            "肺动脉高压"
          ],
          "cardiac": [
            "心包炎",
            "传导系统疾病",
            "瓣膜疾病",
            "加速动脉粥样硬化"
          ],
          "ocular": [
            "干燥性角结膜炎",
            "巩膜炎",
            "巩膜软化症"
          ],
          "neurologic": [
            "颈椎不稳",
            "周围神经病变",
            "腕管综合征"
          ],
          "hematologic": [
            "贫血（慢性病性贫血）",
            "血小板增多",
            "Felty综合征"
          ]
        },
        "endocrine_associations": {
          "bone_metabolism": {
            "osteoporosis": {
              "prevalence": "明显高于正常人群",
              "mechanisms": [
                "炎症因子直接作用",
                "糖皮质激素使用",
                "活动减少"
              ],
              "fracture_risk": "髋部骨折风险增加2倍"
            },
            "bone_erosions": "局部骨质破坏和全身骨丢失并存"
          },
          "adrenal_axis": {
            "hpa_dysfunction": "下丘脑-垂体-肾上腺轴功能异常",
            "relative_deficiency": "相对性糖皮质激素不足",
            "steroid_dependency": "长期激素治疗后继发性肾上腺功能不全"
          },
          "thyroid_dysfunction": {
            "autoimmune_thyroiditis": "桥本甲状腺炎患病率增加",
            "prevalence": "10-15%RA患者伴甲状腺疾病"
          },
          "insulin_resistance": {
            "mechanisms": [
              "慢性炎症状态",
              "糖皮质激素治疗",
              "活动减少"
            ],
            "cardiovascular_risk": "代谢综合征风险增加"
          }
        }
      },
      "diagnostics": {
        "clinical_criteria": {
          "acr_eular_2010": {
            "joint_involvement": "大关节（0-1分）、小关节（2-3分）、其他（5分）",
            "serology": "RF和抗CCP阴性（0分）、低阳性（2分）、高阳性（3分）",
            "duration": "症状持续≥6周（1分）",
            "acute_phase": "ESR或CRP异常（1分）",
            "threshold": "≥6分确诊RA"
          }
        },
        "laboratory_tests": {
          "autoantibodies": {
            "rheumatoid_factor": {
              "sensitivity": "70-80%",
              "specificity": "70-80%",
              "prognostic_value": "阳性者关节破坏风险高"
            },
            "anti_ccp": {
              "sensitivity": "60-70%",
              "specificity": "95-98%",
              "early_disease": "可在临床症状前数年出现"
            }
          },
          "inflammatory_markers": {
            "esr": "血沉升高反映疾病活动",
            "crp": "C反应蛋白更敏感",
            "ferritin": "铁蛋白升高"
          },
          "bone_metabolism": {
            "alkaline_phosphatase": "骨型ALP升高",
            "ctx_ntx": "骨吸收标志物",
            "p1np": "骨形成标志物"
          }
        },
        "imaging": {
          "conventional_radiography": {
            "early_changes": "关节周围软组织肿胀",
            "progressive_changes": "关节间隙狭窄、骨质疏松",
            "advanced_changes": "骨侵蚀、畸形、强直"
          },
          "ultrasound": {
            "synovial_thickening": "滑膜增厚",
            "power_doppler": "血流信号评估炎症活动",
            "bone_erosions": "早期骨侵蚀检出"
          },
          "mri": {
            "bone_marrow_edema": "骨髓水肿（炎症早期征象）",
            "synovitis": "滑膜炎评估",
            "structural_damage": "软骨和骨质破坏"
          }
        }
      },
      "treatment": {
        "treatment_principles": {
          "early_intervention": "早期诊断，早期治疗",
          "treat_to_target": "达标治疗（缓解或低疾病活动度）",
          "dmard_first": "DMARD为基础的治疗策略"
        },
        "disease_activity_assessment": {
          "das28": "28关节疾病活动评分",
          "cdai": "临床疾病活动指数",
          "sdai": "简化疾病活动指数"
        },
        "pharmacotherapy": {
          "conventional_dmards": {
            "methotrexate": {
              "first_line": "一线DMARD",
              "dose": "7.5-25mg/周",
              "folic_acid": "叶酸补充减少不良反应",
              "monitoring": "血常规、肝肾功能"
            },
            "sulfasalazine": {
              "dose": "1-3g/day",
              "indications": "MTX不耐受或禁忌",
              "monitoring": "血常规"
            },
            "hydroxychloroquine": {
              "mild_disease": "轻症或联合治疗",
              "dose": "200-400mg/day",
              "monitoring": "眼科检查"
            },
            "leflunomide": {
              "alternative": "MTX替代选择",
              "dose": "10-20mg/day",
              "wash_out": "停药需考虑洗脱治疗"
            }
          },
          "biologic_dmards": {
            "tnf_inhibitors": {
              "agents": ["英夫利昔单抗", "阿达木单抗", "依那西普", "戈利木单抗", "塞妥珠单抗"],
              "indications": "MTX治疗6个月反应不佳",
              "screening": "结核、乙肝筛查",
              "monitoring": "感染风险"
            },
            "non_tnf_biologics": {
              "rituximab": "抗CD20单抗",
              "abatacept": "T细胞共刺激调节剂",
              "tocilizumab": "抗IL-6受体单抗",
              "anakinra": "IL-1受体拮抗剂"
            }
          },
          "jak_inhibitors": {
            "tofacitinib": "口服JAK抑制剂",
            "baricitinib": "JAK1/2选择性抑制剂",
            "monitoring": "血常规、感染风险"
          },
          "corticosteroids": {
            "bridging_therapy": "过渡治疗",
            "low_dose": "≤7.5mg/day泼尼松",
            "intra_articular": "关节腔内注射"
          }
        },
        "non_pharmacologic": {
          "patient_education": "疾病教育和自我管理",
          "physical_therapy": "维持关节活动度和肌力",
          "occupational_therapy": "关节保护和辅助器具",
          "surgery": "关节置换、滑膜切除"
        },
        "comorbidity_management": {
          "cardiovascular_risk": [
            "血压控制",
            "血脂管理",
            "糖尿病管理",
            "戒烟"
          ],
          "bone_health": {
            "osteoporosis_prevention": [
              "钙剂和维生素D",
              "双磷酸盐",
              "负重运动"
            ],
            "dexa_monitoring": "骨密度定期评估"
          },
          "infection_prevention": "疫苗接种，预防性抗生素"
        }
      },
      "prognosis": {
        "disease_course": "慢性进行性疾病",
        "functional_disability": "20%患者10年内重度残疾",
        "mortality": "生存期缩短3-10年",
        "prognostic_factors": [
          "抗CCP抗体阳性",
          "高疾病活动度",
          "关节外表现",
          "早期骨侵蚀"
        ]
      }
    },
    {
      "id": "RHEUM_006",
      "type": "Disease",
      "name": "干燥综合征",
      "category": "系统性风湿病", 
      "icd10": "M35.0",
      "synonyms": ["SS", "舍格伦综合征", "Sjögren's syndrome"],
      "definition": "以外分泌腺淋巴细胞浸润为特征的慢性自身免疫性疾病，主要累及唾液腺和泪腺",
      "epidemiology": {
        "prevalence": "0.1-0.6%",
        "gender_ratio": "女:男 = 9:1",
        "peak_age": "40-60岁",
        "classification": {
          "primary": "原发性干燥综合征",
          "secondary": "继发于其他结缔组织病"
        }
      },
      "pathophysiology": {
        "autoimmune_exocrinopathy": {
          "lymphocytic_infiltration": "外分泌腺淋巴细胞浸润",
          "glandular_dysfunction": "腺体分泌功能减退",
          "molecular_mimicry": "病毒感染与自身抗原分子模拟"
        },
        "systemic_autoimmunity": {
          "b_cell_hyperactivity": "B细胞过度激活",
          "germinal_center_formation": "异位淋巴滤泡形成",
          "lymphoma_transformation": "淋巴瘤转化风险"
        }
      },
      "clinical_manifestations": {
        "glandular_features": {
          "keratoconjunctivitis_sicca": {
            "symptoms": ["眼干", "异物感", "烧灼感", "视疲劳"],
            "signs": ["结膜充血", "角膜染色阳性", "泪液分泌减少"],
            "complications": "角膜溃疡、穿孔"
          },
          "xerostomia": {
            "symptoms": ["口干", "吞咽困难", "味觉异常"],
            "signs": ["唾液分泌减少", "舌质红光", "牙龈炎"],
            "complications": ["龋齿", "口腔感染", "吞咽障碍"]
          },
          "parotid_enlargement": "腮腺肿大（50%患者）"
        },
        "extraglandular_manifestations": {
          "musculoskeletal": [
            "关节炎（非糜烂性）",
            "肌痛",
            "纤维肌痛"
          ],
          "pulmonary": [
            "间质性肺疾病",
            "支气管扩张",
            "肺囊肿"
          ],
          "renal": [
            "肾小管间质性肾炎",
            "远端肾小管酸中毒",
            "肾性尿崩症"
          ],
          "neurologic": [
            "周围神经病变",
            "中枢神经系统受累",
            "认知功能障碍"
          ],
          "vascular": [
            "雷诺现象",
            "血管炎",
            "肺动脉高压"
          ],
          "hematologic": [
            "淋巴细胞减少",
            "贫血",
            "血小板减少",
            "淋巴瘤（5%患者）"
          ]
        },
        "endocrine_associations": {
          "thyroid_dysfunction": {
            "autoimmune_thyroiditis": {
              "prevalence": "30-40%患者",
              "association": "桥本甲状腺炎最常见",
              "antibodies": "抗TPO、抗TG抗体阳性",
              "clinical_significance": "甲减风险增加"
            },
            "thyroid_lymphoma": "原发性甲状腺淋巴瘤风险增加"
          },
          "pancreatic_involvement": {
            "exocrine_insufficiency": "胰腺外分泌功能不全",
            "diabetes_risk": "1型糖尿病风险轻度增加"
          },
          "adrenal_involvement": "肾上腺皮质功能异常（罕见）"
        }
      },
      "diagnostics": {
        "classification_criteria": {
          "acr_eular_2016": {
            "objective_ocular_dryness": "Schirmer试验≤5mm/5min或OSS≥5",
            "objective_oral_dryness": "唾液流率≤0.1ml/min",
            "anti_ro_la": "抗Ro52、Ro60或La抗体阳性",
            "focal_lymphocytic_sialadenitis": "唇腺活检focus score≥1",
            "parotid_sialography": "腮腺造影异常"
          }
        },
        "laboratory_tests": {
          "autoantibodies": {
            "anti_ro_ssa": {
              "ro52": "抗Ro52抗体（系统性表现相关）",
              "ro60": "抗Ro60抗体",
              "clinical_significance": "先天性心脏传导阻滞、新生儿狼疮"
            },
            "anti_la_ssb": {
              "prevalence": "40-50%患者",
              "association": "腺体功能损害严重"
            },
            "rheumatoid_factor": "80-90%患者阳性",
            "centromere_antibodies": "与肺动脉高压相关"
          },
          "immunological_abnormalities": {
            "hypergammaglobulinemia": "多克隆γ球蛋白增高",
            "complement": "低补体血症（C3、C4降低）",
            "cryoglobulinemia": "冷球蛋白血症"
          },
          "glandular_function_tests": {
            "schirmer_test": "泪液分泌功能测定",
            "salivary_scintigraphy": "唾液腺显像",
            "unstimulated_saliva": "静息状态唾液流率"
          }
        },
        "tissue_diagnosis": {
          "minor_salivary_gland_biopsy": {
            "procedure": "下唇小唾液腺活检",
            "findings": "淋巴细胞浸润focus score≥1",
            "complications": "局部麻木、感染风险"
          }
        }
      },
      "treatment": {
        "symptomatic_treatment": {
          "ocular_dryness": {
            "artificial_tears": "人工泪液（首选治疗）",
            "punctal_plugs": "泪点塞",
            "cyclosporine_drops": "环孢素眼药水",
            "protective_measures": "避免干燥环境，佩戴护目镜"
          },
          "oral_dryness": {
            "saliva_substitutes": "人工唾液",
            "sialogogues": {
              "pilocarpine": "毛果芸香碱5mg tid",
              "cevimeline": "西维美林30mg tid"
            },
            "oral_hygiene": "定期牙科检查，氟化物治疗"
          }
        },
        "systemic_treatment": {
          "immunosuppressants": {
            "hydroxychloroquine": {
              "indications": "关节炎、皮疹、疲劳",
              "dose": "200-400mg/day",
              "monitoring": "眼科检查"
            },
            "methotrexate": {
              "indications": "关节炎、肺部病变",
              "dose": "7.5-15mg/周",
              "folic_acid": "叶酸补充"
            },
            "corticosteroids": {
              "indications": "严重系统性表现",
              "dose": "泼尼松0.5-1mg/kg/day",
              "duration": "短期使用"
            },
            "rituximab": {
              "refractory_cases": "难治性系统性病变",
              "evidence": "腺体功能改善有限"
            }
          }
        },
        "organ_specific_treatment": {
          "pulmonary": "间质性肺病的免疫抑制治疗",
          "renal": "肾小管间质性肾炎治疗",
          "neurologic": "周围神经病变的对症治疗"
        }
      },
      "complications": {
        "glandular": [
          "严重干眼症",
          "口腔感染",
          "牙齿破坏"
        ],
        "systemic": [
          "肺间质病变",
          "肾功能损害",
          "周围神经病变"
        ],
        "malignant": {
          "lymphoma": {
            "risk": "较正常人群高44倍",
            "type": "多为MALT淋巴瘤",
            "sites": "唾液腺、甲状腺、肺、胃"
          }
        }
      },
      "prognosis": {
        "overall": "总体预后良好，但生活质量受影响",
        "glandular_function": "腺体功能进行性减退",
        "systemic_complications": "系统性并发症影响预后",
        "lymphoma_risk": "需终身监测淋巴瘤发生"
      }
    }

    ],

    "relationships": [
      {
        "id": "REL_001",
        "type": "comorbidity",
        "source": "DIS_001",
        "target": "HTN_001",
        "description": "糖尿病与高血压常共存，相互影响",
        "prevalence": 0.75,
        "bidirectional": true,
        "management_impact": "需要更严格的血压控制目标"
      },
      {
        "id": "REL_002",
        "type": "comorbidity",
        "source": "DIS_001", 
        "target": "DLP_001",
        "description": "糖尿病与血脂异常共病，增加心血管风险",
        "prevalence": 0.60,
        "risk_multiplier": 3.5,
        "treatment_modification": "LDL-C目标更严格"
      },
      {
        "id": "REL_003",
        "type": "increases_risk",
        "source": "HTN_001", 
        "target": "DLP_001",
        "description": "高血压增加血脂异常风险",
        "risk_ratio": 2.3,
        "confidence_interval": "1.8-2.9"
      },
      {
        "id": "REL_004",
        "type": "metabolic_association",
        "source": "THY_001",
        "target": "DIS_001", 
        "description": "甲亢可导致血糖升高和胰岛素抵抗",
        "mechanism": "甲状腺激素增加糖原分解和糖异生",
        "prevalence": 0.15,
        "treatment_consideration": "甲亢控制后血糖通常改善"
      },
      {
        "id": "REL_005",
        "type": "metabolic_association", 
        "source": "THY_002",
        "target": "DLP_001",
        "description": "甲减常伴血脂升高",
        "mechanism": "甲状腺激素缺乏影响脂质代谢",
        "prevalence": 0.85,
        "reversibility": "甲状腺激素替代治疗可改善血脂"
      },
      {
        "id": "REL_006",
        "type": "hormonal_interaction",
        "source": "ADR_002",
        "target": "DIS_001",
        "description": "库欣综合征导致糖尿病",
        "mechanism": "皮质醇过多引起胰岛素抵抗",
        "prevalence": 0.80,
        "severity": "通常为严重糖尿病"
      },
      {
        "id": "REL_007", 
        "type": "hormonal_interaction",
        "source": "ADR_002",
        "target": "HTN_001",
        "description": "库欣综合征导致高血压",
        "mechanism": "皮质醇的盐皮质激素作用",
        "prevalence": 0.85,
        "characteristics": "难治性高血压"
      },
      {
        "id": "REL_008",
        "type": "direct_cause",
        "source": "ADR_001", 
        "target": "HTN_001",
        "description": "原发性醛固酮增多症是继发性高血压的重要原因",
        "prevalence_in_htn": 0.10,
        "diagnostic_clue": "难治性高血压+低钾血症",
        "treatment_outcome": "手术可治愈高血压"
      },
      {
        "id": "REL_009",
        "type": "drug_interaction",
        "source": "THY_001", 
        "target": "DLP_001",
        "description": "甲亢治疗药物与他汀类药物相互作用",
        "interaction_type": "药物代谢竞争",
        "clinical_significance": "需监测肝功能",
        "management": "调整剂量或选择替代药物"
      },
      {
        "id": "REL_010",
        "type": "shared_pathophysiology",
        "source": "DIS_001",
        "target": "PIT_003", 
        "description": "糖尿病患者IGF-1水平影响生长激素治疗",
        "mechanism": "IGF-1介导的负反馈调节",
        "clinical_impact": "需调整GH替代治疗剂量"
      },
      {
        "id": "REL_011",
        "type": "metabolic_comorbidity",
        "source": "GON_001",
        "target": "DIS_001",
        "description": "PCOS患者糖尿病发病风险显著增加",
        "prevalence": 0.35,
        "relative_risk": 4.0,
        "mechanism": "胰岛素抵抗是共同病理基础",
        "screening_recommendation": "PCOS患者应定期进行糖尿病筛查"
      },
      {
        "id": "REL_012", 
        "type": "metabolic_comorbidity",
        "source": "GON_001",
        "target": "DLP_001",
        "description": "PCOS患者血脂异常高发",
        "prevalence": 0.70,
        "characteristics": "甘油三酯升高，HDL-C降低",
        "management_impact": "需积极的血脂管理"
      },
      {
        "id": "REL_013",
        "type": "metabolic_comorbidity", 
        "source": "GON_001",
        "target": "HTN_001",
        "description": "PCOS患者高血压风险增加",
        "prevalence": 0.40,
        "mechanism": "胰岛素抵抗和肥胖相关",
        "treatment_consideration": "首选ACEI/ARB类降压药"
      },
      {
        "id": "REL_014",
        "type": "hormonal_association",
        "source": "GON_002", 
        "target": "DIS_001",
        "description": "男性性腺功能减退与2型糖尿病相互关联",
        "bidirectional": true,
        "mechanism": "睾酮影响胰岛素敏感性，糖尿病影响性腺轴",
        "treatment_synergy": "睾酮替代可改善糖代谢"
      },
      {
        "id": "REL_015",
        "type": "hormonal_association",
        "source": "GON_002",
        "target": "DLP_001", 
        "description": "男性性腺功能减退常伴血脂异常",
        "mechanism": "睾酮缺乏影响脂质代谢",
        "characteristics": "LDL-C升高，HDL-C降低",
        "treatment_response": "睾酮替代可改善血脂谱"
      },
      {
        "id": "REL_016",
        "type": "secondary_cause",
        "source": "PIT_002",
        "target": "GON_002",
        "description": "高泌乳素血症可导致男性性腺功能减退",
        "mechanism": "泌乳素抑制GnRH和LH分泌",
        "reversibility": "泌乳素正常化后可恢复",
        "treatment_priority": "首先治疗高泌乳素血症"
      },
      {
        "id": "REL_017", 
        "type": "secondary_cause",
        "source": "PIT_002",
        "target": "GON_003",
        "description": "高泌乳素血症导致女性性腺功能减退",
        "clinical_manifestation": "闭经-溢乳综合征",
        "mechanism": "抑制下丘脑-垂体-卵巢轴",
        "treatment_outcome": "多巴胺激动剂治疗可恢复月经"
      },
      {
        "id": "REL_018",
        "type": "differential_diagnosis", 
        "source": "GON_001",
        "target": "ADR_002",
        "description": "PCOS需与库欣综合征鉴别",
        "shared_features": ["肥胖", "高雄激素血症", "胰岛素抵抗"],
        "distinguishing_features": {
          "pcos": "多囊卵巢超声表现",
          "cushings": "皮质醇昼夜节律消失"
        },
        "diagnostic_tests": ["地塞米松抑制试验", "24小时尿皮质醇"]
      },
      {
        "id": "REL_019",
        "type": "treatment_interaction",
        "source": "GON_001", 
        "target": "THY_002",
        "description": "PCOS合并甲减的治疗相互作用",
        "clinical_consideration": [
          "甲状腺功能影响PCOS症状",
          "二甲双胍可能影响甲状腺激素吸收",
          "甲状腺激素替代可改善胰岛素敏感性"
        ],
        "management_strategy": "同时优化甲状腺功能和代谢状态"
      },
      {
        "id": "REL_020",
        "type": "increases_risk",
        "source": "DIS_001",
        "target": "CVD_001",
        "description": "糖尿病显著增加冠心病风险",
        "risk_ratio": 2.5,
        "confidence_interval": "2.1-3.0",
        "mechanisms": [
          "高血糖促进动脉粥样硬化",
          "炎症反应激活",
          "内皮功能障碍",
          "血小板聚集增强"
        ],
        "prevention_strategy": "严格血糖控制，LDL-C目标<1.8mmol/L"
      },
      {
        "id": "REL_021", 
        "type": "increases_risk",
        "source": "DIS_001",
        "target": "CVD_002",
        "description": "糖尿病患者心肌梗死风险增加且预后更差",
        "risk_ratio": 3.0,
        "silent_mi_risk": "糖尿病患者无症状心梗风险增加2倍",
        "prognosis": "糖尿病患者心梗后死亡率增加50%",
        "management_considerations": [
          "早期识别非典型症状",
          "积极的血运重建策略",
          "强化二级预防"
        ]
      },
      {
        "id": "REL_022",
        "type": "increases_risk", 
        "source": "DIS_001",
        "target": "CBVD_001",
        "description": "糖尿病增加缺血性脑卒中风险",
        "risk_ratio": 2.3,
        "confidence_interval": "1.9-2.8",
        "age_specific_risk": {
          "young_adults": "年轻糖尿病患者卒中风险增加更显著",
          "elderly": "老年患者绝对风险更高"
        },
        "stroke_characteristics": [
          "多为小血管病变引起",
          "更易发生多发性梗死",
          "预后相对较差"
        ],
        "prevention": {
          "primary": "血糖、血压、血脂综合控制",
          "antiplatelet": "阿司匹林一级预防（高危患者）"
        }
      },
      {
        "id": "REL_023",
        "type": "comorbidity",
        "source": "HTN_001",
        "target": "CVD_001", 
        "description": "高血压是冠心病的主要危险因素",
        "prevalence": 0.85,
        "synergistic_effect": "与其他危险因素协同作用",
        "blood_pressure_targets": {
          "general": "<140/90 mmHg",
          "diabetes": "<130/80 mmHg",
          "coronary_disease": "<130/80 mmHg"
        },
        "preferred_agents": [
          "ACEI/ARB（一线药物）",
          "β受体阻滞剂（心梗后）",
          "钙拮抗剂（稳定性心绞痛）"
        ]
      },
      {
        "id": "REL_024",
        "type": "comorbidity",
        "source": "HTN_001", 
        "target": "CBVD_001",
        "description": "高血压是脑卒中最重要的可控危险因素",
        "population_attributable_risk": "50-60%",
        "dose_response": "收缩压每升高10mmHg，卒中风险增加28%",
        "prevention_efficacy": "降压治疗可降低卒中风险35-40%",
        "special_considerations": {
          "acute_stroke": "急性期避免过度降压", 
          "chronic_prevention": "长期规律降压治疗"
        }
      },
      {
        "id": "REL_025",
        "type": "increases_risk",
        "source": "CVD_004",
        "target": "CBVD_001", 
        "description": "心房颤动显著增加缺血性脑卒中风险",
        "risk_ratio": 5.0,
        "stroke_characteristics": [
          "心源性栓塞型卒中",
          "梗死面积较大",
          "预后相对较差",
          "复发风险高"
        ],
        "prevention": {
          "risk_stratification": "CHA2DS2-VASc评分",
          "anticoagulation": "评分≥2分推荐抗凝",
          "agents": "华法林或新型口服抗凝药"
        }
      },
      {
        "id": "REL_026",
        "type": "increases_risk",
        "source": "DIS_001",
        "target": "NEURO_001", 
        "description": "糖尿病是周围神经病变的主要病因",
        "prevalence": "糖尿病患者中20-50%出现",
        "risk_factors": [
          "病程长",
          "血糖控制不良",
          "HbA1c持续>8%"
        ],
        "prevention": "严格血糖控制可预防或延缓神经病变"
      },
      {
        "id": "REL_027", 
        "type": "increases_risk",
        "source": "DIS_001",
        "target": "NEURO_002",
        "description": "糖尿病自主神经病变严重影响心血管预后",
        "cardiovascular_impact": [
          "无症状心肌梗死风险增加",
          "猝死风险增加2-3倍",
          "运动耐量下降"
        ],
        "screening": "糖尿病患者应定期筛查自主神经功能"
      },
      {
        "id": "REL_028",
        "type": "increases_risk",
        "source": "THY_001",
        "target": "CVD_004",
        "description": "甲状腺功能亢进增加心房颤动风险",
        "risk_ratio": 3.8,
        "age_dependency": "老年患者风险更高",
        "reversibility": "甲亢治疗后房颤可能转复",
        "management": [
          "控制甲状腺功能",
          "β受体阻滞剂控制心率",
          "评估抗凝治疗需要"
        ]
      },
      {
        "id": "REL_029",
        "type": "increases_risk", 
        "source": "ADR_001",
        "target": "CVD_001",
        "description": "原发性醛固酮增多症增加心血管事件风险",
        "cardiovascular_risk": "较原发性高血压增加2-3倍风险",
        "mechanisms": [
          "醛固酮直接心血管毒性",
          "血管重构",
          "内皮功能障碍"
        ],
        "treatment_benefit": "手术或药物治疗可显著降低心血管风险"
      },
      {
        "id": "REL_030",
        "type": "complication_of",
        "source": "CBVD_001", 
        "target": "NEURO_001",
        "description": "脑卒中后可出现继发性神经功能缺损",
        "neurological_sequelae": [
          "偏瘫",
          "感觉障碍", 
          "语言功能障碍",
          "认知功能损害"
        ],
        "rehabilitation": "多学科康复团队综合治疗"
      }
    ],

    "comorbidity_patterns": [
      {
        "pattern_id": "PATTERN_001",
        "name": "代谢综合征",
        "description": "糖尿病、高血压、血脂异常、肥胖的聚集",
        "components": ["DIS_001", "HTN_001", "DLP_001", "OBESITY"],
        "prevalence": "成人中20-25%",
        "shared_mechanisms": [
          "胰岛素抵抗",
          "炎症反应",
          "内皮功能障碍",
          "交感神经激活"
        ],
        "cardiovascular_risk": "增加2-3倍",
        "management_strategy": {
          "lifestyle": "减重、运动、饮食调节",
          "pharmacological": "多重危险因素综合管理",
          "targets": {
            "hba1c": "<7%",
            "bp": "<130/80 mmHg", 
            "ldl_c": "<100 mg/dL"
          }
        }
      },
      {
        "pattern_id": "PATTERN_002",
        "name": "内分泌性高血压",
        "description": "继发于内分泌疾病的高血压",
        "causes": ["ADR_001", "ADR_002", "ADR_003", "THY_001", "PIT_003"],
        "prevalence": "高血压患者中5-10%",
        "screening_indications": [
          "年龄<40岁高血压",
          "难治性高血压",
          "高血压+低钾血症",
          "高血压+内分泌症状"
        ],
        "diagnostic_approach": {
          "hormonal_screening": "针对性激素检查",
          "imaging": "肾上腺、垂体影像学",
          "functional_testing": "动态激素功能试验"
        }
      },
      {
        "pattern_id": "PATTERN_003", 
        "name": "甲状腺-代谢疾病关联",
        "description": "甲状腺疾病与代谢异常的双向关联",
        "associations": [
          {"source": "THY_001", "target": "DIS_001", "bidirectional": false},
          {"source": "THY_002", "target": "DLP_001", "bidirectional": false},
          {"source": "DIS_001", "target": "THY_002", "bidirectional": false}
        ],
        "clinical_implications": [
          "糖尿病患者需定期甲功筛查",
          "甲减患者血脂异常可通过甲状腺激素治疗改善",
          "甲亢患者血糖管理需考虑甲状腺功能状态"
        ]
      },
      {
        "pattern_id": "PATTERN_004",
        "name": "PCOS-代谢综合征复合体",
        "description": "PCOS与代谢综合征组分的聚集",
        "components": ["GON_001", "DIS_001", "HTN_001", "DLP_001", "OBESITY"],
        "prevalence": "PCOS患者中47-67%",
        "shared_mechanisms": [
          "胰岛素抵抗",
          "慢性低级别炎症",
          "雄激素过多",
          "内脏脂肪堆积"
        ],
        "long_term_risks": [
          "心血管疾病风险增加3倍",
          "2型糖尿病风险增加4倍", 
          "子宫内膜癌风险增加2.7倍",
          "非酒精性脂肪肝"
        ],
        "management_strategy": {
          "lifestyle": "减重是核心治疗，目标减重5-10%",
          "pharmacological": [
            "二甲双胍改善胰岛素敏感性",
            "他汀类药物管理血脂",
            "ACEI/ARB类降压药",
            "GLP-1激动剂减重和改善代谢"
          ],
          "reproductive_management": [
            "来曲唑促排卵(生育需求)",
            "复合口服避孕药(无生育需求)",
            "螺内酯抗雄激素治疗"
          ],
          "monitoring": {
            "metabolic": "每年OGTT、血脂、血压监测",
            "reproductive": "定期妇科检查，子宫内膜评估",
            "psychological": "抑郁焦虑筛查"
          }
        }
      },
      {
        "pattern_id": "PATTERN_005", 
        "name": "男性代谢-性腺功能障碍综合征",
        "description": "男性性腺功能减退与代谢异常的相互关联",
        "components": ["GON_002", "DIS_001", "HTN_001", "DLP_001", "OBESITY"],
        "prevalence": "肥胖男性中30-40%",
        "bidirectional_relationship": true,
        "pathophysiology": [
          "肥胖导致芳香化酶活性增加",
          "雌激素升高抑制LH分泌",
          "睾酮降低促进内脏脂肪堆积",
          "胰岛素抵抗进一步抑制性腺轴"
        ],
        "clinical_assessment": [
          "晨间睾酮水平测定",
          "性功能评估量表",
          "代谢指标全面评估",
          "身体成分分析"
        ],
        "treatment_approach": {
          "weight_management": "减重是首要措施，可显著提高睾酮水平",
          "testosterone_replacement": {
            "indications": "减重后仍有症状性低睾酮",
            "benefits": ["改善性功能", "增加肌量", "改善胰岛素敏感性"],
            "monitoring": ["前列腺安全性", "红细胞压积", "心血管风险"]
          },
          "metabolic_management": "标准糖尿病、高血压、血脂异常治疗"
        }
      }
    ],

    "inference_rules": [
      {
        "id": "RULE_001",
        "name": "糖尿病高血压共病管理",
        "description": "糖尿病合并高血压患者的综合管理策略",
        "condition": {
          "diseases": ["糖尿病", "高血压"],
          "hba1c": ">7%",
          "blood_pressure": ">130/80"
        },
        "action": {
          "treatment_priority": "同时控制血糖和血压",
          "drug_preference": "ACE抑制剂或ARB优先",
          "targets": {
            "hba1c": "<7%",
            "bp": "<130/80 mmHg"
          },
          "monitoring": "每3个月评估"
        },
        "evidence_grade": "A"
      },
      {
        "id": "RULE_002", 
        "name": "甲状腺功能异常诊断",
        "description": "基于TSH和甲状腺激素水平的诊断规则",
        "condition": {
          "tsh_low": "<0.1 mIU/L",
          "ft4_high": ">23 pmol/L"
        },
        "conclusion": {
          "diagnosis": "甲状腺功能亢进",
          "confidence": 0.95,
          "next_steps": ["TRAb检测", "甲状腺超声", "心电图"]
        }
      }
    ],

    "clinical_validation_cases": [
      {
        "case_id": "CASE_001",
        "title": "糖尿病合并甲亢的综合管理",
        "patient_profile": {
          "age": 45,
          "gender": "女性",
          "chief_complaint": "心悸、多汗、体重下降3个月"
        },
        "clinical_data": {
          "symptoms": ["心悸", "多汗", "体重下降", "多饮多尿"],
          "lab_results": {
            "glucose": "15.2 mmol/L",
            "hba1c": "9.8%", 
            "tsh": "0.02 mIU/L",
            "ft4": "35.6 pmol/L",
            "trab": "12.5 IU/L"
          }
        },
        "kg_diagnosis": {
          "primary": "Graves病",
          "secondary": "2型糖尿病",
          "confidence": 0.92
        },
        "treatment_plan": {
          "immediate": [
            "甲巯咪唑10mg tid",
            "普萘洛尔40mg bid",
            "二甲双胍1000mg bid"
          ],
          "monitoring": [
            "每2周复查甲功和血糖",
            "每月评估心率血压",
            "3个月后评估HbA1c"
          ]
        },
        "outcome": {
          "3_months": {
            "tsh": "2.1 mIU/L",
            "ft4": "18.2 pmol/L", 
            "hba1c": "7.8%",
            "weight": "体重增加5kg"
          },
          "conclusion": "甲亢控制良好，血糖改善显著"
        }
      }
    ],

    "RHEUM_007": {
      "id": "RHEUM_007",
      "name": "多腺体自身免疫综合征I型 (APS-1)",
      "alternate_names": [
        "自身免疫性多内分泌病I型",
        "APECED (Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy)",
        "慢性皮肤黏膜念珠菌病-多内分泌病-外胚层发育不良综合征"
      ],
      "category": "自身免疫性多腺体疾病",
      "pathophysiology": {
        "genetic_basis": {
          "gene": "AIRE (Autoimmune Regulator)",
          "chromosome": "21q22.3",
          "inheritance": "常染色体隐性遗传",
          "protein_function": "转录调节因子，调控胸腺髓质上皮细胞中自身抗原表达",
          "mutations": {
            "common_types": [
              "无义突变",
              "剪接位点突变",
              "框移突变",
              "错义突变"
            ],
            "functional_impact": "AIRE蛋白功能缺失导致中枢免疫耐受破坏"
          }
        },
        "immune_mechanism": {
          "central_tolerance_defect": "胸腺阴性选择缺陷",
          "autoantigen_presentation": "组织特异性抗原胸腺内表达减少",
          "t_cell_selection": "自反应T细胞逃逸阴性选择",
          "autoantibody_production": "多器官特异性自身抗体产生"
        },
        "molecular_pathways": {
          "transcriptional_regulation": "AIRE调控的转录组异常",
          "promiscuous_gene_expression": "胸腺内异位基因表达受损",
          "immune_tolerance": "自身免疫耐受机制破坏"
        }
      },
      "clinical_manifestations": {
        "classic_triad": {
          "candidiasis": {
            "description": "慢性皮肤黏膜念珠菌感染",
            "onset": "通常首发症状（2-5岁）",
            "sites": [
              "口腔（鹅口疮）",
              "食管",
              "皮肤",
              "指甲",
              "生殖器"
            ],
            "characteristics": "反复发作，难以根治",
            "complications": "食管狭窄，口腔癌风险"
          },
          "hypoparathyroidism": {
            "prevalence": "89-96%患者",
            "onset_age": "5-10岁",
            "symptoms": [
              "手足搐搦",
              "癫痫",
              "喉痉挛",
              "感觉异常",
              "肌肉痛性痉挛"
            ],
            "biochemical": "低钙血症，高磷血症，PTH降低",
            "complications": [
              "白内障",
              "基底节钙化",
              "智力发育障碍"
            ]
          },
          "addison_disease": {
            "prevalence": "72-100%患者",
            "onset_age": "青少年期",
            "manifestations": [
              "色素沉着",
              "乏力，体重下降",
              "恶心呕吐",
              "低血压",
              "电解质紊乱"
            ],
            "crisis_risk": "肾上腺危象风险高"
          }
        },
        "additional_endocrine_features": {
          "gonadal_dysfunction": {
            "prevalence": "60%患者",
            "manifestations": [
              "原发性性腺功能减退",
              "青春期发育延迟",
              "不孕不育",
              "闭经"
            ]
          },
          "diabetes_mellitus": {
            "type": "1型糖尿病",
            "prevalence": "12-18%患者",
            "onset": "通常青少年期"
          },
          "thyroid_disease": {
            "hypothyroidism": "自身免疫性甲状腺炎",
            "prevalence": "4-10%患者"
          },
          "growth_hormone_deficiency": {
            "prevalence": "罕见",
            "manifestations": "生长发育迟缓"
          }
        },
        "non_endocrine_features": {
          "ectodermal_dystrophy": {
            "dental_abnormalities": [
              "牙釉质发育不良",
              "龋齿易感",
              "牙齿缺失"
            ],
            "nail_dystrophy": "甲板增厚，甲沟炎",
            "alopecia": "斑秃或弥漫性脱发"
          },
          "gastrointestinal": {
            "autoimmune_hepatitis": "慢性活动性肝炎",
            "pernicious_anemia": "恶性贫血（B12缺乏）",
            "malabsorption": "肠道吸收不良"
          },
          "dermatologic": {
            "vitiligo": "白癜风",
            "autoimmune_skin_conditions": "各种自身免疫性皮肤病"
          },
          "ocular": {
            "keratoconjunctivitis": "角膜结膜炎",
            "uveitis": "葡萄膜炎"
          }
        }
      },
      "diagnosis": {
        "clinical_criteria": {
          "major_criteria": [
            "慢性皮肤黏膜念珠菌感染",
            "甲状旁腺功能减退",
            "肾上腺功能不全"
          ],
          "minor_criteria": [
            "性腺功能减退",
            "1型糖尿病",
            "自身免疫性甲状腺炎",
            "恶性贫血",
            "慢性活动性肝炎",
            "斑秃",
            "白癜风"
          ],
          "diagnostic_threshold": "≥2个主要标准 或 1个主要+≥2个次要标准"
        },
        "laboratory_investigations": {
          "autoantibodies": {
            "21_hydroxylase": "抗21-羟化酶抗体（肾上腺）",
            "side_chain_cleavage": "抗胆固醇侧链裂解酶抗体",
            "17_hydroxylase": "抗17α-羟化酶抗体",
            "calcium_sensing_receptor": "抗钙敏感受体抗体",
            "interferon_omega": "抗干扰素ω抗体（高特异性）",
            "interferon_alpha": "抗干扰素α抗体",
            "il22": "抗IL-22抗体",
            "il17": "抗IL-17抗体"
          },
          "hormone_assessment": {
            "adrenal": "皮质醇，ACTH，醛固酮，肾素",
            "parathyroid": "PTH，钙，磷，维生素D",
            "gonadal": "LH，FSH，睾酮/雌二醇",
            "thyroid": "TSH，T4，T3，抗TPO",
            "pancreatic": "胰岛素，C肽，HbA1c"
          },
          "immunological": {
            "candida_immunity": "念珠菌特异性T细胞反应",
            "cytokine_profiles": "Th17/Th1细胞因子",
            "complement": "补体系统评估"
          }
        },
        "genetic_testing": {
          "aire_sequencing": "AIRE基因全外显子测序",
          "family_screening": "家系成员基因筛查",
          "prenatal_diagnosis": "产前基因诊断（家族史阳性）"
        },
        "imaging": {
          "adrenal_ct": "肾上腺CT（萎缩征象）",
          "thyroid_ultrasound": "甲状腺超声",
          "bone_density": "骨密度检测",
          "brain_ct": "颅脑CT（基底节钙化）"
        }
      },
      "treatment": {
        "hormone_replacement": {
          "adrenal": {
            "hydrocortisone": "15-25mg/day分次服用",
            "fludrocortisone": "0.05-0.2mg/day（盐皮质激素）",
            "emergency_management": "应激状态下剂量调整"
          },
          "parathyroid": {
            "calcitriol": "0.25-2μg/day",
            "calcium_carbonate": "1-3g/day元素钙",
            "monitoring": "定期监测血钙、尿钙"
          },
          "gonadal": {
            "testosterone": "男性睾酮补充治疗",
            "estrogen_progesterone": "女性雌孕激素替代"
          },
          "thyroid": {
            "levothyroxine": "甲状腺功能减退时补充"
          },
          "diabetes": {
            "insulin": "1型糖尿病胰岛素治疗"
          }
        },
        "antimycotic_therapy": {
          "systemic_antifungals": {
            "fluconazole": "100-400mg/day长期维持",
            "itraconazole": "100-200mg/day",
            "posaconazole": "难治性感染时选择"
          },
          "topical_treatment": {
            "nystatin": "口腔念珠菌感染",
            "clotrimazole": "皮肤念珠菌感染"
          },
          "prophylaxis": "长期抗真菌预防治疗"
        },
        "immunomodulatory_therapy": {
          "investigational": [
            "免疫抑制剂（环孢素A）",
            "生物制剂（抗IL-17）",
            "造血干细胞移植"
          ],
          "supportive_care": "营养支持，感染预防"
        },
        "monitoring_strategy": {
          "hormone_levels": "定期激素水平监测",
          "autoantibody_screening": "新发自身免疫疾病筛查",
          "infection_surveillance": "感染并发症监测",
          "malignancy_screening": "口腔癌筛查（念珠菌感染区域）"
        }
      },
      "prognosis": {
        "life_expectancy": "激素替代治疗下预后良好",
        "quality_of_life": "需要终生多种激素替代治疗",
        "complications": [
          "肾上腺危象",
          "低钙血症性癫痫",
          "感染相关并发症",
          "恶性肿瘤风险增加"
        ],
        "genetic_counseling": "家族遗传咨询重要"
      },
      "research_insights": {
        "aire_function": "AIRE蛋白免疫耐受机制研究",
        "therapeutic_targets": "新型免疫调节治疗靶点",
        "gene_therapy": "基因治疗策略探索",
        "biomarkers": "疾病活动度生物标志物"
      }
    },

    "RHEUM_008": {
      "id": "RHEUM_008", 
      "name": "多腺体自身免疫综合征II型 (APS-2)",
      "alternate_names": [
        "Schmidt综合征",
        "自身免疫性多内分泌病II型",
        "多腺体功能缺陷综合征II型"
      ],
      "category": "自身免疫性多腺体疾病",
      "pathophysiology": {
        "genetic_susceptibility": {
          "hla_associations": {
            "class_ii": {
              "dr3": "DRB1*0301-DQB1*0201单倍型",
              "dr4": "DRB1*0404-DQB1*0302单倍型",
              "relative_risk": "DR3/DR4杂合子风险最高（RR=20-40）"
            },
            "class_i": "HLA-A1, B8单倍型"
          },
          "non_hla_genes": {
            "ctla4": "细胞毒性T淋巴细胞相关抗原4",
            "ptpn22": "蛋白酪氨酸磷酸酶22",
            "cd25": "IL-2受体α链",
            "fcrl3": "Fc受体样蛋白3",
            "il2ra": "白介素-2受体α"
          },
          "polygenic_inheritance": "多基因遗传模式，穿透率不完全"
        },
        "autoimmune_mechanisms": {
          "molecular_mimicry": "病原体与自身抗原分子模拟",
          "epitope_spreading": "抗原表位扩散",
          "regulatory_t_cell_dysfunction": "调节性T细胞功能缺陷",
          "cytokine_imbalance": "Th1/Th17炎症反应优势",
          "b_cell_activation": "B细胞过度活化和抗体产生"
        },
        "organ_specific_pathology": {
          "adrenal": "淋巴细胞浸润，皮质细胞破坏，纤维化",
          "thyroid": "淋巴细胞浸润，滤泡破坏，间质纤维化",
          "pancreas": "胰岛β细胞选择性破坏",
          "gonads": "生殖细胞和支持细胞自身免疫损伤"
        }
      },
      "clinical_manifestations": {
        "core_components": {
          "addison_disease": {
            "prevalence": "100%患者（定义性特征）",
            "presentation": {
              "primary_insufficiency": "原发性肾上腺皮质功能减退",
              "symptoms": [
                "进行性乏力",
                "体重下降",
                "色素沉着（关节、瘢痕、黏膜）",
                "低血压",
                "消化道症状"
              ],
              "biochemical": "低钠，高钾，低皮质醇，高ACTH",
              "crisis_triggers": [
                "感染",
                "手术",
                "情绪应激",
                "药物（巴比妥类）"
              ]
            }
          },
          "autoimmune_thyroid_disease": {
            "prevalence": "70%患者",
            "types": {
              "hashimoto_thyroiditis": {
                "most_common": "最常见类型",
                "progression": "亚临床→显性甲减",
                "antibodies": "抗TPO，抗TG"
              },
              "graves_disease": {
                "less_common": "较少见",
                "can_coexist": "可与甲减交替出现",
                "antibodies": "TSI，TRAb"
              }
            }
          },
          "type_1_diabetes": {
            "prevalence": "52%患者",
            "onset_pattern": {
              "adult_onset": "成人起病多见",
              "lada_phenotype": "LADA表型常见",
              "ketosis_prone": "易发生酮症酸中毒"
            },
            "autoantibodies": [
              "抗GAD65",
              "抗IA-2",
              "抗ZnT8",
              "抗胰岛素（儿童）"
            ]
          }
        },
        "associated_conditions": {
          "primary_hypogonadism": {
            "prevalence": "4-9%患者",
            "manifestations": [
              "闭经，不孕",
              "性欲减退",
              "骨质疏松",
              "潮热"
            ],
            "antibodies": "抗卵巢抗体，抗精子抗体"
          },
          "autoimmune_gastritis": {
            "pernicious_anemia": "恶性贫血",
            "antibodies": "抗内因子，抗壁细胞抗体",
            "complications": "维生素B12缺乏，胃癌风险"
          },
          "vitiligo": {
            "prevalence": "4.8%患者",
            "distribution": "对称性色素脱失",
            "progression": "缓慢进展"
          },
          "alopecia_areata": {
            "prevalence": "1-2%患者",
            "pattern": "斑片状脱发"
          },
          "myasthenia_gravis": {
            "rare_association": "罕见伴发",
            "antibodies": "抗AChR抗体"
          }
        },
        "atypical_presentations": {
          "incomplete_syndrome": "不完全型（仅1-2种腺体受累）",
          "sequential_development": "成分疾病顺序出现",
          "subclinical_phase": "亚临床期长达数年"
        }
      },
      "diagnosis": {
        "diagnostic_criteria": {
          "classic_aps2": "Addison病 + 自身免疫性甲状腺病 和/或 1型糖尿病",
          "incomplete_aps2": "Addison病 + 器官特异性自身抗体阳性",
          "potential_aps2": "≥2种器官特异性自身抗体阳性但无临床症状"
        },
        "laboratory_evaluation": {
          "adrenal_function": {
            "basal_cortisol": "8AM皮质醇<138nmol/L提示不足",
            "acth_stimulation": "短促试验，峰值<550nmol/L异常",
            "acth_levels": "ACTH显著升高（>22pmol/L）",
            "aldosterone_renin": "醛固酮降低，肾素升高"
          },
          "thyroid_function": {
            "tsh_t4": "TSH升高，T4降低（甲减）",
            "antibodies": "抗TPO，抗TG升高",
            "ultrasound": "甲状腺弥漫性低回声，不均匀"
          },
          "pancreatic_function": {
            "glucose_tolerance": "OGTT或随机血糖",
            "hba1c": "糖化血红蛋白",
            "c_peptide": "C肽水平评估β细胞功能",
            "autoantibodies": "抗GAD，抗IA-2，抗ZnT8"
          },
          "organ_specific_autoantibodies": {
            "adrenal": {
              "21_hydroxylase": "抗21-羟化酶（95%阳性）",
              "17_hydroxylase": "抗17α-羟化酶",
              "side_chain_cleavage": "抗胆固醇侧链裂解酶"
            },
            "thyroid": {
              "tpo": "抗甲状腺过氧化物酶",
              "thyroglobulin": "抗甲状腺球蛋白",
              "tsi": "甲状腺刺激性免疫球蛋白"
            },
            "pancreas": {
              "gad65": "抗谷氨酸脱羧酶",
              "ia2": "抗胰岛细胞抗原2",
              "znt8": "抗锌转运蛋白8"
            },
            "gastric": {
              "intrinsic_factor": "抗内因子抗体",
              "parietal_cell": "抗壁细胞抗体"
            },
            "gonadal": {
              "steroid_cell": "抗类固醇细胞抗体",
              "ovarian": "抗卵巢抗体"
            }
          }
        },
        "genetic_testing": {
          "hla_typing": "HLA-DR/DQ单倍型分析",
          "risk_stratification": "基于HLA型别的风险评估",
          "family_screening": "一级亲属筛查（20%患病风险）"
        },
        "imaging_studies": {
          "adrenal_imaging": {
            "ct_scan": "肾上腺萎缩（自身免疫性）vs 增大（转移瘤）",
            "mri": "T2加权像评估肾上腺形态"
          },
          "thyroid_imaging": "超声评估甲状腺结构和血流",
          "bone_density": "DEXA骨密度检测（激素缺乏继发）"
        }
      },
      "treatment": {
        "hormone_replacement_therapy": {
          "adrenal_replacement": {
            "glucocorticoids": {
              "hydrocortisone": "15-25mg/day分2-3次",
              "prednisolone": "3-5mg/day（替代选择）",
              "dexamethasone": "0.25-0.5mg晚上（特殊情况）"
            },
            "mineralocorticoids": {
              "fludrocortisone": "0.05-0.2mg/day",
              "monitoring": "血压，电解质，肾素"
            },
            "stress_dosing": {
              "minor_stress": "双倍剂量2-3天",
              "major_stress": "氢化可的松100mg q8h",
              "surgery": "围手术期方案"
            },
            "emergency_management": {
              "adrenal_crisis": "氢化可的松100mg IV + 生理盐水",
              "patient_education": "应激状态识别和处理"
            }
          },
          "thyroid_replacement": {
            "levothyroxine": {
              "initial_dose": "1.6μg/kg/day",
              "titration": "每6-8周调整剂量",
              "target_tsh": "0.5-2.5mU/L",
              "special_considerations": "肾上腺功能不全时先治疗后甲状腺"
            }
          },
          "diabetes_management": {
            "insulin_therapy": {
              "intensive_regimen": "多次注射或胰岛素泵",
              "glycemic_targets": "个体化HbA1c目标",
              "hypoglycemia_prevention": "肾上腺功能不全增加风险"
            }
          },
          "gonadal_replacement": {
            "female": {
              "estrogen": "雌激素补充治疗",
              "progestin": "孕激素周期治疗",
              "contraindications": "血栓风险评估"
            },
            "male": {
              "testosterone": "睾酮替代治疗",
              "monitoring": "血常规，前列腺检查"
            }
          }
        },
        "supportive_therapy": {
          "vitamin_supplementation": {
            "vitamin_b12": "恶性贫血时肌注补充",
            "vitamin_d": "骨健康维护",
            "calcium": "骨质疏松预防"
          },
          "dietary_management": {
            "sodium_intake": "适当增加钠盐摄入",
            "carbohydrate_counting": "糖尿病饮食管理"
          }
        },
        "monitoring_protocol": {
          "routine_follow_up": {
            "frequency": "3-6个月定期复查",
            "laboratory": "激素水平，电解质，血糖",
            "clinical": "症状评估，体重监测"
          },
          "screening_new_diseases": {
            "autoantibody_monitoring": "年度自身抗体筛查",
            "organ_function": "潜在受累器官功能检测"
          },
          "complication_surveillance": {
            "cardiovascular": "心血管风险因素管理",
            "bone_health": "骨密度定期检测",
            "malignancy": "相关恶性肿瘤筛查"
          }
        }
      },
      "prognosis": {
        "overall_outlook": {
          "life_expectancy": "适当治疗下接近正常人群",
          "quality_of_life": "需要终生激素替代和监测",
          "complications": [
            "肾上腺危象",
            "糖尿病并发症",
            "骨质疏松",
            "心血管疾病",
            "感染易感性"
          ]
        },
        "disease_progression": {
          "additive_risk": "新发自身免疫疾病风险持续存在",
          "family_risk": "家族成员患病风险增加",
          "genetic_counseling": "生育咨询和基因筛查"
        },
        "predictive_factors": {
          "hla_type": "HLA型别影响疾病范围",
          "autoantibody_profile": "抗体阳性预测器官累及",
          "age_at_onset": "早发病预后相对较差"
        }
      },
      "research_directions": {
        "immunomodulation": {
          "early_intervention": "疾病早期免疫调节治疗",
          "targeted_therapy": "特异性免疫抑制剂",
          "tolerance_induction": "免疫耐受重建策略"
        },
        "biomarkers": {
          "disease_activity": "疾病活动度标志物",
          "progression_predictors": "疾病进展预测因子",
          "treatment_response": "治疗反应监测指标"
        },
        "regenerative_medicine": {
          "cell_replacement": "细胞替代治疗",
          "tissue_engineering": "组织工程学应用",
          "gene_therapy": "基因治疗策略"
        }
      }
    },

    "METAB_009": {
      "id": "METAB_009",
      "name": "高尿酸血症",
      "alternate_names": [
        "高尿酸血症",
        "无症状性高尿酸血症",
        "Hyperuricemia",
        "Asymptomatic hyperuricemia"
      ],
      "category": "代谢性疾病",
      "pathophysiology": {
        "uric_acid_metabolism": {
          "production": {
            "endogenous_sources": [
              "嘌呤核苷酸分解（80%）",
              "细胞凋亡和更新",
              "组织缺氧和ATP降解"
            ],
            "exogenous_sources": [
              "膳食嘌呤摄入（20%）",
              "高嘌呤食物（动物内脏、海鲜）",
              "酒精（特别是啤酒）"
            ],
            "key_enzymes": [
              "黄嘌呤氧化酶（XO）- 限速酶",
              "腺嘌呤磷酸核糖转移酶（APRT）",
              "次黄嘌呤-鸟嘌呤磷酸核糖转移酶（HPRT）"
            ]
          },
          "excretion": {
            "renal_excretion": {
              "percentage": "70%",
              "mechanisms": [
                "肾小球滤过",
                "近曲小管重吸收（URAT1, GLUT9）",
                "远曲小管分泌（OAT1, OAT3, ABCG2）"
              ],
              "transporters": {
                "urat1": "主要重吸收转运体",
                "glut9": "基底侧重吸收",
                "oat1_oat3": "分泌转运体",
                "abcg2": "管腔侧分泌"
              }
            },
            "intestinal_excretion": {
              "percentage": "30%",
              "mechanism": "肠道尿酸酶分解"
            }
          },
          "pathogenic_mechanisms": {
            "overproduction": [
              "嘌呤代谢酶缺陷",
              "细胞增殖性疾病",
              "组织损伤和坏死",
              "酒精代谢异常"
            ],
            "underexcretion": [
              "肾功能不全",
              "尿酸转运体异常",
              "药物干扰排泄",
              "内分泌代谢异常"
            ]
          }
        },
        "endocrine_interactions": {
          "insulin_resistance": {
            "bidirectional_relationship": "胰岛素抵抗与高尿酸血症相互促进",
            "mechanisms": [
              "胰岛素促进肾小管尿酸重吸收",
              "尿酸激活RAAS系统",
              "氧化应激和炎症介导",
              "NO生物利用度下降"
            ]
          },
          "thyroid_function": {
            "hypothyroidism_effect": "甲减导致肾清除率下降",
            "metabolic_rate": "基础代谢率影响嘌呤代谢"
          },
          "growth_hormone": {
            "gh_deficiency": "生长激素缺乏影响肾功能",
            "igf1_effects": "IGF-1对尿酸代谢的调节作用"
          }
        }
      },
      "epidemiology": {
        "prevalence": {
          "global": "8.4-13.3%",
          "china": "13.3%（2019年数据）",
          "gender_difference": {
            "male": "19.4%",
            "female": "7.9%"
          },
          "age_trend": "患病率随年龄增长而上升"
        },
        "trends": {
          "increasing": "全球发病率持续上升",
          "urbanization": "城市化进程相关",
          "lifestyle_factors": "生活方式改变的影响"
        }
      },
      "risk_factors": {
        "non_modifiable": {
          "genetics": [
            "URAT1基因多态性",
            "GLUT9基因变异",
            "ABCG2基因突变",
            "APRT酶缺陷"
          ],
          "gender": "男性>女性（绝经前）",
          "age": "年龄增长",
          "ethnicity": "种族差异"
        },
        "modifiable": {
          "dietary": [
            "高嘌呤食物摄入",
            "果糖过量摄入",
            "酒精消费（特别是啤酒）",
            "蛋白质摄入过多"
          ],
          "lifestyle": [
            "肥胖",
            "缺乏运动",
            "睡眠不足",
            "吸烟"
          ],
          "medical": [
            "利尿剂使用",
            "免疫抑制剂",
            "化疗药物",
            "低剂量阿司匹林"
          ]
        },
        "comorbidities": {
          "metabolic": [
            "代谢综合征",
            "2型糖尿病",
            "肥胖症",
            "胰岛素抵抗"
          ],
          "cardiovascular": [
            "高血压",
            "血脂异常",
            "冠心病",
            "心力衰竭"
          ],
          "renal": [
            "慢性肾脏病",
            "肾结石",
            "急性肾损伤"
          ]
        }
      },
      "clinical_manifestations": {
        "asymptomatic_phase": {
          "description": "无症状性高尿酸血症",
          "duration": "可持续数年至数十年",
          "progression_risk": "年进展率2-5%至有症状痛风"
        },
        "target_organ_damage": {
          "joints": {
            "gout_arthritis": "痛风性关节炎",
            "tophi_formation": "痛风石形成",
            "joint_destruction": "关节破坏"
          },
          "kidneys": {
            "chronic_kidney_disease": "慢性肾脏病",
            "uric_acid_nephropathy": "尿酸性肾病",
            "kidney_stones": "肾结石（10-25%患者）"
          },
          "cardiovascular": {
            "hypertension": "高血压发生风险增加",
            "atherosclerosis": "动脉粥样硬化",
            "endothelial_dysfunction": "内皮功能障碍"
          }
        },
        "associated_symptoms": {
          "metabolic": [
            "胰岛素抵抗症状",
            "体重增加",
            "腹型肥胖",
            "疲劳乏力"
          ],
          "cardiovascular": [
            "高血压",
            "心悸",
            "胸闷"
          ]
        }
      },
      "diagnosis": {
        "laboratory_criteria": {
          "serum_uric_acid": {
            "hyperuricemia_definition": {
              "male": ">420 μmol/L (7.0 mg/dL)",
              "female": ">360 μmol/L (6.0 mg/dL)",
              "postmenopausal_female": ">420 μmol/L"
            },
            "target_levels": {
              "general_population": "<360 μmol/L (6.0 mg/dL)",
              "gout_patients": "<300 μmol/L (5.0 mg/dL)",
              "severe_gout": "<240 μmol/L (4.0 mg/dL)"
            },
            "measurement_considerations": [
              "空腹8-12小时采血",
              "避免高嘌呤饮食",
              "停止影响尿酸的药物",
              "重复测量确认"
            ]
          },
          "24h_urine_uric_acid": {
            "normal_range": "1.48-4.43 mmol/24h",
            "overproduction": ">4.43 mmol/24h",
            "underexcretion": "<1.48 mmol/24h",
            "clinical_utility": "鉴别高尿酸血症类型"
          },
          "uric_acid_clearance": {
            "normal_range": "6.6-12.6 mL/min",
            "reduced_clearance": "<6.6 mL/min"
          }
        },
        "imaging_studies": {
          "ultrasound": {
            "joint_ultrasound": "检测关节内尿酸盐结晶",
            "renal_ultrasound": "评估肾结石和肾脏形态"
          },
          "dual_energy_ct": {
            "urate_crystal_detection": "双能CT检测尿酸盐沉积",
            "sensitivity_specificity": "敏感性90%，特异性85%"
          }
        },
        "differential_diagnosis": {
          "secondary_causes": [
            "肾功能不全",
            "甲状腺功能减退",
            "药物相关",
            "血液系统疾病"
          ],
          "genetic_causes": [
            "HPRT缺陷（Lesch-Nyhan综合征）",
            "PRPP合成酶过度活跃",
            "葡萄糖-6-磷酸酶缺陷"
          ]
        }
      },
      "treatment": {
        "lifestyle_interventions": {
          "dietary_modifications": {
            "purine_restriction": {
              "high_purine_foods": "限制动物内脏、海鲜、浓汤",
              "moderate_purine_foods": "适量摄入瘦肉、鱼类",
              "low_purine_foods": "推荐蔬菜、水果、谷物"
            },
            "fructose_limitation": "限制果糖摄入（<50g/天）",
            "alcohol_restriction": {
              "beer": "严格限制啤酒",
              "spirits": "限制烈性酒",
              "wine": "红酒可适量"
            },
            "hydration": "充分饮水（>2000mL/天）"
          },
          "weight_management": {
            "target": "BMI <25 kg/m²",
            "gradual_loss": "缓慢减重（0.5-1kg/周）",
            "avoid_crash_diets": "避免快速减重"
          },
          "exercise": {
            "aerobic_exercise": "中等强度有氧运动",
            "frequency": "每周150分钟",
            "benefits": "改善胰岛素敏感性，促进尿酸排泄"
          }
        },
        "pharmacotherapy": {
          "indications": {
            "absolute": [
              "痛风发作史",
              "痛风石存在",
              "尿酸性肾病",
              "肾结石史"
            ],
            "relative": [
              "血尿酸>480 μmol/L",
              "合并代谢综合征",
              "慢性肾脏病",
              "心血管疾病高危"
            ]
          },
          "urate_lowering_therapy": {
            "first_line": {
              "allopurinol": {
                "mechanism": "黄嘌呤氧化酶抑制剂",
                "starting_dose": "100mg/day",
                "maintenance_dose": "200-400mg/day",
                "maximum_dose": "800mg/day",
                "monitoring": "肝肾功能，血常规",
                "contraindications": "HLA-B*5801阳性（亚洲人群筛查）"
              },
              "febuxostat": {
                "mechanism": "选择性黄嘌呤氧化酶抑制剂",
                "starting_dose": "40mg/day",
                "maintenance_dose": "40-80mg/day",
                "advantages": "可用于轻中度肾功能不全",
                "cardiovascular_risk": "注意心血管事件风险"
              }
            },
            "second_line": {
              "benzbromarone": {
                "mechanism": "促尿酸排泄剂",
                "dose": "50-100mg/day",
                "contraindications": "严重肾功能不全",
                "monitoring": "肝功能"
              },
              "probenecid": {
                "mechanism": "抑制肾小管尿酸重吸收",
                "dose": "250mg bid，逐渐增至500mg bid",
                "limitations": "需要充分饮水"
              }
            },
            "newer_agents": {
              "pegloticase": {
                "mechanism": "重组尿酸酶",
                "indication": "难治性痛风",
                "administration": "静脉输注，每2周一次"
              }
            }
          },
          "prophylaxis_during_initiation": {
            "colchicine": {
              "dose": "0.5mg daily",
              "duration": "6个月",
              "mechanism": "预防痛风发作"
            },
            "nsaids": {
              "low_dose_nsaid": "替代colchicine",
              "contraindications": "肾功能不全，胃肠道疾病"
            }
          }
        },
        "comorbidity_management": {
          "diabetes_mellitus": {
            "glucose_control": "优化血糖控制改善尿酸代谢",
            "medication_choice": "避免使用利尿剂",
            "metformin_benefit": "二甲双胍可能降低尿酸水平"
          },
          "hypertension": {
            "preferred_agents": [
              "ACE抑制剂（有降尿酸作用）",
              "ARB（部分有降尿酸作用）",
              "钙通道阻滞剂"
            ],
            "avoid": "利尿剂（特别是噻嗪类）"
          },
          "dyslipidemia": {
            "statin_therapy": "他汀类药物治疗",
            "fenofibrate": "非诺贝特可降低尿酸"
          },
          "chronic_kidney_disease": {
            "dose_adjustment": "根据肾功能调整药物剂量",
            "monitoring": "密切监测肾功能变化"
          }
        }
      },
      "monitoring": {
        "treatment_targets": {
          "serum_uric_acid": "<300 μmol/L (5.0 mg/dL)",
          "time_to_target": "通常3-6个月",
          "monitoring_frequency": "治疗开始后每2-4周检测"
        },
        "safety_monitoring": {
          "allopurinol": [
            "肝功能（ALT, AST）",
            "肾功能（SCr, eGFR）",
            "血常规",
            "皮肤反应观察"
          ],
          "febuxostat": [
            "肝功能",
            "心血管事件",
            "血常规"
          ]
        },
        "efficacy_assessment": {
          "clinical": "痛风发作频率和严重程度",
          "laboratory": "血尿酸水平",
          "imaging": "痛风石消退情况"
        }
      },
      "prognosis": {
        "untreated_course": {
          "gout_development": "20年内20-30%发展为痛风",
          "kidney_disease": "慢性肾病风险增加",
          "cardiovascular_events": "心血管事件风险升高"
        },
        "treated_outcomes": {
          "urate_lowering": "95%患者可达到目标尿酸水平",
          "gout_prevention": "显著减少痛风发作",
          "tophi_resolution": "痛风石可逐渐消退",
          "kidney_protection": "延缓肾功能恶化"
        },
        "prognostic_factors": {
          "good_prognosis": [
            "早期诊断和治疗",
            "良好的治疗依从性",
            "生活方式改善",
            "无严重合并症"
          ],
          "poor_prognosis": [
            "延迟治疗",
            "多种合并症",
            "药物不耐受",
            "生活方式不良"
          ]
        }
      },
      "prevention": {
        "primary_prevention": {
          "population_screening": "高危人群尿酸筛查",
          "lifestyle_education": "健康生活方式宣教",
          "dietary_guidance": "低嘌呤饮食指导"
        },
        "secondary_prevention": {
          "early_treatment": "早期降尿酸治疗",
          "comorbidity_control": "积极控制相关疾病",
          "regular_monitoring": "定期监测随访"
        }
      }
    },

    "RHEUM_009": {
      "id": "RHEUM_009",
      "name": "痛风",
      "alternate_names": [
        "痛风性关节炎",
        "急性痛风",
        "慢性痛风",
        "Gout",
        "Gouty arthritis"
      ],
      "category": "晶体性关节病",
      "pathophysiology": {
        "crystal_formation": {
          "urate_crystallization": {
            "mechanism": "单钠尿酸盐结晶形成",
            "conditions": [
              "尿酸浓度过饱和",
              "pH值偏低（<6.5）",
              "温度较低（关节远端）",
              "局部蛋白质浓度"
            ],
            "crystal_characteristics": {
              "shape": "针状双折光结晶",
              "polarization": "强负双折光性",
              "phagocytosis": "可被中性粒细胞吞噬"
            }
          },
          "inflammatory_cascade": {
            "initial_trigger": "尿酸盐结晶激活",
            "cellular_response": [
              "中性粒细胞聚集",
              "巨噬细胞活化",
              "NLRP3炎性小体激活"
            ],
            "mediators": {
              "il1_beta": "白介素-1β（关键炎症因子）",
              "tnf_alpha": "肿瘤坏死因子-α",
              "il6": "白介素-6",
              "complement": "补体系统激活"
            },
            "resolution": {
              "mechanism": "TGF-β介导的炎症消退",
              "timeline": "通常7-14天自限性缓解"
            }
          }
        },
        "disease_progression": {
          "stages": {
            "asymptomatic_hyperuricemia": {
              "duration": "数年至数十年",
              "characteristics": "血尿酸升高但无临床症状"
            },
            "acute_gout": {
              "first_attack": "通常累及第一跖趾关节",
              "characteristics": "剧烈疼痛，红肿热痛"
            },
            "intercritical_period": {
              "description": "发作间歇期",
              "duration": "可长达数年",
              "progression": "发作间隔逐渐缩短"
            },
            "chronic_tophaceous_gout": {
              "timeline": "发病10-20年后",
              "characteristics": "痛风石形成，关节破坏"
            }
          }
        }
      },
      "clinical_manifestations": {
        "acute_gout_attack": {
          "onset": {
            "timing": "常于夜间或清晨发作",
            "rapidity": "数小时内达到疼痛高峰",
            "triggers": [
              "酒精摄入",
              "高嘌呤食物",
              "外伤",
              "手术应激",
              "药物（利尿剂、化疗）"
            ]
          },
          "clinical_features": {
            "pain": {
              "severity": "剧烈疼痛（10/10分）",
              "description": "刀割样、撕裂样疼痛",
              "exacerbation": "轻触即痛"
            },
            "inflammation": {
              "redness": "皮肤潮红",
              "swelling": "关节肿胀",
              "heat": "局部发热",
              "function": "功能严重受限"
            }
          },
          "joint_distribution": {
            "first_attack": {
              "mtp1": "第一跖趾关节（50-70%）",
              "characteristics": "单关节受累多见"
            },
            "subsequent_attacks": {
              "common_sites": [
                "踝关节",
                "膝关节",
                "腕关节",
                "手指关节"
              ],
              "polyarticular": "可累及多个关节"
            },
            "atypical_presentations": {
              "elderly": "老年人可累及手部小关节",
              "women": "女性更易累及手部关节",
              "polyarticular_onset": "同时累及多个关节"
            }
          },
          "systemic_symptoms": {
            "fever": "可有低热或中等热",
            "malaise": "全身不适",
            "leukocytosis": "外周血白细胞升高",
            "acute_phase_reactants": "ESR、CRP升高"
          }
        },
        "chronic_gout": {
          "tophi_formation": {
            "definition": "尿酸盐结晶在组织中的沉积",
            "common_locations": [
              "耳轮",
              "指关节",
              "肘部鹰嘴突",
              "Achilles腱",
              "关节滑膜"
            ],
            "characteristics": {
              "appearance": "乳白色结节状病变",
              "consistency": "质硬，可破溃",
              "contents": "白垩样尿酸盐结晶"
            },
            "complications": [
              "皮肤溃疡",
              "继发感染",
              "关节功能障碍",
              "美容问题"
            ]
          },
          "chronic_arthropathy": {
            "joint_destruction": {
              "mechanism": "尿酸盐结晶引起软骨和骨质破坏",
              "imaging_features": [
                "关节间隙狭窄",
                "骨质糜烂",
                "痛风石影",
                "关节畸形"
              ]
            },
            "functional_impact": {
              "mobility": "关节活动受限",
              "deformity": "关节畸形",
              "disability": "功能障碍"
            }
          }
        },
        "renal_manifestations": {
          "uric_acid_nephropathy": {
            "pathogenesis": "尿酸盐结晶在肾间质沉积",
            "clinical_features": [
              "慢性肾功能不全",
              "蛋白尿",
              "高血压",
              "肾小管功能异常"
            ]
          },
          "uric_acid_nephrolithiasis": {
            "prevalence": "10-25%痛风患者",
            "risk_factors": [
              "酸性尿液（pH<5.5）",
              "尿酸排泄增加",
              "脱水",
              "低尿量"
            ],
            "complications": [
              "肾绞痛",
              "血尿",
              "尿路感染",
              "梗阻性肾病"
            ]
          },
          "acute_uric_acid_nephropathy": {
            "mechanism": "大量尿酸结晶阻塞肾小管",
            "triggers": [
              "肿瘤溶解综合征",
              "化疗",
              "大量细胞破坏"
            ],
            "clinical_features": [
              "急性肾功能衰竭",
              "少尿或无尿",
              "血尿酸显著升高"
            ]
          }
        }
      },
      "diagnosis": {
        "clinical_criteria": {
          "2015_acr_eular_criteria": {
            "entry_criterion": "≥1次关节或滑囊肿胀、疼痛、触痛发作",
            "sufficient_criterion": "滑液或痛风石中发现尿酸盐结晶",
            "scoring_domains": [
              "临床表现（最高8分）",
              "实验室检查（最高4分）",
              "影像学检查（最高4分）"
            ],
            "cutoff_score": "≥8分诊断痛风"
          },
          "clinical_features_scoring": {
            "joint_involvement": {
              "mtp1": "第一跖趾关节受累（+2分）",
              "characteristic_episodes": "典型发作（+2分）"
            },
            "time_course": {
              "rapid_onset": "发作<24小时达高峰（+1分）",
              "resolution": "14天内完全缓解（+1分）"
            },
            "clinical_signs": {
              "erythema": "发作时红斑（+1分）",
              "difficulty_walking": "行走困难（+1分）"
            }
          }
        },
        "laboratory_investigations": {
          "synovial_fluid_analysis": {
            "gold_standard": "偏振光显微镜下发现尿酸盐结晶",
            "crystal_characteristics": {
              "morphology": "针状或棒状",
              "birefringence": "强负双折光性",
              "location": "细胞内和细胞外"
            },
            "fluid_characteristics": {
              "appearance": "浑浊或脓性",
              "cell_count": ">2000/μL（急性期）",
              "predominant_cells": "中性粒细胞",
              "glucose": "正常或轻度降低"
            }
          },
          "serum_uric_acid": {
            "limitations": [
              "急性发作时可能正常（30%患者）",
              "需要在发作缓解2-4周后复查",
              "不能单独用于诊断"
            ],
            "diagnostic_value": "支持诊断但非必需"
          },
          "inflammatory_markers": {
            "acute_phase": [
              "ESR升高",
              "CRP升高",
              "白细胞计数升高"
            ],
            "limitations": "非特异性改变"
          },
          "24h_urine_uric_acid": {
            "indication": "考虑促尿酸排泄治疗前",
            "interpretation": {
              "low_excretion": "<1.48 mmol/24h",
              "normal_excretion": "1.48-4.43 mmol/24h",
              "high_excretion": ">4.43 mmol/24h"
            }
          }
        },
        "imaging_studies": {
          "conventional_radiography": {
            "early_stages": "通常正常",
            "chronic_changes": [
              "关节间隙狭窄",
              "骨质糜烂（punched-out病变）",
              "痛风石软组织影",
              "关节畸形"
            ],
            "limitations": "敏感性低，需要长期病变"
          },
          "ultrasound": {
            "findings": [
              "双轨征（double contour sign）",
              "痛风石回声",
              "关节积液",
              "滑膜增厚"
            ],
            "advantages": [
              "无创，成本低",
              "可检测早期病变",
              "指导关节穿刺"
            ]
          },
          "dual_energy_ct": {
            "mechanism": "基于尿酸盐与钙盐的X线衰减差异",
            "advantages": [
              "高特异性（90-95%）",
              "可检测无症状沉积",
              "监测治疗效果"
            ],
            "limitations": [
              "成本较高",
              "辐射暴露",
              "假阳性可能"
            ]
          },
          "mri": {
            "indications": "评估深部痛风石和骨髓水肿",
            "findings": [
              "T1低信号，T2高信号",
              "增强后环形强化"
            ]
          }
        },
        "differential_diagnosis": {
          "septic_arthritis": {
            "distinguishing_features": [
              "关节液培养阳性",
              "更严重的全身症状",
              "持续发热"
            ],
            "overlap": "可与痛风共存"
          },
          "pseudogout": {
            "crystal_type": "焦磷酸钙二水合物结晶",
            "birefringence": "弱正双折光性",
            "common_joints": "膝关节、腕关节"
          },
          "rheumatoid_arthritis": {
            "symmetry": "对称性关节受累",
            "morning_stiffness": "晨僵>1小时",
            "rf_acpa": "RF和ACPA阳性"
          },
          "osteoarthritis": {
            "onset": "慢性起病",
            "inflammation": "炎症轻微",
            "joint_pattern": "负重关节多见"
          }
        }
      },
      "treatment": {
        "acute_attack_management": {
          "general_principles": {
            "timing": "越早治疗效果越好（<24小时）",
            "duration": "持续治疗至症状完全缓解",
            "urate_lowering": "急性期暂缓调整降尿酸药物"
          },
          "first_line_therapy": {
            "nsaids": {
              "preferred_agents": [
                "双氯芬酸 50mg tid",
                "萘普生 500mg bid", 
                "塞来昔布 200mg bid"
              ],
              "contraindications": [
                "肾功能不全",
                "消化道疾病",
                "心血管疾病"
              ],
              "duration": "症状缓解后继续2-3天"
            },
            "colchicine": {
              "mechanism": "抑制中性粒细胞功能",
              "dosing": {
                "loading": "1.2mg立即，1小时后0.6mg",
                "maintenance": "0.6mg bid直至症状缓解"
              },
              "advantages": "特异性强，诊断价值",
              "side_effects": [
                "胃肠道反应（腹泻、恶心）",
                "剂量相关毒性"
              ],
              "contraindications": [
                "严重肾功能不全",
                "严重肝功能不全"
              ]
            },
            "corticosteroids": {
              "indications": [
                "NSAID和秋水仙碱禁忌",
                "多关节受累",
                "全身症状明显"
              ],
              "routes": {
                "oral": "泼尼松0.5mg/kg/day，3-5天后减量",
                "intra_articular": "单关节受累首选",
                "parenteral": "严重病例或不能口服"
              },
              "duration": "短期使用，逐渐减量"
            }
          },
          "combination_therapy": {
            "indications": "严重急性发作",
            "combinations": [
              "NSAID + 秋水仙碱",
              "激素 + 秋水仙碱"
            ]
          },
          "supportive_measures": {
            "rest": "患肢休息，避免负重",
            "ice_application": "冰敷减轻炎症",
            "hydration": "充分饮水",
            "dietary": "避免酒精和高嘌呤食物"
          }
        },
        "urate_lowering_therapy": {
          "indications": {
            "absolute": [
              "痛风发作≥2次/年",
              "痛风石存在",
              "慢性关节病",
              "尿酸性肾病"
            ],
            "relative": [
              "首次发作但高危因素多",
              "血尿酸>480 μmol/L",
              "肾结石史"
            ]
          },
          "timing": "急性发作完全缓解2-4周后开始",
          "target": "血尿酸<300 μmol/L（5.0 mg/dL）",
          "xanthine_oxidase_inhibitors": {
            "allopurinol": {
              "starting_dose": "50-100mg/day",
              "titration": "每2-4周增加50-100mg",
              "maximum_dose": "800mg/day",
              "renal_adjustment": "需要根据肾功能调整",
              "monitoring": [
                "肝肾功能",
                "血常规",
                "HLA-B*5801（亚洲人群）"
              ],
              "adverse_effects": [
                "皮疹（最常见）",
                "Stevens-Johnson综合征（罕见）",
                "肝功能异常"
              ]
            },
            "febuxostat": {
              "starting_dose": "40mg/day",
              "maintenance": "40-80mg/day",
              "advantages": [
                "轻中度肾功能不全无需调整剂量",
                "与allopurinol过敏患者可用"
              ],
              "cardiovascular_concern": "可能增加心血管事件风险",
              "monitoring": "肝功能，心血管症状"
            }
          },
          "uricosuric_agents": {
            "indications": [
              "XOI不耐受或禁忌",
              "尿酸排泄不足型（<300mg/24h）",
              "作为联合治疗"
            ],
            "benzbromarone": {
              "dose": "50-100mg/day",
              "contraindications": "eGFR<30ml/min",
              "monitoring": "肝功能",
              "hydration": "需要充分饮水"
            },
            "probenecid": {
              "dose": "250mg bid起始，逐渐增至500mg bid",
              "drug_interactions": "影响多种药物排泄"
            }
          },
          "combination_therapy": {
            "indications": "单药治疗无法达标",
            "combinations": [
              "Allopurinol + benzbromarone",
              "Febuxostat + benzbromarone"
            ]
          },
          "prophylaxis_during_initiation": {
            "rationale": "防止治疗初期痛风发作",
            "agents": {
              "colchicine": "0.5mg qd-bid，持续6个月",
              "low_dose_nsaid": "替代选择"
            },
            "contraindications": "严重肾功能不全"
          }
        },
        "lifestyle_management": {
          "dietary_modifications": "参见高尿酸血症治疗",
          "weight_management": "BMI控制在正常范围",
          "alcohol_limitation": "特别限制啤酒摄入",
          "hydration": "充分饮水预防肾结石"
        },
        "comorbidity_management": {
          "hypertension": "首选ACE抑制剂或ARB",
          "diabetes": "优化血糖控制",
          "dyslipidemia": "积极降脂治疗",
          "chronic_kidney_disease": "延缓肾功能恶化"
        },
        "special_situations": {
          "asymptomatic_hyperuricemia": "通常不需要药物治疗",
          "elderly_patients": "起始剂量减半，缓慢滴定",
          "renal_impairment": "药物剂量调整，避免肾毒性",
          "pregnancy": "避免大多数降尿酸药物"
        }
      },
      "monitoring": {
        "treatment_response": {
          "serum_uric_acid": {
            "frequency": "治疗开始后每2-4周",
            "target": "<300 μmol/L",
            "maintenance": "达标后每3-6个月"
          },
          "clinical_assessment": {
            "gout_attacks": "发作频率和严重程度",
            "tophi_resolution": "痛风石大小变化",
            "joint_function": "关节活动度评估"
          }
        },
        "safety_monitoring": {
          "liver_function": "治疗开始6个月内每月检查",
          "kidney_function": "每3-6个月评估",
          "complete_blood_count": "定期监测",
          "adverse_reactions": "皮疹等过敏反应"
        }
      },
      "prognosis": {
        "acute_episodes": {
          "untreated": "7-14天自行缓解",
          "treated": "24-48小时内明显改善"
        },
        "long_term_outcomes": {
          "with_ult": [
            "发作频率显著减少",
            "痛风石逐渐消退",
            "关节功能改善",
            "肾功能保护"
          ],
          "without_treatment": [
            "发作频率增加",
            "关节破坏进展",
            "痛风石形成",
            "肾功能恶化"
          ]
        },
        "prognostic_factors": {
          "good": [
            "早期诊断治疗",
            "良好依从性",
            "生活方式改善",
            "达到目标尿酸水平"
          ],
          "poor": [
            "延迟治疗",
            "治疗不规范",
            "多种合并症",
            "持续高尿酸血症"
          ]
        }
      },
      "complications": {
        "joint_complications": [
          "慢性关节炎",
          "关节破坏和畸形",
          "功能障碍",
          "继发感染"
        ],
        "renal_complications": [
          "慢性肾脏病",
          "肾结石",
          "急性肾损伤"
        ],
        "cardiovascular_complications": [
          "高血压",
          "冠心病",
          "心力衰竭"
        ]
      }
    },

    "BONE_001": {
      "id": "BONE_001",
      "name": "骨质疏松症",
      "alternate_names": [
        "原发性骨质疏松症",
        "继发性骨质疏松症",
        "Osteoporosis",
        "Primary osteoporosis",
        "Secondary osteoporosis"
      ],
      "category": "骨代谢疾病",
      "icd10": "M80.9",
      "definition": "以骨量低、骨微结构破坏、骨脆性增加、易发生骨折为特征的全身性代谢性骨病",
      "pathophysiology": {
        "bone_remodeling_imbalance": {
          "normal_remodeling": {
            "bone_formation": "成骨细胞合成骨基质",
            "bone_resorption": "破骨细胞破坏老化骨组织",
            "balance": "健康状态下形成与吸收平衡"
          },
          "osteoporosis_mechanism": {
            "increased_resorption": "破骨细胞活性增加",
            "decreased_formation": "成骨细胞功能下降",
            "net_bone_loss": "骨形成<骨吸收，净骨丢失"
          }
        },
        "hormonal_regulation": {
          "estrogen": {
            "mechanism": "抑制破骨细胞活性，促进成骨细胞功能",
            "deficiency_effects": "绝经后雌激素缺乏导致骨吸收增加",
            "rankl_opg_system": "调节RANKL/OPG比值影响骨代谢"
          },
          "parathyroid_hormone": {
            "physiologic_role": "维持血钙稳态",
            "bone_effects": "间歇性PTH促进骨形成，持续升高促进骨吸收",
            "secondary_hyperparathyroidism": "维生素D缺乏或肾功能不全引起"
          },
          "vitamin_d": {
            "calcium_absorption": "促进肠道钙吸收",
            "bone_mineralization": "必需的骨矿化因子",
            "deficiency_consequences": "继发性甲状旁腺功能亢进"
          },
          "thyroid_hormones": {
            "bone_turnover": "甲亢加速骨转换",
            "fracture_risk": "长期甲亢增加骨折风险"
          },
          "glucocorticoids": {
            "bone_formation": "抑制成骨细胞分化和功能",
            "bone_resorption": "促进破骨细胞活性",
            "iatrogenic_osteoporosis": "糖皮质激素性骨质疏松"
          },
          "growth_hormone_igf1": {
            "bone_anabolism": "刺激成骨细胞增殖和胶原合成",
            "deficiency": "GH/IGF-1缺乏导致骨密度下降"
          }
        },
        "cytokine_regulation": {
          "rank_rankl_opg": {
            "rankl": "破骨细胞分化因子",
            "opg": "骨保护素，RANKL拮抗剂",
            "ratio": "RANKL/OPG比值决定骨吸收程度"
          },
          "inflammatory_cytokines": {
            "il1_il6_tnf": "促进骨吸收的细胞因子",
            "chronic_inflammation": "慢性炎症加速骨丢失"
          }
        }
      },
      "classification": {
        "etiology_based": {
          "primary_osteoporosis": {
            "type_1": {
              "description": "绝经后骨质疏松",
              "age_group": "51-75岁女性",
              "mechanism": "雌激素缺乏",
              "predominant_site": "松质骨（椎体、桡骨远端）"
            },
            "type_2": {
              "description": "老年性骨质疏松",
              "age_group": ">70岁男女",
              "mechanism": "年龄相关的骨形成减少",
              "predominant_site": "皮质骨和松质骨"
            }
          },
          "secondary_osteoporosis": {
            "endocrine_causes": [
              "甲状腺功能亢进",
              "甲状旁腺功能亢进",
              "Cushing综合征",
              "性腺功能减退",
              "糖尿病",
              "甲状旁腺功能减退"
            ],
            "drug_induced": [
              "糖皮质激素",
              "抗癫痫药",
              "肝素",
              "芳香化酶抑制剂",
              "GnRH激动剂"
            ],
            "systemic_diseases": [
              "类风湿关节炎",
              "慢性肾病",
              "炎症性肠病",
              "慢性阻塞性肺病",
              "肝病"
            ]
          }
        },
        "severity_based": {
          "osteopenia": {
            "t_score": "-1.0到-2.5之间",
            "description": "骨量减少"
          },
          "osteoporosis": {
            "t_score": "≤-2.5",
            "description": "骨质疏松症"
          },
          "severe_osteoporosis": {
            "criteria": "骨质疏松症+脆性骨折",
            "description": "严重骨质疏松症"
          }
        }
      },
      "epidemiology": {
        "prevalence": {
          "global": "全球>2亿人患病",
          "china": {
            "overall": "中国50岁以上人群患病率约13%",
            "women": "绝经后女性患病率30-50%",
            "men": "男性患病率相对较低，约为女性1/4"
          }
        },
        "fracture_epidemiology": {
          "lifetime_risk": "50岁后终生骨折风险：女性40%，男性20%",
          "common_sites": [
            "髋部（死亡率最高）",
            "脊椎（最常见）",
            "桡骨远端",
            "肱骨近端"
          ],
          "mortality": "髋部骨折1年死亡率15-25%"
        },
        "economic_burden": {
          "medical_costs": "年医疗费用数千亿",
          "indirect_costs": "护理、失能等间接成本巨大"
        }
      },
      "risk_factors": {
        "non_modifiable": {
          "age": "最重要的危险因素",
          "gender": "女性>男性",
          "race": "白种人和亚洲人风险较高",
          "genetics": [
            "COL1A1基因多态性",
            "维生素D受体基因变异",
            "雌激素受体基因多态性"
          ],
          "family_history": "骨折家族史增加风险2倍",
          "previous_fracture": "既往脆性骨折是最强预测因子"
        },
        "potentially_modifiable": {
          "hormonal_factors": [
            "早绝经（<45岁）",
            "晚初潮（>15岁）",
            "性腺功能减退",
            "不孕或少孕"
          ],
          "lifestyle_factors": [
            "低钙摄入（<800mg/天）",
            "维生素D缺乏",
            "吸烟",
            "过量饮酒（>2单位/天）",
            "缺乏运动",
            "低体重（BMI<19）"
          ],
          "medical_conditions": [
            "类风湿关节炎",
            "炎症性肠病",
            "慢性肾病",
            "慢性阻塞性肺病",
            "恶性肿瘤"
          ],
          "medications": [
            "糖皮质激素（>3个月）",
            "抗癫痫药",
            "质子泵抑制剂",
            "噻嗪类利尿剂",
            "抗凝剂"
          ]
        }
      },
      "clinical_manifestations": {
        "asymptomatic_phase": {
          "description": "早期通常无明显症状",
          "silent_progression": "骨密度逐渐降低但无临床表现",
          "importance": "需要主动筛查才能发现"
        },
        "symptomatic_phase": {
          "bone_pain": {
            "characteristics": "慢性、钝痛，活动后加重",
            "location": "腰背部最常见",
            "mechanism": "微骨折或骨小梁断裂"
          },
          "height_loss": {
            "mechanism": "胸腰椎压缩性骨折",
            "progression": "身高逐渐降低，>4cm提示椎体骨折"
          },
          "kyphosis": {
            "description": "胸椎后凸畸形（驼背）",
            "consequence": "多个椎体压缩性骨折累积效应"
          },
          "functional_impairment": {
            "mobility": "活动能力下降",
            "balance": "平衡功能受损",
            "falls_risk": "跌倒风险增加"
          }
        },
        "fragility_fractures": {
          "definition": "轻微外伤或无外伤情况下发生的骨折",
          "vertebral_fractures": {
            "prevalence": "最常见的骨质疏松性骨折",
            "clinical_presentation": [
              "急性腰背痛",
              "身高降低",
              "后凸畸形",
              "呼吸功能受限"
            ],
            "complications": "疼痛、畸形、肺功能下降"
          },
          "hip_fractures": {
            "types": "股骨颈骨折、转子间骨折",
            "consequences": "致残率和死亡率最高",
            "recovery": "需要手术，恢复时间长"
          },
          "distal_radius_fractures": {
            "mechanism": "跌倒时手掌撑地",
            "typical_patients": "绝经后早期女性"
          }
        }
      },
      "diagnosis": {
        "clinical_assessment": {
          "history_taking": [
            "骨折史和家族史",
            "药物使用史",
            "生活方式评估",
            "内分泌疾病史",
            "消化系统疾病史"
          ],
          "physical_examination": [
            "身高和体重测量",
            "脊柱检查（后凸、压痛）",
            "肌力和平衡评估",
            "跌倒风险评估"
          ]
        },
        "bone_density_measurement": {
          "dexa_scan": {
            "gold_standard": "双能X线骨密度测定",
            "measurement_sites": "腰椎、髋部、前臂",
            "t_score": "与同性别峰值骨密度比较",
            "z_score": "与同年龄同性别比较"
          },
          "quantitative_ct": {
            "advantages": "真正的体积骨密度",
            "applications": "椎体骨密度测量",
            "limitations": "辐射剂量高，费用昂贵"
          },
          "ultrasound": {
            "sites": "跟骨、胫骨",
            "parameters": "声速（SOS）、宽带超声衰减（BUA）",
            "applications": "筛查工具，不能诊断"
          }
        },
        "biochemical_markers": {
          "bone_formation_markers": [
            "骨特异性碱性磷酸酶（BALP）",
            "骨钙蛋白（OC）",
            "I型前胶原氨基端肽（PINP）"
          ],
          "bone_resorption_markers": [
            "I型胶原羧基端肽（CTX）",
            "尿N-端中分子片段（NTX）",
            "尿吡啶啉、脱氧吡啶啉"
          ],
          "clinical_applications": [
            "治疗监测",
            "骨转换评估",
            "预后判断"
          ]
        },
        "secondary_causes_evaluation": {
          "laboratory_tests": [
            "血钙、磷、镁",
            "25-羟维生素D",
            "甲状旁腺激素（PTH）",
            "甲状腺功能",
            "性激素水平",
            "24小时尿钙",
            "肾功能",
            "肝功能",
            "炎症指标"
          ],
          "additional_tests": [
            "血清蛋白电泳（排除多发性骨髓瘤）",
            "尿本-琼蛋白",
            "皮质醇（疑似Cushing综合征）"
          ]
        },
        "imaging_evaluation": {
          "spine_xray": {
            "purpose": "检测椎体骨折",
            "findings": "椎体高度丢失、楔形变、双凹征"
          },
          "vertebral_fracture_assessment": {
            "vfa": "椎体骨折评估",
            "method": "DXA侧位脊柱成像",
            "advantages": "低辐射、快速"
          }
        }
      },
      "treatment": {
        "non_pharmacological": {
          "lifestyle_modifications": {
            "nutrition": {
              "calcium": "1000-1200mg/天",
              "vitamin_d": "800-1000IU/天",
              "protein": "1.0-1.2g/kg体重/天",
              "dietary_sources": "乳制品、绿叶蔬菜、鱼类"
            },
            "exercise": {
              "weight_bearing": "步行、慢跑、爬楼梯",
              "resistance_training": "肌肉力量训练",
              "balance_training": "太极、瑜伽防跌倒",
              "frequency": "每周3-4次，每次30-45分钟"
            },
            "fall_prevention": {
              "home_safety": "移除障碍物、增加照明",
              "vision_correction": "定期眼科检查",
              "medication_review": "避免增加跌倒风险的药物",
              "assistive_devices": "手杖、助行器的使用"
            },
            "lifestyle_changes": {
              "smoking_cessation": "戒烟",
              "alcohol_moderation": "限制酒精摄入",
              "maintain_healthy_weight": "避免低体重"
            }
          }
        },
        "pharmacological": {
          "antiresorptive_agents": {
            "bisphosphonates": {
              "mechanism": "抑制破骨细胞活性",
              "agents": [
                "阿仑膦酸钠（每周70mg）",
                "利塞膦酸钠（每周35mg）",
                "伊班膦酸钠（每月150mg）",
                "唑来膦酸（每年5mg静脉）"
              ],
              "efficacy": "降低椎体骨折50-70%，髋部骨折40-50%",
              "side_effects": [
                "上消化道刺激",
                "急性期反应（发热、肌痛）",
                "颌骨坏死（罕见）",
                "非典型股骨骨折（长期使用）"
              ],
              "contraindications": [
                "食道狭窄",
                "严重肾功能不全（GFR<30ml/min）",
                "低钙血症"
              ]
            },
            "denosumab": {
              "mechanism": "RANKL单克隆抗体",
              "dosage": "60mg皮下注射，每6个月1次",
              "efficacy": "椎体骨折68%，髋部骨折40%",
              "advantages": "不依赖肾功能清除",
              "side_effects": [
                "感染风险增加",
                "低钙血症",
                "皮肤反应",
                "颌骨坏死"
              ],
              "rebound_effect": "停药后骨丢失快速反弹"
            },
            "selective_estrogen_receptor_modulators": {
              "raloxifene": {
                "mechanism": "选择性雌激素受体调节剂",
                "dosage": "60mg/天",
                "efficacy": "椎体骨折30-50%，无髋部骨折获益",
                "additional_benefits": "降低浸润性乳腺癌风险",
                "side_effects": [
                  "静脉血栓栓塞风险增加",
                  "潮热",
                  "腿部痉挛"
                ]
              }
            }
          },
          "anabolic_agents": {
            "parathyroid_hormone_analogs": {
              "teriparatide": {
                "mechanism": "重组人甲状旁腺激素1-34",
                "dosage": "20μg/天皮下注射",
                "duration": "最长24个月",
                "efficacy": "椎体骨折65%，非椎体骨折53%",
                "indications": "严重骨质疏松，多发骨折",
                "contraindications": [
                  "恶性肿瘤病史",
                  "骨肉瘤风险",
                  "严重肾功能不全"
                ]
              },
              "abaloparatide": {
                "mechanism": "PTHrP类似物",
                "advantages": "较特立帕肽副作用更少"
              }
            },
            "sclerostin_inhibitor": {
              "romosozumab": {
                "mechanism": "sclerostin单克隆抗体",
                "dosage": "210mg皮下注射，每月1次",
                "duration": "12个月",
                "efficacy": "椎体骨折73%，髋部骨折38%",
                "cardiovascular_risk": "心血管事件风险可能增加"
              }
            }
          },
          "hormone_replacement": {
            "estrogen_therapy": {
              "indications": "绝经后早期症状明显的女性",
              "benefits": "骨密度增加，骨折风险降低",
              "risks": [
                "乳腺癌风险增加",
                "静脉血栓栓塞",
                "卒中风险",
                "冠心病风险"
              ],
              "considerations": "风险效益权衡，个体化治疗"
            },
            "testosterone_replacement": {
              "indications": "男性性腺功能减退伴骨质疏松",
              "monitoring": "前列腺安全性"
            }
          }
        },
        "combination_therapy": {
          "sequential_therapy": {
            "anabolic_first": "先使用促骨形成药物",
            "followed_by_antiresorptive": "后续抗骨吸收治疗维持"
          },
          "monitoring": {
            "bone_density": "每1-2年复查DXA",
            "biochemical_markers": "治疗3-6个月后评估",
            "safety_monitoring": "定期评估药物不良反应"
          }
        }
      },
      "complications": {
        "fracture_complications": {
          "vertebral_fractures": [
            "慢性疼痛",
            "脊柱后凸畸形",
            "身高丢失",
            "肺功能受限",
            "胃肠功能异常"
          ],
          "hip_fractures": [
            "长期卧床并发症",
            "深静脉血栓",
            "肺栓塞",
            "泌尿系感染",
            "压疮",
            "肌肉萎缩"
          ],
          "cascade_fractures": "一次骨折后后续骨折风险显著增加"
        },
        "quality_of_life": {
          "physical_function": "活动能力下降，自理能力受损",
          "psychological_impact": "抑郁、焦虑、社会退缩",
          "social_consequences": "家庭和社会负担增加"
        },
        "mortality": {
          "hip_fracture_mortality": "髋部骨折后1年死亡率15-25%",
          "vertebral_fracture_mortality": "椎体骨折死亡率增加23%",
          "excess_mortality": "骨质疏松相关超额死亡"
        }
      },
      "prevention": {
        "primary_prevention": {
          "target_population": "尚未发生骨质疏松的人群",
          "strategies": [
            "优化峰值骨量（青少年期）",
            "维持骨量（成年期）",
            "减缓骨丢失（绝经期）"
          ],
          "interventions": [
            "充足钙和维生素D摄入",
            "规律体力活动",
            "健康生活方式",
            "避免危险因素"
          ]
        },
        "secondary_prevention": {
          "target_population": "已有骨质疏松但未发生骨折",
          "goal": "预防首次骨折",
          "interventions": "药物治疗+非药物治疗"
        },
        "tertiary_prevention": {
          "target_population": "已发生脆性骨折",
          "goal": "防止后续骨折",
          "fracture_liaison_service": "骨折联络服务模式"
        }
      },
      "prognosis": {
        "factors_affecting_prognosis": [
          "年龄",
          "基线骨密度",
          "骨折史",
          "伴发疾病",
          "治疗依从性"
        ],
        "treatment_response": {
          "bone_density_improvement": "治疗1-2年骨密度增加3-8%",
          "fracture_risk_reduction": "抗骨吸收药物降低骨折风险30-70%",
          "time_to_benefit": "椎体骨折6-12个月，髋部骨折2-3年"
        },
        "long_term_outcomes": {
          "continued_treatment": "长期治疗可持续获益",
          "drug_holidays": "某些患者可考虑停药假期",
          "lifelong_monitoring": "需要终身监测和管理"
        }
      }
    },

    "BONE_002": {
      "id": "BONE_002",
      "name": "骨软化症",
      "alternate_names": [
        "软骨病",
        "维生素D缺乏性骨病",
        "Osteomalacia",
        "Rickets (in children)",
        "Adult rickets"
      ],
      "category": "骨代谢疾病",
      "icd10": "M83.9",
      "definition": "由于骨基质矿化缺陷导致的骨病，特征是骨基质正常但矿物质沉积不足",
      "pathophysiology": {
        "mineralization_defect": {
          "normal_bone_formation": "成骨细胞正常合成骨基质（类骨质）",
          "impaired_mineralization": "钙磷酸盐晶体沉积障碍",
          "accumulation_of_osteoid": "未矿化的类骨质异常增多"
        },
        "vitamin_d_metabolism": {
          "synthesis_pathway": {
            "step1": "皮肤7-脱氢胆固醇→维生素D3（阳光照射）",
            "step2": "肝脏25-羟化酶→25(OH)D3（储存形式）",
            "step3": "肾脏1α-羟化酶→1,25(OH)2D3（活性形式）"
          },
          "physiological_functions": {
            "intestinal_calcium_absorption": "促进小肠钙吸收（主要功能）",
            "phosphate_absorption": "促进磷酸盐吸收",
            "bone_mineralization": "直接促进骨矿化",
            "pth_regulation": "抑制甲状旁腺激素分泌",
            "fgf23_interaction": "与FGF23相互调节磷代谢"
          },
          "deficiency_consequences": {
            "decreased_calcium_absorption": "肠道钙吸收减少",
            "secondary_hyperparathyroidism": "继发性甲状旁腺功能亢进",
            "phosphate_wasting": "肾脏磷酸盐丢失增加",
            "mineralization_failure": "骨和牙齿矿化障碍"
          }
        },
        "calcium_phosphate_homeostasis": {
          "normal_mineral_balance": {
            "serum_calcium": "2.20-2.60mmol/L",
            "serum_phosphate": "0.85-1.45mmol/L",
            "calcium_phosphate_product": "正常时>40"
          },
          "disturbed_homeostasis": {
            "low_serum_calcium": "维生素D缺乏导致低钙血症",
            "low_serum_phosphate": "继发性甲状旁腺功能亢进导致磷酸盐流失",
            "inadequate_mineral_product": "钙磷乘积不足以支持矿化"
          }
        },
        "bone_matrix_abnormalities": {
          "osteoid_accumulation": {
            "mechanism": "类骨质合成正常但矿化延迟",
            "histological_features": "类骨质厚度增加，矿化滞后时间延长",
            "osteoid_volume": "正常<5%，骨软化症>12%"
          },
          "pseudofractures": {
            "looser_zones": "Looser假性骨折线",
            "locations": "肋骨、骨盆、股骨内侧皮质",
            "mechanism": "重复微损伤和修复不良"
          }
        }
      },
      "etiology": {
        "vitamin_d_deficiency": {
          "inadequate_sunlight_exposure": [
            "室内工作人群",
            "高纬度地区居民",
            "宗教文化因素（全身覆盖）",
            "空气污染严重地区"
          ],
          "dietary_insufficiency": [
            "素食主义者",
            "乳糖不耐受",
            "饮食结构单一",
            "食物维生素D含量低"
          ],
          "malabsorption": [
            "脂肪泻",
            "炎症性肠病",
            "胃切除术后",
            "胰腺功能不全",
            "胆汁酸合成障碍"
          ]
        },
        "vitamin_d_metabolism_disorders": {
          "1alpha_hydroxylase_deficiency": {
            "genetic_defect": "CYP27B1基因突变",
            "clinical_name": "维生素D依赖性佝偻病I型",
            "biochemical_profile": "25(OH)D正常，1,25(OH)2D低"
          },
          "vitamin_d_receptor_defects": {
            "genetic_defect": "VDR基因突变",
            "clinical_name": "维生素D依赖性佝偻病II型",
            "biochemical_profile": "1,25(OH)2D高，组织抵抗"
          },
          "24_hydroxylase_mutations": {
            "genetic_defect": "CYP24A1基因突变",
            "consequence": "维生素D分解减少，中毒易感性"
          }
        },
        "phosphate_depletion": {
          "hereditary_hypophosphatemic_rickets": {
            "x_linked": "PHEX基因突变（最常见）",
            "autosomal_dominant": "FGF23基因突变",
            "autosomal_recessive": "DMP1或ENPP1基因突变",
            "mechanism": "FGF23过度表达导致肾脏磷酸盐丢失"
          },
          "tumor_induced_osteomalacia": {
            "mechanism": "肿瘤分泌FGF23类似物质",
            "tumor_types": "间叶性肿瘤、前列腺癌、肺癌",
            "clinical_course": "肿瘤切除后快速恢复"
          },
          "drug_induced": [
            "磷酸结合剂过量",
            "抗癫痫药物",
            "铁剂螯合剂",
            "双膦酸盐（大剂量）"
          ]
        },
        "renal_tubular_disorders": {
          "fanconi_syndrome": "近端肾小管功能全面异常",
          "distal_renal_tubular_acidosis": "远端肾小管酸化功能缺陷",
          "chronic_kidney_disease": "肾脏1α-羟化酶活性下降"
        },
        "matrix_disorders": {
          "hypophosphatasia": {
            "enzyme_defect": "组织非特异性碱性磷酸酶缺陷",
            "clinical_spectrum": "从致命性到轻微骨病",
            "biochemical_marker": "血清碱性磷酸酶低，尿磷酸乙醇胺高"
          },
          "fibrogenesis_imperfecta_ossium": "罕见的骨基质异常疾病"
        }
      },
      "clinical_manifestations": {
        "adult_presentation": {
          "bone_pain": {
            "characteristics": "弥漫性、深部钝痛",
            "distribution": "腰背部、髋部、胸部最常见",
            "aggravating_factors": "活动、负重",
            "pattern": "对称性分布"
          },
          "muscle_weakness": {
            "pattern": "近端肌群受累为主",
            "manifestations": [
              "上楼困难",
              "从坐位站起困难",
              "举臂无力",
              "步态摇摆"
            ],
            "mechanism": "维生素D缺乏直接影响肌肉功能"
          },
          "skeletal_deformities": {
            "spinal_deformity": "脊柱侧弯、后凸",
            "chest_deformity": "漏斗胸、鸡胸",
            "limb_deformity": "下肢弯曲变形",
            "pelvic_deformity": "骨盆狭窄（影响分娩）"
          },
          "fractures": {
            "types": "病理性骨折",
            "common_sites": "脊椎、髋部、前臂",
            "healing": "骨折愈合延迟"
          }
        },
        "pediatric_presentation": {
          "growth_retardation": "身高和体重增长迟缓",
          "dental_problems": [
            "牙齿萌出延迟",
            "牙釉质缺陷",
            "龋齿多发",
            "牙齿松动"
          ],
          "cranial_changes": {
            "craniotabes": "颅骨软化",
            "delayed_fontanelle_closure": "囟门闭合延迟",
            "frontal_bossing": "前额突出"
          },
          "thoracic_deformity": {
            "rachitic_rosary": "佝偻病串珠（肋软骨交界处膨大）",
            "harrison_groove": "横行胸沟",
            "pectus_deformity": "鸡胸或漏斗胸"
          },
          "limb_deformities": {
            "genu_valgum": "膝外翻（X型腿）",
            "genu_varum": "膝内翻（O型腿）",
            "coxa_vara": "髋内翻",
            "delayed_walking": "行走延迟"
          }
        },
        "systemic_manifestations": {
          "hypocalcemic_symptoms": [
            "手足搐搦症",
            "肌肉痉挛",
            "感觉异常",
            "癫痫发作"
          ],
          "secondary_hyperparathyroidism": [
            "骨痛加重",
            "尿路结石",
            "肾功能损害",
            "高血压"
          ],
          "immune_dysfunction": [
            "感染易感性增加",
            "自身免疫疾病风险",
            "疫苗应答减弱"
          ]
        }
      },
      "diagnosis": {
        "clinical_assessment": {
          "history": [
            "膳食习惯评估",
            "阳光照射史",
            "药物使用史",
            "消化系统疾病史",
            "肾脏疾病史",
            "家族史"
          ],
          "physical_examination": [
            "骨骼系统检查",
            "肌力评估",
            "神经系统检查",
            "Chvostek征和Trousseau征"
          ]
        },
        "biochemical_markers": {
          "vitamin_d_status": {
            "25_oh_d": {
              "test": "血清25-羟维生素D",
              "deficiency": "<20ng/mL (50nmol/L)",
              "insufficiency": "20-30ng/mL (50-75nmol/L)",
              "sufficiency": ">30ng/mL (75nmol/L)"
            },
            "1_25_oh2_d": {
              "test": "血清1,25-二羟维生素D",
              "normal_range": "20-60pg/mL",
              "clinical_utility": "评估肾脏1α-羟化酶功能"
            }
          },
          "mineral_metabolism": {
            "serum_calcium": {
              "typical_finding": "正常或轻度降低",
              "severe_deficiency": "明显低钙血症"
            },
            "serum_phosphate": {
              "pattern": "通常降低",
              "mechanism": "继发性甲状旁腺功能亢进"
            },
            "parathyroid_hormone": {
              "finding": "显著升高",
              "range": "正常值的2-10倍"
            },
            "alkaline_phosphatase": {
              "pattern": "升高（骨型ALP）",
              "significance": "反映骨转换增加"
            }
          },
          "bone_turnover_markers": {
            "formation_markers": [
              "骨特异性碱性磷酸酶升高",
              "骨钙蛋白升高",
              "PINP升高"
            ],
            "resorption_markers": [
              "CTX升高",
              "NTX升高"
            ]
          },
          "urinary_markers": {
            "24h_urine_calcium": "通常降低",
            "24h_urine_phosphate": "继发性甲状旁腺功能亢进时增加",
            "tubular_reabsorption_phosphate": "降低"
          }
        },
        "imaging_studies": {
          "conventional_radiography": {
            "characteristic_findings": [
              "骨密度普遍降低",
              "皮质骨变薄",
              "小梁骨稀疏",
              "Looser假性骨折线"
            ],
            "looser_zones": {
              "definition": "对称性透明带，垂直于骨皮质",
              "common_sites": [
                "股骨内侧颈部",
                "耻骨支",
                "肋骨",
                "肩胛骨内缘"
              ],
              "pathognomonic": "骨软化症的特征性表现"
            },
            "pediatric_findings": [
              "骨骺钙化延迟",
              "干骺端杯状变形",
              "骨干弯曲变形",
              "颅骨软化"
            ]
          },
          "bone_densitometry": {
            "dexa_findings": "骨密度显著降低",
            "pattern": "全身性骨密度减少",
            "monitoring": "治疗效果评估"
          },
          "advanced_imaging": {
            "bone_scintigraphy": {
              "pattern": "多发性骨痛区域摄取增加",
              "pseudofracture_sites": "Looser带区域异常摄取"
            },
            "mri_findings": [
              "骨髓水肿",
              "应力性改变",
              "肌肉信号异常"
            ]
          }
        },
        "bone_biopsy": {
          "indications": [
            "诊断不明确时",
            "疑似其他骨病",
            "治疗反应差",
            "研究目的"
          ],
          "histological_features": {
            "increased_osteoid": "类骨质体积>12%",
            "delayed_mineralization": "矿化滞后时间>100天",
            "osteoid_thickness": "类骨质厚度增加",
            "mineralization_front": "矿化前沿稀少"
          },
          "technique": "经皮髂骨活检（双标记技术）"
        },
        "differential_diagnosis": {
          "osteoporosis": {
            "distinguishing_features": "骨软化症有假性骨折线和肌肉症状",
            "biochemical_differences": "骨软化症PTH明显升高，25(OH)D缺乏"
          },
          "hyperparathyroidism": {
            "primary_hpt": "骨软化症PTH升高是继发性的",
            "calcium_levels": "原发性甲状旁腺功能亢进血钙升高"
          },
          "malignancy": {
            "metastatic_bone_disease": "影像学和病史可鉴别",
            "multiple_myeloma": "血清蛋白电泳、骨髓检查"
          }
        }
      },
      "treatment": {
        "vitamin_d_replacement": {
          "vitamin_d3_cholecalciferol": {
            "standard_dose": "1000-4000IU/天（维持）",
            "loading_dose": "50000IU/周，持续8-12周（严重缺乏）",
            "high_dose": "10000-50000IU/天（严重骨软化症）",
            "duration": "通常需要终身补充"
          },
          "vitamin_d2_ergocalciferol": {
            "equivalency": "与维生素D3基本等效",
            "dosing": "类似维生素D3方案",
            "preference": "维生素D3更优（生物利用度更好）"
          },
          "active_metabolites": {
            "calcitriol": {
              "indications": [
                "严重肾功能不全",
                "1α-羟化酶缺陷",
                "急需快速纠正低钙血症"
              ],
              "dosing": "0.25-2.0μg/天",
              "monitoring": "密切监测血钙避免中毒"
            },
            "alfacalcidol": {
              "mechanism": "1α-羟维生素D3，需肝脏25-羟化",
              "dosing": "0.5-3.0μg/天",
              "advantages": "较calcitriol作用温和持久"
            }
          }
        },
        "mineral_supplementation": {
          "calcium_supplementation": {
            "elemental_calcium": "1000-1500mg/天",
            "forms": [
              "碳酸钙（含钙40%）",
              "柠檬酸钙（含钙21%，吸收更好）",
              "醋酸钙（含钙25%）"
            ],
            "timing": "分次服用，餐时或餐后",
            "monitoring": "避免过量导致结石"
          },
          "phosphate_supplementation": {
            "indications": "遗传性低磷血症性佝偻病",
            "forms": [
              "磷酸钠",
              "磷酸钾",
              "中性磷酸盐"
            ],
            "dosing": "30-60mg/kg/天（分3-4次）",
            "side_effects": [
              "腹泻",
              "腹痛",
              "恶心",
              "继发性甲状旁腺功能亢进"
            ]
          }
        },
        "specific_therapies": {
          "hereditary_rickets": {
            "xlh_treatment": {
              "conventional": "磷酸盐+活性维生素D",
              "burosumab": {
                "mechanism": "FGF23单克隆抗体",
                "dosing": "0.8-1.2mg/kg皮下注射，每2周一次",
                "efficacy": "显著改善磷酸盐水平和骨病变",
                "monitoring": "肾功能、甲状旁腺功能"
              }
            },
            "vddr1_treatment": {
              "calcitriol": "0.5-2.0μg/天",
              "calcium": "1000-1500mg/天",
              "response": "通常反应良好"
            },
            "vddr2_treatment": {
              "high_dose_calcitriol": "5-30μg/天",
              "intravenous_calcium": "重症患者需要静脉补钙",
              "prognosis": "部分患者对治疗抵抗"
            }
          },
          "tumor_induced_osteomalacia": {
            "tumor_localization": [
              "全身PET-CT扫描",
              "奥曲肽扫描",
              "静脉取样检测FGF23"
            ],
            "surgical_treatment": "完整肿瘤切除",
            "medical_management": "手术前或不能手术时磷酸盐补充"
          }
        },
        "supportive_care": {
          "physical_therapy": {
            "objectives": [
              "改善肌力",
              "增加关节活动度",
              "防止跌倒",
              "矫正姿势"
            ],
            "exercise_program": [
              "水中运动（减少关节负荷）",
              "等长肌力训练",
              "平衡训练",
              "柔韧性练习"
            ]
          },
          "orthopedic_intervention": {
            "indications": [
              "严重骨骼畸形",
              "病理性骨折",
              "关节功能障碍"
            ],
            "procedures": [
              "截骨矫正术",
              "内固定治疗",
              "关节置换术"
            ],
            "timing": "通常在生化指标纠正后进行"
          },
          "dietary_counseling": {
            "vitamin_d_rich_foods": [
              "富脂鱼类（鲑鱼、鲭鱼）",
              "强化乳制品",
              "蛋黄",
              "强化谷物"
            ],
            "calcium_rich_foods": [
              "乳制品",
              "绿叶蔬菜",
              "坚果和种子",
              "豆制品"
            ]
          }
        }
      },
      "monitoring": {
        "biochemical_monitoring": {
          "frequency": "治疗前3个月每月检查，稳定后每3-6个月",
          "parameters": [
            "血清钙",
            "血清磷",
            "甲状旁腺激素",
            "25-羟维生素D",
            "碱性磷酸酶",
            "24小时尿钙"
          ],
          "target_levels": {
            "25_oh_d": ">30ng/mL (75nmol/L)",
            "pth": "恢复正常范围",
            "serum_calcium": "正常范围",
            "urine_calcium": "<4mg/kg/天"
          }
        },
        "clinical_monitoring": {
          "symptoms": "骨痛、肌力、行走能力改善",
          "imaging": "每6-12个月骨密度检查，必要时X线复查",
          "complications": "监测维生素D中毒、肾结石、肾功能"
        },
        "treatment_response": {
          "early_response": "2-4周内症状开始改善",
          "biochemical_normalization": "3-6个月内PTH和ALP开始下降",
          "radiological_healing": "6-12个月假性骨折线愈合",
          "complete_recovery": "1-2年骨密度显著改善"
        }
      },
      "prognosis": {
        "factors_affecting_outcome": [
          "诊断和治疗及时性",
          "维生素D缺乏严重程度",
          "患者年龄和依从性",
          "潜在病因是否可纠正"
        ],
        "treatment_response": {
          "nutritional_osteomalacia": "治疗反应通常很好",
          "genetic_forms": "需要终身治疗，预后变异较大",
          "tumor_induced": "肿瘤切除后可完全恢复"
        },
        "complications": {
          "untreated_consequences": [
            "进行性骨骼畸形",
            "病理性骨折",
            "肌无力和功能障碍",
            "生长发育迟缓（儿童）"
          ],
          "treatment_complications": [
            "维生素D中毒",
            "高钙血症",
            "肾结石",
            "肾功能损害"
          ]
        }
      }
    },

    "BONE_003": {
      "id": "BONE_003", 
      "name": "甲状旁腺性骨病",
      "alternate_names": [
        "甲状旁腺功能亢进性骨病",
        "纤维囊性骨炎",
        "褐色瘤",
        "Hyperparathyroid bone disease",
        "Osteitis fibrosa cystica",
        "Brown tumor"
      ],
      "category": "骨代谢疾病",
      "icd10": "E21.0",
      "definition": "由甲状旁腺激素过多分泌引起的骨代谢异常，特征是骨吸收增加、纤维组织增生和囊性病变",
      "pathophysiology": {
        "parathyroid_hormone_effects": {
          "bone_remodeling": {
            "increased_osteoclast_activity": "PTH直接和间接激活破骨细胞",
            "rankl_opg_system": "PTH上调RANKL表达，下调OPG",
            "bone_resorption": "骨吸收显著增加，超过骨形成"
          },
          "calcium_homeostasis": {
            "bone_calcium_mobilization": "从骨骼释放钙入血",
            "renal_calcium_reabsorption": "肾小管钙重吸收增加",
            "intestinal_absorption": "通过促进1,25(OH)2D3合成间接促进肠道钙吸收"
          },
          "phosphate_metabolism": {
            "renal_phosphate_wasting": "抑制近端肾小管磷重吸收",
            "hypophosphatemia": "血磷降低",
            "fgf23_interaction": "与FGF23相互作用调节磷代谢"
          }
        },
        "bone_histological_changes": {
          "osteitis_fibrosa": {
            "mechanism": "过度骨吸收后纤维组织填充",
            "microscopy": "骨小梁减少，纤维组织增生，破骨细胞增多",
            "severity_grading": "轻度→中度→重度纤维囊性骨炎"
          },
          "brown_tumors": {
            "pathogenesis": "局灶性骨吸收和出血形成含铁血黄素沉积",
            "locations": "颌骨、肋骨、骨盆、长骨最常见",
            "histology": "巨细胞、纤维组织、含铁血黄素"
          },
          "subperiosteal_resorption": {
            "definition": "骨膜下皮质骨吸收",
            "classic_sites": "指骨桡侧、锁骨远端、骶髂关节",
            "radiologic_appearance": "虫蚀样改变"
          }
        },
        "systemic_effects": {
          "hypercalcemia_consequences": [
            "神经肌肉症状",
            "肾脏损害",
            "胃肠道症状",
            "心血管影响"
          ],
          "bone_fragility": {
            "cortical_thinning": "皮质骨变薄",
            "trabecular_loss": "小梁骨丢失",
            "fracture_risk": "病理性骨折风险增加"
          }
        }
      },
      "etiology": {
        "primary_hyperparathyroidism": {
          "parathyroid_adenoma": {
            "prevalence": "80-85%的原发性甲状旁腺功能亢进",
            "characteristics": "单个腺体良性肿瘤",
            "pth_secretion": "自主性PTH分泌"
          },
          "parathyroid_hyperplasia": {
            "prevalence": "15%",
            "types": [
              "弥漫性四腺体增生",
              "结节性增生",
              "不均匀增生"
            ],
            "genetic_associations": [
              "MEN1综合征",
              "MEN2A综合征", 
              "家族性低钙尿性高钙血症"
            ]
          },
          "parathyroid_carcinoma": {
            "prevalence": "<1%",
            "characteristics": "恶性肿瘤，PTH极度升高",
            "clinical_features": "严重高钙血症，骨病变显著"
          },
          "multiple_adenomas": {
            "prevalence": "2-5%",
            "challenge": "术中识别所有病变腺体"
          }
        },
        "secondary_hyperparathyroidism": {
          "chronic_kidney_disease": {
            "mechanism": [
              "1α-羟化酶活性下降",
              "磷潴留",
              "钙吸收减少",
              "代谢性酸中毒"
            ],
            "stages": "CKD 3期开始出现PTH升高",
            "bone_disease": "肾性骨病（ROD）"
          },
          "vitamin_d_deficiency": {
            "mechanism": "肠道钙吸收减少触发PTH分泌",
            "bone_effects": "与骨软化症并存",
            "reversibility": "维生素D补充可逆转"
          },
          "malabsorption_syndromes": [
            "炎症性肠病",
            "胃肠道手术后",
            "胰腺功能不全",
            "乳糜泻"
          ],
          "medications": [
            "双膦酸盐过量",
            "去氟骨化醇",
            "磷酸结合剂过量"
          ]
        },
        "tertiary_hyperparathyroidism": {
          "definition": "继发性甲状旁腺功能亢进基础上腺体自主化",
          "common_setting": "慢性肾病透析患者",
          "characteristics": "PTH分泌不受血钙调节",
          "treatment": "通常需要外科干预"
        }
      },
      "clinical_manifestations": {
        "bone_symptoms": {
          "bone_pain": {
            "characteristics": "弥漫性骨痛，活动时加重",
            "distribution": "脊柱、骨盆、四肢长骨",
            "severity": "与PTH水平和病程相关"
          },
          "pathological_fractures": {
            "common_sites": [
              "椎体压缩骨折",
              "髋部骨折",
              "前臂骨折",
              "肋骨骨折"
            ],
            "healing": "骨折愈合可能延迟",
            "prevention": "及时治疗甲状旁腺功能亢进"
          },
          "joint_symptoms": {
            "arthralgia": "关节疼痛",
            "chondrocalcinosis": "软骨钙化症（假痛风）",
            "gout": "继发性痛风（高钙抑制尿酸排泄）"
          }
        },
        "brown_tumor_manifestations": {
          "locations_and_symptoms": {
            "maxillofacial": {
              "sites": "颌骨、上颌窦",
              "symptoms": "面部肿胀、牙齿松动、咀嚼困难"
            },
            "extremities": {
              "sites": "股骨、胫骨、桡骨",
              "symptoms": "局部肿胀、疼痛、功能障碍"
            },
            "axial_skeleton": {
              "sites": "脊椎、肋骨、骨盆",
              "symptoms": "背痛、胸痛、神经压迫症状"
            }
          },
          "differential_diagnosis": [
            "原发性骨肿瘤",
            "转移性骨病",
            "感染性骨病",
            "血管瘤"
          ]
        },
        "systemic_manifestations": {
          "hypercalcemia_symptoms": {
            "neuropsychiatric": [
              "抑郁、焦虑",
              "记忆力减退",
              "人格改变", 
              "意识模糊",
              "昏迷（严重时）"
            ],
            "neuromuscular": [
              "肌无力",
              "疲乏",
              "肌肉萎缩",
              "反射减弱"
            ],
            "gastrointestinal": [
              "食欲不振",
              "恶心呕吐",
              "便秘",
              "腹痛",
              "消化性溃疡"
            ],
            "cardiovascular": [
              "心律失常",
              "QT间期缩短",
              "高血压",
              "心肌收缩力增强"
            ],
            "renal": [
              "多尿、烦渴",
              "肾结石",
              "肾功能不全",
              "肾钙化"
            ]
          }
        },
        "laboratory_abnormalities": {
          "calcium_elevation": "血钙>2.65mmol/L",
          "phosphate_decrease": "血磷通常降低",
          "pth_elevation": "PTH显著升高",
          "alkaline_phosphatase": "反映骨转换增加"
        }
      },
      "diagnosis": {
        "biochemical_diagnosis": {
          "primary_tests": {
            "serum_calcium": {
              "measurement": "总钙或离子钙",
              "correction": "按白蛋白水平校正",
              "elevation": "持续性高钙血症"
            },
            "parathyroid_hormone": {
              "assay": "完整PTH（iPTH）",
              "interpretation": "高钙血症时PTH不抑制或升高",
              "normal_reference": "根据实验室参考值"
            },
            "serum_phosphate": {
              "pattern": "通常降低或正常低值",
              "mechanism": "PTH促进肾脏磷排泄"
            },
            "25_hydroxyvitamin_d": {
              "importance": "排除维生素D缺乏",
              "target_level": ">75nmol/L (30ng/mL)"
            }
          },
          "additional_tests": {
            "24h_urine_calcium": {
              "purpose": "鉴别FHH与原发性甲状旁腺功能亢进",
              "calcium_creatinine_clearance_ratio": "FHH时<0.01"
            },
            "bone_turnover_markers": {
              "formation_markers": "PINP、骨钙蛋白升高",
              "resorption_markers": "CTX、NTX升高"
            }
          }
        },
        "imaging_studies": {
          "bone_imaging": {
            "conventional_radiography": {
              "classic_findings": [
                "骨膜下皮质骨吸收",
                "褐色瘤",
                "普遍性骨质疏松",
                "病理性骨折"
              ],
              "specific_sites": [
                "手指骨桡侧面",
                "锁骨远端",
                "骶髂关节",
                "牙槽骨"
              ]
            },
            "bone_densitometry": {
              "pattern": "皮质骨丢失>松质骨",
              "sites": "前臂（1/3桡骨）最明显",
              "monitoring": "治疗后骨密度改善"
            },
            "bone_scintigraphy": {
              "findings": "弥漫性摄取增加",
              "brown_tumors": "局灶性摄取增加",
              "superscan": "严重病例可见"
            }
          },
          "parathyroid_localization": {
            "indications": "确诊后术前定位",
            "ultrasound": {
              "sensitivity": "腺瘤80-90%，增生较低",
              "operator_dependent": "操作者依赖性强",
              "limitations": "胸骨后病变难以显示"
            },
            "sestamibi_scan": {
              "mechanism": "甲状旁腺细胞线粒体摄取",
              "sensitivity": "单腺体病变>80%",
              "limitations": "多腺体病变敏感性降低"
            },
            "4d_ct": {
              "advantages": "高分辨率，多期扫描",
              "sensitivity": "90%以上",
              "radiation": "辐射暴露相对高"
            },
            "mri": {
              "indications": "其他检查阴性时",
              "advantages": "无辐射，软组织对比好"
            }
          }
        },
        "genetic_testing": {
          "indications": [
            "年龄<40岁",
            "多腺体病变",
            "家族史阳性",
            "伴发其他内分泌肿瘤"
          ],
          "genes_to_test": [
            "MEN1基因",
            "RET基因（MEN2）",
            "CASR基因（FHH）",
            "CDKN1B基因（MEN4）"
          ]
        },
        "differential_diagnosis": {
          "other_causes_hypercalcemia": [
            "恶性肿瘤（PTHrP分泌）",
            "肉芽肿性疾病",
            "维生素D中毒",
            "甲状腺功能亢进",
            "制动综合征",
            "药物引起"
          ],
          "familial_hypocalciuric_hypercalcemia": {
            "key_differences": [
              "尿钙排泄低",
              "家族史",
              "症状轻微",
              "CASR基因突变"
            ]
          }
        }
      },
      "treatment": {
        "surgical_treatment": {
          "indications": {
            "absolute": [
              "症状性高钙血症",
              "血钙>2.85mmol/L",
              "年龄<50岁",
              "肾结石病史",
              "T评分<-2.5",
              "eGFR<60ml/min"
            ],
            "relative": [
              "无法长期随访",
              "患者要求手术",
              "高钙尿症"
            ]
          },
          "surgical_approaches": {
            "minimally_invasive_parathyroidectomy": {
              "requirements": [
                "单腺体病变",
                "术前成功定位",
                "术中PTH监测"
              ],
              "advantages": "创伤小、恢复快、美容效果好"
            },
            "bilateral_neck_exploration": {
              "indications": [
                "多腺体病变",
                "术前定位失败",
                "家族性疾病",
                "再次手术"
              ],
              "procedure": "四腺体探查"
            },
            "parathyroid_hyperplasia_surgery": {
              "subtotal_parathyroidectomy": "保留部分最正常腺体",
              "total_parathyroidectomy_with_autotransplant": "全切除后前臂移植"
            }
          },
          "intraoperative_monitoring": {
            "pth_monitoring": {
              "timing": "切除病变腺体后10-15分钟",
              "success_criteria": "PTH下降>50%或至正常范围",
              "miami_criterion": "最常用标准"
            },
            "frozen_section": "必要时病理冷冻切片"
          },
          "complications": {
            "temporary_complications": [
              "暂时性低钙血症",
              "暂时性声嘶",
              "血肿"
            ],
            "permanent_complications": [
              "永久性甲状旁腺功能减退症",
              "永久性声带麻痹",
              "甲状腺功能减退"
            ],
            "prevention": "经验丰富的外科医生、术中神经监测"
          }
        },
        "medical_treatment": {
          "perioperative_management": {
            "severe_hypercalcemia": {
              "fluid_resuscitation": "生理盐水扩容",
              "loop_diuretics": "呋塞米促进钙排泄",
              "bisphosphonates": "唑来膦酸等抑制骨吸收",
              "calcitonin": "快速降钙作用"
            },
            "preoperative_preparation": {
              "calcium_normalization": "术前尽可能纠正高钙血症",
              "vitamin_d_repletion": "补充维生素D至充足水平",
              "cardiac_evaluation": "评估心血管风险"
            }
          },
          "non_surgical_candidates": {
            "calcimimetics": {
              "cinacalcet": {
                "mechanism": "钙敏感受体激动剂",
                "dosing": "30-180mg/天",
                "effects": "降低PTH和血钙",
                "side_effects": "恶心、呕吐、低钙血症"
              },
              "etelcalcetide": {
                "indication": "透析患者继发性甲状旁腺功能亢进",
                "administration": "透析时静脉给药"
              }
            },
            "bisphosphonates": {
              "mechanism": "抑制破骨细胞活性",
              "agents": "阿仑膦酸、唑来膦酸等",
              "effects": "改善骨密度，不影响PTH",
              "monitoring": "肾功能、颌骨坏死风险"
            }
          },
          "chronic_kidney_disease": {
            "phosphate_binders": "控制血磷水平",
            "active_vitamin_d": "骨化三醇、帕立骨化醇",
            "calcimimetics": "西那卡塞降低PTH",
            "parathyroidectomy": "药物治疗失败时"
          }
        },
        "postoperative_management": {
          "calcium_monitoring": {
            "frequency": "术后6小时开始，每6小时",
            "duration": "至少48小时",
            "target": "维持血钙正常下限"
          },
          "hypocalcemia_management": {
            "oral_calcium": "碳酸钙1-2g每4小时",
            "calcitriol": "0.25-0.5μg每12小时",
            "intravenous_calcium": "症状性低钙血症时"
          },
          "hungry_bone_syndrome": {
            "definition": "术后骨骼快速再矿化导致严重低钙血症",
            "risk_factors": "术前严重骨病、高PTH、高ALP",
            "management": "大量钙剂和活性维生素D补充"
          }
        }
      },
      "monitoring": {
        "postoperative_monitoring": {
          "short_term": {
            "parameters": [
              "血清钙",
              "血清磷",
              "PTH",
              "症状评估"
            ],
            "frequency": "1周、1个月、3个月、6个月",
            "success_criteria": "血钙正常，PTH正常或适当抑制"
          },
          "long_term": {
            "bone_density": "术后1年复查，之后每1-2年",
            "renal_function": "年度评估",
            "cardiovascular_risk": "血压、血脂监测"
          }
        },
        "non_surgical_monitoring": {
          "frequency": "每3-6个月",
          "parameters": [
            "血清钙",
            "肾功能",
            "骨密度（年度）",
            "肾结石筛查",
            "症状评估"
          ],
          "intervention_triggers": [
            "血钙进一步升高",
            "出现症状",
            "骨密度显著下降",
            "肾功能恶化"
          ]
        }
      },
      "prognosis": {
        "surgical_outcomes": {
          "cure_rates": {
            "single_adenoma": "95-99%",
            "multiple_adenomas": "90-95%",
            "hyperplasia": "85-90%"
          },
          "bone_recovery": {
            "timeline": "术后6-12个月开始",
            "extent": "T评分改善1-2个标准差",
            "factors": "年龄、术前骨病严重程度"
          },
          "symptom_improvement": {
            "bone_pain": "数周内开始缓解",
            "neuromuscular": "数月内显著改善",
            "nephrolithiasis": "复发风险显著降低",
            "neuropsychiatric": "改善变异大"
          }
        },
        "brown_tumor_resolution": {
          "timeline": "术后6个月-2年",
          "mechanism": "PTH正常后骨重塑恢复",
          "monitoring": "影像学随访评估"
        },
        "complications_and_recurrence": {
          "recurrence_rate": "<5%（单腺体病变）",
          "risk_factors": [
            "多腺体病变",
            "家族性疾病",
            "不完全切除",
            "异位甲状旁腺"
          ],
          "long_term_monitoring": "终身随访"
        },
        "quality_of_life": {
          "improvement_areas": [
            "骨痛缓解",
            "体力活动能力",
            "精神状态",
            "社会功能"
          ],
          "persistent_issues": [
            "部分神经精神症状可能持续",
            "严重骨病变可能不完全恢复"
          ]
        }
      }
    },

    "NUTRI_001": {
        "id": "NUTRI_001",
        "name": "肥胖症",
        "category": "营养代谢疾病",
        "icd10": "E66.9",
        "definition": "由于能量摄入超过能量消耗，导致体内脂肪积聚过多而引起的慢性代谢性疾病",
        "pathophysiology": {
            "energy_balance": {
                "mechanism": "长期能量正平衡导致脂肪组织堆积",
                "contributing_factors": ["遗传因素", "环境因素", "行为因素", "代谢因素"],
                "adipocyte_dysfunction": "脂肪细胞增大和增多，分泌功能紊乱"
            },
            "hormonal_dysregulation": {
                "leptin_resistance": "瘦素抵抗导致饱腹感减弱",
                "insulin_resistance": "胰岛素抵抗促进脂肪合成",
                "cortisol": "皮质醇分泌异常影响脂肪分布",
                "growth_hormone": "生长激素分泌减少影响脂肪代谢"
            },
            "inflammatory_response": {
                "adipokines": "脂肪因子分泌失调",
                "chronic_inflammation": "慢性低级炎症状态",
                "immune_dysfunction": "免疫功能异常"
            }
        },
        "clinical_features": {
            "anthropometric_measurements": {
                "bmi": "体质指数≥30 kg/m²（亚洲人≥25 kg/m²）",
                "waist_circumference": "腹围：男性≥90cm，女性≥80cm",
                "body_fat_percentage": "体脂率：男性≥25%，女性≥35%"
            },
            "metabolic_complications": {
                "insulin_resistance": "胰岛素抵抗和高胰岛素血症",
                "dyslipidemia": "血脂异常：高TG、低HDL-C",
                "hypertension": "高血压发病率增加",
                "fatty_liver": "非酒精性脂肪肝"
            },
            "physical_symptoms": {
                "respiratory": "睡眠呼吸暂停综合征",
                "musculoskeletal": "关节负荷增加，活动受限",
                "dermatological": "皮肤皱褶处感染，黑棘皮症",
                "cardiovascular": "心脏负荷增加"
            }
        },
        "diagnostic_criteria": {
            "primary_criteria": {
                "bmi_asian": "≥25 kg/m² (亚洲标准)",
                "bmi_who": "≥30 kg/m² (WHO标准)",
                "waist_hip_ratio": "男性>0.9，女性>0.85"
            },
            "classification": {
                "overweight": "BMI 25-29.9 kg/m²",
                "obesity_class_I": "BMI 30-34.9 kg/m²",
                "obesity_class_II": "BMI 35-39.9 kg/m²",
                "obesity_class_III": "BMI ≥40 kg/m²"
            }
        },
        "laboratory_findings": {
            "metabolic_parameters": {
                "fasting_glucose": "空腹血糖可能升高",
                "hba1c": "糖化血红蛋白可能异常",
                "insulin": "空腹胰岛素和胰岛素抵抗指数升高",
                "lipid_profile": "甘油三酯升高，HDL-C降低"
            },
            "inflammatory_markers": {
                "crp": "C反应蛋白升高",
                "il6": "白介素-6水平升高",
                "tnf_alpha": "肿瘤坏死因子-α升高"
            },
            "hormonal_assessment": {
                "leptin": "血清瘦素水平升高",
                "adiponectin": "脂联素水平降低",
                "cortisol": "皮质醇节律可能异常"
            }
        },
        "treatment_approach": {
            "lifestyle_modification": {
                "dietary_intervention": "低热量饮食，营养均衡",
                "physical_activity": "有氧运动+阻抗训练",
                "behavioral_therapy": "认知行为治疗，生活方式指导"
            },
            "pharmacological_treatment": {
                "orlistat": "脂肪酶抑制剂",
                "liraglutide": "GLP-1受体激动剂",
                "phentermine_topiramate": "食欲抑制剂组合"
            },
            "surgical_options": {
                "bariatric_surgery": "减重手术：胃旁路、袖状胃切除",
                "indications": "BMI≥40或BMI≥35伴严重合并症"
            }
        }
    },
    
    "NUTRI_002": {
        "id": "NUTRI_002", 
        "name": "代谢综合征",
        "category": "营养代谢疾病",
        "icd10": "E88.81",
        "definition": "以胰岛素抵抗为核心，包括腹型肥胖、高血糖、血脂异常和高血压的病理生理综合征",
        "pathophysiology": {
            "insulin_resistance": {
                "central_mechanism": "胰岛素抵抗是代谢综合征的核心机制",
                "tissue_effects": {
                    "muscle": "骨骼肌糖摄取减少",
                    "liver": "肝脏葡萄糖生成增加，脂质合成增多",
                    "adipose": "脂肪组织脂解增加"
                }
            },
            "visceral_adiposity": {
                "mechanism": "内脏脂肪堆积释放游离脂肪酸",
                "inflammatory_response": "促炎因子分泌增加",
                "hormonal_effects": "脂肪因子分泌紊乱"
            }
        },
        "diagnostic_criteria": {
            "idf_criteria": {
                "central_obesity": "腹围：男性≥90cm，女性≥80cm（亚洲）",
                "plus_two_of": [
                    "甘油三酯≥1.7 mmol/L",
                    "HDL-C：男性<1.03，女性<1.29 mmol/L", 
                    "血压≥130/85 mmHg或已用降压药",
                    "空腹血糖≥5.6 mmol/L或已诊断糖尿病"
                ]
            },
            "ncep_atp_iii": {
                "criteria": "以下5项中符合3项或以上",
                "parameters": [
                    "腹围：男性>102cm，女性>88cm",
                    "甘油三酯≥1.7 mmol/L",
                    "HDL-C：男性<1.03，女性<1.3 mmol/L",
                    "血压≥130/85 mmHg",
                    "空腹血糖≥6.1 mmol/L"
                ]
            }
        },
        "clinical_manifestations": {
            "metabolic_abnormalities": {
                "glucose_intolerance": "空腹血糖受损或糖耐量异常",
                "dyslipidemia": "高TG血症和低HDL-C血症",
                "hypertension": "血压升高，多为轻中度"
            },
            "vascular_complications": {
                "endothelial_dysfunction": "血管内皮功能紊乱",
                "atherosclerosis": "动脉粥样硬化加速进展",
                "thrombotic_tendency": "血栓形成倾向增加"
            }
        },
        "treatment_strategy": {
            "lifestyle_intervention": {
                "weight_reduction": "减重5-10%",
                "dietary_modification": "Mediterranean饮食模式",
                "exercise_program": "150分钟/周中等强度运动"
            },
            "targeted_therapy": {
                "glucose_control": "二甲双胍首选",
                "lipid_management": "他汀类药物",
                "blood_pressure": "ACEI/ARB类药物优选"
            }
        }
    },
    
    "NUTRI_003": {
        "id": "NUTRI_003",
        "name": "维生素D缺乏症", 
        "category": "营养代谢疾病",
        "icd10": "E55.9",
        "definition": "由于维生素D摄入不足、合成减少或代谢异常导致的维生素D缺乏状态",
        "pathophysiology": {
            "vitamin_d_metabolism": {
                "synthesis": "皮肤7-脱氢胆固醇在紫外线作用下合成维生素D3",
                "activation": {
                    "liver": "25羟化酶生成25(OH)D3",
                    "kidney": "1α羟化酶生成1,25(OH)2D3（骨化三醇）"
                }
            },
            "physiological_functions": {
                "calcium_homeostasis": "促进肠钙吸收，维持血钙平衡",
                "bone_metabolism": "促进骨基质矿化",
                "parathyroid_regulation": "抑制PTH分泌",
                "immune_function": "调节免疫系统功能"
            },
            "deficiency_consequences": {
                "calcium_malabsorption": "肠钙吸收减少",
                "secondary_hyperparathyroidism": "继发性甲状旁腺功能亢进",
                "bone_demineralization": "骨质疏松和骨软化"
            }
        },
        "clinical_features": {
            "skeletal_manifestations": {
                "adults": "骨痛、骨软化症、骨质疏松",
                "children": "佝偻病、骨骼畸形、生长迟缓",
                "fracture_risk": "脆性骨折风险增加"
            },
            "non_skeletal_symptoms": {
                "muscular": "肌无力、肌痛、跌倒风险增加",
                "neurological": "抽搐、手足搐搦、癫痫",
                "cardiovascular": "心肌收缩力下降",
                "immune": "感染易感性增加"
            }
        },
        "laboratory_diagnosis": {
            "primary_marker": {
                "25_oh_d": "25羟维生素D",
                "normal_range": "75-150 nmol/L (30-60 ng/ml)",
                "deficiency": "<50 nmol/L (<20 ng/ml)",
                "insufficiency": "50-75 nmol/L (20-30 ng/ml)"
            },
            "secondary_changes": {
                "pth": "甲状旁腺激素升高",
                "calcium": "血钙可能正常或偏低",
                "phosphorus": "血磷可能降低",
                "alkaline_phosphatase": "碱性磷酸酶升高"
            }
        },
        "risk_factors": {
            "environmental": ["日照不足", "空气污染", "高纬度地区"],
            "dietary": ["维生素D摄入不足", "素食", "吸收不良"],
            "physiological": ["老年", "妊娠哺乳期", "深色皮肤"],
            "pathological": ["肾病", "肝病", "吸收不良综合征"]
        },
        "treatment_protocol": {
            "supplementation": {
                "prophylactic": "维生素D3 800-1000 IU/日",
                "treatment": "维生素D3 50000 IU/周，持续6-8周",
                "maintenance": "维生素D3 1000-2000 IU/日"
            },
            "monitoring": {
                "target_level": "25(OH)D >75 nmol/L (>30 ng/ml)",
                "follow_up": "3-6月复查25(OH)D水平",
                "safety": "避免过量，监测血钙"
            }
        }
    },

    "REPRO_001": {
        "id": "REPRO_001",
        "name": "多囊卵巢综合征",
        "alternate_names": ["PCOS", "Polycystic Ovary Syndrome", "Stein-Leventhal综合征"],
        "category": "生殖内分泌疾病",
        "icd10": "E28.2",
        "definition": "以慢性无排卵、高雄激素血症和胰岛素抵抗为特征的生殖内分泌代谢性疾病",
        "pathophysiology": {
            "hormonal_dysregulation": {
                "hyperandrogenism": {
                    "mechanism": "卵巢和肾上腺雄激素分泌增加",
                    "sources": ["睾酮", "雄烯二酮", "DHEA-S"],
                    "effects": ["排卵障碍", "多毛症", "痤疮", "脱发"]
                },
                "lh_fsh_ratio": {
                    "abnormal_ratio": "LH/FSH比值>2:1",
                    "mechanism": "GnRH脉冲频率增加",
                    "consequences": "卵泡发育异常，无排卵"
                },
                "insulin_resistance": {
                    "prevalence": "60-70%的PCOS患者存在胰岛素抵抗",
                    "mechanism": "胰岛素受体后信号转导异常",
                    "metabolic_effects": ["高胰岛素血症", "糖耐量异常", "脂代谢紊乱"]
                }
            },
            "ovarian_morphology": {
                "polycystic_appearance": "多囊样改变：≥12个直径2-9mm的卵泡",
                "stromal_hyperplasia": "卵巢间质增生和硬化",
                "volume_increase": "卵巢体积增大>10ml"
            }
        },
        "clinical_features": {
            "reproductive_manifestations": {
                "menstrual_irregularities": {
                    "oligomenorrhea": "月经稀发（>35天）",
                    "amenorrhea": "闭经（>3个月无月经）",
                    "anovulation": "排卵功能障碍或无排卵"
                },
                "infertility": {
                    "prevalence": "75%的PCOS患者存在不孕",
                    "mechanism": "慢性无排卵",
                    "pregnancy_complications": ["流产率增加", "妊娠期糖尿病", "子痫前期"]
                }
            },
            "hyperandrogenic_signs": {
                "hirsutism": {
                    "definition": "Ferriman-Gallwey评分≥6分",
                    "distribution": "面部、胸部、腹部、大腿内侧毛发增多",
                    "prevalence": "60-80%"
                },
                "acne": "雄激素性痤疮，成年期持续存在",
                "male_pattern_baldness": "男性型脱发或发际线后移",
                "virilization": "严重病例可出现声音低沉、阴蒂肥大"
            },
            "metabolic_features": {
                "obesity": {
                    "prevalence": "50-80%的PCOS患者肥胖",
                    "pattern": "腹型肥胖为主",
                    "bmi_distribution": "亚洲人群BMI≥23即需关注"
                },
                "insulin_resistance_manifestations": {
                    "acanthosis_nigricans": "黑棘皮症，颈部、腋下色素沉着",
                    "glucose_intolerance": "糖耐量异常发生率20-40%",
                    "type2_diabetes_risk": "2型糖尿病风险增加5-10倍"
                }
            }
        },
        "diagnostic_criteria": {
            "rotterdam_criteria_2003": {
                "requirement": "以下3项中符合2项",
                "criteria": [
                    "排卵功能障碍或无排卵",
                    "临床和/或生化高雄激素血症",
                    "超声显示多囊卵巢形态"
                ],
                "exclusions": ["21-羟化酶缺陷", "库欣综合征", "雄激素分泌肿瘤"]
            },
            "androgen_excess_society_criteria": {
                "requirement": "高雄激素血症+以下1项",
                "additional_criteria": [
                    "排卵功能障碍",
                    "多囊卵巢形态"
                ]
            }
        },
        "laboratory_findings": {
            "hormonal_profile": {
                "androgens": {
                    "total_testosterone": ">2.0 nmol/L提示高雄激素血症",
                    "free_testosterone": "游离睾酮升高更敏感",
                    "androstenedione": "雄烯二酮升高",
                    "dhea_s": "DHEA-S升高提示肾上腺来源"
                },
                "gonadotropins": {
                    "lh_elevation": "LH水平升高",
                    "lh_fsh_ratio": "LH/FSH≥2",
                    "fsh_normal": "FSH通常正常或轻度降低"
                },
                "other_hormones": {
                    "amh": "抗苗勒氏管激素显著升高（>35 pmol/L）",
                    "shbg": "性激素结合球蛋白降低",
                    "prolactin": "泌乳素可轻度升高"
                }
            },
            "metabolic_parameters": {
                "glucose_metabolism": {
                    "ogtt": "75g葡萄糖耐量试验筛查糖代谢异常",
                    "homa_ir": "胰岛素抵抗指数>2.5",
                    "fasting_insulin": "空腹胰岛素>15 mU/L"
                },
                "lipid_profile": {
                    "triglycerides": "甘油三酯常升高",
                    "hdl_cholesterol": "HDL-C常降低",
                    "ldl_cholesterol": "LDL-C可升高",
                    "total_cholesterol": "总胆固醇升高"
                }
            }
        },
        "imaging_findings": {
            "transvaginal_ultrasound": {
                "ovarian_criteria": {
                    "follicle_count": "单侧卵巢≥12个直径2-9mm卵泡",
                    "ovarian_volume": "卵巢体积>10ml",
                    "stromal_echogenicity": "间质回声增强"
                },
                "optimal_timing": "月经周期早期（第3-5天）检查"
            }
        },
        "treatment_approach": {
            "lifestyle_intervention": {
                "weight_management": {
                    "target": "减重5-10%即可显著改善症状",
                    "diet": "低糖指数饮食，控制碳水化合物",
                    "exercise": "有氧运动+阻抗训练，每周150分钟"
                }
            },
            "pharmacological_treatment": {
                "insulin_sensitizers": {
                    "metformin": {
                        "dosage": "500-2000mg/日，分次服用",
                        "effects": "改善胰岛素抵抗，降低雄激素",
                        "indications": "肥胖、糖代谢异常的PCOS患者"
                    },
                    "pioglitazone": "替代选择，15-45mg/日"
                },
                "hormonal_therapy": {
                    "combined_ocs": {
                        "mechanism": "抑制LH分泌，增加SHBG",
                        "selection": "含抗雄激素作用的孕激素",
                        "contraindications": "血栓风险、肝病、高血压"
                    },
                    "antiandrogens": {
                        "spironolactone": "50-200mg/日",
                        "finasteride": "5mg/日",
                        "flutamide": "250mg 2次/日"
                    }
                },
                "ovulation_induction": {
                    "first_line": "克罗米芬50-150mg/日，月经第3-7天",
                    "second_line": "来曲唑2.5-7.5mg/日",
                    "third_line": "促性腺激素注射"
                }
            }
        }
    },

    "REPRO_002": {
        "id": "REPRO_002",
        "name": "男性性腺功能减退症",
        "alternate_names": ["Male Hypogonadism", "睾酮缺乏综合征", "迟发性性腺功能减退"],
        "category": "生殖内分泌疾病", 
        "icd10": "E29.1",
        "definition": "由于下丘脑-垂体-性腺轴功能异常导致的睾酮分泌不足和/或精子生成障碍",
        "classification": {
            "primary_hypogonadism": {
                "definition": "原发性性腺功能减退，睾丸本身病变",
                "characteristics": "低睾酮，高LH/FSH",
                "etiology": ["克氏综合征", "睾丸炎", "放疗", "化疗", "外伤"]
            },
            "secondary_hypogonadism": {
                "definition": "继发性性腺功能减退，下丘脑-垂体病变",
                "characteristics": "低睾酮，低/正常LH/FSH",
                "etiology": ["垂体肿瘤", "头部外伤", "感染", "药物", "系统性疾病"]
            },
            "late_onset_hypogonadism": {
                "definition": "迟发性性腺功能减退",
                "age_related": "年龄相关的睾酮水平下降",
                "prevalence": ">40岁男性中患病率20-30%"
            }
        },
        "pathophysiology": {
            "testosterone_deficiency": {
                "production_sites": {
                    "leydig_cells": "间质细胞分泌睾酮95%",
                    "adrenal_glands": "肾上腺分泌5%"
                },
                "regulation": {
                    "hpg_axis": "下丘脑GnRH-垂体LH/FSH-睾丸睾酮轴",
                    "negative_feedback": "睾酮对下丘脑垂体负反馈调节"
                }
            },
            "consequences": {
                "reproductive": "性功能减退、不育",
                "metabolic": "胰岛素抵抗、脂代谢异常",
                "musculoskeletal": "肌肉量减少、骨密度降低",
                "psychological": "抑郁、认知功能下降"
            }
        },
        "clinical_features": {
            "sexual_symptoms": {
                "libido_decrease": "性欲减退是最早出现的症状",
                "erectile_dysfunction": "勃起功能障碍",
                "decreased_orgasm": "性高潮强度和频率减少",
                "infertility": "精子质量下降导致不育"
            },
            "physical_manifestations": {
                "body_composition": {
                    "muscle_mass_loss": "肌肉量和力量减少",
                    "fat_accumulation": "尤其是腹部脂肪增加",
                    "bone_density_loss": "骨密度降低，骨折风险增加"
                },
                "secondary_sexual_characteristics": {
                    "body_hair_loss": "体毛、面部毛发减少",
                    "gynecomastia": "乳房发育",
                    "testicular_atrophy": "睾丸萎缩"
                }
            },
            "metabolic_consequences": {
                "glucose_metabolism": "胰岛素抵抗、糖尿病风险增加",
                "lipid_disorders": "血脂异常，心血管风险增加",
                "metabolic_syndrome": "代谢综合征患病率增加"
            },
            "psychological_symptoms": {
                "depression": "抑郁症状",
                "irritability": "易怒、情绪不稳定",
                "cognitive_decline": "记忆力减退、注意力不集中",
                "fatigue": "疲劳、精力不足"
            }
        },
        "diagnostic_approach": {
            "clinical_assessment": {
                "symptom_questionnaires": {
                    "aging_males_symptoms": "AMS评分量表",
                    "androgen_deficiency": "ADAM问卷",
                    "international_index": "国际勃起功能指数"
                }
            },
            "biochemical_diagnosis": {
                "testosterone_measurement": {
                    "total_testosterone": {
                        "timing": "上午8-11点空腹测定",
                        "normal_range": "12-35 nmol/L (3.5-10 ng/ml)",
                        "deficiency": "<8 nmol/L (<2.3 ng/ml)"
                    },
                    "free_testosterone": {
                        "calculation": "基于总睾酮、SHBG、白蛋白计算",
                        "direct_measurement": "平衡透析法金标准"
                    }
                },
                "confirmatory_tests": {
                    "repeat_measurement": "确认诊断需重复检测",
                    "lh_fsh": "区分原发性和继发性性腺功能减退",
                    "prolactin": "排除高泌乳素血症"
                }
            }
        },
        "treatment_options": {
            "testosterone_replacement": {
                "preparations": {
                    "injections": {
                        "testosterone_cypionate": "200-250mg，2-3周注射1次",
                        "testosterone_undecanoate": "1000mg，10-12周注射1次"
                    },
                    "transdermal": {
                        "gels": "50-100mg/日外用",
                        "patches": "每日更换贴剂"
                    },
                    "oral": "口服十一酸睾酮40-80mg，2-3次/日"
                },
                "monitoring": {
                    "effectiveness": "症状改善、睾酮水平正常化",
                    "safety": "血细胞计数、肝功能、PSA",
                    "contraindications": "前列腺癌、乳腺癌、严重心衰"
                }
            },
            "alternative_treatments": {
                "hcg_therapy": "人绒毛膜促性腺激素，保留生育能力",
                "clomiphene": "克罗米芬刺激内源性睾酮分泌",
                "lifestyle_intervention": "减重、运动、睡眠改善"
            }
        }
    },

    "REPRO_003": {
        "id": "REPRO_003",
        "name": "卵巢早衰",
        "alternate_names": ["POI", "Premature Ovarian Insufficiency", "早发性卵巢功能不全"],
        "category": "生殖内分泌疾病",
        "icd10": "E28.31",
        "definition": "40岁之前卵巢功能衰竭，导致继发性闭经、雌激素缺乏和生育能力丧失",
        "pathophysiology": {
            "follicle_depletion": {
                "accelerated_atresia": "卵泡过度凋亡和闭锁",
                "reduced_pool": "原始卵泡库枯竭",
                "dysfunction": "残存卵泡功能异常"
            },
            "etiology": {
                "genetic_factors": {
                    "x_chromosome": "X染色体异常（Turner综合征变异）",
                    "fmr1_premutation": "FMR1基因前突变",
                    "other_genes": "BMP15、GDF9、FOXL2等基因突变"
                },
                "autoimmune": {
                    "ovarian_antibodies": "卵巢抗体阳性",
                    "polyglandular_syndrome": "多腺体自身免疫综合征",
                    "associated_diseases": "甲状腺炎、Addison病、1型糖尿病"
                },
                "iatrogenic": {
                    "chemotherapy": "化疗药物卵巢毒性",
                    "radiation": "放疗对卵巢的损伤",
                    "surgery": "卵巢手术导致血供受损"
                }
            }
        },
        "clinical_presentation": {
            "menstrual_disorders": {
                "secondary_amenorrhea": "继发性闭经>4个月",
                "oligomenorrhea": "月经稀发前驱期",
                "irregular_cycles": "月经周期不规律"
            },
            "hypoestrogenic_symptoms": {
                "vasomotor": "潮热、盗汗",
                "genitourinary": "阴道干燥、性交痛、尿路症状",
                "psychological": "抑郁、焦虑、情绪不稳定",
                "sleep_disturbances": "失眠、睡眠质量差"
            },
            "long_term_consequences": {
                "osteoporosis": "骨质疏松和骨折风险增加",
                "cardiovascular": "心血管疾病风险增加",
                "cognitive": "认知功能下降风险",
                "mortality": "总体死亡率增加"
            }
        },
        "diagnostic_criteria": {
            "clinical_definition": {
                "age": "<40岁",
                "amenorrhea": "闭经>4个月",
                "fsh_elevation": "FSH>25 IU/L（间隔>4周重复2次）",
                "exclusion": "排除妊娠和其他闭经原因"
            },
            "staging": {
                "early_stage": "月经不规律，FSH偶尔升高",
                "late_stage": "持续闭经，FSH持续升高",
                "end_stage": "完全性卵巢功能衰竭"
            }
        },
        "laboratory_evaluation": {
            "hormonal_assessment": {
                "fsh": "促卵泡刺激素>25 IU/L",
                "lh": "促黄体生成素升高",
                "estradiol": "雌二醇<50 pmol/L",
                "amh": "抗苗勒氏管激素<1.0 ng/ml"
            },
            "autoimmune_screening": {
                "ovarian_antibodies": "卵巢抗体（抗17α-羟化酶）",
                "adrenal_antibodies": "21-羟化酶抗体",
                "thyroid_antibodies": "甲状腺过氧化物酶抗体"
            },
            "genetic_testing": {
                "karyotype": "染色体核型分析",
                "fmr1": "FMR1基因CGG重复数检测",
                "other_genes": "基于家族史的其他基因检测"
            }
        },
        "management_approach": {
            "hormone_replacement": {
                "estrogen_progestin": {
                    "estradiol": "2-4mg/日或透皮贴剂",
                    "progesterone": "微粒化黄体酮100-200mg/日",
                    "duration": "直至自然绝经年龄（~51岁）"
                },
                "contraceptive_pills": "年轻患者的替代选择",
                "monitoring": "定期评估症状、骨密度、心血管风险"
            },
            "fertility_preservation": {
                "donor_eggs": "供卵是主要的生育选择",
                "ovarian_tissue": "卵巢组织冷冻保存（实验性）",
                "spontaneous_pregnancy": "10%患者可能自然受孕"
            },
            "bone_health": {
                "calcium_vitamin_d": "钙剂1200mg/日+维生素D 800IU/日",
                "bone_density": "定期DEXA扫描监测",
                "bisphosphonates": "重度骨质疏松时考虑"
            },
            "cardiovascular_protection": {
                "lifestyle": "健康饮食、规律运动、戒烟",
                "risk_assessment": "定期心血管风险评估",
                "hrt_benefits": "HRT对心血管的保护作用"
            }
        }
    },

    "rheumatic_endocrine_relationships": {
      "description": "风湿免疫疾病与内分泌系统疾病的复杂关联关系网络",
      "bidirectional_interactions": {
        "hormones_affect_immunity": "激素调节免疫系统功能和自身免疫疾病发生发展",
        "immunity_affects_endocrine": "免疫系统异常影响内分泌腺体功能和激素分泌",
        "shared_pathogenesis": "共同的遗传易感性、环境触发因素和分子机制"
      },
      
      "disease_relationship_matrix": {
        "type_1_diabetes_relationships": {
          "source_id": "RHEUM_001",
          "target_diseases": {
            "thyroid_diseases": {
              "hashimoto_thyroiditis": {
                "relationship_type": "共病",
                "prevalence": "15-30%的1型糖尿病患者合并",
                "shared_mechanisms": [
                  "HLA-DQ2/DQ8遗传易感性",
                  "Th1型免疫反应优势",
                  "分子模拟机制",
                  "调节性T细胞功能缺陷"
                ],
                "clinical_implications": "需要定期监测甲状腺功能和抗体",
                "screening_recommendations": "诊断时及每年筛查TSH、抗TPO"
              },
              "graves_disease": {
                "relationship_type": "共病",
                "prevalence": "1-5%",
                "mechanism": "共同的HLA易感基因和自身免疫机制",
                "management": "甲亢可能加重糖尿病酮症酸中毒风险"
              }
            },
            "adrenal_diseases": {
              "addison_disease": {
                "relationship_type": "共病（APS-1/APS-2成分）",
                "prevalence": "罕见，多见于多腺体综合征",
                "shared_antigens": "21-羟化酶等共同自身抗原",
                "clinical_significance": "增加低血糖和酮症酸中毒风险"
              }
            },
            "parathyroid_diseases": {
              "hypoparathyroidism": {
                "relationship_type": "共病（主要见于APS-1）",
                "mechanism": "钙敏感受体自身抗体",
                "clinical_impact": "低钙血症影响胰岛素敏感性"
              }
            }
          }
        },

        "hashimoto_thyroiditis_relationships": {
          "source_id": "RHEUM_002", 
          "target_diseases": {
            "diabetes": {
              "type_1_diabetes": {
                "relationship_type": "双向关联",
                "prevalence": "甲状腺疾病患者中糖尿病发病率增加2-3倍",
                "mechanisms": [
                  "共同HLA易感基因",
                  "细胞免疫和体液免疫异常",
                  "甲状腺激素影响胰岛素敏感性"
                ]
              },
              "type_2_diabetes": {
                "relationship_type": "关联",
                "mechanism": "甲状腺功能减退导致胰岛素抵抗",
                "prevalence": "甲减患者糖尿病风险增加"
              }
            },
            "reproductive_endocrine": {
              "pcos": {
                "relationship_type": "共病",
                "prevalence": "PCOS患者甲状腺疾病发病率增加",
                "mechanism": "胰岛素抵抗和激素相互作用"
              },
              "infertility": {
                "relationship_type": "因果关联",
                "mechanism": "甲状腺激素影响生殖轴功能"
              }
            },
            "bone_metabolism": {
              "osteoporosis": {
                "relationship_type": "继发性关联",
                "mechanism": "长期甲状腺激素替代治疗影响骨代谢"
              }
            }
          }
        },

        "addison_disease_relationships": {
          "source_id": "RHEUM_003",
          "target_diseases": {
            "thyroid_disorders": {
              "relationship_type": "多腺体综合征成分",
              "prevalence": "70-80%的APS-2患者",
              "sequential_pattern": "通常在Addison病诊断前后数年出现"
            },
            "diabetes_mellitus": {
              "type_1_diabetes": {
                "relationship_type": "APS-2核心成分",
                "prevalence": "52%的APS-2患者",
                "clinical_challenge": "肾上腺功能不全增加低血糖风险"
              }
            },
            "gonadal_dysfunction": {
              "primary_hypogonadism": {
                "relationship_type": "共病",
                "mechanism": "自身免疫性卵巢炎/睾丸炎",
                "impact": "加重骨质疏松和代谢异常"
              }
            },
            "parathyroid_disorders": {
              "hypoparathyroidism": {
                "relationship_type": "APS-1成分",
                "prevalence": "89-96%的APS-1患者",
                "electrolyte_management": "复杂的电解质平衡管理"
              }
            }
          }
        },

        "systemic_lupus_relationships": {
          "source_id": "RHEUM_004",
          "target_diseases": {
            "thyroid_diseases": {
              "autoimmune_thyroiditis": {
                "relationship_type": "共病",
                "prevalence": "15-20%的SLE患者",
                "mechanism": "共同的自身免疫机制和遗传背景"
              }
            },
            "diabetes_complications": {
              "insulin_resistance": {
                "relationship_type": "继发性",
                "mechanism": "慢性炎症和糖皮质激素治疗",
                "prevalence": "25-50%的SLE患者"
              },
              "steroid_diabetes": {
                "relationship_type": "药物相关",
                "mechanism": "长期糖皮质激素治疗"
              }
            },
            "reproductive_endocrine": {
              "menstrual_disorders": {
                "relationship_type": "直接影响",
                "mechanism": "疾病活动和药物治疗影响HPG轴"
              },
              "pregnancy_complications": {
                "relationship_type": "高风险",
                "complications": "妊娠期糖尿病、甲状腺功能异常"
              }
            },
            "bone_endocrine": {
              "osteoporosis": {
                "relationship_type": "多因素",
                "mechanisms": [
                  "疾病本身的炎症",
                  "糖皮质激素治疗",
                  "维生素D缺乏",
                  "性激素缺乏"
                ]
              }
            },
            "adrenal_function": {
              "secondary_adrenal_insufficiency": {
                "relationship_type": "药物相关",
                "mechanism": "长期糖皮质激素治疗后HPA轴抑制"
              }
            }
          }
        },

        "rheumatoid_arthritis_relationships": {
          "source_id": "RHEUM_005",
          "target_diseases": {
            "diabetes_mellitus": {
              "type_2_diabetes": {
                "relationship_type": "双向关联",
                "prevalence": "RA患者糖尿病风险增加1.5-2倍",
                "mechanisms": [
                  "慢性炎症导致胰岛素抵抗",
                  "糖皮质激素和其他药物治疗",
                  "活动减少和肥胖"
                ]
              }
            },
            "thyroid_disorders": {
              "hypothyroidism": {
                "relationship_type": "共病",
                "prevalence": "10-15%的RA患者",
                "mechanism": "共同的自身免疫背景"
              }
            },
            "bone_metabolism": {
              "osteoporosis": {
                "relationship_type": "多重机制",
                "prevalence": "30-50%的RA患者",
                "mechanisms": [
                  "炎性细胞因子影响骨重建",
                  "糖皮质激素治疗",
                  "活动受限",
                  "维生素D缺乏"
                ]
              }
            },
            "reproductive_health": {
              "fertility_issues": {
                "relationship_type": "治疗相关",
                "mechanism": "MTX等药物对生殖功能的影响"
              }
            },
            "adrenal_function": {
              "hpa_axis_dysfunction": {
                "relationship_type": "疾病相关",
                "mechanism": "慢性炎症对HPA轴的影响"
              }
            }
          }
        },

        "sjogren_syndrome_relationships": {
          "source_id": "RHEUM_006",
          "target_diseases": {
            "thyroid_diseases": {
              "autoimmune_thyroiditis": {
                "relationship_type": "高度共病",
                "prevalence": "30-50%的SS患者",
                "mechanism": "腺体自身免疫的共同病理机制"
              }
            },
            "diabetes_mellitus": {
              "type_1_diabetes": {
                "relationship_type": "共病",
                "mechanism": "胰岛自身免疫和腺体破坏"
              }
            },
            "reproductive_endocrine": {
              "ovarian_dysfunction": {
                "relationship_type": "腺体受累",
                "mechanism": "卵巢腺体自身免疫破坏"
              }
            },
            "bone_health": {
              "osteoporosis": {
                "relationship_type": "多因素",
                "mechanisms": [
                  "慢性炎症",
                  "维生素D吸收不良",
                  "激素缺乏"
                ]
              }
            }
          }
        },

        "aps1_relationships": {
          "source_id": "RHEUM_007",
          "endocrine_manifestations": {
            "hypoparathyroidism": {
              "prevalence": "89-96%",
              "onset_age": "5-10岁",
              "relationship_type": "核心成分"
            },
            "addison_disease": {
              "prevalence": "72-100%", 
              "onset_age": "青少年期",
              "relationship_type": "核心成分"
            },
            "primary_hypogonadism": {
              "prevalence": "60%",
              "relationship_type": "主要成分"
            },
            "type_1_diabetes": {
              "prevalence": "12-18%",
              "relationship_type": "次要成分"
            },
            "autoimmune_thyroiditis": {
              "prevalence": "4-10%",
              "relationship_type": "次要成分"
            }
          },
          "non_endocrine_associations": {
            "chronic_candidiasis": "首发症状，与内分泌功能缺陷相互影响",
            "ectodermal_dystrophy": "发育异常影响生长发育"
          }
        },

        "aps2_relationships": {
          "source_id": "RHEUM_008",
          "core_endocrine_triad": {
            "addison_disease": {
              "prevalence": "100%",
              "relationship_type": "定义性特征"
            },
            "autoimmune_thyroid_disease": {
              "prevalence": "70%",
              "relationship_type": "核心成分"
            },
            "type_1_diabetes": {
              "prevalence": "52%",
              "relationship_type": "核心成分"
            }
          },
          "associated_conditions": {
            "primary_hypogonadism": {
              "prevalence": "4-9%",
              "relationship_type": "伴发条件"
            },
            "autoimmune_gastritis": {
              "prevalence": "变异",
              "relationship_type": "消化内分泌关联"
            }
          }
        },

        "hyperuricemia_gout_relationships": {
          "source_id": "METAB_009/RHEUM_009",
          "target_diseases": {
            "diabetes_mellitus": {
              "type_2_diabetes": {
                "relationship_type": "双向关联",
                "prevalence": "糖尿病患者高尿酸血症发病率25-40%",
                "mechanisms": [
                  "胰岛素抵抗促进肾小管尿酸重吸收",
                  "高胰岛素血症激活URAT1转运体",
                  "尿酸激活RAAS系统加重胰岛素抵抗",
                  "氧化应激和慢性炎症共同通路"
                ],
                "clinical_implications": [
                  "血糖控制改善可降低血尿酸水平",
                  "降尿酸治疗可能改善胰岛素敏感性",
                  "需要监测药物相互作用"
                ]
              },
              "gestational_diabetes": {
                "relationship_type": "关联",
                "mechanism": "妊娠期胰岛素抵抗影响尿酸代谢",
                "prevalence": "GDM患者血尿酸水平显著升高"
              }
            },
            "thyroid_disorders": {
              "hypothyroidism": {
                "relationship_type": "因果关联",
                "prevalence": "甲减患者高尿酸血症风险增加2-3倍",
                "mechanisms": [
                  "基础代谢率下降影响嘌呤代谢",
                  "肾血流量减少，尿酸清除率下降",
                  "甲状腺激素调节尿酸转运体表达"
                ],
                "treatment_considerations": "甲状腺激素替代治疗可改善高尿酸血症"
              },
              "hyperthyroidism": {
                "relationship_type": "保护性关联",
                "mechanism": "代谢率增加促进尿酸排泄",
                "clinical_note": "甲亢治疗后需要监测血尿酸水平变化"
              }
            },
            "metabolic_syndrome": {
              "core_component": {
                "relationship_type": "组成成分",
                "prevalence": "代谢综合征患者高尿酸血症发病率60-70%",
                "pathophysiological_links": [
                  "中心性肥胖与尿酸产生增加",
                  "胰岛素抵抗核心机制",
                  "血脂异常与尿酸代谢相互影响",
                  "高血压与肾脏尿酸处理异常"
                ]
              }
            },
            "adrenal_disorders": {
              "cushings_syndrome": {
                "relationship_type": "合并症",
                "mechanism": "皮质醇过多影响嘌呤代谢和肾功能",
                "prevalence": "Cushing综合征患者高尿酸血症发病率增加"
              },
              "primary_aldosteronism": {
                "relationship_type": "关联",
                "mechanism": "盐皮质激素过多影响肾小管功能",
                "clinical_impact": "影响降尿酸药物疗效"
              }
            },
            "reproductive_endocrine": {
              "pcos": {
                "relationship_type": "双向关联",
                "prevalence": "PCOS患者高尿酸血症发病率40-60%",
                "shared_mechanisms": [
                  "胰岛素抵抗共同通路",
                  "慢性低度炎症状态",
                  "雄激素过多影响代谢"
                ],
                "therapeutic_implications": "改善胰岛素敏感性可同时改善两种疾病"
              },
              "menopause": {
                "relationship_type": "关联",
                "mechanism": "雌激素缺乏影响尿酸代谢",
                "clinical_significance": "绝经后女性高尿酸血症发病率显著上升"
              }
            },
            "growth_disorders": {
              "acromegaly": {
                "relationship_type": "合并症",
                "mechanism": "生长激素过多影响嘌呤代谢",
                "prevalence": "肢端肥大症患者高尿酸血症发病率增加"
              },
              "growth_hormone_deficiency": {
                "relationship_type": "关联", 
                "mechanism": "GH缺乏影响肾功能和代谢率",
                "clinical_consideration": "GH替代治疗对尿酸代谢的影响"
              }
            }
          }
        },

        "bone_metabolism_endocrine_relationships": {
          "source_id": "BONE_001/BONE_002/BONE_003",
          "description": "骨代谢疾病与内分泌系统的复杂相互作用关系",
          "target_diseases": {
            "diabetes_mellitus": {
              "type_1_diabetes": {
                "relationship_type": "双向关联",
                "prevalence": "1型糖尿病患者骨密度降低风险增加2-4倍",
                "mechanisms": [
                  "胰岛素缺乏影响成骨细胞功能",
                  "IGF-1水平下降影响骨形成",
                  "高血糖产生糖基化终产物损伤骨基质",
                  "慢性炎症状态影响骨重建"
                ],
                "clinical_implications": [
                  "年轻患者也需要骨密度筛查",
                  "血糖控制对骨健康至关重要",
                  "骨折愈合可能延迟"
                ],
                "bone_disease_patterns": {
                  "osteoporosis": "主要表现为骨质疏松",
                  "fracture_sites": "椎体、髋部骨折风险增加"
                }
              },
              "type_2_diabetes": {
                "relationship_type": "复杂关联",
                "paradox": "骨密度可正常或增加但骨折风险仍增加",
                "mechanisms": [
                  "骨质量下降（微结构损伤）",
                  "糖基化终产物影响胶原交联",
                  "跌倒风险增加",
                  "某些降糖药物影响骨代谢"
                ],
                "drug_considerations": {
                  "thiazolidinediones": "噻唑烷二酮类增加骨折风险",
                  "sglt2_inhibitors": "SGLT2抑制剂可能影响骨代谢",
                  "insulin": "胰岛素有益于骨健康"
                }
              }
            },
            "thyroid_disorders": {
              "hyperthyroidism": {
                "relationship_type": "因果关联",
                "prevalence": "甲亢患者骨质疏松发病率增加5-10倍",
                "mechanisms": [
                  "甲状腺激素直接刺激破骨细胞活性",
                  "骨转换加速，吸收>形成",
                  "钙磷代谢紊乱",
                  "维生素D代谢异常"
                ],
                "reversibility": "甲亢控制后骨密度可部分恢复",
                "monitoring": "需要骨密度定期监测"
              },
              "hypothyroidism": {
                "relationship_type": "保护与风险并存",
                "untreated_effects": "未治疗甲减相对保护骨密度",
                "treatment_effects": "过度LT4替代可能增加骨丢失",
                "monitoring_importance": "TSH维持在适宜范围"
              },
              "thyroid_cancer_survivors": {
                "tsh_suppression_therapy": "TSH抑制治疗增加骨丢失",
                "risk_stratification": "根据复发风险平衡治疗获益与骨风险"
              }
            },
            "parathyroid_disorders": {
              "primary_hyperparathyroidism": {
                "relationship_type": "直接因果关联",
                "bone_disease": "甲状旁腺性骨病的直接原因",
                "manifestations": [
                  "骨质疏松（皮质骨>松质骨）",
                  "骨膜下皮质骨吸收",
                  "褐色瘤形成",
                  "病理性骨折"
                ],
                "surgical_benefit": "甲状旁腺切除术后骨密度显著改善"
              },
              "hypoparathyroidism": {
                "relationship_type": "治疗相关骨病",
                "mechanisms": [
                  "PTH缺乏导致骨转换极度下降",
                  "骨基质矿化异常",
                  "皮质骨增厚但骨质量下降"
                ],
                "treatment_challenges": "传统治疗难以维持正常骨代谢"
              },
              "secondary_hyperparathyroidism": {
                "ckd_mbd": "慢性肾病骨矿物质代谢紊乱",
                "vitamin_d_deficiency": "维生素D缺乏引起继发性甲状旁腺功能亢进",
                "mixed_bone_disease": "骨软化症与纤维囊性骨炎并存"
              }
            },
            "adrenal_disorders": {
              "cushings_syndrome": {
                "relationship_type": "强烈因果关联",
                "prevalence": "Cushing综合征患者骨质疏松发病率>50%",
                "mechanisms": [
                  "皮质醇抑制成骨细胞分化和功能",
                  "促进破骨细胞活性",
                  "抑制肠道钙吸收",
                  "影响性激素合成"
                ],
                "rapid_onset": "骨丢失可在短期内快速发生",
                "fracture_risk": "椎体骨折风险极高"
              },
              "addison_disease": {
                "relationship_type": "复杂关联",
                "cortisol_deficiency": "皮质醇缺乏对骨代谢的影响",
                "treatment_effects": "糖皮质激素替代治疗的骨影响",
                "monitoring": "需要平衡激素替代与骨健康"
              }
            },
            "reproductive_endocrine": {
              "menopause": {
                "relationship_type": "强烈因果关联",
                "estrogen_deficiency": "雌激素缺乏是绝经后骨质疏松主因",
                "bone_loss_pattern": "绝经后5-10年骨丢失加速",
                "hrt_considerations": "激素替代治疗的获益风险评估"
              },
              "male_hypogonadism": {
                "relationship_type": "因果关联",
                "testosterone_effects": "睾酮对男性骨健康的重要性",
                "replacement_therapy": "睾酮替代治疗改善骨密度"
              },
              "pcos": {
                "relationship_type": "复杂关联",
                "androgen_effects": "雄激素过多对骨代谢的影响",
                "insulin_resistance": "胰岛素抵抗与骨代谢相互作用"
              }
            },
            "growth_hormone_disorders": {
              "acromegaly": {
                "relationship_type": "双向关联",
                "active_disease": "活动期骨转换增加但骨密度可能正常",
                "post_treatment": "治疗后骨密度可能下降",
                "fracture_paradox": "骨密度正常但骨折风险可能增加"
              },
              "gh_deficiency": {
                "relationship_type": "因果关联",
                "adult_ghd": "成人生长激素缺乏导致骨密度下降",
                "replacement_therapy": "GH替代治疗改善骨代谢"
              }
            },
            "vitamin_d_disorders": {
              "vitamin_d_deficiency": {
                "relationship_type": "直接因果关联",
                "primary_cause": "骨软化症的主要病因",
                "secondary_effects": "继发性甲状旁腺功能亢进",
                "global_prevalence": "全球性维生素D缺乏问题"
              },
              "genetic_rickets": {
                "relationship_type": "直接因果关联",
                "hereditary_forms": "遗传性维生素D代谢异常",
                "lifelong_management": "需要终身专业管理"
              }
            }
          },
          "integrated_management_approaches": {
            "multidisciplinary_care": {
              "endocrinologist": "内分泌激素平衡管理",
              "orthopedist": "骨科并发症处理",
              "rheumatologist": "骨代谢专业评估",
              "nutritionist": "营养素缺乏纠正"
            },
            "prevention_strategies": {
              "hormonal_optimization": "激素水平的优化管理",
              "lifestyle_interventions": "生活方式干预措施",
              "pharmacological_prevention": "药物预防策略",
              "monitoring_protocols": "规范化监测方案"
            },
            "treatment_priorities": {
              "underlying_endocrine": "首先治疗潜在内分泌疾病",
              "bone_specific_therapy": "必要时加用骨特异性治疗",
              "fracture_prevention": "骨折预防为核心目标",
              "quality_of_life": "改善生活质量"
            }
          }
        }
      },

      "nutritional_metabolic_endocrine_relationships": {
        "source_id": "NUTRI_001/NUTRI_002/NUTRI_003",
        "description": "营养代谢疾病与内分泌系统的综合关联关系",
        "target_diseases": {
          "obesity_endocrine_interactions": {
            "insulin_resistance": {
              "relationship_type": "双向关联",
              "mechanism": "肥胖导致胰岛素抵抗，胰岛素抵抗促进脂肪堆积",
              "clinical_implications": [
                "2型糖尿病发病风险增加10-20倍",
                "代谢综合征患病率>50%",
                "胰岛β细胞功能逐渐下降"
              ]
            },
            "thyroid_dysfunction": {
              "relationship_type": "复杂关联",
              "subclinical_hypothyroidism": "肥胖患者甲状腺功能减退患病率增加",
              "leptin_resistance": "瘦素抵抗影响TSH分泌",
              "weight_gain_cycle": "甲减加重肥胖，肥胖影响甲状腺功能"
            },
            "reproductive_endocrine": {
              "pcos_relationship": {
                "prevalence": "肥胖女性PCOS患病率增加3-5倍",
                "mechanisms": ["胰岛素抵抗", "雄激素过多", "慢性炎症"],
                "treatment_synergy": "减重改善生殖内分泌功能"
              },
              "hypogonadism": {
                "male_obesity": "内脏肥胖导致睾酮水平下降",
                "aromatase_activity": "脂肪组织芳香化酶活性增加"
              }
            }
          },
          "metabolic_syndrome_correlations": {
            "diabetes_progression": {
              "prediabetes_stage": "代谢综合征是糖尿病前期重要标志",
              "conversion_rate": "年转化率5-10%",
              "prevention_strategies": "生活方式干预有效预防"
            },
            "cardiovascular_endocrine": {
              "aldosterone_system": "RAAS系统激活与代谢综合征",
              "cortisol_dysregulation": "皮质醇节律异常",
              "growth_hormone": "生长激素分泌减少"
            }
          },
          "vitamin_d_endocrine_network": {
            "parathyroid_interactions": {
              "secondary_hyperparathyroidism": {
                "mechanism": "维生素D缺乏→PTH升高→骨代谢异常",
                "prevalence": "维生素D缺乏患者PTH升高率>60%",
                "clinical_cascade": "骨质疏松、肾结石、心律不齐风险"
              }
            },
            "insulin_sensitivity": {
              "vitamin_d_insulin": "维生素D受体存在于胰岛β细胞",
              "glucose_metabolism": "维生素D缺乏影响葡萄糖代谢",
              "diabetes_risk": "血清25(OH)D每降低25nmol/L，糖尿病风险增加24%"
            },
            "thyroid_interactions": {
              "autoimmune_thyroid": "维生素D缺乏与自身免疫甲状腺病相关",
              "hashimoto_correlation": "桥本甲状腺炎患者维生素D水平显著降低"
            }
          }
        },
        "therapeutic_implications": {
          "integrated_management": {
            "obesity_treatment": {
              "endocrine_evaluation": "筛查继发性肥胖内分泌原因",
              "hormonal_therapy": "GLP-1激动剂双重获益",
              "metabolic_surgery": "减重手术改善多重内分泌异常"
            },
            "metabolic_syndrome_approach": {
              "multitarget_therapy": "同时改善胰岛素敏感性、血脂、血压",
              "endocrine_optimization": "甲状腺、性腺功能评估优化",
              "lifestyle_medicine": "营养、运动、行为综合干预"
            },
            "vitamin_d_supplementation": {
              "dosing_strategies": "个体化剂量调整",
              "monitoring_protocols": "25(OH)D、PTH、血钙监测",
              "combination_therapy": "与钙剂、其他维生素联用"
            }
          }
        }
      },

      "reproductive_endocrine_relationships": {
        "source_id": "REPRO_001/REPRO_002/REPRO_003",
        "description": "生殖内分泌疾病与其他内分泌系统的复杂相互作用",
        "target_diseases": {
          "pcos_metabolic_connections": {
            "insulin_resistance_axis": {
              "relationship_type": "双向促进",
              "mechanism": "胰岛素抵抗↔高雄激素血症恶性循环",
              "clinical_implications": [
                "PCOS患者T2DM风险增加5-10倍",
                "代谢综合征患病率>50%",
                "心血管疾病风险显著增加"
              ],
              "therapeutic_targets": "二甲双胍改善胰岛素抵抗和生殖功能"
            },
            "thyroid_interactions": {
              "hypothyroidism_prevalence": "PCOS患者甲减患病率增加2-3倍",
              "mechanism": "共同的代谢和免疫基础",
              "clinical_overlap": ["月经不调", "不孕", "代谢异常"],
              "screening_importance": "PCOS患者需常规甲状腺功能筛查"
            },
            "adrenal_hyperandrogenism": {
              "dhea_s_elevation": "20-30%的PCOS患者DHEA-S升高",
              "differential_diagnosis": "需排除21-羟化酶缺陷",
              "treatment_considerations": "肾上腺来源雄激素的特异性治疗"
            }
          },
          "male_hypogonadism_associations": {
            "metabolic_syndrome_bidirectional": {
              "testosterone_metabolism": "低睾酮促进内脏脂肪积累",
              "insulin_resistance": "胰岛素抵抗抑制睾酮合成",
              "prevalence": "代谢综合征男性中性腺功能减退率40%",
              "treatment_synergy": "睾酮替代改善代谢参数"
            },
            "thyroid_function_effects": {
              "hypothyroidism_impact": "甲减加重性腺功能减退",
              "shbg_changes": "甲状腺功能影响SHBG水平",
              "combined_treatment": "甲减治疗可部分改善性功能"
            },
            "growth_hormone_interactions": {
              "age_related_decline": "GH和睾酮随年龄同步下降",
              "body_composition": "共同影响肌肉量和脂肪分布",
              "bone_health": "协同维护骨密度"
            }
          },
          "poi_endocrine_network": {
            "autoimmune_clustering": {
              "aps_association": "20%的POI患者合并其他自身免疫内分泌病",
              "common_targets": ["甲状腺", "肾上腺", "胰岛β细胞"],
              "screening_protocol": "需系统性自身免疫内分泌评估",
              "genetic_susceptibility": "HLA-DRB1和DQA1关联"
            },
            "bone_metabolism_effects": {
              "estrogen_deficiency": "雌激素缺乏导致快速骨丢失",
              "pth_changes": "PTH分泌和作用异常",
              "vitamin_d_metabolism": "1α-羟化酶活性下降",
              "fracture_risk": "骨折风险增加3-7倍"
            },
            "cardiovascular_endocrine": {
              "estrogen_protection_loss": "失去雌激素心血管保护",
              "lipid_metabolism": "LDL升高，HDL下降",
              "insulin_sensitivity": "胰岛素敏感性下降",
              "early_menopause_risks": "心血管事件风险提前"
            }
          }
        },
        "fertility_endocrine_interactions": {
          "pregnancy_endocrine_changes": {
            "insulin_resistance": "妊娠期生理性胰岛素抵抗",
            "thyroid_adaptations": "hCG对甲状腺的刺激作用",
            "adrenal_modifications": "皮质醇和醛固酮分泌增加",
            "calcium_homeostasis": "PTHrP分泌和钙代谢调节"
          },
          "lactation_hormonal_effects": {
            "prolactin_dominance": "泌乳素抑制GnRH脉冲",
            "hypothalamic_amenorrhea": "哺乳期闭经机制",
            "bone_calcium_mobilization": "哺乳期骨钙动员",
            "metabolic_adaptations": "脂肪和葡萄糖代谢重塑"
          }
        },
        "therapeutic_considerations": {
          "hormone_replacement_principles": {
            "pcos_management": {
              "insulin_sensitizers": "二甲双胍作为一线治疗",
              "ovulation_induction": "来曲唑 vs 克罗米芬",
              "antiandrogen_therapy": "螺内酯、醋酸环丙孕酮",
              "metabolic_monitoring": "定期评估糖脂代谢"
            },
            "male_hrt_protocols": {
              "testosterone_preparations": "注射、凝胶、贴剂选择",
              "monitoring_parameters": "血红蛋白、PSA、肝功能",
              "contraindications": "前列腺癌、严重心力衰竭",
              "fertility_preservation": "hCG+FSH保留生育力"
            },
            "poi_hrt_strategies": {
              "estrogen_replacement": "生理性雌激素替代",
              "progestin_protection": "子宫内膜保护",
              "bone_health_focus": "骨密度监测和干预",
              "cardiovascular_benefits": "年轻女性HRT获益明确"
            }
          }
        }
      },

      "clinical_decision_pathways": {
        "screening_protocols": {
          "diabetes_patients": {
            "thyroid_screening": "诊断时和年度TSH、抗TPO筛查",
            "adrenal_screening": "有症状时21-羟化酶抗体检测",
            "celiac_screening": "腹部症状时抗组织转谷氨酰胺酶抗体"
          },
          "thyroid_patients": {
            "diabetes_screening": "年度空腹血糖或OGTT",
            "autoantibody_panel": "抗GAD、抗IA-2筛查",
            "other_autoimmune": "根据症状筛查其他自身免疫疾病"
          },
          "addison_patients": {
            "comprehensive_screening": "诊断时全面多腺体功能评估",
            "family_screening": "一级亲属20%患病风险筛查",
            "long_term_monitoring": "终生监测新发自身免疫疾病"
          }
        },

        "treatment_considerations": {
          "drug_interactions": {
            "steroid_diabetes": "糖皮质激素治疗需要密切监测血糖",
            "thyroid_adrenal": "甲状腺激素替代前必须先纠正肾上腺功能",
            "immunosuppression_infections": "免疫抑制治疗增加机会感染风险"
          },
          "monitoring_protocols": {
            "multi_gland_failure": "多腺体功能衰竭的综合监测策略",
            "stress_response": "应激状态下的激素调整方案",
            "pregnancy_management": "妊娠期多种激素替代治疗管理"
          }
        }
      },

      "research_implications": {
        "shared_biomarkers": {
          "genetic_markers": "HLA基因型、非HLA易感基因多态性",
          "immunological_markers": "细胞因子谱、调节性T细胞功能",
          "metabolic_markers": "代谢组学标志物、氧化应激指标"
        },
        "therapeutic_targets": {
          "immune_checkpoints": "CTLA-4、PD-1通路调节",
          "cytokine_pathways": "IL-17、TNF-α、干扰素通路",
          "metabolic_pathways": "胰岛素敏感性、甲状腺激素信号"
        },
        "precision_medicine": {
          "genetic_risk_scoring": "多基因风险评分预测疾病发生",
          "biomarker_guided_therapy": "基于生物标志物的个体化治疗",
          "prevention_strategies": "高风险人群的预防性干预"
        }
      }
    },

    "llm_integration_architecture": {
      "rag_system": {
        "vector_database": {
          "embedding_model": "text-embedding-3-large",
          "index_type": "HNSW",
          "dimensions": 3072,
          "similarity_metric": "cosine"
        },
        "retrieval_strategy": {
          "hybrid_search": "语义搜索+关键词匹配",
          "reranking": "临床相关性重排序",
          "context_window": "32K tokens",
          "chunk_size": "1024 tokens",
          "chunk_overlap": "200 tokens"
        },
        "query_processing": {
          "intent_classification": "疾病咨询/治疗建议/诊断支持/用药指导",
          "entity_extraction": "医学实体识别和标准化",
          "context_enrichment": "相关疾病和共病信息增强"
        }
      },
      "structured_extraction": {
        "clinical_ner": {
          "entities": [
            "疾病名称", "症状", "药物", "检查项目", 
            "实验室指标", "治疗方案", "剂量", "时间"
          ],
          "model": "BioBERT + CRF",
          "accuracy": ">95%"
        },
        "relation_extraction": {
          "relationships": [
            "疾病-症状", "疾病-治疗", "药物-副作用",
            "检查-疾病", "共病关系", "因果关系"
          ],
          "model": "BERT-based relation classifier"
        },
        "data_standardization": {
          "terminology": "ICD-10, SNOMED-CT, ATC",
          "unit_conversion": "自动单位标准化",
          "value_normalization": "数值范围标准化"
        }
      },
      "api_endpoints": [
        {
          "endpoint": "/api/v1/diagnose",
          "method": "POST",
          "description": "基于症状和检查结果的智能诊断",
          "input_schema": {
            "patient_info": "患者基本信息",
            "symptoms": "症状列表", 
            "lab_results": "实验室检查结果",
            "imaging": "影像学检查"
          },
          "output_schema": {
            "differential_diagnosis": "鉴别诊断列表",
            "confidence_scores": "诊断置信度",
            "recommendations": "进一步检查建议"
          }
        },
        {
          "endpoint": "/api/v1/treatment",
          "method": "POST", 
          "description": "个性化治疗方案推荐",
          "input_schema": {
            "diagnosis": "确诊疾病",
            "patient_profile": "患者特征", 
            "comorbidities": "合并症",
            "contraindications": "禁忌症"
          },
          "output_schema": {
            "treatment_plans": "治疗方案列表",
            "medication_details": "药物详细信息",
            "monitoring_schedule": "监测计划"
          }
        },
        {
          "endpoint": "/api/v1/drug_interaction",
          "method": "POST",
          "description": "药物相互作用检查",
          "input_schema": {
            "medications": "药物列表"
          },
          "output_schema": {
            "interactions": "相互作用详情",
            "severity": "严重程度",
            "alternatives": "替代方案"
          }
        }
      ]
    },

    "research_support_features": {
      "cohort_identification": {
        "query_interface": "自然语言查询界面",
        "inclusion_criteria": "基于知识图谱的智能筛选",
        "exclusion_criteria": "禁忌症和共病排除",
        "sample_size_calculation": "统计功效分析"
      },
      "outcome_tracking": {
        "primary_endpoints": "主要终点事件监测",
        "secondary_endpoints": "次要终点追踪",
        "adverse_events": "不良事件记录和分析",
        "biomarker_trends": "生物标志物趋势分析"
      },
      "data_analytics": {
        "descriptive_statistics": "描述性统计分析",
        "survival_analysis": "生存分析和风险建模", 
        "machine_learning": "预测模型构建",
        "causal_inference": "因果关系推断"
      },
      "hypothesis_generation": {
        "pattern_discovery": "数据模式发现",
        "association_mining": "关联规则挖掘",
        "literature_integration": "文献证据整合",
        "research_suggestions": "研究方向建议"
      }
    }
  }
}
